GIP and exendin hybrid polypeptides

ABSTRACT

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

RELATED APPLICATIONS

The present application is a continuation of and claims priority tocommonly-owned and U.S. patent application Ser. No. 11/840,921 filedAug. 17, 2007, now issued as U.S. Pat. No. 8,263,545, and claimspriority to abandoned U.S. patent application Ser. No. 11/507,081 filedAug. 17, 2006, and United States provisional applications: U.S.Provisional Application No. 60/652,662 filed Feb. 11, 2005; U.S.Provisional Application No. 60/653,433 filed Feb. 15, 2005; U.S.Provisional Application No. 60/651,647 filed Feb. 11, 2005; U.S.Provisional Application No. 60/707,244 filed Aug. 11, 2005; U.S.Provisional Application No. 60/707,369 filed Aug. 11, 2005; U.S.Provisional Application No. 60/709,320 filed Aug. 17, 2005; U.S.Provisional Application No. 60/709,316 filed Aug. 17, 2005; andPCT/US2006/005020 filed 10 Feb. 2006, each of which are herebyincorporated by reference in their entirety. Also incorprated herein byreference is PCT application number PCT/US2007/018415 entitled “GIPANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES” filed withthe USPTO RO on Aug. 17, 2007.

REFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAMLISTING APPENDIX SUBMITTED AS AN ASCII TEXT FILE

The Sequence Listing written in file 92494-863579_ST25. TXT, created onFeb. 7, 2013, 461,227 bytes, machine format IBM-PC, MS-Windows operatingsystem, is hereby incorporated by reference.

FIELD OF THE INVENTION

The present invention relates to peptide chemistry and pharmaceuticals,and more particularly to novel gastric inhibitory peptide (“GIP”) analogand GIP-containing hybrid polypeptides with selectable properties. Itfurther relates to the use of these and other GIP compounds either aloneor in adjunct with other compounds such as glucagon-like peptide 1(“GLP1”), exendin-4, or amylin polypeptides, to treat metabolicdisorders and conditions.

BACKGROUND OF THE INVENTION

Incretin peptides are hormones and peptide mimetics that cause anincrease in the amount of insulin released when glucose levels arenormal or particularly when they are elevated. These incretin peptideshave other actions beyond the initial incretin action defined by insulinsecretion. For instance, they may also have actions to reduce glucagonproduction and delay gastric emptying. In addition, they may haveactions to improve insulin sensitivity, and they may increase islet cellneogenesis—the formation of new islets.

The concept of the incretin effect developed from the observation thatinsulin responses to oral glucose exceeded those measured afterintravenous administration of equivalent amounts of glucose. It wasconcluded that gut-derived factors, or incretins, influencedpostprandial insulin release. Nutrient entry into the stomach andproximal gastrointestinal tract causes release of incretin hormones,which then stimulate insulin secretion. This insulinotropism, or abilityto stimulate insulin secretion, can be quantified by comparing insulinor C-peptide responses to oral vs. intravenous glucose loads. In thisway, it has been shown that the incretin effect is responsible for about50% to 70% of the insulin response to oral glucose in healthyindividuals.

Although many postprandial hormones have incretin-like activity,predominant incretin peptides include glucose-dependent insulinotropicpolypeptide, also known as gastric inhibitory polypeptide (GIP),glucagon-like peptide-1 (GLP-1), and exendin peptides (which arenon-endogenous incretin mimetics). GIP and GLP-1 both belong to theglucagon peptide superfamily and thus share amino acid sequencehomology. GIP and GLP-1 are secreted by specialized cells in thegastrointestinal tract and have receptors located on islet cells as wellas other tissues. As incretins, both are secreted from the intestine inresponse to ingestion of nutrients, which results in enhanced insulinsecretion. The insulinotropic effect of GIP and GLP-1 is dependent onelevations in ambient glucose. Both are rapidly inactivated by theubiquitous enzyme dipeptidyl peptidase IV (DPP-IV).

Native human GIP is a single 42-amino acid peptide synthesized in andsecreted by specialized enteroendocrine K-cells. These cells areconcentrated primarily in the duodenum and proximal jejunum, althoughthey also can be found throughout the intestine. The main stimulant forGIP secretion is ingestion of carbohydrate- and lipid-rich meals.Following ingestion, circulating plasma GIP levels increase 10- to20-fold. The half-life of intact GIP is estimated to be approximately7.3 minutes in healthy subjects and 5.2 minutes in diabetic subjects.

The physiologic effects of GIP have been elucidated using GIP receptorantagonists, GIP peptide antagonists, and GIP receptor knockout mice, inaddition to GIP infusion protocols. Blocking GIP binding to its receptorresults in attenuated glucose-dependent insulin secretion following oralglucose load in rats and mice. Similarly, administration of GIPantagonists or GIP antisera markedly reduces the postprandial insulinrelease in rats. GIP receptor knockout mice demonstrate normal fastingglucose levels but mild glucose intolerance following oral glucoseloads. Interestingly, they also exhibit resistance to diet-inducedobesity following months of high-fat feeding. Additionally, in theleptin-deficient ob/ob mouse, the GIP receptor knockout genotype appearsto decrease the extent of obesity that develops.

GIP infusion has consistently demonstrated stimulation of insulinsecretion in isolated rat islets, isolated perfused rat pancreas, dogs,and humans. During stepwise euglycemic, mild hyperglycemic (54 mg/dLabove basal), and moderate hyperglycemic (143 mg/dL above basal) clamps,it has been demonstrated that GIP infusion results in insulin secretiononly in the presence of elevated glucose concentrations. Furthermore, ithas been demonstrated that GIP is not glucagonotropic in normal humansduring either euglycemic or hyperglycemic conditions. Thus, the effectof endogenously released GIP appears to be an important mechanism ofpostprandial insulin secretion and does not appear to play a role in thefasting state.

GIP has many non-incretin effects as well. Unlike other insulinsecretagogues, GIP stimulates beta-cell proliferation and cell survivalin INS-1 islet cell-line studies. Furthermore, animal studies havesuggested a role for GIP in lipid metabolism by stimulating lipoproteinlipase activity, inducing fatty acid incorporation into adipose tissueand stimulating fatty acid synthesis. However, in humans, there is noclear evidence for an effect of GIP on lipid metabolism. GIP alsoappears to stimulate glucagon secretion from the isolated perfused ratpancreas, although human studies have not demonstrated any significantinfluence on glucagon secretion. Furthermore, unlike GLP-1, GIP appearsto act by accelerating emptying of the stomach rather than by inhibitinggastrointestinal motility.

The GIP-receptor, a member of the G-protein-coupled receptor family hasa high specificity for GIP and does not bind other peptides of theglucagon family. For this reason, GLP-1/GIP chimeric peptides shownearly no affinity for the GIP-receptor. From such studies it has beenconcluded that the GIP(1-30) sequence of the GIP(1-42) is sufficient forrecognizing the receptor. GIP(6-30)-amide contains the high affinitybinding region of GIP(1-42) but exhibits antagonist activity.

Despite potent glucoregulatory actions through glucose-dependantstimulation of insulin secretion, the insulinotropic effect of GIP issignificantly reduced in diabetic subjects compared to normalindividuals (16-18). Consequently, clinical use of GIP has not beensignificantly advanced. Further, there remains a need to developadditional diabetic treatment modalities as well as treatments formetabolic diseases, conditions, and disorders. Accordingly, it is anobject of the present invention to provide GIP analog and GIP-containinghybrid polypeptides and methods for their use to treat or preventmetabolic diseases, conditions, and disorders.

The issued patents, applications, and references that are cited hereinare hereby incorporated by reference to the same extent as if each wasspecifically and individually indicated to be incorporated by referenceand as though fully set forth herein.

SUMMARY OF THE INVENTION

Provided are methods for treating or preventing metabolic diseases anddisorders including those which can be alleviated by control of plasmaglucose levels, insulin levels, and/or insulin secretion, such asdiabetes and diabetes-related conditions, and conditions and disordersincluding, but not limited to, hypertension, dyslipidemia,cardiovascular disease, eating disorders, insulin-resistance, obesity,and diabetes mellitus of any kind, including type 1, type 2, andgestational diabetes. The methods comprise administering atherapeutically or prophylactically effective amount of a GIP or GIPanalog, fragment or derivative thereof, or a GIP hybrid or derivativesthereof as described herein, alone (monotherapy) or in combination withanother agent or therapy (adjunct therapy), for example a glucoselowering agent (e.g., antidiabetic) or agents or methods that inhibit orreduce gastric emptying (examples of such agents are presented herein),to a subject in need thereof. By providing a GIP bioactivity as part ofa GIP hybrid having one or more other hormonal bio-activities, e.g.,pramlintide, exendin, BNP, compounds with one or more selectablefunctions will have the additional benefit of a property of a GIPbio-activity such as lowering plasma glucose, increasing insulinsecretion, without the side effects associated with other incretinmolecules. For example, a GIP-sCT hybrid compound of the invention canhave a selectable property of a salmon calcitonin, such as decreasingbone loss and bone resorption or reducing cartilage turnover(chondroprotection), and a property of a GIP, such as plasma glucoselowering (concomitant with an anti-catabolic aspect as described herein)and/or inhibiting bone resorption and maintaining or increasing bonedensity. A GIP hybrid with such selectable properties can enhancetreatment of osteoporosis or conditions of high cartilage turnover,particularly in those who can also benefit from glycemic control, suchas subjects with diabetes or under going critical care.

In one embodiment are provided novel GIP analogs having one or moreenhanced properties. The GIP analogs have increased resistance to DPP-IVor to other proteases, such as those found in human plasma and/or onkidney brush border membranes, which increases in vivo half-life. In afurther embodiment the GIP analogs have at least one substitution,modification, insertion or deletion in amino acids 4-30. These changescan provide enhanced properties such as increased GIP receptor binding,increased receptor selectivity, and/or increased resistance todegradation by chemical and/or proteolytic means. In another embodimentthe GIP analog further has least 50% sequence identity to nativeGIP(1-30), native GIP(1-14), native GIP(19-30) or native GIP(1-42) overthe entire length of each molecule, and at least one biological propertyof a GIP. In certain embodiments, novel GIP analog polypeptides includeunnatural amino acids, such as a D amino acid. In a further embodiment aGIP analog or hybrid is modified to have reduced renal clearance, suchas by fatty acyl derivatization.

In another embodiment are provided novel GIP-containing hybridpolypeptides with selectable properties. The hybrid polypeptides exhibitat least one hormonal activity. In one embodiment the GIP-hybridpolypeptides comprise at least two biologically active (“bio-active”)peptide hormone modules covalently linked together, wherein at least oneof the bio-active peptide hormone modules comprises a GIP polypeptide.The other bio-active peptide hormone module can be: (a) a nativecomponent peptide hormone, (b) an analog or derivative of a nativecomponent peptide hormone that retains hormonal activity, (c) a fragmentof a native component peptide hormone that retains hormonal activity,(d) a fragment of analogs or derivatives of a native component peptidehormone that retains hormonal activity, (e) a structural motif of anative component peptide hormone that imparts a desired chemicalstability, conformational stability, metabolic stability,bioavailability, organ/tissue targeting, receptor interaction, proteaseinhibition, plasma protein binding, and/or other pharmacokineticcharacteristic to the hybrid polypeptide; or (f) a structural motif ofanalogs or derivatives of a native component peptide hormone thatimparts a desired chemical stability, conformational stability,metabolic stability, bioavailability, organ/tissue targeting, receptorinteraction, protease inhibition, plasma protein binding, and/or otherpharmacokinetic characteristic to the hybrid polypeptide. The structuralmotifs of (e) and (f) will collectively be referred to herein as“peptidic enhancers”. An example of a peptidic enhancer is a Trp cagesequence, particularly one derived from exendin-4.

In a further embodiment a GIP-hybrid polypeptide comprises at least twobio-active peptide hormone modules covalently linked together, whereinat least one of the bio-active peptide hormone modules is comprised of aGIP polypeptide, and the second exhibits at least one hormonal activityof a component peptide hormone. The bio-active peptide hormone modulesare independently selected from: component peptide hormones, fragmentsof component peptide hormones that exhibit at least one hormonalactivity of the component peptide hormones, analogs and derivatives ofcomponent peptide hormones that exhibit at least one hormonal activityof the component peptide hormones, and fragments of analogs andderivatives of component peptide hormones that exhibit at least onehormonal activity of the component peptide hormones.

In one embodiment the GIP-hybrid polypeptides comprise a novel GIPanalog polypeptide of the invention covalently linked to at least oneadditional bio-active peptide hormone module. In a further embodimentthe bio-active peptide hormone module is a peptidic enhancer. In oneembodiment the GIP hybrid polypeptide of the invention will exhibit atleast 50% sequence identity to a native GIP(1-30), native GIP(1-14),native GIP(19-30) or native GIP(1-42) over the entire length of the GIPportion. In certain embodiments the GIP portion can comprise a novel GIPanalog further comprising a peptidic enhancer, such as a trp-cage motif.Accordingly, a GIP hybrid can comprise a GIP portion that is a GIPanalog, fragment or derivative thereof with a peptidic enhancer, such asa trp-cage motif, and having enhanced properties, that is linkedcovalently to an additional bio-active peptide hormone module, such asanother hormone or growth factor or fragment thereof.

Component peptide hormones for use in a GIP-hybrid polypeptide include:amylin, adrenomedullin (ADM), calcitonin (CT), calcitonin gene relatedpeptide (CGRP), intermedin, cholecystokinin (“CCK”), leptin, peptide YY(PYY), glucagon-like peptide-1 (GLP-1), glucagon-like peptide 2 (GLP-2),oxyntomodulin (OXM), natriuretic peptides (e.g. ANP, BNP, CNP orurodilatin), urocortin family peptide, e.g., Ucn-2 and Ucn-3, neuromedinfamily peptide, e.g. neuromedin U25 or splice variants, exendin-3 andexendin-4.

In other GIP hybrid embodiments the GIP portion is combined with agastrin/CCK receptor ligand; an amylin receptor ligand; a calcitoninreceptor ligand; a CGRP receptor ligand, a PYY receptor ligand, an EGFreceptor ligand; a Glucagon-like peptide 1 receptor ligand; aGlucagon-like peptide 2 receptor ligand; a gastric inhibitorypolypeptide (GIP) receptor ligand; a keratinocyte growth factor (KGF)receptor 1 ligand; a dipeptidyl peptidase IV inhibitor; a REG proteinreceptor ligand; a Growth Hormone receptor ligand; a Prolactin (PRL)receptor ligand; an Insulin-like Growth Factor (IGF) receptor ligand;PTH-related protein (PTHrP) receptor ligand; hepatocyte growth factor(HGF) receptor ligand; a bone morphogenetic protein (BMP) receptorligand, a transforming growth factor (TGF receptor ligand; a lamininreceptor ligand; a vasoactive intestinal peptide (VIP) receptor ligand;a fibroblast growth factor (FGF) receptor ligand; a nerve growth factor(NGF) receptor ligand; an islet neogenesis associated protein (INGAP)receptor ligand; an Activin-A receptor ligand; a vascular endothelialgrowth factor (VEGF) receptor ligand; an erythropoietin (EPO) receptorligand; a pituitary adenylate cyclase activating polypeptide (PACAP)receptor ligand; a granulocyte colony stimulating factor (G-CSF)receptor ligand; a granulocyte-macrophage colony stimulating factor(GM-CSF); a platelet-derived growth factor (PDGF) receptor ligand, acannabinoid CB1 receptor antagonist, and a secretin receptor ligand.

In one embodiment desirable GIP hybrid polypeptides include anN-terminal GIP or novel GIP analog fragment in combination with aC-terminal polypeptide or fragment thereof having a glucose loweringactivity (e.g., antidiabetics, exendin) or the ability to inhibit orreduce gastric emptying. Such desirable GIP hybrids include anN-terminal GIP fragment or novel GIP analog or derivative fragment incombination with a C-terminal exendin, GLP1, pramlintide, amylin, CCK,gastrin, PYY, secretin, GRP, neuromedins, urocortin, calcitonin, orsalmon calcitonin, a natriuretic peptide (e.g., ANP, BNP, CNP,urodilatin) or analog (e.g. amylin-sCT-amylin chimera), derivative orfragment thereof. In other embodiments desirable GIP hybrids include aC-terminal GIP or novel GIP analog fragment in combination with anN-terminal polypeptide or fragment thereof having a glucose loweringactivity (e.g., antidiabetics, exendin) or the ability to inhibit orreduce gastric emptying. In such embodiments, the chimeric polypeptidescan include a C-terminal GIP, a novel GIP analog, or fragment thereof,in combination with a N-terminal exendin, GLP1, pramlintide, amylin,CCK, gastrin, PYY, secretin, GRP, neuromedins, urocortin, calcitonin, orsalmon calcitonin, a natriuretic peptide or analog, derivative orfragment thereof.

In other embodiments the peptidic enhancer is a tail or terminalextension derived from a second hormone, such as exendin, human GLP-1,or frog GLP-1, or is empirically determined. In one embodiment thepeptidic enhancer is a heterologous C-terminal tail or terminalextension to the GIP portion. As with the other GIP hybrids describedherein, in one embodiment of the peptidic-enhancer containing hybrid,the GIP portion can be native GIP, an active fragment thereof, or theiranalogs or derivatives. In another aspect the GIP portion of the hybridcomprises at least one modification, substitution, deletion or additionthat provides one or more enhanced properties, e.g. increased resistanceto proteolytic digestion (thus prolonging half-life), fatty acylderivatization that reduces renal clearance. In one embodiment the tailcomprises a Trp-cage motif sequence. In another embodiment the GIPanalog polypeptide portion includes unnatural amino acids, such as a Damino acid, e.g. that inhibits to reduces the rate of proteolysis byDPP-IV.

The present invention also provides for the treatment and prevention ofmetabolic diseases and disorders, particularly those which can bealleviated by control of plasma glucose levels, insulin levels, and/orinsulin secretion, such as diabetes and diabetes-related conditions.Such conditions and disorders include, but are not limited to,hypertension, dyslipidemia, cardiovascular disease, eating disorders,insulin-resistance, obesity, and diabetes mellitus of any kind,including type 1, type 2, and gestational diabetes, diabetescomplications (e.g. neuropathy (treating with a GIP hybrid containing anexendin family hormone module for example), neuropathic pain (treatingwith GIP hybrids comprising an amylin family hormone module forexample), retinopathy, nephropathy, conditions of insufficientpancreatic beta cell mass (based on, e.g., islet neogenesis actions ofexendin-4 and GLP-1). Accordingly, provided are methods for treating orpreventing such conditions, wherein the method comprises administering atherapeutically or prophylactically effective amount of a GIP or ananalog or derivative thereof, including a novel GIP analog of theinvention, or a GIP-hybrid of the invention, including one having apeptidic enhancer, to a subject in need thereof. In one embodiment thepolypeptides of the invention can be provided as monotherapy. In anotherembodiment for treating diabetes or conditions associated with elevatedglucose levels, the GIP compound can be administered in adjunct therapywith a glucose lowering agents (e.g., antidiabetics) or agents ormethods that inhibit or reduce gastric emptying. Examples of such agentsare presented herein. For example, in one embodiment is provided anadjunct therapy method for reducing blood glucose levels of a subject,e.g., one having type 1, type 2 or gestational diabetes mellitus,comprising administering to the subject a therapeutically effectiveamount of an exendin or an exendin agonist, such as wherein said exendinagonist is a peptide, in adjunct therapy with a GIP or novel GIP analogof the invention, or an effective amount of a GIP-exendin hybrid.

Compounds of the invention, alone or in combination with a glucoselowering agent (e.g., antidiabetics) or with agents or methods thatinhibit or reduce gastric emptying, can also be useful for potentiating,inducing, enhancing or restoring glucose responsivity in pancreaticislets or cells. These actions may also be used to treat or preventconditions associated with metabolic disorders such as those describedabove and in U.S. Patent Application No. US20040228846, incorporatedherein by reference in its entirety.

In another aspect methods for treating or preventing obesity areprovided, wherein the method comprises administering a therapeuticallyor prophylactically effective amount of a GIP or an analog or derivativethereof, including a novel GIP analog of the invention, or a GIP-hybridof the invention, including those having a peptidic enhancer, to asubject in need thereof. In one embodiment, the subject is an obese oroverweight subject. While “obesity” is generally defined as a body massindex over 30, for purposes of this disclosure, any subject, includingthose with a body mass index of less than 30, who needs or wishes toreduce body weight is included in the scope of “obese.” Subjects who areinsulin resistant, glucose intolerant, or have any form of diabetesmellitus (e.g., type 1, 2 or gestational diabetes) can benefit from thismethod. Compounds of the invention can also be useful in treating orpreventing other conditions associated with obesity including stroke,cancer (e.g.,. endometrial, breast, prostate, and colon cancer),gallbladder disease, sleep apnea, reduced fertility, and osteoarthritis,(see Lyznicki et al, Am. Fam. Phys. 63:2185, 2001). Where conditions areassociated with elevated glucose or hyperglycemia, the method comprisesadministering a therapeutically or prophylactically effective amount ofa GIP compound, alone or in combination with a glucose lowering agent(e.g., antidiabetic) or agent or method that inhibits or reduces gastricemptying.

In yet another aspect, GIP compounds, particularly GIP hybrids of theinvention, can be used in methods of reducing food intake, reducingappetite, inducing satiety, reducing nutrient availability, reducingcaloric efficiency, causing weight loss, affecting body composition,altering body energy content or energy expenditure, and improving lipidprofile (including reducing LDL cholesterol and triglyceride levelsand/or changing HDL cholesterol levels) wherein the methods compriseadministering to a subject an effective amount of a GIP compound,particularly a GIP hybrid compound, of the invention. In one embodiment,the methods of the invention are used to treat or prevent conditions ordisorders which can be alleviated by reducing nutrient availability in asubject in need thereof, comprising administering to said subject atherapeutically or prophylactically effective amount of a GIP compoundof the invention. Conditions and disorders include, but are not limitedto, hypertension, dyslipidemia, cardiovascular disease, eatingdisorders, insulin-resistance, obesity, and diabetes mellitus of anykind, including type 1, type 2, and gestational diabetes, diabetescomplications (neuropathy (based on, e.g., neurotrophic actions ofexendin-4), neuropathic pain (based on, e.g., amylin action),retinopathy, nephropathy, conditions of insufficient pancreatic betacell mass (based on, e.g., islet neogenesis actions of exendin-4 andGLP-1). Where conditions are associated with elevated glucose orhyperglycemia, the method comprises administering a therapeutically orprophylactically effective amount of a GIP compound, alone or incombination with a glucose lowering agent (e.g., antidiabetic) or agentor method that inhibits or reduces gastric emptying.

In addition to the amelioration of hypertension in subjects in needthereof as a result of reduced food intake, weight loss, and/or treatingobesity, compounds of the invention may be used to treat or preventhypotension and conditions associated therewith.

In another aspect GIP analogs and hybrids are useful for decreasing orinhibiting bone resorption and maintaining or increasing bone density.When combined with an appropriate second hormonal module, GIP hybridsare useful to treat these conditions as well as decreasing plasmacalcium, and/or inducing an analgesic effect, particularly to treat bonedisorders such as osteopenia and osteoporosis, and treating painfulneuropathy. In one embodiment such hybrids contain an exendin, GLP1,amylin and/or sCT portion. For example, a GIP-sCT or GIP-amylin/sCThybrid compound of the invention can have a selectable property of asalmon calcitonin or amylin/sCT/Amylin chimera, such as decreasing boneloss and bone resorption or reducing cartilage turnover(chondroprotection), and a property of a GIP, such as plasma glucoselowering (concomitant with an anabolic aspect as described herein)and/or inhibiting bone resorption and maintaining or increasing bonedensity. A GIP hybrid with such selectable properties can enhancetreatment of osteoporosis or conditions of high cartilage turnover,particularly in those who can also benefit from glycemic control, suchas subjects with diabetes or under going critical care.

GIP compounds, particularly GIP analogs, extended half-life GIP hybrids(e.g. DPP-IV cleavage resistant (such as a D-Ala2, N-Acetyl orN-pyroglutamyl analogs) optionally further comprising a peptidicenhancer such as a heterologous C-terminal tail, and GIP hybridscomprising other hormone modules known to provide beneficialcardiovascular effects, are useful to treat cardiovascular disease andrelated conditions. As demonstrated herein GIP compounds increasecardiac contractility (dp/dt), decrease blood pressure (for example byacute vasodilatation), decrease systolic pressure, decrease diastolicpressure, and can provide a direct beneficial action on cardiac cells.GIP compounds also improve cardiac function via metabolic actions, e.g.glucose lowering, insulin secretion, beta cell proliferation. However,by also providing direct effects on cardiovascular system, the GIPcompounds are surprisingly even more beneficial.

Compounds of the invention can also be useful in the treatment orprevention of any number of gastrointestinal disorders that areassociated with excess gastric secretion, excess intestinal electrolytesand water secretion as well as decreased absorption, e.g., infectious(e.g., viral or bacterial) diarrhea, inflammatory diarrhea, short bowelsyndrome, or the diarrhea which typically occurs following surgicalprocedure, e.g., ileostomy (see e.g., Harrison's principles of InternalMedicine, McGraw Hill Inc., New York, 12th ed.). Examples of infectiousdiarrhea include, without limitation, acute viral diarrhea, acutebacterial diarrhea (e.g., salmonella, campylobacter, and clostridium) ordiarrhea due to protozoal infections, or travelers' diarrhea (e.g.,Norwalk virus or rotavirus). Examples of inflammatory diarrhea include,without limitation, malabsorption syndrome, tropical spue, chronicpancreatitis, Crohn's disease, diarrhea, and irritable bowel syndrome.GIP and GIP compounds of the invention can be used to treat or preventan emergency or life-threatening situation involving a gastrointestinaldisorder, e.g., after surgery or due to cholera. Furthermore, thecompounds can be used to treat intestinal dysfunction in patients withAcquired Immune Deficiency Syndrome (AIDS), especially during cachexia.The compounds may also be useful for inhibiting small intestinal fluidand electrolyte secretion, and augmenting nutrient transport, as well asincreasing cell proliferation in the gastrointestinal tract, regulatinglipolysis in, e.g., adipose tissue and regulating blood flow in a mammalGIP compounds of the invention may also be useful for treating orpreventing the above conditions by their gastrointestinal protectiveactivity (e.g., inhibition of gastric secretion). Accordingly, a GIPcompound of the invention may be used to treat gastrointestinal ormucosal damage. Exemplary types of damage include, but are not limitedto, inflammatory bowel disease, bowel atrophy, conditions characterizedby loss of bowel mucosa or bowel mucosal function, and other conditionsof the gastrointestinal tract, including those which may be broughtabout by exposure to cytotoxic agents, radiation, toxicity, infectionand/or injury. Moreover, these compounds of the invention may becombined with analgesics, anti-inflammatory agents, growth hormone,heparin, or any other therapies that may be used to treat inflammatorybowel disease or other conditions listed above.

In another embodiment GIP compounds can be useful for treating orpreventing gastritis, pancreatitis, Barrett's esophagus,Gastroesophageal Reflux Disease (GERD) and conditions associatedtherewith. Such conditions can include, but are not limited to,heartburn, heartburn accompanied by regurgitation of gastric/intestinalcontents into the mouth or the lungs, difficulty in swallowing,coughing, intermittent wheezing and vocal cord inflammation (conditionsassociated with GERD), esophageal erosion, esophageal ulcer, esophagealstricture, Barrett's metaplasia (replacement of normal esophagealepithelium with abnormal epithelium), and pulmonary aspiration. GIPcompounds can have anti-secretory properties, such as inhibition ofgastric acids, inhibition of bile acids, and inhibition of pancreaticenzymes. Moreover, GIP compounds can also have gastroprotective effects.Accordingly, GIP compounds of the invention may be particularly usefulin the treatment or prevention of gastritis, pancreatitis, Barrett'sesophagus, and/or GERD and related or associated conditions.

The present invention also relates to pharmaceutical compositionscomprising a therapeutically or prophylactically effective amount of atleast one novel GIP analog or GIP hybrid polypeptide of the invention,or a pharmaceutically acceptable salt thereof, together withpharmaceutically acceptable diluents, preservatives, solubilizers,emulsifiers, adjuvants and/or carriers useful in the delivery of the GIPcompound.

These and other aspects of the invention will be more clearly understoodwith reference to the following embodiments and detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B present views of the exendin-4 Trp-cage. FIG. 1A showsan NMR-derived ensemble structure of exendin-4 in 30% aqueoustrifluoroethanol. The Trp-cage can be seen folding back towards thecentral region of exendin. FIG. 1B shows a CPK view of the “Trp-cage”motif (residues 21-38) of a representative structure from thesolution-state NMR structure ensemble of exendin-4.

FIG. 2 presents sequences and receptor binding and glucose lowering(oral glucose tolerance test (OGTT) in non-diabetic NIH/Swiss mice)activities of reference sequences and novel GIP analog sequences of theinvention.

FIGS. 3A and 3B present suppression of glucose excursion following anOGTT, and basal glucose lowering activity of GIP and Compound G inNIH/Swiss mice. In FIG. 3A, bars represent mean ±sd, n=6-10. Peptide wasinjected IP at t=−5 into overnight-fasted NIH/Swiss mice. Gavage(1.5g/kg) was given at t=0. Sample was taken at t=30 min. Blood glucosewas measured with a OneTouch® Ultra® (LifeScan, Inc., a Johnson &Johnson Company, Milpitas, Calif.) * p<0.05 vs. vehicle control; ANOVA,Dunnett's test. In FIG. 3B, points represent mean ±sem, n=8-15. Peptidewas injected IP at t=0 immediately following baseline sample into 2-hourfasted NIH/Swiss mice. Samples were taken at t=60, 120, and 180 minutes.Blood glucose was measured with a OneTouch® Ultra® (LifeScan, Inc., aJohnson & Johnson Company, Milpitas, Calif.). *p<0.05 vs. vehiclecontrol; ANOVA, Dunnett's test. Compound No. G is(D-Ala2)GIP(1-30)-PSSGAPPPS (SEQ ID NO: 1) amide form: sequenceY(D-Ala)EGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2(SEQ ID NO:186).

FIG. 4 presents a comparison of the glucose lowering action of CompoundG with full length GIP and exendin-4 in diabetic db/db mice. Pointsrepresent mean±sem. n=6-10. Peptide was injected IP at t=0 immediatelyfollowing baseline sample into 2-hour fasted db/db mice. Samples weretaken at 60, 120, and 180 min. Blood glucose was measured with aOneTouch® Ultra® (LifeScan, Inc., a Johnson & Johnson Company, Milpitas,Calif.)* p<0.05 vs. vehicle control; ANOVA, Dunnett's test.

FIGS. 5A to 5D present examples of GIP phybrids comprising GIP andamylin/calcitonin-like analog peptides. The compounds would have bothGIP activity (e.g., glucose lowering) and reduction of gastric emptying.

FIG. 6 depicts the structures of various chemical groups mentionedherein.

FIG. 7 depicts the structures of various chemical Fmoc derivativesmentioned herein.

FIGS. 8A and 8B depict glucose lowering effect of novel GIP analogs. Thefigures demonstrate that a D-alanine substitution at position 2 in theanalogs herein improves glucose lowering ability. Points representmean±sem. Peptide was injected IP at t=0 immediately following baselinesample into 2-hour fasted NIH/Swiss mice. Samples were taken at t=60,120, 180 and 240 minutes. Blood glucose was measured with a OneTouch®Ultra® (LifeScan, Inc., a Johnson & Johnson Company, Milpitas, Calif.).*p<0.05 vs. vehicle control; ANOVA, Dunnett's test.

FIG. 9 depicts glucose lowering effect of novel GIP analogs,particularly the effect of a Trp-cage. Points represent mean±sem.Peptide was injected IP at t=0 immediately following baseline sampleinto 2-hour fasted NIH/Swiss mice. Samples were taken at t=60, 120, 180and 240 min. Blood glucose was measured with a OneTouch® Ultra®(LifeScan, Inc., a Johnson & Johnson Company, Milpitas, Calif.). *p<0.05vs. vehicle control; ANOVA, Dunnett's test.

FIGS. 10A and 10B depict glucose lowering effect of various analogs. Inthis example, Ac modification and a Pro3 substitution did notsignificantly enhance glucose lowering ability. Points representmean±sem. Peptide was injected IP at t=0 immediately following baselinesample into 2-hour fasted NIH/Swiss mice. Samples were taken at t=60,120, 180 and 240 min. Blood glucose was measured with a OneTouch® Ultra®(LifeScan, Inc., a Johnson & Johnson Company, Milpitas, Calif.). *p<0.05vs. vehicle control; ANOVA, Dunnett's test.

FIG. 11 demonstrates superior protease resistance of an exemplary GIPhybrid, 0601GIP3794 versus a native GIP.

FIGS. 12.15 to 12.65 depict further exemplary analogs and referencepeptides of the invention. It is intended that the various modificationsand variants shown are to be used in the present invention, and may becombined as discussed herein. For example, the terms exendin tail orexendin trp-cage motif includes any of the exendin tail variantsdepicted, which are useful as shield sequences (peptidic enhancers). Offurther interest are the frog GLP1 C-terminal extensions as shown in thefigures, which are yet another example of a shield sequence that can beused in place of an exendin tail.

FIGS. 13A and 13B demonstrate food intake inhibition and lowering ofblood glucose by GIP hybrids.

FIG. 14. Effect of GIP hybrids in food intake assay.

FIG. 15. Effect of GIP hybrid in food intake assay.

FIGS. 16A and 16B demonstrate effect of Compound 10 (also known asAC2307) (FIG. 16A) and sCT (FIG. 16B) in food intake assay.

FIG. 17 demonstrates effect of GIP hybrids on lowering of blood glucose.

FIGS. 18A and 18B depict cAMP production in whole cardiomyocytes fromreceptor activation in response to varying doses of test compound, humanGIP(1-42) free acid form (FIG. 18A) and GIP hybrid compound G (FIG.18B).

FIGS. 19A to 19E depict the response of mean arterial pressure (FIG.19A), heart rate (FIG. 19B), and rate of change in blood pressure(dP/dt, FIG. 19C), systolic pressure (FIG. 19D) and diastolic pressure(FIG. 19E) as determined by telemetry in conscious rats toadministration of GIP compounds. Mean arterial pressure is presented as% of predose values measured over the 30 minutes prior to drugadministration. FIG. 19C reflects the inotropic response to GIPcompounds. The rate of change of blood pressure (dP/dt) is indicative ofcardiac contractility.

FIGS. 20A, 20B and 20C depict the lack an acute effect of GIP(1-42) anda GIP DPP-IV-resistant-analog/exendin-tail hybrid on food intake incontrast to exendin-4. The pancreatic hormone amylin produced asignificant effect as expected.

FIG. 21 depicts the lack of effect on weight loss in diet-inducedobesity mice, in contrast to the effect of exendin-4.

FIG. 22 provides an alignment of mammalian and non-mammalian GIP.Positions Y1, E3, D9, S11, D15, F22, V23, L26, L27 and K32 are conservedacross all species.

FIGS. 23A and B depict beneficial activity of a GIP-amylin/sCT/amylinhybrid in slowing of gastric emptying and reducing intracellular calciumlevels.

FIG. 24 depicts further linkers useful in the invention.

FIG. 25 depicts the reduction of body weight by GIP-amylin familyhybrids of the invention.

FIG. 26 depicts the improvement of body composition by a lean-sparing,fat reducing activity of by GIP-amylin family hybrids of the invention.

FIG. 27 presents an exemplary pH versus solubility profile and a pHversus stability profile of a GIP analog.

DETAILED DESCRIPTION OF THE INVENTION

Gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1)are gut peptide hormones that exert potent glucoregulatory actionthrough their glucose-dependant stimulation of insulin secretion.Consequently, these incretin hormones have attracted great interest aspotential anti-diabetic agents with reduced risk for hypoglycemia.Whereas GLP-1, GLP-1 analogs and mimetics have been shown to beefficacious in controlling glucose levels in type 2 diabetic patients,the insulinotropic effect of GIP is reportedly significantly reduced indiabetic subjects, compared to normal individuals (16-18). Thepreservation of insulinotropic action of GLP-1 but not of GIP in thesame diabetic subjects suggests that GIP signal transduction is impairedin type 2 diabetes. Reduced GIP receptor expression in pancreatic betacells has been proposed to contribute to overall reduced incretineffects in diabetic subjects (19). Despite the reduced insulinotropicresponse to GIP in subjects with type 2 diabetes, it is possible thatadministration of elevated pharmacological doses of GIP or analoguescould have therapeutic utility. Of note, GIP lacks the gastrointestinaleffects of GLP-1 (20) that has limited the latter peptide's therapeuticwindow, thus permitting the possibility of higher dosing regimens (21).

One of the major hurdles in the therapeutic development of theseincretin hormones is their short duration of action due to enzymaticdegradation in vivo. The enzyme dipeptidyl peptidase IV (DPP-IV) plays akey role in the N-terminal cleavage of the peptides in vivo, and morerecently, neutral endopeptidase 24.11 (NEP) has also be implicated intheir degradation (22-26). Several studies have reported greater in vivoefficacy of DPP-1V resistant GIP analogues in rodent diabetic models(27-28).

Provided herein are novel GIP analogs and GIP-containing hybridpolypeptides, or derivatives thereof, which have enhanced or novelproperties, including enhanced DPP-IV resistance, dual hormonalactivity, and improved plasma half-life. Also provided are methods fortreating or preventing metabolic diseases and disorders including thosewhich can be alleviated by control of plasma glucose levels, insulinlevels, and/or insulin secretion, such as diabetes and diabetes-relatedconditions, and conditions and disorders including, but not limited to,hypertension, dyslipidemia, cardiovascular disease, eating disorders,insulin-resistance, obesity, and diabetes mellitus of any kind,including type 1, type 2, and gestational diabetes. The methods compriseadministering a therapeutically or prophylactically effective amount ofa GIP or GIP analog, fragment or derivative thereof or a novel GIPanalog or GIP hybrid or derivatives thereof as described herein, alone(monotherapy) or in combination with another agent or therapy (adjuncttherapy), for example a glucose lowering agent (e.g., antidiabetic) oragents or methods that inhibit or reduce gastric emptying (examples ofsuch agents are presented herein), to a subject in need thereof.

In addition to novel GIP analogs and derivatives, the present inventionrelates to novel, GIP-containing selectable hybrid polypeptides usefulas agents for the treatment and prevention of metabolic diseases anddisorders which can be alleviated by control of plasma glucose levels,insulin levels, and/or insulin secretion, such as diabetes anddiabetes-related conditions. Such conditions and disorders include, butare not limited to, hypertension, dyslipidemia, cardiovascular disease,eating disorders, insulin-resistance, obesity, and diabetes mellitus ofany kind, including type 1, type 2, and gestational diabetes.

In one aspect, the invention involves the modular assembly ofphysiologically, metabolically, and/or pharmacokinetically activepeptidic modules that may be selectable based on “bio-activities”, e.g.,therapeutic efficacy, scope of function, duration of action,physicochemical properties, and/or other pharmacokinetic properties.

Without intending to be limited by theory, the present invention relatesat least in part to a “toolbox” approach, wherein bio-active peptidehormone modules are linked in binary, tertiary or higher ordercombinations to create novel, efficacious therapeutic agents withselectable properties. The “bio-active peptide hormone modules” may bepeptide hormones, peptide fragments with hormonal activity, orstructural motifs of peptide hormones that impart chemical, metabolic,and/or other pharmacokinetic stability. The peptide hormones can includenative peptide hormones, as well as peptide hormone analogs andderivatives, as known in the art and described herein.

In one aspect of the invention, it has been found that the combinationof certain physicochemical characteristics of two or more peptidehormones into a single modality can facilitate intervention at severalpoints in a dysfunctional metabolic circuit. As such, in one aspect ofthe invention, rationally-designed hybrid polypeptides are provided thatintegrate selectable bio-activities into a single polypeptide agent. Inone embodiment, the selectable hybrid polypeptides of the invention mayinvolve the use of chemically stable linkers to covalently attach thebio-active modules. In another embodiment, the selectable hybridpolypeptides of the invention may involve the use of cleavable linkers,which themselves may be or form part of a bio-active module.

Again, without intending to be limited by theory, design of the hybridpolypeptides of the present invention may generally involve: (1) theidentification, selection and pairing of bio-active peptide hormonemodules for desired efficacy and therapeutic use, and (2) the covalentlinking of the bio-active modules (e.g. native peptide hormones, peptidehormone analogs or derivatives with hormonal activity, peptide hormonefragments with hormonal activity, stabilizing motifs, etc.) eitherdirectly or via a linker without loss of bio-activity of the componentmodules. In certain embodiments, module selection criteria may include,but not be limited to: (a) desired in vivo efficacy for desiredtherapeutic or prophylactic indication, such as an additive or asynergistic effect; (b) optional synergism or dual action of the linkedmodules for multiple therapeutic or prophylactic indications; and/or (c)a desired chemical stability, conformational stability, metabolicstability, bioavailability, organ/tissue targeting, receptorinteraction, protease inhibition, plasma protein binding, and/or otherpharmacokinetic characteristic.

GIP, GIP Analogs and Novel GIP Analogs. (The section headings are usedherein for organizational purposes only, and are not to be construed asin any way limiting the subject matter described.) Reference sequencesinclude human GIP, truncated GIP, human GLP-1, exendin-4, an exemplaryTrp-cage, and exemplary “shield” sequences (e.g. a short and a long“exendin tail”):

SEQ ID NO: Description Sequence   2 GIP(1-42)YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ-OH acid 293 GIP(1-30)YAEGTFISDYSIAMDKIHQQDFVNWLLAQK-NH2   4 GLP-1HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2   5 Exendin-4HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2   6 Ex-4 tail/long..........................KNGGPSSGAPPPS   1 Ex-4 tail/short..............................PSSGAPPPS   7 Trp-cage.....................FIEWLKNGGPSSGAPPPS 421 frog GLP-1 PKKIRYS “tail”

Useful in the therapies disclosed herein and in the novel GIP hybridsdisclosed herein, are native GIP peptide hormones, and functionalpeptide analogs and derivatives-thereof. Certain exemplary nativepeptides, peptide analogs and derivatives are described herein, howeverit should be recognized that any known GIP peptide that exhibitshormonal activity known in the art may be used either as a component ofa novel GIP analog or hybrid herein or in the novel adjunct therapiesdisclosed herein. In one embodiment, the GIP peptide analogs andderivatives have at least one hormonal activity of a native GIP peptide.In certain embodiments, the GIP peptide analogs are agonists of areceptor that a native GIP peptide is capable of specifically binding.Exemplary GIP peptide analogs and derivatives include those described inthe references herein, which are hereby incorporated by reference. Whilethe present application describes GIP polypeptide compounds as GIPanalogs, novel GIP analogs, and novel GIP hybrids for use in the methodsand therapies described herein, it is further intended that any suitableGIP agonist can be administered in place of a GIP compound, suchagonists include agonist antibodies and antibody fragments andderivatives, and small molecule GIP receptor agonists. Accordingly, whena GIP compound or polypeptide is indicated for use in a particulartherapeutic method, in another embodiment it is intended that a GIPagonist be used, particularly an agonist antibody or fragment orderivative thereof.

In serum, GIP is degraded by dipeptidyl peptidase IV (DPP-IV). Theresulting short biological half-life (about 2 minutes in vivo) limitsthe therapeutic use of GIP.

The following references relate to various GIP analogs that are usefulto provide as components for the novel GIP analogs and GIP hybrids ofthe present invention and find use in the novel therapies of the presentinvention based on their function on various target organs.

German Patent Application 19921537 discloses a method for extending thesurvival of insulin producing beta-cells by stimulation of theirproliferation and prevention of their programmed cell death. Thespecific goal is to increase the endogenous insulin content and insulinresponse to elevated blood glucose levels. An important component ofthis invention is the activation of protein kinase B/Akt in insulinproducing beta-cells in response to the administration of effectors suchas GLP-1, GIP, Exendin-4 or GLP-1 receptor agonists or GIP-receptoragonists.

European Patent Application 0479210 discloses GIP analogs of the formulaGIP(1-13)-X-GIP(15-30)-Y, wherein X is an amino acid residue other thanMet, and Y is selected from homoserine (inclusive homoserine-lactone)(referred to as “Hse”), homoserine amide (Hse-NH2),H-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln-Hse (SEQ ID NO: 8) orH-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln-Hse-NH2 (SEQ ID NO:9).

United States Patent Application 20030232761 by Hinke et al, publishedDec. 18, 2003, reports C-terminal truncated fragments and N-terminalmodified analogs of GIP as well as various GIP analogs with a reducedpeptide bond or alterations of the amino acids close to the dipeptidylpeptidase IV (DPP-IV)-specific cleavage site providing DPP-IV-resistanceand prolonged half-life. Also reported are analogs with differentlinkers between potential receptor binding sites of GIP.

WO98/24464 discloses an antagonist of glucose-dependent insulinotropicpolypeptide (GIP) consisting essentially of a 24 amino acid polypeptidecorresponding to positions 7-30 of the sequence of GIP, a method oftreating non-insulin dependent diabetes mellitus and a method ofimproving glucose tolerance in a non-insulin dependent diabetes mellituspatient.

WO 00/58360 and EP1171465 disclose peptides, which stimulate the releaseof insulin. This disclosure provides a process of N terminally-modifyingGIP and the use of the peptide analogues for treatment of diabetes. Thespecific peptide analog, which is disclosed in this invention, comprisesat least 15 amino acid residues from the N terminal end of GIP (1-42).In another embodiment, Tyr1-glucitol GIP (1-42) is disclosed.

WO 00/20592 discloses GIP or anti-idiotypic antibodies of GIP orfragments thereof as GIP-analogs for maintaining or increasing bonedensity or bone formation.

Kuhn-Wache et al. (2000) discloses analogs of GIP with increaseddipeptidyl peptidase IV resistance (Kuhn-Wache et al, in Langner &Ansorge, Cellular peptidases in Immune Functions and Diseases 2. KluwerAcademic/Plenum Publishers, 187-195.)

O'Harte et al. and Gault et al. have reported GIP(1-30)analogs—Tyr1-glucitol-GIP and (Pro3)GIP-displaying DPP-IV resistance andenhanced bioactivity. (O'Harte et al., NH2-terminally modified gastricinhibitory polypeptide exhibits amino-peptidase resistance and enhancedantihyperglycemic activity, Diabetes 48, 758-765 (1999)); and see Gaultet al. “Characterization of the cellular and metabolic effects of anovel enzyme-resistant antagonist of Glucose-dependent insulinotropicpolypeptide.” Biochemical and Biophysical Research Communications 290,1420-1426 (2002)).

Specific active GIP and GIP analogs known in the art include:

SEQ ID NO: Description Sequence  2 hGIP(1-42)YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ  3 hGIP(1-30)YAEGTFISDYSIAMDKIHQQDFVNWLLAQK 10 MouseYAEGTFISDYSIAMDKIRQQDFVNWLLAQRGKKSDWKHNITQ 11 RatYAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKNDWKHNLTQ 12 PigYAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWKHNITQ 13 BovineYAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWIHNITQ 14 GIP(1-14) YAEGTFISDYSIAM15 GIP(19-30) QQDFVNWLLAQK 16 GIP(3-42)EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ antagonist

Of particular interest are analogs modified at or near the dipeptidylpeptidase IV (DPP-IV) specific cleavage site, which improveDPP-IV-resistance and consequently prolong half-life Amino acidalterations include modifications of the first 3 or 4 residues of GIPand/or the bond between residues 2 and 3, which is cleaved by DPP-IV.Modifications and substitutions include N-terminal modifications,L-amino acids, D-amino acids, proteinogenic and non-proteinogenic aminoacids. Proteinogenic amino acids are defined as natural protein-derivedalpha-amino acids. Non-proteinogenic amino acids are defined as allother amino acids, which are not building blocks of common naturalproteins.

Of further interest are novel GIP analogs having one or moremodifications as described herein and that exhibit at least 50%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95% or at least 98% sequence identityto a native GIP(1-30), native GIP(1-26), native GIP(1-14), nativeGIP(1-39), native GIP(19-30), native GIP(19-26), native GIP(19-39),native GIP(19-42) or native GIP(1-42) over the entire length of the GIPportion.

Of particular interest are those GIP compounds comprising at least 11,12, 13, 14 or 15 amino acid residues from the N-terminal end of a GIP,e.g., GIP(1-42), having a least one amino acid substitution ormodification at position 1-3 and being biologically active. Thisincludes modification by fatty acid addition at an epsilon amino groupof at least one lysine residue, either present in or introduced into themolecule. Particular modifications include Tyr1-glucitol of a GIP, forexample Tyr1-Glucitol GIP(1-42) or Tyr1-glucitol GIP(1-30). GIP analogsof interest include those comprising a substitution or modificationselected from the group comprising D-amino acid substitutions in 1, 2and/or 3 positions and/or N-terminal glycation, alkylation, acetylationor acylation, or other N-terminal modifications described herein. Offurther interest are analogs wherein the amino acid in the 2 or 3position is substituted by lysine, serine, 4-amino butyric amino acid,Aib, D-alanine, Sarcosine or proline. Further exemplary substitutions inthe 1, 2, or 3 position, and more particularly in the 2 position of GIPare dAla, Val, dnorVal, dSer, Abu, dAbu, homo-Ser, d-homoSer, dPro,cyclopropyl Ala, d-cyclopropyl Ala, cycloHexyl Ala, d-cyclohexyl Ala,A(NMe), Aib, and cyclpropGly.

In one embodiment, a GIP analog or hybrid has a serine at position 2 inorder to reduce DPP-IV cleavage, while retaining receptor binding andactivation. Thus, specifically contemplated herein is a Ser2 analog ofeach of the GIP analogs and hybrids disclosed herein. By way of example,the analog of 0601GIP3794 having a serine substitution for the dAla atposition 2 is specifically contemplated.

Further exemplary GIP analog compounds have a modification at theN-terminus, retaining their GIP Receptor binding, in which theN-terminus modification includes H, isocap, isoBuOCO, octylglycine,Y(NMe) and succinoyl. Further exemplary GIP compounds include those withfatty acid modifications or combinations of modifications as describedherein, while retaining their GIP Receptor binding and receptoractivation activity, For example, an N-terminus modification can becombined with a substitution or modification at positions 1, 2 or 3(which imparts resistance to DPP-IV as described herein) or with a fattyacyl derivative modification (which can reduce renal clearance). Inanother example, a substitution or modification at positions 1, 2 or 3is combined with a fatty acyl derivative. For example an N-terminusoctylglycine is combined with a d-amino acid at 1, 2, or, particularly aD-Ala at position 2. In one embodiment a fatty acyl substitution is aoctylglycine for lysine at position 16 or methionine at position 14. Inother embodiments the methionine at position 14 is deleted, and which,for example, can be further combined with a octylglycine for lysine atposition 16 or 30. Another substitution is acylation of the lysine atposition 16 or 30, for example with an octyl or palmitoyl group. Otherembodiments include a fatty acyl substitution where an octylglycine issubstituted for lysine at position 16 or 30 or for methionine atposition 14. To eliminate or reduce oxidation, the methionine atposition 14 is deleted or substituted, for example with a leucine orother small hydrophobic amino acid, and/or the tryptophan at position 25is deleted or substituted, for example with a phenylalanine.

In one embodiment are analogs having at least one or two amino aciddeletions in amino acids 1-30 of GIP, those having one or two deletionsin amino acids 4 to 30, and those having one or more deletions in aminoacids 4-15, and those having one amino acid deletion in amino acids1-30, 4-30 or 4-15 of a GIP. Of course it is intended that such amodification can be combined with at least one other change as describedherein, such as a change that imparts DPP-IV resistance, reduces oreliminates oxidation, reduces renal clearance, improves receptorbinding, or improves receptor activation.

Further exemplary substitutions are those derived from GIP of other(non-human) species, for example the methionine 14 replaced by leucine,the D at position 9 or 21 replaced by E, the histidine 18 replaced byalanine, arginine or lysine, the lysine at position 30 replaced byalanine, arginine or histidine, the alanine at position 13 replaced byleucine, and the alanine at position 28 replaced by serine.

In one embodiment the GIP analogs have one or more of the followingmodifications: dAla2 to Abu, Ala, Gly, or Ser; Met14 to Leu; His18 toAla, Arg, or Lys; Asp21 to Glu; Lys30 to Arg or His; and/or anN-terminus as Gly(Oct).

Further exemplary GIP modifications and combinations are shown in thefollowing compounds:

SEQ ID NO: Sequence   3 YAEGTFISDYSIAMDKIHQQDFVNWLLAQK 433YaEGTFISDYSIALDKIAQQEFVNWLLAQR 434 YaEGTFISDYSIALDKIRQQEFVNWLLAQR 435YaEGTFISDYSIALDKIKQQEFVNWLLAQR 436 YaEGTFISDYSIALDKIAQQEFVNWLLAQH 437YaEGTFISDYSIALDKIRQQEFVNWLLAQH 438 YaEGTFISDYSIALDKIKQQEFVNWLLAQH 439YaEGTFISDYSIAMDKIHQVKFVNWLLAQK 440 YaEGTFISDYSIALDKIRQQEFVNWLLAQK 441YaEGTFISDYSIALDKIKQQEFVNWLLAQK 442 YaEGTFISDYSIALDKIAQQEFVNWLLAQK 443YaEGTFISDYSIALDKIRQQEFVNWLLAQH 444 YaEGTFTADYSKALDKIHQQDFVNWLLAQK 445YaEGTFTSDYSKALDKIHQQDFVNWLLAQK 446 YaEGTFISDYSKAMDKIRQQEFVNWLLAQK 447YaEGTFISDYSIALEKIRQQKFVNWLLAQK 448 YaEGTFISDYSIALDKIRQQDFVEWLLAQK 449YaEGTFISDYSIALDKIRQQEFVNWLLAQK 450 YaEGTFISDYSIALDKIRQQEFVNWLLAQK 451YaEGTFISDYSIAMDKIHQQLFIEWLKNGG 452 YaEGTFISDYSIAMDKIRQQEFVNWLLAQK 453YaEGTFISDYSIAMDKIHQQDFVNFLLAQK  17 YAEGTFISDYSIAMDKIHQQDFVNFLLAQK

Accordingly, it is intended that the modifications described herein canbe combined with at least one other change as described herein, such asa change that imparts DPP-IV resistance, reduces or eliminatesoxidation, reduces renal clearance, improves receptor binding, orimproves receptor activation. For example, intended are specific analogsthat have one or more replacements or modifications as described herein,such as a GIP D-Ala2 or L-Ala2 analog that also has a Phe for Trpreplacement at position 25.

GIP Hybrid Polypeptides.

Bio-Active Peptide Hormone Modules.

As discussed herein the GIP hybrid polypeptides of the present invention(also referred to as “phybrids”), generally comprise at least twobio-active peptide hormone modules covalently linked together, with aGIP peptide as one of the modules. The bio-active peptide hormonemodules may be: (a) native component peptide hormones, (b) analogs orderivatives of native component peptide hormones that retain hormonalactivity, (c) fragments of native component peptide hormones that retainhormonal activity, (d) fragments of analogs or derivatives of nativecomponent peptide hormones that retain hormonal activity, (e) structuralmotifs of native component peptide hormones that impart a desiredchemical stability, conformational stability, metabolic stability,bioavailability, organ/tissue targeting, receptor interaction, proteaseinhibition, plasma protein binding, and/or other pharmacokineticcharacteristic to the hybrid polypeptide; or (f) structural motifs ofanalogs or derivatives of native component peptide hormones that imparta desired chemical stability, conformational stability, metabolicstability, bioavailability, organ/tissue targeting, receptorinteraction, protease inhibition, plasma protein binding, and/or otherpharmacokinetic characteristic to the hybrid polypeptide. The structuralmotifs of (e) and (f) will collectively be referred to herein as“peptidic enhancers”. An example of a peptidic enhancer is a Trp cagesequence, particularly one derived from exendin-4, such as the Ex-4short or long tails.

Exemplary bio-active peptide hormone modules include native peptidehormones selected from: amylin, ADM, CT, CGRP, intermedin, CCK(1-33),CCK-8, leptin, PYY(1-36), PYY(3-36), an PYY-NPY chimera, GLP-1(1-37),GLP-1(7-37), GLP-1(7-36), GLP-2, OXM, exendin-3, exendin-4, catestatinfamily peptides, natriuretic peptide hormones, urocortin familypeptides, e.g., Ucn-2 and Ucn-3, neuromedin family peptides, e.g.neuromedin U25 or splice variants, and ANP, BNP, CNP or urodilatin.

Other exemplary bio-active peptide hormone modules include analogs andderivatives of a component peptide hormone selected from: amylin, ADM,CT, CGRP, intermedin, CCK, leptin, PYY(1-36), PYY(3-36), PYY-NPYchimera, GLP-1(1-37), GLP-1(7-37), GLP-1(7-36), GLP-2, OXM, a catestatinfamily peptide, a natriuretic peptide hormone, a urocortin familypeptide, e.g., Ucn-2 and Ucn-3, a neuromedin family peptide, e.g.neuromedin U25 or splice variants, exendin-3, and exendin-4, wherein theanalog or derivative exhibits at least one hormonal activity of thecomponent peptide hormone. The analog may comprise one or moreinsertions, deletions, or substitutions of the amino acid sequence ofthe component peptide hormone, and the derivative may comprise one ormore chemical modifications of an amino acid residue of an analog orcomponent peptide hormone, as described more fully herein and known inthe art.

More specifically, analogs and derivatives may be selected from anydescribed above and/or known in the art. Particularly exemplary analogsand derivatives that exhibit at least one hormonal activity useful asbio-active peptide hormone modules of the invention include thefollowing:

Amylin: ²Ala-h-amylin, ^(2,7)Ala-h-amylin, ²⁸Pro-h-amylin,^(25,28)Pro-h-amylin, ^(25,28,29)Pro-h- amylin, ²⁵Pro, ²⁶Val,^(28,29)Pro-h-amylin, ¹⁸Arg, ^(25,28)Pro-h-amylin, ¹⁸Arg,^(25,28,29)Pro-h- amylin, ²⁵Pro, ²⁶Val, ^(28,29)Pro-h-amylin, ¹⁸Arg,²³Leu, ^(25,28,29)Pro-h-amylin, ¹⁸Arg²³Leu, ^(25,28)Pro-h-amylin, and2,7-Cyclo-[²Asp,⁷Lys]-h-amylin CT: ¹⁴Glu-sCT, ¹⁸Arg-sCT,^(11,18)Arg-sCT, ¹⁴Glu, ¹⁸Arg-sCT, ¹⁴Glu, ^(11,18)Arg-Sct CGRP:³⁶D-Ser-CGRP, ³⁶D-Thr-CGRP, ³⁶D-Asp-CGRP, ³⁶D-Asn-CGRP, ³⁶Ser-CGRP,³⁶Hse-CGRP, ³⁶Asp-CGRP, ³⁶Thr-CGRP, ³⁶Asn-CGRP AFP-6:TQAQLLRVGCGNLSTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY (SEQ ID NO: 18),TQAQLLRVGCDTATCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY (SEQ ID NO: 19),TQAQLLRVGMVLGTMQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY (SEQ ID NO: 20),TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVEPSSPHSY (SEQ ID NO: 21),TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQESAPVEPSSPHSY (SEQ ID NO: 22), CCK:DY(OSO₃H)MGWMDF (SEQ ID NO: 23), DYMGWMDF (SEQ ID NO: 24), MGWMDF (SEQID NO: 25), GWMDF (SEQ ID NO: 26), WMDF (SEQ ID NO: 27),KDY(OSO₃H)MGWMDF (SEQ ID NO: 28), KDYMGWMDF (SEQ ID NO: 29), KMGWMDF(SEQ ID NO: 30), KGWMDF (SEQ ID NO: 31), KWMDF (SEQ ID NO: 32) Leptin:⁴³Asp-leptin, ⁴³Glu-leptin, ⁴⁸Ala-leptin, ⁴⁹Glu-leptin, ⁴⁹Des-AA-leptin,⁷⁵Ala-leptin, ⁸⁹Leu-leptin, ⁹³Asp-leptin, ⁹³Glu-leptin, ⁹⁸Ala-leptin,¹³⁹Leu-leptin, PYY: ³Leu-PYY, ³Val-PYY, ⁴Arg-PYY, ⁴Gln-PYY, ⁴Asn-PYY,²⁵Lys-PYY, ³⁴Pro-PYY, ³⁴His-PYY, ^(1,36)Tyr-PYY, ¹³Pro¹⁴Ala-PYY,³¹Leu³⁴Pro-PYY, des-AA-4-PYY GLP-1 ⁹Gln-GLP-1(7-37), D-⁹Gln-GLP-1(7-37),¹⁶Thr-¹⁸Lys⁻GLP-1(7-37), ¹⁸Lys-GLP- 1(7-37), ⁸Gly-GLP-1 (7-36),⁹Gln-GLP-1 (7-37), D-⁹Gln-GLP-1 (7-37), acetyl-⁹Lys- GLP-1(7-37),⁹Thr-GLP-1(7-37), D-⁹Thr-GLP-1 (7-37), ⁹Asn-GLP-1 (7-37), D- ⁹Asn-GLP-1(7-37), ²²Ser²³Arg²⁴Arg²⁶Gln-GLP-1(7-37), ¹⁶Thr¹⁸Lys-GLP-1(7-37),¹⁸Lys-GLP-1(7-37), ²³Arg-GLP-1(7-37), ²⁴Arg-GLP-1(7-37) GIP Y-dAla²-GIPExendin ¹⁴Leu, ²⁵Phe-exendin-4, ¹⁴Leu, ²⁵Phe-exendin-4, ⁵Ala, ¹⁴Leu,²⁵Phe-exendin-4, and ¹⁴Leu, ²²Ala, ²⁵Phe-exendin-4.

As known in the art, such peptide compounds may preferably be amidated,but within the context of the present invention, may optionally be inthe acid form unless otherwise specified.

Still other exemplary bioactive peptide hormone modules includefragments of a component peptide hormone selected from: amylin, ADM, CT,CGRP, intermedin, CCK, leptin, PYY(1-36), PYY(3-36), GLP-1(1-37),GLP-1(7-37), GLP-1(7-36), GLP-2, OXM, a natriuretic peptide, a urocortinfamily peptide, e.g., Ucn-2 and Ucn-3, a neuromedin family peptide, e.g.neuromedin U25 or splice variant, exendin-3, and exendin-4, wherein thefragment exhibits at least one hormonal activity of the componentpeptide hormone.

Yet other exemplary bioactive peptide hormone modules include fragmentsof analogs or derivatives of a component peptide hormone selected from:amylin, ADM, CT, CGRP, intermedin, CCK, leptin, PYY(1-36), PYY(3-36),the specific PYY-NPY chimera sequences disclosed herein, GLP-1(1-37),GLP-1(7-37), GLP-1(7-36), GLP-2, human catestatin, OXM, ANP, BNP, CNP,urodilatin, Ucn-2 and Ucn-3, neuromedin U25 or splice variant,neuromedin S, exendin-3 and exendin-4, wherein the fragment exhibits atleast one hormonal activity of the component peptide hormone. Again, theanalog may comprise one or more insertions, deletions, or substitutionsof the amino acid sequence of the component peptide hormone, and thederivative may comprise one or more chemical modifications of an aminoacid residue of an analog or component peptide hormone, as describedmore fully herein and known in the art.

Certain exemplary fragments that exhibit at least one hormonal activityinclude the following. However, it should be understood thatcombinations of the above-described analogs and derivatives taken withfragments known in the art, including the exemplary fragments describedherein, are contemplated.

Amylin: amylin(1-36), amylin(1-35), amylin(1-20), amylin(1-18),amylin(1-17), amylin(1-16), amylin(1-15), amylin(1-7) CT: CT(8-32),CT(8-27), CT(8-26), CT(8-10), CT(18-26), CT(18-27) AFP-6: AFP-6(18-27)CCK: CCK-8, CCK-5, CCK-4 Leptin: leptin (22-167), leptin(56-73) PYY:PYY(1-35), PYY(1-30), PYY(1-25), PYY(1-15), PYY(1-10), PYY(2-36),PYY(3-36), PYY(4-36), PYY(5-36) GLP-1 GLP-1(7-37), GLP-1(7-36),GLP-1(7-35) GIP GIP(1-14), GIP(1-30) or longer, GIP(1-39) or longerExendin exendin-4(1-27), exendin-4(1-28), exendin-4(1-29),exendin-4(1-30) or longer

Again, as known in the art, such peptide compounds may preferably beamidated, but within the context of the present invention, mayoptionally be in the acid form unless otherwise specified. Further, theabove exemplary fragments may be combined with any of the analogs orderivatives discussed herein or known in the art. For example, exemplaryanalog fragments may include ⁵Ala, ¹⁴Leu, ²⁵Phe-exendin-4(1-28), ¹⁴Leu,²⁵Phe-exendin-4(1-27), ⁵Ala, ¹⁴Leu, ²⁵Phe-exendin-4(1-28), ¹⁴Leu,²⁵Phe-exendin-4(1-27), or any other combinations of the disclosedfragments, analogs, and derivatives. Further embodiments include NN2211and ZP-10.

Yet other exemplary bio-active peptide modules include “peptidicenhancer”, i.e., structural motifs of component peptide hormones(including analogs and derivatives thereof) that impart a desiredchemical stability, conformational stability, metabolic stability,bioavailability, organ/tissue targeting, receptor interaction, proteaseinhibition, plasma protein binding, and/or other pharmacokineticcharacteristic to the hybrid polypeptide. Exemplary peptidic enhancersinclude the following.

Amylin Family amylin(32-37), amylin(33-37), amylin(34-37),amylin(35-37), amylin(36-37), amylin(37), ADM(47-52), ADM(48-52),ADM(49-52), ADM(50-52), ADM(51-52), ADM(52), CT(27-32), CT(27-32),CT(28-32), CT(29-32), CT(30-32), CT(31-32), CT(32), CGRP(32-37),CGRP(33-37), CGRP(34-37), CGRP(35-37), CGRP(36-37), CGRP(37), intermedin(42-47), intermedin (43-47), intermedin (44-47), intermedin (45-47),intermedin (46-47), intermedin (47) PYY PYY(25-36), PYY(26-36),PYY(27-36), PYY(28-36), PYY(29-36), PYY(30-36), PYY(31-36), PYY(32-36),PYY(25-35), PYY(26-35), PYY(27-35), PYY(28-35), PYY(29-35), PYY(30-35),PYY(31-35), PYY(32-35); PPY-NPY chimera Ile, Lys, Pro, Glu, His, Pro,Gly, Glu, Asp, Ala, Ser, Pro, Glu, Glu, Leu, Ala, Arg, Tyr, Tyr, Ala,Ser, Leu, Arg, Ala, Tyr, Ile, Asn, Leu, Ile, Thr, Arg, Gln, Arg, Tyr(SEQ ID No. 454) GLP-1 and 2 frog GLP-1(29-37); frog GLP-1(30-37); frogGLP-2(24-31), frog GLP-2(25-31) GIP GIP(31-42), GIP(32-42), GIP(33-42),GIP(34-42), GIP(35-42), GIP(36-42), GIP(37-42), GIP(38-42), GIP(39-42),GIP(40-42), GIP(41-42), GIP(42) Exendin-4 exendin-4(31-39),exendin-4(32-39), exendin-4(33-39), exendin-4(34-39), exendin-4(35-39),exendin-4(36-39), exendin-4(37-39), exendin-4(38-39), exendin-4(39)

Again, it should be understood that combinations of the above-describedGIP analogs and derivatives taken together with the bio-active peptidemodules described herein are contemplated. For example, the last sixamino acid residues of amylin family peptide hormone analogs andderivatives known in the art and/or described above are alsocontemplated as exemplary bio-active peptide modules. For example, asfurther discussed herein, the peptidic enhancer Ex-4 short tail, whichis an exemplary Trp-Cage sequence, or analog thereof, is added to theC-terminus of any GIP analog, and in further embodiments the peptidicenhancer is attached using a linker.

In one aspect, the novel GIP hybrid include a GIP portion exhibiting atleast 50%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95% or at least 98%sequence identity to a native GIP(1-30), native GIP(1-26), nativeGIP(1-14), native GIP(1-39), native GIP(19-30), native GIP(19-26),native GIP(19-39), native GIP(19-42) or native GIP(1-42) over the entirelength of that GIP portion.

Accordingly, in certain embodiments the GIP portion of a GIP hybrid cancomprise a trp-cage motif. Such desirable GIP hybrids include anN-terminal GIP or novel GIP analog fragment in combination with aC-terminal polypeptide or fragment thereof having a glucose loweringactivity (e.g., antidiabetics, exendin) or the ability to inhibit orreduce gastric emptying. Such desirable GIP hybrids include anN-terminal GIP fragment or novel GIP analog fragment in combination witha C-terminal exendin, GLP1, pramlintide, amylin, CCK, gastrin, PYY,secretin, GRP, neuromedins, urocortin, calcitonin, or salmon calcitonin,or fragment thereof. In other embodiments desirable GIP hybrids includea C-terminal GIP or novel GIP analog fragment in combination with anN-terminal polypeptide or fragment thereof having a glucose loweringactivity (e.g., antidiabetics, exendin) or the ability to inhibit orreduce gastric emptying. In such embodiments, the chimeric polypeptidescan include a C-terminal GIP, a novel GIP analog (in which case aTrp-cage forming sequence is present), or fragment thereof, incombination with a N-terminal exendin, GLP1, pramlintide, amylin, CCK,gastrin, PYY, secretin, GRP, neuromedins, urocortin, calcitonin, orsalmon calcitonin, or fragment thereof.

In other embodiments the GIP or novel GIP analog is combined with agastrin/CCK receptor ligand; an amylin receptor ligand; a calcitoninreceptor ligand; an CGRP receptor ligand, a PYY receptor ligand, an EGFreceptor ligand; a Glucagon-like peptide 1 receptor ligand; aGlucagon-like peptide 2 receptor ligand; a gastric inhibitorypolypeptide (GIP) receptor ligand; a keratinocyte growth factor (KGF)receptor 1 ligand; a dipeptidyl peptidase IV inhibitor; a REG proteinreceptor ligand; a Growth Hormone receptor ligand; a Prolactin (PRL)receptor ligand; an Insulin-like Growth Factor (IGF) receptor ligand;PTH-related protein (PTHrP) receptor ligand; hepatocyte growth factor(HGF) receptor ligand; a bone morphogenetic protein (BMP) receptorligand, a transforming growth factor (TGF receptor ligand; a lamininreceptor ligand; a vasoactive intestinal peptide (VIP) receptor ligand;a fibroblast growth factor (FGF) receptor ligand; a nerve growth factor(NGF) receptor ligand; an islet neogenesis associated protein (INGAP)receptor ligand; an Activin-A receptor ligand; a vascular endothelialgrowth factor (VEGF) receptor ligand; an erythropoietin (EPO) receptorligand; a pituitary adenylate cyclase activating polypeptide (PACAP)receptor ligand; a granulocyte colony stimulating factor (G-CSF)receptor ligand; a granulocyte-macrophage colony stimulating factor(GM-CSF); a platelet-derived growth factor (PDGF) receptor ligand, and asecretin receptor ligand.

The polypeptides of the present invention will preferably retain, atleast in part, a biological activity of native human GIP, e.g., thepolypeptides of the present invention will generally be GIP agonists orantagonists. In one embodiment, the polypeptides of the presentinvention will exhibit biological activity in the treatment andprevention of metabolic conditions and disorders. Further, the novel GIPanalog polypeptides of the invention may include internal linkercompounds, may include chemical modifications at internal amino acidresidues, or may be chemically modified at the N-terminal or C-terminalresidue. In yet another embodiment, the polypeptides of the inventioninclude only natural L amino acid residues and/or modified natural Lamino acid residues. Alternatively, in another embodiment, thepolypeptides of the invention do not include unnatural amino acidresidues.

In exemplary GIP hybrid embodiments, the GIP portion comprises a GIPN-terminal region modified or substituted to provide DPP-IV resistancesuperior to that of native GIP.

Exemplary Peptide Component Families.

Native peptide hormones are known in the art, as are their analogs andderivatives. For reference, the sequences of several native peptidehormones are provided herein.

Exemplary Peptide Hormones

Seq ID Description Sequence 33 Rat AmylinKCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTY 34 h-AmylinKCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 35 h-ADMYRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDN VAPRSKISPQGY 36 s-CTCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP 37 h-CTCGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP 38 h-CGRP αACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF 39 h-CGRP βACNTATCVTHRLAGLLSRSGGMVKSNFVPTNVGSKAF 40 h-AFP-6 (1-47)TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPV DPSSPHSY 41 h-AFP-6 (8-47)VGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY 42 Mouse AFP-6 (1-47)PHAQLLRVGCVLGTCQVQNLSHRLWQLVRPAGRRDSAPVD PSSPHSY 43 Mouse AFP-6 (8-47)VGCVLGTCQVQNLSHRLWQLVRPAGRRDSAPVDPSSPHSY 289 CCK-8-sulfatedDY(SO₃)MGWMDF 45 h-Leptin MHWGTLCGFLWLWPYLFYVQAVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASGYSTEVVALSRLQGSLQDMLWQLDLSP GC 46 h-PYYYPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY 47 h-PYY (3-36)IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY 48 hGLP-1 (1-37)HDEFERHAEGTFTSDVSSTLEGQAALEFIAWLVKGRG 49 Frog GLP-1HAEGTYTNDVTEYLEEKAAKEFIEWLIKGKPKKIRYS-OH; 50 Frog GLP-1HAEGTFTSDVTQQLDEKAAKEFIDWLINGGPSKEIIS-OH 51 h-GLP-1 (7-36)HAEGTFTSDVSSYLEGQAALEFIAWLVKGR 52 h-GLP-2HADGSFSDEMNTILDNLAARDFINWLIETKITD 53 Frog GLP-2HAEGTFTNDMTNYLEEKAAKEFVGWLIKGRP-OH 54 OXMHSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA 55 Exendin-3HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS 5 Exendin-4HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS 423 Urocortin II (Mouse)VILSLDVPIGLLRILLEQARYKAARNQAATNAQILAHV-NH2 424 WP-24 (Urocortin)WSPGARNQGGGARALLLLLAERFP-OH 425 TV-18 (Urocortin) TQSQRERAEQNRIIFDSV-NH2426 Human Urocortin DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2 427SE-20 (Urocortin- SFHYLRSRDASSGEEEEGKE-OH 111/Stresscopin) 428AI-13 (Urocortin- AQAAANAHLMAQI-OH III/Stresscopin) 429DA-21 (Urocortin) DNPSLSIDLTFHLLRTLLELA-OH 430 TL-26 (Urocortin-III/TKFTLSLDVPTNIMNLLFNIAKAKNL-OH Stresscopin) 431 Human Urocortin IIIFTLSLDVPTNIMNLLFNIAKAKNLRAQAAANAHLMAQI-NH2 432 FN-38 (SLM14)FLFHYSKTQKLGKSNVVEELQSPFASQSRGYFLFRPRN-NH2 456 alpha-Atrial NatriureticSLRRSSCFGGRMDRIGAQSGLGCNSFRY-OH Polypeptide (1-28)human, porcine, bovine 485 Brain natriuretic peptide,c(NSKMAHSSSCFGQKIDRIGAVSRLGCDGLRLF)-OH Rat; BNP, Rat 486Brain Natriuretic Peptide SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH-OH(BNP) (human) 487 C-TYPE Natriuretic GLSKGCFGLKLDRIGSMSGLGC-OHpeptide, Porcine; Cnp, Porcine 488 Neuromedin U-8 YFLFRPRN-NH2 (porcine)489 Neuromedin U (rat) YKVNEYQGPVAPSGGFFLFRPRN-NH2 490 Neuromedin U-9GYFLFRPRN-NH2 491 Neuromedin (U25), FRVDEEFQSPFASQSRGYFLFRPRN-NH2 human

These peptides are generally C-terminally amidated when expressedphysiologically, but need not be for the purposes of the instantinvention. In other words, the C-terminus of these peptides, as well asthe GIP hybrid polypeptides of the present invention, may have a free—OH or —NH2 group. These peptides may also have other post-translationalmodifications. One skilled in the art will appreciate that the hybridpolypeptides of the present invention may also be constructed with anN-terminal methionine residue.

Exemplary peptide modules for use in the invention further include,N-terminally extendable peptide modules (and their analogs andfragments) including Apelin, which exists in 2 forms, Apelin 36 and 13,both active at the AJP receptor (LVQPRGSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF-OH(SEQ ID NO: 493) and pERPRLSHKGPMPF-OH (SEQ ID NO:494)); ProlactinReleasing peptide, which exists in 2 forms, PRP31 and PRP20, equallyactive at GPR10 (SRTHRHSMEIRTPDINPAWYASRGIRPVGRF-NH2 (SEQ ID NO: 495)and TPDINPAWYASRGIRPVGRF-NH2 (SEQ ID NO: 496)); Gastrin, which exists asbig gastrin and mini-gastrin, the bulk of activity however residing inresides in pentagastrin (QLGPQGPPHLVADPSKKQGPWLEEEEEAYGWMDF-NH2 (SEQ IDNO: 497); pEGPWLEEEEEAYGWMDF-NH2 (SEQ ID NO: 498); beta-AWMDF-NH2 (SEQID NO: 499)); CCK, which exists as CCK33 or CCK8 (central vs.peripheral; KAPSGRMSIVKNLQNLDPSHRISDRDYMGWMDF-NH2 (SEQ ID NO: 500);DYMGWMDF-NH2) (SEQ ID NO: 55); Cortistatin, which exists as cortistatin17 or 29 (QEGAPPQQSARRDRMPCRNFFWKTFSSCK-OH (SEQ ID NO: 501) andDRMPCRNFFWKTFSSCK-OH (SEQ ID NO: 502)); somatostatin, which exists assomatostatin 14 or 28 (SANSNPAMAPRERKAGCKNFFWKTFTSC-OH (SEQ ID NO: 503);AGCKNFFWKTFTSC-OH (SEQ ID NO: 504)); GRP for which a C-terminal 10 aminoacid sequence possesses most of the activity(VPLPAGGGTVLTKMYPRGNHWAVGHLM-NH2 (SEQ ID NO: 505); GNHWAVGHLM-NH2 (SEQID NO: 506)); Neuromedin B for which a C-terminal 10 amino acid regionpossesses most of the activity (LSWDLPEPRSRASKIRVHSRGNLWATGHFM-NH2 (SEQID NO: 507); GNLWATGHFM-NH2 (SEQ ID NO: 508)); Neuromedin S for which aC-terminal 9 amino acid region possesses most of the activity(ILQRGSGTAAVDFTKKDHTATWGRPFFLFRPRN-NH2 (SEQ ID NO: 492); PFFLFRPRN-NH2(SEQ ID NO: 509)); Neuromedin U for which a C-terminal 9 amino acidregion possesses most of the activity (FRVDEEFQSPFASQSRGYFLFRPRN-NH2(SEQ ID NO: 491); GYFLFRPRN-NH2 (SEQ ID NO: 490)); Neurotensin, whichexists as long and short forms (KIPYILKRQLYENKPRRPYIL-OH (SEQ ID NO:510); QLYENKPRRPYIL-OH) (SEQ ID NO: 511); Kiss-1 whose activity liesmainly in its C-terminus(GTSLSPPPESSGSPQQPGLSAPHSRQIPAPQGAVLVQREKDLPNYNWNSFGLRF-NH2 (SEQ ID NO:512); EKDLPNYNWNSFGLRF-NH2 (SEQ ID NO: 513)); RF-amide-3, whoseC-terminal fragments possess activity(SAGATANLPLRSGRNMEVSLVRRVPNLPQRF-NH2 (SEQ ID NO: 514); VPNLPQRF-NH2 (SEQID NO: 515)); Dynorphin, which exists as big dynorphin (A) of dynorphinB (rimorphin) (YGGFLRRIRPKLKWDNQKRYGGFLRRQFKVVT-OH (SEQ ID NO: 516) andYGGFLRRQFKVVT-OH (SEQ ID NO: 517)); PYY whose C-terminal fragments areactive at Y2 receptor (YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2 (SEQ IDNO: 46); SLRHYLNLVTRQRY-NH2 (SEQ ID NO: 518)); AFP-6 whose 7-47 regionretains activity (TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY-NH2(SEQ ID NO: 40); VGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY-NH2 (SEQ IDNO: 41)); the amylin family including adrenomedullin, calcitonin andCGRP; Oxytocin whose C-terminal amide is generally needed for activityand can tolerate N-terminal extensions.

Exemplary peptide modules for use in the invention further include,C-Terminally extendable peptide modules including, Endothelin I, II andIII: ETI (CSCSSLMDKECVYFCHLDIIWVNTPEHVVPYGLGSPRS-OH (SEQ ID NO: 519);CSCSSLMDKECVYFCHLDIIW-OH (SEQ ID NO: 529)), ETII(CSCSSWLDKECVYFCHLDIIWVNTPEQTAPYGLGNPP-OH (SEQ ID NO: 521);CSCSSWLDKECVYFCHLDIIW-OH (SEQ ID NO: 522)) and ETIII(CTCFTYKDKECVYYCHLDIIWINTPEQTVPYGLSNYRGSFR-NH2 (SEQ ID NO: 523);CTCFTYKDKECVYYCHLDIIW-OH (SEQ ID NO: 524)); ghrelin whose activity liesmainly in its first 10 residues (GSSFLSPEHQRVQQRKESKKPPAKLQP-OH (SEQ IDNO: 525); GSSFLSPEHQ-OH (SEQ ID NO: 526)); glucagons, includingoxyntomodulin which is a C-terminally extended glucagon withglucagons-like activity (HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-OH (SEQID NO: 527); HSQGTFTSDYSKYLDSRRAQDFVQWLMNT-OH (SEQ ID NO: 528));GLP-1/GLP-2 whose activities are retained with or without a C-terminalamide; GIP, which circulates in 2 forms, GIP1-42 and GIP1-30, both fullyactive at GIP Receptor (YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ-OH(SEQ ID NO: 529); YAEGTFISDYSIAMDKIHQQDFVNWLLAQK-NH2 (SEQ ID NO: 530));neuropeptide W, which exists as NPW23 and NPW30, equally active at GPR7and 8 (WYKHVASPRYHTVGRAAGLLMGLRRSPYLW-OH (SEQ ID NO: 531);WYKHVASPRYHTVGRAAGLLMGL-OH (SEQ ID NO: 532)); PACAP which exists in 2forms, PACAP27 and 38 (HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2 (SEQID NO: 533); HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2 (SEQ ID NO: 534)); PHI andPHV (HADGVFTSDFSKLLGQLSAKKYLESLMGKRVSSNISEDPVPV-OH (SEQ ID NO: 535);HADGVFTSDFSKLLGQLSAKKYLESLM-NH2 (SEQ ID NO: 536)); GRF, which exists in2 forms GRF29 and GRF40(YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2 (SEQ ID NO: 537);YADAIFTNSYRKVLGQLSARKLLQDIMS-OH (SEQ ID NO:538)); PTH 1-34 and 1-37forms which possess activity of full length PTH 1-84(SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNVLTKAKSQ (SEQ ID NO: 539);SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVAL-OH (SEQ ID NO: 540);SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF-OH (SEQ ID NO: 541)) PTH-RP for which1-36 possesses activity of full length 1-86(AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEIRATSEVSPNSKPSPNTKNHPVRFGSDDEGRYLTQETNKVETYKEQPLKTPGKKKKGKP-NH2 (SEQ ID NO: 542);AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEI-OH (SEQ ID NO:543)) gamma-MSH forwhich the shorter gamma-MSH1 and the longer gamma-MSH3 have similaractivities (YVMGHFRWDRFGRRNSSSSGSSGAGQ-OH (SEQ ID NO: 544);YVMGHFRWDRF-NH2 (SEQ ID NO: 545)); MSH for which alpha-MSH is an activeportion of ACTH (SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF-OH (SEQ ID NO:546); SYSMEHFRWGKPV-NH2 (SEQ ID NO: 547)); and endorphins for which theA, delta, and γ endorphin are active subpeptides of the larger βendorphin (YGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE-OH (SEQ ID NO: 548);YGGFMTSEKSQTPLVTLFKNAIIKNAY-OH (SEQ ID NO:549); YGGFMTSEKSQTPLVTL-OH(SEQ ID NO: 373); YGGFMTSEKSQTPLVT-OH (SEQ ID NO: 550)).

For example, the melanocortins are peptides from thepro-opiomelanocortin gene, including alpha-melanocyte-stimulatinghormone (alpha-MSH) and adrenocorticotrophic hormone (ACTH), and fivemelanocortin receptors are known, MC1-5R. MC4R appears to play a role inenergy balance and obesity. See, for example, Anderson et al., ExpertOpin. Ther. Patents 11:1583-1592 (2001), Speake et al., Expert Opin.Ther. Patents 12:1631-1638 (2002), Bednarek et al., Expert Opin. Ther.Patents 14:327-336 (2004).

It is also intended that in addition to comprising a GIP hybrid, inother embodiments the hormones described herein can be used in adjuncttherapy, co-administered with, a GIP analog of the invention.

The Amylin Family. As discussed herein component peptide hormones usefulin the present invention with a GIP or a novel GIP analog include amylinfamily peptide hormones including amylin, adrenomedullin (“ADM”),calcitonin (“CT”), calcitonin gene related peptide (“CGRP”), intermedin(also known as “AFP-6”) and related peptides. Native amylin familypeptide hormones are known in art, as are functional peptide analogs andderivatives. Certain exemplary native peptides, peptide analogs andderivatives are described herein, however it should be recognized thatany known amylin family peptides that exhibit hormonal activity known inthe art may be used in conjunction with the present invention. Anyamylin analog or derivative known in the art may be used in conjunctionwith the present invention.

Another family of peptide hormones implicated in metabolic diseases anddisorders is the amylin family of peptide hormones, including amylin,calcitonin, calcitonin gene related peptide, adrenomedullin, andintermedin (also known as “AFP-6”). Amylin is a 37-amino acid peptidehormone. It was isolated, purified and chemically characterized as themajor component of amyloid deposits in the islets of pancreases of humanType 2 diabetics (Cooper et al., Proc. Natl. Acad. Sci., USA,84:8628-8632 (1987)). The amylin molecule has two post-translationalmodifications: the C-terminus is amidated, and the cysteines inpositions 2 and 7 are cross-linked to form an N-terminal loop. Thesequence of the open reading frame of the human amylin gene shows thepresence of the Lys-Arg dibasic amino acid proteolytic cleavage signal,prior to the N-terminal codon for Lys, and the Gly prior to the Lys-Argproteolytic signal at the N-terminal position, a typical sequence foramidation by protein amidating enzyme, PAM (Cooper et al., Biochem.Biophys. Acta, 1014:247-258 (1989)). By “adrenomedullin” or “ADM” ismeant the human peptide hormone and species variants thereof. Moreparticularly, ADM is generated from a 185 amino acid preprohormonethrough consecutive enzymatic cleavage and amidation. This processculminates in the liberation of a 52 amino acid bioactive peptide. By“calcitonin” or “CT” is meant the human peptide hormone and speciesvariants thereof, including salmon calcitonin (“sCT”). Moreparticularly, CT is a 32 amino acid peptide cleaved from a largerprohormone. It contains a single disulfide bond, which causes the aminoterminus to assume the shape of a ring. Alternative splicing of thecalcitonin pre-mRNA can yield a mRNA encoding calcitonin gene-relatedpeptide; that peptide appears to function in the nervous and vascularsystems. The calcitonin receptor has been cloned and shown to be amember of the seven-transmembrane, G protein-coupled receptor family. By“calcitonin gene related peptide” or “CGRP” is meant the human peptidehormone and species variants thereof, in any physiological form. By“intermedin” or “AFP-6” is meant the human peptide hormone and speciesvariants thereof, in any physiological form.

Amylin is believed to regulate gastric emptying, and suppress glucagonsecretion and food intake, thus regulating the rate of glucoseappearance in the circulation. It appears to complement the actions ofinsulin, which regulates the rate of glucose disappearance from thecirculation and its uptake by peripheral tissues. These actions aresupported by experimental findings in rodents and humans, which indicatethat amylin complements the effects of insulin in postprandial glucosecontrol by at least three independent mechanisms, all of which affectthe rate of glucose appearance. First, amylin suppresses postprandialglucagon secretion. Compared to healthy adults, patients with type 1diabetes have no circulating amylin and patients with type 2 diabeteshave diminished postprandial amylin concentrations. Furthermore,infusion of an amylin specific monoclonal antibody, which boundcirculating amylin, again resulted in greatly elevated glucagonconcentrations relative to controls. Both of these results point to aphysiological role of endogenous amylin in the regulation ofpostprandial glucagon secretion. Second, amylin slows gastrointestinalmotility and gastric emptying. Finally, intrahypothalamic injections ofrat amylin were shown to reduce feeding in rats and alterneurotransmitter metabolism in the hypothalamus. In certain studies,food intake was significantly reduced for up to eight hours followingthe intrahypothalamic injection of rat amylin and rat CGRP. In humantrials, an amylin analog, pramlintide, has been shown to reduce weightor weight gain. Amylin may be beneficial in treating metabolicconditions such as diabetes and obesity. Amylin may also be used totreat pain, bone disorders, gastritis, to modulate lipids, in particulartriglycerides, or to affect body composition such as the preferentialloss of fat and sparing of lean tissue.

The hormone calcitonin (CT) was named for its secretion in response toinduced hypercalcemia and its rapid hypocalcemic effect. It is producedin and secreted from neuroendocrine cells in the thyroid that have sincebeen termed C cells. The best-studied action of CT(1-32) is its effecton the osteoclast. In vitro effects of CT include the rapid loss ofruffled borders and decreased release of lysosomal enzymes. Ultimately,the inhibition of osteoclast functions by CT results in a decrease inbone resorption. However, neither a chronic reduction of serum CT in thecase of thyroidectomy nor the increased serum CT found in medullarythyroid cancer appears to be associated with changes in serum calcium orbone mass. It is thus most likely that a major function of CT(1-32) isto combat acute hypercalcemia in emergency situations and/or protect theskeleton during periods of “calcium stress” such as growth, pregnancy,and lactation. (Reviewed in Becker, JCEM, 89(4): 1512-1525 (2004) andSexton, Current Medicinal Chemistry 6: 1067-1093 (1999)). Consistentwith this is recent data from the calcitonin gene knockout mouse, whichremoves both the calcitonin and the CGRP-I peptides, that revealed thatthe mouse had normal levels of basal calcium-related values, but anincreased calcemic response (Kurihara H, et al., Hypertens Res. 2003February; 26 Suppl:S105-8).

CT has an effect on plasma calcium levels and inhibits osteoclastfunction and is widely used for the treatment of osteoporosis.Therapeutically, salmon CT (sCT) appears to increase bone density anddecrease fracture rates with minimal adverse effects. CT has also beensuccessfully used over the past 25 years as a therapy for Paget'sdisease of bone, which is a chronic skeletal disorder that may result inenlarged or deformed bones in one or more regions of the skeleton. CT isalso widely used for its analgesic effect on bone pain experiencedduring osteoporosis, although the mechanism for this effect is notclearly understood.

Calcitonin gene related peptide (CGRP) is a neuropeptide whose receptorsare widely distributed in the body, including the nervous system and thecardiovascular system. This peptide seems to modulate sensoryneurotransmission and is one of the most potent endogenous vasodilatorypeptide discovered to date. Reported biological effects for CGRPinclude: modulation of substance P in inflammation, nicotinic receptoractivity at the neuromuscular junction, stimulation of pancreatic enzymesecretion, a reduction of gastric acid secretion, peripheralvasodilation, cardiac acceleration, neuro-modulation, regulation ofcalcium metabolism, osteogenic stimulation, insulin secretion, anincrease in body temperature and a decrease in food intake.(Wimalawansa, Amylin, calcitonin gene-related peptide, calcitonin andADM: a peptide superfamily. Crit. Rev Neurobiol. 1997; 11(2-3):167-239).An important role of CGRP is to control blood flow to various organs byits potent vasodilatory actions, as evidenced by a decrease of meanarterial pressure following intravenous administration of α-CGRP. Thevasodilatory actions are also supported by recent analysis of homozygousknockout CGRP mice, which demonstrated elevated peripheral vascularresistance and high blood pressure caused by increased peripheralsympathetic activity (Kurihara H, et al., Targeted disruption of ADM andαCGRP genes reveals their distinct biological roles. Hypertens Res. 2003February; 26 Suppl:S105-8). Thus, CGRP appears to elicit vasodilatoryeffects, hypotensive effects and an increase in heart rate among otheractions.

Prolonged infusion of CGRP into patients with congestive cardiac failurehas shown a sustained beneficial effect on hemodynamic functions withoutadverse effects, suggesting a use in heart failure. Other indications ofCGRP use include renal failure, acute and chronic coronary arteryischemia, treatment of cardiac arrhythmia, other peripheral vasculardisease such as Raynaud's phenomenon, subarachnoid hemorrhage,hypertension, and pulmonary hypertension. Preeclamptic toxemia ofpregnancy and preterm labor are also potentially treatable.(Wimalawansa, 1997). Recent therapeutic uses include the use of CGRPantagonists for the treatment of migraine headaches.

Adrenomedullin (ADM) is almost ubiquitously expressed with many moretissues containing the peptide than not. A published review of ADM,(Hinson, J. P. et al., Endocrine Reviews (2000) 21(2): 138-167) detailsits effects on the cardiovascular system, cellular growth, the centralnervous system and the endocrine system, with a range of biologicalactions including vasodilation, cell growth, regulation of hormonesecretion, and natriuresis. Studies in rat, cat, sheep, and man confirmthat intravenous infusion of ADM results in potent and sustainedhypotension, and is comparable to that of CGRP. However, the hypotensiveeffect of ADM on mean arterial pressure in the anesthetized rat is notinhibited by the CGRP antagonist CGRP8-37 suggesting that this effect isnot mediated via CGRP receptors. Acute or chronic administration ofhuman ADM in rats, anesthetized, conscious or hypertensive, results in asignificant decrease in total peripheral resistance accompanied by afall in blood pressure, with a concomitant rise in heart rate, cardiacoutput and stroke volume.

ADM has also been proposed as an important factor in embryogenesis anddifferentiation and as an apoptosis survival factor for rat endothelialcells. This is supported by recent mouse ADM knockout studies, in whichmice homozygous for loss of the ADM gene demonstrated defective vascularformation during embryogenesis and thus died mid-gestation. It wasreported that ADM+/−heterozygous mice had high blood pressure along withsusceptibility to tissue injury (Kurihara H, et al., Hypertens Res. 2003February; 26 Suppl:S105-8).

ADM affects such endocrine organs as the pituitary, the adrenal gland,reproductive organs and the pancreas. The peptide appears to have a rolein inhibiting ACTH release from the pituitary. In the adrenal gland, itappears to affect the secretory activity of the adrenal cortex in bothrat and human and it increases adrenal blood flow, acting as avasodilator in the adrenal vascular bed in intact rats. ADM has beenshown to be present throughout the female reproductive tract and plasmalevels are elevated in normal pregnancy. Studies in a rat model ofpreeclampsia show that ADM can reverse hypertension and decrease pupmortality when given to rats during late gestation. Because it did nothave a similar effect in animals in early gestation or non-pregnant ratsin the preeclampsia model, this suggests that ADM may play an importantregulatory role in the utero-placental cardiovascular system. In thepancreas, ADM most likely plays an inhibitory role since it attenuatedand delayed insulin response to an oral glucose challenge, resulting ininitial elevated glucose levels. ADM can also affect renal function. Abolus administered peripherally can significantly lower mean arterialpressure and raise renal blood flow, glomerular filtration rate andurine flow. In some cases, there is also an increase in Na+ excretion.

ADM also has other peripheral effects on bone and on the lung. For bone,studies have supported a role beyond the cardiovascular system and fluidhomeostasis and have demonstrated that ADM acts on fetal and adultrodent osteoblasts to increase cell growth comparable to those of knownosteoblast growth factors such as transforming growth factor-alpha. Thisis important clinically as one of the major challenges in osteoporosisresearch is to develop a therapy that increases bone mass viaosteoblastic stimulation. In the lung, ADM not only causes pulmonaryvasodilation, but also inhibits bronchoconstriction induced by histamineor acetylcholine. Recent studies using aerosolized ADM to treatpulmonary hypertension in a rat model indicate that inhalation treatmentof this condition is effective, as evidenced by the fact that meanpulmonary arterial pressure and total pulmonary resistance were markedlylower in rats treated with ADM than in those given saline. This resultwas achieved without an alteration in systemic arterial pressure orheart rate (Nagaya N et al., Am J Physiol Heart Circ Physiol. 2003;285:H2125-31).

In healthy volunteers, i.v. infusion of ADM has been shown to reducearterial pressure and to stimulate heart rate, cardiac output, plasmalevels of cAMP, prolactin, norepinephrine and rennin. In these patients,there was little or no increase in urine volume or sodium excretionobserved. In patients with heart failure or chronic renal failure, i.v.ADM had similar effects to those seen in normal subjects, and alsoinduced diuresis and natriuresis, depending on the dose administered(Nicholls, M G et al. Peptides. 2001; 22:1745-1752) Experimental ADMtreatment has also been shown to be beneficial in arterial and pulmonaryhypertension, septic shock and ischemia/reperfusion injury (BeltowskiJ., Pol J Pharmacol. 2004; 56:5-27). Other indications for ADM treatmentinclude: peripheral vascular disease, subarachnoid hemorrhage,hypertension, preeclamptic toxemia of pregnancy and preterm labor, andosteoporosis.

Expression of AFP-6 (i.e., intermedin) is primarily in the pituitary andgastrointestinal tract. A specific receptor for AFP-6 has not beenreported; however, binding studies indicate that AFP-6 binds to all theknown receptors of the Amylin Family. AFP-6 has been shown to increasecAMP production in SK-N-MC and L6 cells expressing endogenous CGRPreceptors and competes with labeled CGRP for binding to its receptors inthese cells. In published in vivo studies, AFP-6 administration led toblood pressure reduction in both normal and spontaneously hypertensiverats, most likely via interactions with the CRLR/RAMP receptors. In vivoadministration in mice led to a suppression of gastric emptying and foodintake. (Roh et al. J Biol. Chem. 2004 Feb. 20; 279(8):7264-74.)

It has been reported that the biological actions of amylin familypeptide hormones are generally mediated via binding to two closelyrelated type II G protein-coupled receptors (GPCRs), the calcitoninreceptor (CTR) and the calcitonin receptor like receptor (CRLR). Cloningand functional studies have shown that CGRP, ADM, and amylin interactwith different combinations of CTR or the CRLR and the receptor activitymodifying protein (RAMP). Many cells express multiple RAMPs. It isbelieved that co-expression of RAMPs and either the CTR or CRLR isrequired to generate functional receptors for calcitonin, CGRP, ADM, andamylin. The RAMP family comprises three members (RAMP1, -2, and -3),which share less then 30% sequence identity, but have a commontopological organization. Co-expression of CRLR and RAMP1 leads to theformation of a receptor for CGRP. Co-expression of CRLR and RAMP2 leadsto the formation of a receptor for ADM. Co-expression of CRLR and RAMP3leads to the formation of a receptor for ADM and CGRP. Co-expression ofhCTR2 and RAMP1 leads to the formation of a receptor for amylin andCGRP. Co-expression of hCTR2 and RAMP3 leads to the formation of areceptor for amylin.

Thus a GIP hybrid comprising an amylin family hormone module can providethe functions and uses associated with the amylin family module, e.g.amylin, amylin/sCT/amylin, ADM, CGRP, as discussed, in addition to a GIPfunction.

In one embodiment, the amylin analogs and derivatives have at least onehormonal activity of native amylin. In certain embodiments, the amylinanalogs are agonists of a receptor which native amylin is capable ofspecifically binding. Exemplary amylin analogs and derivatives includethose described in US 2003/0026812 A1, which is hereby incorporated byreference.

Exemplary amylin analogs include:

^(25,28,29)Pro-h-amylin (pramlintide) des-¹Lys-h-amylin ²⁵Pro, ²⁶Val,^(28,29)Pro-h-amylin ¹⁸Arg, ^(25,28)Pro-h-amylin des-¹Lys, ¹⁸Arg,^(25,28)Pro-h-amylin ¹⁸Arg, ^(25,28,29)Pro-h-amylin des-¹Lys, ¹⁸Arg,^(25,28,29)Pro-h-amylin des-¹, Lys^(25,28,29)Pro-h-amylin ²⁵Pro, ²⁶Val,^(28,29)Pro-h-amylin ²⁸Pro-h-amylin, 2,7-Cyclo-[²Asp,⁷Lys]-h-amylin²⁻³⁷h-amylin ¹Ala-h-amylin ²Ala-h-amylin ^(2,7)Ala-h-amylin¹Ser-h-amylin ²⁹Pro-h-amylin ^(25,28)Pro-h-amylin des-¹Lys,^(25,28)Pro-h-amylin ²³Leu, ²⁵Pro, ²⁶Val, ^(28,29)Pro-h-amylin²³Leu²⁵Pro²⁶Val²⁸Pro-h-amylin des-¹Lys, ²³Leu, ²⁵Pro, ²⁶Val,²⁸Pro-h-amylin ¹⁸Arg, ²³Leu, ²⁵Pro, ²⁶Val, ²⁸Pro-h-amylin ¹⁸Arg, ²³Leu,^(25,28,29)Pro-h-amylin ¹⁸Arg²³Leu, ^(25,28)Pro-h-amylin ¹⁷Ile, ²³Leu,^(25,28,29)Pro-h-amylin ¹⁷Ile, ^(25,28,29)Pro-h-amylin des-¹Lys, ¹⁷Ile,²³Leu, ^(25,28,29)Pro-h-amylin ¹⁷Ile, ¹⁸Arg, ²³Leu-h-amylin ¹⁷Ile,¹⁸Arg, ²³Leu, ²⁶Val, ²⁹Pro-h-amylin ¹⁷Ile, ¹⁸Arg, ²³Leu, ²⁵Pro, ²⁶Val,^(28,29)Pro-h-amylin, ¹³Thr, ²¹His, ²³Leu, ²⁶Ala, ²⁸Leu, ²⁹Pro,³¹Asp-h-amylin ¹³Thr, ²¹His, ²³Leu, ²⁶Ala, ²⁹Pro, ³¹Asp-h-amylindes-¹Lys, ¹³Thr, ²¹His, ²³Leu, ²⁶Ala, ²⁸Pro, ³¹Asp-h-amylin ¹³Thr,¹⁸Arg, ²¹His, ²³Leu, ²⁶Ala, ²⁹Pro, ³¹Asp-h-amylin ¹³Thr, ¹⁸Arg, ²¹His,²³Leu, ^(28,29)Pro, ³¹Asp-h-amylin ¹³Thr, ¹⁸Arg, ²¹His, ²³Leu, ²⁵Pro,²⁶Ala, ^(28,29)Pro, ³¹Asp-h- amylin

As known in the art, such amylin analogs are preferably amidated, butwithin the context of the present invention, may optionally be in theacid form unless otherwise specified.

Any ADM analog or derivative known in the art may be used in conjunctionwith the present invention. In one embodiment, the ADM analogs andderivatives have at least one hormonal activity of native ADM. Incertain embodiments, the ADM analogs are agonists of a receptor whichnative ADM is capable of specifically binding.

Any CT analog or derivative known in the art may be used in conjunctionwith the present invention. In one embodiment, the CT analogs andderivatives have at least one hormonal activity of native CT. In certainembodiments, the CT analogs are agonists of a receptor which native CTis capable of specifically binding. Exemplary CT analogs and derivativesinclude those described in U.S. Pat. Nos. 4,652,627; 4,606,856;4,604,238; 4,597,900; 4,537,716; 4,497,731; 4,495,097; 4,444,981;4,414,149; 4,401,593; and 4,397,780, which are hereby incorporated byreference.

Exemplary CT analogs include:

⁸Gly-CT ²²Leu-CT ²Gly, ³Ser, ⁸Gly, ²²des-Tyr-CT ¹⁴Glu-sCT, ¹⁸Arg-sCT,^(11,18)Arg-sCT, ¹⁴Glu, ¹⁸Arg-sCT, ¹⁴Glu, ^(11,18)Arg-sCT

As known in the art, such CT analogs are preferably amidated, but withinthe context of the present invention, may optionally be in the acid formunless otherwise specified.

Any CGRP analog or derivative known in the art may be used inconjunction with the present invention. In one embodiment, the CGRPanalogs and derivatives have at least one hormonal activity of nativeCGRP. In certain embodiments, the CGRP analogs are agonists of areceptor which native CGRP is capable of specifically binding. ExemplaryCGRP analogs and derivatives include those described in U.S. Pat. Nos.4,697,002; and 4,687,839, which are hereby incorporated by reference.

Exemplary CGRP analogs include:

³⁶D-Ser-CGRP ³⁶D-Thr-CGRP ³⁶D-Asp-CGRP ³⁶D-Asn-CGRP ³⁶Ser-CGRP³⁶Hse-CGRP ³⁶Asp-CGRP ³⁶Thr-CGRP ³⁶Asn-CGRP

Any AFP-6 analog or derivative known in the art may be used inconjunction with the present invention. In one embodiment, the AFP-6analogs and derivatives have at least one hormonal activity of nativeAFP-6. In certain embodiments, the AFP-6 analogs are agonists of areceptor which native AFP-6 is capable of specifically binding.Exemplary AFP-6 analogs and derivatives include those described in WO2003/022304, which is hereby incorporated by reference.

Exemplary AFP-6 analogs include:

SEQ ID No: Sequence 18 TQAQLLRVGCGNLSTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSP HSY19 TQAQLLRVGCDTATCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPH SY 20TQAQLLRVGMVLGTMQVQNLSHRLWQLMGPAGRQDSAPVDPSSPH SY 21TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVEPSSPH SY 22TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQESAPVEPSSPH SY 56TQAQLLRVGCVLGTCQVQNLSHRLWQL----RQDSAPVDPSSPH SY 57TQAQLLRVGCVLGTCQVQNLSHRLWQL----DSAPVDPSSPHSY 58RVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY 59VGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVEPSSPHSY 60VGCVLGTCQVQNLSHRLWQL----RQDSAPVEPSSPHSY 61GCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY 62GCNTATCQVQNLSHRLWQL----RQDSAPVDPSSPHSY 63GCNTATCQVQNLSHRLWQL----RQDSAPVEPSSPHSY 64GCSNLSTCQVQNLSHRLWQL----RQDSAPVEPSSPHSY 65GCGNLSTCQVQNLSHRLWQL----RQDSAPVEPSSPHSY 66GCVLGTCQVQNLSHRLWQL----RQESAPVEPSSPHSY 67CVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY 68QVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY 69 VQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY 70VQNLSHRL----QLMGPAGRQDSAPVDPSSPHSY 71 GTMQVQNLSHRLWQL----RQDSAPVEPSSPHSY

As known in the art, such AFP-6 analogs are preferably amidated, butwithin the context of the present invention, may optionally be in theacid form unless otherwise specified.

The CCK Family. CCKs, including hCCK (cholecystokinin) and speciesvariants, and various analogs thereof are known in the art. Generally,CCK has a 33-amino acid sequence first identified in humans, andincludes a 8-amino acid in vivo C-terminal fragment (“CCK-8”) that hasbeen reportedly demonstrated in pig, rat, chicken, chinchilla, dog andhumans. Other species variants include a 39-amino acid sequence found inpig, dog and guinea pig, and a 58-amino acid found in cat, dog andhumans, and a 47-amino acid sequences homologous to both CCK andgastrin. The C-terminal tyrosine-sulfated octapeptide sequence (CCK-8)is relatively conserved across species, and may be the minimum sequencefor biological activity in the periphery of rodents. Thus, the termCCK-33 will generally refer to human CCK(1-33), while CCK-8 (CCK(26-33))will refer to the C-terminal octapeptide generically in both thesulfated and unsulfated unless otherwise specified. Further,pentagastrin or CCK-5 will refer to the C-terminal peptide CCK(29-33),and the CCK-4 will refer to the C-terminal tetrapeptide CCK(30-33).

CCK was reportedly identified in 1928 from preparations of intestinalextracts by its ability to stimulate gallbladder contraction. Otherbiological actions of CCK have since been reported, includingstimulation of pancreatic secretion, delayed gastric emptying,stimulation of intestinal motility and stimulation of insulin secretion.See Lieverse et al., Ann. N.Y. Acad. Sci. 713: 268-272 (1994). Theactions of CCK, also reportedly include effects on cardiovascularfunction, respiratory function, neurotoxicity and seizures, cancer cellproliferation, analgesia, sleep, sexual and reproductive behaviors,memory, anxiety and dopamine-mediated behaviors. Crawley and Corwin,Peptides 15: 731-755 (1994). Other reported effects of CCK includestimulation of pancreatic growth, stimulation of gallbladdercontraction, inhibition of gastric acid secretion, pancreaticpolypeptide release and a contractile component of peristalsis.Additional reported effects of CCK include vasodilation. Walsh,“Gastrointestinal Hormones,” In Physiology of the Gastrointestinal Tract(3d ed. 1994; Raven Press, New York).

It has been reported that injections of combinations of glucagon, CCKand bombesin potentiated the inhibition of intake of condensed milk testmeals in nondeprived rats over the inhibitions observed with individualcompounds. Hinton et al., Brain Res. Bull. 17:615-619 (1986). It hasalso been reported that glucagon and CCK synergistically inhibit shamfeeding in rats. LeSauter and Geary, Am. J. Physiol. 253:R217-225(1987); Smith and Gibbs, Annals N.Y. Acad. Sci. 713:236-241 (1994). Ithas also been suggested that estradiol and CCK can have a synergisticeffect on satiety. Dulawa et al., Peptides 15:913-918 (1994); Smith andGibbs, supra. It has also been proposed that signals arising from thesmall intestine in response to nutrients therein may interactsynergistically with CCK to reduce food intake. Cox, Behav. Brain Res.38:35-44 (1990). Additionally, it has been reported that CCK inducessatiety in several species. For example, it has been reported thatfeeding depression was caused by CCK injected intraperitoneally in rats,intraarterially in pigs, intravenously in cats and pigs, into thecerebral ventricles in monkeys, rats, dogs and sheep, and intravenouslyin obese and non-obese humans. See Lieverse et al., supra. Studies fromseveral laboratories have reportedly confirmed the behavioralspecificity of low doses of CCK on inhibition in feeding, by comparingresponding for food to responding for nonfood reinforcers in bothmonkeys and rats and by showing that CCK elicits the sequence ofbehaviors normally observed after meal ingestion (i.e., the postprandialsatiety sequence). Additionally, comparison of behavior after CCK tobehavior after food ingestion, alone or in combination with CCK hasreportedly revealed behavioral similarities between CCK and foodingestion. Crawley and Corwin, supra. It has also been reported that CCKin physiological plasma concentrations inhibits food intake andincreases satiety in both lean and obese humans. See Lieverse et al.,supra.

CCK was characterized in 1966 as a 33-amino acid peptide. Crawley andCorwin, supra. Species-specific molecular variants of the amino acidsequence of CCK have been identified. The 33-amino acid sequence and atruncated peptide, its 8-amino acid C-terminal sequence (CCK-8) havebeen reportedly identified in pig, rat, chicken, chinchilla, dog andhumans. A 39-amino acid sequence was reportedly found in pig, dog andguinea pig. A 58-amino acid sequence was reported to have been found incat, dog and humans. Frog and turtle reportedly show 47-amino acidsequences homologous to both CCK and gastrin. Very fresh human intestinehas been reported to contain small amounts of an even larger molecule,termed CCK-83. In the rat, a principal intermediate form has beenreportedly identified, and is termed CCK-22. Walsh, “GastrointestinalHormones,” In Physiology of the Gastrointestinal Tract (3d ed. 1994;Raven Press, New York). A non-sulfated CCK-8 and a tetrapeptide (termedCCK-4 (CCK(30-33)) have been reported in rat brain. The C-terminalpentapeptide (termed CCK-4 (CCK(29-33)) conserves the structuralhomology of CCK, and also homology with the neuropeptide, gastrin. TheC-terminal sulfated octapeptide sequence, CCK-8, is reportedlyrelatively conserved across species. Cloning and sequence analysis of acDNA encoding preprocholecystokinin from rat thyroid carcinoma, porcinebrain, and porcine intestine reportedly revealed 345 nucleotides codingfor a precursor to CCK, which is 115 amino acids and contains all of theCCK sequences previously reported to have been isolated. Crawley andCorwin, supra.

CCK is said to be distributed throughout the central nervous system andin endocrine cells and enteric nerves of the upper small intestine. CCKagonists include CCK itself (also referred to as CCK-33), CCK-8(CCK(26-33)), non-sulfated CCK-8, pentagastrin (CCK-5 or CCK(29-33)),and the tetrapeptide, CCK-4 (CCK(30-33)). At the pancreatic CCKreceptor, CCK-8 reportedly displaced binding with a 1000-5000 greaterpotency than unsulfated CCK-8 or CCK-4, and CCK-8 has been reported tobe approximately 1000-fold more potent than unsulfated CCK-8 or CCK-4 instimulating pancreatic amylase secretion. Crawley and Corwin, supra. Inhomogenates from the cerebral cortex, CCK receptor binding was said tobe displaced by unsulfated CCK-8 and by CCK-4 at concentrations thatwere equimolar, 10-fold or 100-fold greater than sulfated CCK-8. Id.Receptors for CCK have been reportedly identified in a variety oftissues, and two primary subtypes have been described: type A receptorsand type B receptors. Type A receptors have been reported in peripheraltissues including pancreas, gallbladder, pyloric sphincter and afferentvagal fibers, and in discrete areas of the brain. The type A receptorsubtype (CCKA) has been reported to be selective for the sulfatedoctapeptide. The Type B receptor subtype (CCKB) has been identifiedthroughout the brain and in the stomach, and reportedly does not requiresulfation or all eight amino acids. See Reidelberger, J. Nutr. 124 (8Suppl.) 1327S-1333S (1994); Crawley and Corwin, supra.

Various in vivo and in vitro screening methods for CCK analogs are knownin the art. Examples include in vivo assays involving the contraction ofthe dog or guinea pig gallbladder after rapid intravenous injection ofthe compound to be tested for CCK-like activity, and in vitro assaysusing strips of rabbit gallbladder. See Walsh, “GastrointestinalHormones”, In Physiology of the Gastrointestinal Tract (3d ed. 1994;Raven Press, New York).

Certain exemplary CCK and CCK analogs with CCK activity include:

SEQ ID  NO: Sequence 72 DY(SO₃H)MGWMDF 24 DYMGWMDF 25 MGWMDF 26 GWMDF 27WMDF 73 KDY(SO₃H)MGWMDF 29 KDYMGWMDF 30 KMGWMDF 31 KGWMDF 32 KWMDF

As known in the art, such CCK peptides are preferably amidated, butwithin the context of the present invention, may optionally be in theacid form unless otherwise specified.

The Leptin Family. Component peptide hormones useful in the presentinvention also include leptin family peptide hormones. Native leptinfamily peptide hormones are known in art, as are functional peptideanalogs and derivatives. Certain exemplary native peptides, peptideanalogs and derivatives are described herein, however it should berecognized that any known leptin family peptides that exhibit hormonalactivity known in the art may be used in conjunction with the presentinvention.

Thus a GIP hybrid comprising a leptin family hormone module can providethe functions and uses associated with the leptin family module, e.g.leptin, leptin fragment, as discussed, in addition to a GIP function.

Any leptin analog or derivative known in the art may be used inconjunction with the present invention. In one embodiment, the leptinanalogs and derivatives have at least one hormonal activity of nativeleptin. In certain embodiments, the leptin analogs are agonists of areceptor which native leptin is capable of specifically binding.Preferred leptin analogs and derivatives include those described in,e.g., WO 2004/039832, WO 98/55139, WO 98/12224, and WO 97/02004, all ofwhich are hereby incorporated by reference.

In one embodiment leptin peptides include MVPIQK (SEQ ID NO: 551),VQDDTK (SEQ ID NO: 552), TLIK (SEQ ID NO: 553), TIVTR (SEQ ID NO: 554),INDISHTQSVSSK (SEQ ID NO: 555), VTGLDFIPGLHPILTLSK (SEQ ID NO: 556),NVIQISNDLENLR (SEQ ID NO: 557), DLLHVLAFSK (SEQ ID NO: 558),SCHLPWASGLETLDSLGGVLEASGYSTEVVALSR (SEQ ID NO: 559) andLQGSLQDMLWQLDLSPGC (SEQ ID NO: 560) as disclosed in WO97046585.

In one embodiment a leptin peptide may have an amino acid sequenceXaan-Ser-Cys-Xaa1-Leu-Pro-Xaa2-Xaa3-Xaan (SEQ ID NO: 561), wherein Xaanmay be zero residues in length, or may be a contiguous stretch ofpeptide residues derived from full length human or mouse leptinsequences, a stretch of between 1 and 7 at either the C-terminus orN-terminus, or wherein the leptin peptide is a total of 15 amino acidsor less in length. In another embodiment, Xaa1, Xaa2 or Xaa3 may be anyamino acid substitution. In yet another embodiment, Xaa1, Xaa2 or Xaa3may be any conservative amino acid substitution of the respectiveresidues in full length mouse or human leptin. In a further embodiment,Xaa1 may be selected from the group consisting of His or Ser, and Xaa2or Xaa3 is any amino acid substitution. In another embodiment, Xaa2 maybe selected from the group consisting of Trp or Gln, and Xaa1 or Xaa3 isany amino acid substitution. In yet another embodiment, Xaa3 may beselected from the group consisting of Ala or Thr, and Xaa1 or Xaa2 isany amino acid substitution. In another embodiment Xaa1 is selected fromthe group consisting of His or Ser, Xaa2 is selected from the groupconsisting of Trp or Gln, and Xaa3 is selected from the group consistingof Ala or Thr. See WO04039832.

In one embodiment leptin peptide comprises the C-terminal amino acidresidues 116-122 of native full length human or mouse leptin(corresponding to positions 95-101 of their mature forms) andD-isoforms, fragments, derivatives, analogs and homologs thereof, whichpossess the ability to modulate body mass homeostasis in test animalsupon i.p. (intraperitoneal) administration. Specific mouse D-substitutedpeptides of sequence SCSLPQT include [D-Ser-1]-, [D-Cys-2]-, [D-Ser-3]-,[D-Leu-4]-, [D-Pro-5]-, [D-Gln-6]-,[D-Thr-7]-SCSLPQT and all [D]SCSLPQT. Specific human D-substituted peptides of SCHLPWA include[D-Ser-1]-, [D-Cys-2]-, [D-His-3]-, [D-Leu-4]-, [D-Pro-5]-, [D-Trp-6]-,[D-Ala-7]-SCHLPWA and all [D]-SCHLPWA. In addition the SCHLPWA andSCSLPQT peptides may contain D-substituted amino acids for any two,three, four, five or six positions. Also disclosed are leptin relatedpeptides comprising N-terminal amino acids 21-35, 31-45, 41-55 and 51-65of native leptin and fragments, derivatives, analogs and homologsthereof. Additional leptin peptides of the invention comprise aminoacids sequences 61-75, 71-85, 81-95, 91-105, 106-120, 116-130, 126-140,136-150, 146-160, and 156-167 of mouse and/or human full length leptin.See WO04039832.

In one embodiment the leptin is of the sequence Ser Cys His Leu Pro XaaAla Ser Gly Leu Glu Thr Leu Asp Ser Leu Gly Gly Val Leu Glu Ala Ser GlyTyr Ser Thr Glu Val Val Ala Leu Ser Arg Leu Xaa Gly Ser Leu Xaa Asp XaaLeu Xaa Xaa Leu Asp Leu Ser Pro Gly Cys (SEQ ID NO: 564) wherein: Xaa atposition 6 is Trp or Gln; Xaa at position 36 is Gln or Glu; Xaa atposition 40 is Gln or Glu; Xaa at position 42 is Ile, Leu, Met ormethionine sulfoxide; Xaa at position 44 is Trp or Gln; and Xaa atposition 45 is Gln or Glu. In another embodiment are leptin of the aboveare where Xaa at position 6 is Trp; Xaa at position 36 is Gln; Xaa atposition 40 is Gln; Xaa at position 42 is Met; Xaa at position 44 isTrp; and Xaa at position 45 is Gln. See U.S. Pat. No. 5,521,283.

In one embodiment leptins are native sequences, including

Murine leptin: Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys Thr Leu IleLys Thr Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr Xaa Ser Val Ser SerLys Gln Lys Val Thr Gly Leu Asp Phe Ile Pro Gly Leu His Pro Ile Leu ThrLeu Ser Lys Met Asp Gln Thr Leu Ala Val Tyr Gln Gln Ile Leu Thr Ser MetPro Ser Arg Asn Val Ile Gln Ile Ser Asn Asp Leu Glu Asn Leu Arg Asp LeuLeu His Val Leu Ala Phe Ser Lys Ser Cys His Leu Pro Gln Ala Ser Gly LeuGlu Thr Leu Glu Ser Leu Gly Gly Val Leu Glu Ala Ser Gly Tyr Ser Thr GluVal Val Ala Leu Ser Arg Leu Gln Gly Ser Leu Gln Asp Met Leu Gln Gln LeuAsp Leu Ser Pro Gly Cys (SEQ ID NO:565), wherein: Xaa at position 28 isGln or absent;Porcine leptin: Val Pro Ile Trp Arg Val Gln Asp Asp Thr Lys Thr Leu IleLys Thr Ile Val Thr Arg Ile Ser Asp Ile Ser His Met Gln Ser Val Ser SerLys Gln Arg Val Thr Gly Leu Asp Phe Ile Pro Gly Leu His Pro Val Leu SerLeu Ser Lys Met Asp Gln Thr Leu Ala Ile Tyr Gln Gln Ile Leu Thr Ser LeuPro Ser Arg Asn Val Ile Gln Ile Ser Asn Asp Leu Glu Asn Leu Arg Asp LeuLeu His Leu Leu Ala Ser Ser Lys Ser Cys Pro Leu Pro Gln Ala Arg Ala LeuGlu Thr Leu Glu Ser Leu Gly Gly Val Leu Glu Ala Ser Leu Tyr Ser Thr GluVal Val Ala Leu Ser Arg Leu Gln Gly Ala Leu Gln Asp Met Leu Arg Gln LeuAsp Leu Ser Pro Gly Cys (SEQ ID NO: 566);Bovine leptin: Val Pro Ile Cys Lys Val Gln Asp Asp Thr Lys Thr Leu IleLys Thr Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr Xaa Ser Val Ser SerLys Gln Arg Val Thr Gly Leu Asp Phe Ile Pro Gly Leu His Pro Leu Leu SerLeu Ser Lys Met Asp Gln Thr Leu Ala Ile Tyr Gln Gln Ile Leu Thr Ser LeuPro Ser Arg Asn Val Val Gln Ile Ser Asn Asp Leu Glu Asn Leu Arg Asp LeuLeu His Leu Leu Ala Ala Ser Lys Ser Cys Pro Leu Pro Gln Val Arg Ala LeuGlu Ser Leu Glu Ser Leu Gly Val Val Leu Glu Ala Ser Leu Tyr Ser Thr GluVal Val Ala Leu Ser Arg Leu Gln Gly Ser Leu Gln Asp Met Leu Arg Gln LeuAsp Leu Ser Pro Gly Cys (SEQ ID NO:567) wherein Xaa at position 28 isGln or absent;Human leptin: Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys Thr Leu IleLys Thr Ile Val Thr Arg Ile Asn Asp Ile Ser His Xaa Xaa Ser Val Ser SerLys Gln Lys Val Thr Gly Leu Asp Phe Ile Pro Gly Leu His Pro Ile Leu ThrLeu Ser Lys Met Asp Gln Thr Leu Ala Val Tyr Gln Gln Ile Leu Thr Ser MetPro Ser Arg Asn Val Ile Gln Ile Ser Asn Asp Leu Glu Asn Leu Arg Asp LeuLeu His Val Leu Ala Phe Ser Lys Ser Cys His Leu Pro Trp Ala Ser Gly LeuGlu Thr Leu Asp Ser Leu Gly Gly Val Leu Glu Ala Ser Gly Tyr Ser Thr GluVal Val Ala Leu Ser Arg Leu Gln Gly Ser Leu Gln Asp Met Leu Trp Gln LeuAsp Leu Ser Pro Gly Cys (SEQ ID NO:568) wherein: Xaa at position 27 isThr or Ala; and Xaa at position 28 is Gln or absent; Rhesus Leptin: ValPro Ile Gln Lys Val Gln Ser Asp Thr Lys Thr Leu Ile Lys Thr Ile Val ThrArg Ile Asn Asp Ile Ser His Thr Gln Ser Val Ser Ser Lys Gln Arg Val ThrGly Leu Asp Phe Ile Pro Gly Leu His Pro Val Leu Thr Leu Ser Gln Met AspGln Thr Leu Ala Ile Tyr Gln Gln Ile Leu Ile Asn Leu Pro Ser Arg Asn ValIle Gln Ile Ser Asn Asp Leu Glu Asn Leu Arg Asp Leu Leu His Leu Leu AlaPhe Ser Lys Ser Cys His Leu Pro Leu Ala Ser Gly Leu Glu Thr Leu Glu SerLeu Gly Asp Val Leu Glu Ala Ser Leu Tyr Ser Thr Glu Val Val Ala Leu SerArg Leu Gln Gly Ser Leu Gln Asp Met Leu Trp Gln Leu Asp Leu Ser Pro GlyCys (SEQ ID NO: 569);; andRat leptin: Val Pro Ile His Lys Val Gln Asp Asp Thr Lys Thr Leu Ile LysThr Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr Gln Ser Val Ser Ala ArgGln Arg Val Thr Gly Leu Asp Phe Ile Pro Gly Leu His Pro Ile Leu Ser LeuSer Lys Met Asp Gln Thr Leu Ala Val Tyr Gln Gln Ile Leu Thr Ser Leu ProSer Gln Asn Val Leu Gln Ile Ala His Asp Leu Glu Asn Leu Arg Asp Leu LeuHis Leu Leu Ala Phe Ser Lys Ser Cys Ser Leu Pro Gln Thr Arg Gly Leu GlnLys Pro Glu Ser Leu Asp Gly Val Leu Glu Ala Ser Leu Tyr Ser Thr Glu ValVal Ala Leu Ser Arg Leu Gln Gly Ser Leu Gln Asp Ile Leu Gln Gln Leu AspLeu Ser Pro Glu Cys (SEQ ID NO:570).

In another embodiment leptin peptide components are of the sequence:

Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys Thr Leu Ile Lys Thr Ile ValThr Arg Ile Xaa Asp Ile Ser His Xaa Xaa Ser Val Ser Ser Lys Gln Lys ValThr Gly Leu Asp Phe Ile Pro Gly Leu His Pro Ile Leu Thr Leu Ser Lys XaaAsp Gln Thr Leu Ala Val Tyr Gln Gln Ile Leu Thr Ser Xaa Pro Ser Arg XaaVal Ile Gln Ile Xaa Asn Asp Leu Glu Asn Leu Arg Asp Leu Leu His Val LeuAla Phe Ser Lys Ser Cys His Leu Pro Trp Ala Ser Gly Leu Glu Thr Leu AspSer Leu Gly GlyVal Leu Glu Ala Ser Xaa Tyr Ser Thr Glu Val Val Ala Leu Ser Arg Leu GlnGly Ser Leu Gln Asp Met Leu Trp Gln Leu Asp Leu Ser Pro Gly Cys (SEQ IDNO:571), wherein: Xaa at position 22 is Asn, Asp or Glu; Xaa at position27 is Thr or Ala; Xaa at position 28 is Gln, Glu, or absent; Xaa atposition 54 s Met or Ala; Xaa at position 68 s Met or Leu; Xaa atposition 72 Asn, Asp or Glu; Xaa at position 77 is Ser or Ala; Xaa atposition 118 is Gly or Leu; said protein having at least onesubstitution selected from the group consisting of: His at position 97is replaced with Ser or Pro; Trp at position 100 is replaced with Gln,Ala or Leu; Ala at position 101 is replaced with Thr or Val; Ser atposition 102 is replaced with Arg; Gly at position 103 is replaced withAla; Glu at position 105 is replaced with Gln; Thr at position 106 isreplaced with Lys or Ser; Leu at position 107 is replaced with Pro; Aspat position 108 is replaced with Glu; or Gly at position 111 is replacedwith Asp.

In another embodiment leptin are of the sequence: Val Pro Ile Gln LysVal Gln Asp Asp Thr Lys Thr Leu Ile Lys Thr Ile Val Thr Arg Ile Asn AspIle Ser His Xaa Gln Ser Val Ser Ser Lys Gln Lys Val Thr Gly Leu Asp PheIle Pro Gly Leu His Pro Ile Leu Thr Leu Ser Lys Met Asp Gln Thr Leu AlaVal Tyr Gln Gln Ile Leu Thr Ser Met Pro Ser Arg Asn Val Ile Gln Ile XaaAsn Asp Leu Glu Asn Leu Arg Asp Leu Leu His Val Leu Ala Phe Ser Lys SerCys His Leu Pro Trp Ala Ser Gly Leu Glu Thr Leu Asp Ser Leu Gly Gly ValLeu Glu Ala Ser Xaa Tyr Ser Thr Glu Val Val Ala Leu Ser Arg Leu Gln GlySer Leu Gln Asp Met Leu Trp Gln Leu Asp Leu Ser Pro Gly Cys (SEQ IDNO:572), wherein: Xaa at position 27 is Thr or Ala; Xaa at position 77is Ser or Ala; Xaa at position 118 is Gly or Leu; said protein having atleast one substitution, preferably having one to five substitutions and,most preferably, one to two substitutions selected from the groupconsisting of: His at position 97 is replaced with Ser; Trp at position100 is replaced with Gln; Ala at position 101 is replaced with Thr; Gluat position 105 is replaced with Gln; Thr at position 106 is replacedwith Lys; Leu at position 107 is replaced with Pro; Asp at position 108is replaced with Glu; or Gly at position 111 is replaced with Asp. Infurther embodiments of the above sequence Xaa at position 27 is Thr; Xaaat position 77 is Ser; Xaa at position 118 is Gly; and the amino acidresidues at positions 97, 100, 101, 105, 106, 107, 108, and 111 are asin the following table:

97 100 101 105 106 107 108 111 native human His Trp Ala Glu Thr Leu AspGly Ser Trp Ala Glu Thr Leu Asp Gly His Gln Ala Glu Thr Leu Asp Gly HisTrp Thr Glu Thr Leu Asp Gly His Trp Ala Gln Thr Leu Asp Gly His Trp AlaGlu Lys Leu Asp Gly His Trp Ala Glu Thr Pro Asp Gly His Trp Ala Glu ThrLeu Glu Gly His Trp Ala Glu Thr Leu Asp Asp Ser Gln Ala Glu Thr Leu AspGly Ser Trp Thr Glu Thr Leu Asp Gly Ser Trp Ala Gln Thr Leu Asp Gly SerTrp Ala Glu Lys Leu Asp Gly Ser Trp Ala Glu Thr Pro Asp Gly Ser Trp AlaGlu Thr Leu Glu Gly Ser Trp Ala Glu Thr Leu Asp Asp His Gln Thr Glu ThrLeu Asp Gly His Gln Ala Gln Thr Leu Asp Gly His Gln Ala Glu Lys Leu AspGly His Gln Ala Glu Thr Pro Asp Gly His Gln Ala Glu Thr Leu Glu Gly HisGln Ala Glu Thr Leu Asp Asp His Trp Thr Gln Thr Leu Asp Gly His Trp ThrGlu Lys Leu Asp Gly His Trp Thr Glu Thr Pro Asp Gly His Trp Thr Glu ThrLeu Glu Gly His Trp Thr Glu Thr Leu Asp Asp His Trp Ala Gln Lys Leu AspGly His Trp Ala Gln Thr Pro Asp Gly His Trp Ala Gln Thr Leu Glu Gly HisTrp Ala Gln Thr Leu Asp Asp His Trp Ala Glu Lys Pro Asp Gly His Trp AlaGlu Lys Leu Glu Gly His Trp Ala Glu Lys Leu Asp Asp His Trp Ala Glu ThrPro Glu Gly His Trp Ala Glu Thr Pro Asp Asp His Trp Ala Glu Thr Leu GluAsp Ser Gln Thr Glu Thr Leu Asp Gly Ser Gln Ala Gln Thr Leu Asp Gly SerGln Ala Glu Lys Leu Asp Gly Ser Gln Ala Glu Thr Pro Asp Gly Ser Gln AlaGlu Thr Leu Glu Gly Ser Gln Ala Glu Thr Leu Asp Asp Ser Trp Thr Gln ThrLeu Asp Gly Ser Trp Thr Glu Lys Leu Asp Gly Ser Trp Thr Glu Thr Pro AspGly Ser Trp Thr Glu Thr Leu Glu Gly Ser Trp Thr Glu Thr Leu Asp Asp SerTrp Ala Gln Lys Leu Asp Gly Ser Trp Ala Gln Thr Pro Asp Gly Ser Trp AlaGln Thr Leu Glu Gly Ser Trp Ala Gln Thr Leu Asp Asp Ser Trp Ala Glu LysPro Asp Gly Ser Trp Ala Glu Lys Leu Glu Gly Ser Trp Ala Glu Lys Leu AspAsp Ser Trp Ala Glu Thr Pro Glu Gly Ser Trp Ala Glu Thr Pro Asp Asp SerTrp Ala Glu Thr Leu Glu Asp His Gln Thr Gln Thr Leu Asp Gly His Gln ThrGlu Lys Leu Asp Gly His Gln Thr Glu Thr Pro Asp Gly His Gln Thr Glu ThrLeu Glu Gly His Gln Thr Glu Thr Leu Asp Asp His Gln Ala Gln Lys Leu AspGly His Gln Ala Gln Thr Pro Asp Gly His Gln Ala Gln Thr Leu Glu Gly HisGln Ala Gln Thr Leu Asp Asp His Gln Ala Glu Lys Pro Asp Gly His Gln AlaGlu Lys Leu Glu Gly His Gln Ala Glu Lys Leu Asp Asp His Gln Ala Glu ThrPro Glu Gly His Gln Ala Glu Thr Pro Asp Asp His Gln Ala Glu Thr Leu GluAsp His Trp Thr Gln Lys Leu Asp Gly His Trp Thr Gln Thr Pro Asp Gly HisTrp Thr Gln Thr Leu Glu Gly His Trp Thr Gln Thr Leu Asp Asp His Trp ThrGlu Lys Pro Asp Gly His Trp Thr Glu Lys Leu Glu Gly His Trp Thr Glu LysLeu Asp Asp His Trp Thr Glu Thr Pro Glu Gly His Trp Thr Glu Thr Pro AspAsp His Trp Thr Glu Thr Leu Glu Asp His Trp Ala Gln Lys Pro Asp Gly HisTrp Ala Gln Lys Leu Glu Gly His Trp Ala Gln Lys Leu Asp Asp His Trp AlaGln Thr Pro Glu Gly His Trp Ala Gln Thr Pro Asp Asp His Trp Ala Gln ThrLeu Glu Asp His Trp Ala Glu Lys Pro Glu Gly His Trp Ala Glu Lys Pro AspAsp His Trp Ala Glu Lys Leu Glu Asp His Trp Ala Glu Thr Pro Glu Asp SerGln Thr Gln Thr Leu Asp Gly Ser Gln Thr Glu Lys Leu Asp Gly Ser Gln ThrGlu Thr Pro Asp Gly Ser Gln Thr Glu Thr Leu Glu Gly Ser Gln Thr Glu ThrLeu Asp Asp Ser Gln Ala Gln Lys Leu Asp Gly Ser Gln Ala Gln Thr Pro AspGly Ser Gln Ala Gln Thr Leu Glu Gly Ser Gln Ala Gln Thr Leu Asp Asp SerGln Ala Glu Lys Pro Asp Gly Ser Gln Ala Glu Lys Leu Glu Gly Ser Gln AlaGlu Lys Leu Asp Asp Ser Gln Ala Glu Thr Pro Glu Gly Ser Gln Ala Glu ThrPro Asp Asp Ser Gln Ala Glu Thr Leu Glu Asp Ser Trp Thr Gln Lys Leu AspGly Ser Trp Thr Gln Thr Pro Asp Gly Ser Trp Thr Gln Thr Leu Glu Gly SerTrp Thr Gln Thr Leu Asp Asp Ser Trp Thr Glu Lys Pro Asp Gly Ser Trp ThrGlu Lys Leu Glu Gly Ser Trp Thr Glu Lys Leu Asp Asp Ser Trp Thr Glu ThrPro Glu Gly Ser Trp Thr Glu Thr Pro Asp Asp Ser Trp Thr Glu Thr Leu GluAsp Ser Trp Ala Gln Lys Pro Asp Gly Ser Trp Ala Gln Lys Leu Glu Gly SerTrp Ala Gln Lys Leu Asp Asp Ser Trp Ala Gln Thr Pro Glu Gly Ser Trp AlaGln Thr Pro Asp Asp Ser Trp Ala Gln Thr Leu Glu Asp Ser Trp Ala Glu LysPro Glu Gly Ser Trp Ala Glu Lys Pro Asp Asp Ser Trp Ala Glu Lys Leu GluAsp Ser Trp Ala Glu Thr Pro Glu Asp His Gln Thr Gln Lys Leu Asp Gly HisGln Thr Gln Thr Pro Asp Gly His Gln Thr Gln Thr Leu Glu Gly His Gln ThrGln Thr Leu Asp Asp His Gln Thr Glu Lys Pro Asp Gly His Gln Thr Glu LysLeu Glu Gly His Gln Thr Glu Lys Leu Asp Asp His Gln Thr Glu Thr Pro GluGly His Gln Thr Glu Thr Pro Asp Asp His Gln Thr Glu Thr Leu Glu Asp HisGln Ala Gln Lys Pro Asp Gly His Gln Ala Gln Lys Leu Glu Gly His Gln AlaGln Lys Leu Asp Asp His Gln Ala Gln Thr Pro Glu Gly His Gln Ala Gln ThrPro Asp Asp His Gln Ala Gln Thr Leu Glu Asp

In one embodiment the leptin is of the sequence: Ile Pro Gly Leu His ProIle Leu Thr Leu Ser Lys Xaa Asp Xaa Thr Leu Ala Val Tyr Xaa Xaa Ile LeuThr Ser Xaa Pro Ser Arg Xaa Val Ile Xaa Ile Ser Xaa Asp Leu Glu Xaa LeuArg Asp Leu Leu His Val Leu Ala Phe Ser Lys Ser Cys His Leu Pro Xaa AlaSer Gly Leu Glu Thr Leu Asp Ser Leu Gly Gly Val Leu Glu Ala Ser Gly TyrSer Thr Glu Val Val Ala Leu Ser Arg Leu Xaa Gly Ser Leu Xaa Asp Xaa LeuXaa Xaa Leu Asp Leu Ser Pro Gly Cys (SEQ ID NO:573), wherein: Xaa atposition 13 is Ile, Leu, Met or methionine sulfoxide; Xaa at position 15is Gln or Glu; Xaa at position 21 is Gln or Glu; Xaa at position 22 isGln or Glu; Xaa at position 27 is Ile, Leu, Met or methionine sulfoxide;Xaa at position 31 is Asn, Asp or Gln; Xaa at position 34 is Gln or Glu;Xaa at position 37 is Asn, Asp or Gln; Xaa at position 41 is Asn, Asp orGln; Xaa at position 59 is Trp or Gln; Xaa at position 89 is Gln or Glu;Xaa at position 93 is Gln or Glu; Xaa at position 95 is Ile, Leu, Met ormethionine sulfoxide; Xaa at position 97 is Trp or Gln; and Xaa atposition 98 is Gln or Glu. In another embodiment the leptin of the aboveformula has Xaa at position 13 is Met; Xaa at position 15 is Gln; Xaa atposition 21 is Gln; Xaa at position 22 is Gln; Xaa at position 27 isMet; Xaa at position 31 is Asn; Xaa at position 34 is Gln; Xaa atposition 37 is Asn; Xaa at position 41 is Asn; Xaa at position 59 isTrp; Xaa at position 89 is Gln; Xaa at position 93 is Gln; Xaa atposition 95 is Met; Xaa at position 97 is Trp; and Xaa at position 98 isGln. See U.S. Pat. No. 5,532,336.

Exemplary leptin analogs include those where the amino acid at position43 is substituted with Asp or Glu; position 48 is substituted Ala;position 49 is substituted with Glu, or absent; position 75 issubstituted with Ala; position 89 is substituted with Leu; position 93is substituted with Asp or Glu; position 98 is substituted with Ala;position 117 is substituted with Ser, position 139 is substituted withLeu, position 167 is substituted with Ser, and any combination thereof.

Certain exemplary leptin and leptin analogs with leptin activityinclude:

⁴³Asp-leptin ⁴³Glu-leptin ⁴⁸Ala-leptin ⁴⁹Glu-leptin ⁴⁹Des-AA-leptin⁷⁵Ala-leptin ⁸⁹Leu-leptin ⁹³Asp-leptin ⁹³Glu-leptin ⁹⁸Ala-leptin¹¹⁷Ser-leptin ¹³⁹Leu-leptin ¹⁶⁷Ser-leptin ⁴³Asp, ⁴⁹Glu-leptin ⁴³Asp,⁷⁵Ala-leptin ⁸⁹Leu, ¹¹⁷Ser-leptin ⁹³Glu, ¹⁶⁷Ser-leptin

The PPF or PYY Family.

Component peptide hormones useful in the present invention also includePancreatic Polypeptide Family (PPF) peptide hormones, including PYY andchimeras of PPY-NPY. Native PPF peptide hormones are known in art, asare functional peptide analogs and derivatives. Certain exemplary nativepeptides, peptide analogs and derivatives are described herein, howeverit should be recognized that any known PYY family peptides that exhibithormonal activity known in the art may be used in conjunction with thepresent invention.

Yet another family of peptide hormones implicated in metabolic diseasesand disorders is the pancreatic polypeptide family (“PPF”). Pancreaticpolypeptide (“PP”) was discovered as a contaminant of insulin extractsand was named by its organ of origin rather than functional importance(Kimmel et al., Endocrinology 83: 1323-30 (1968)). PP is a 36-amino acidpeptide containing distinctive structural motifs. A related peptide wassubsequently discovered in extracts of intestine and named Peptide YY(“PYY”) because of the N- and C-terminal tyrosines (Tatemoto, Proc.Natl. Acad. Sci. USA 79: 2514-8 (1982)). A third related peptide waslater found in extracts of brain and named Neuropeptide Y (“NPY”)(Tatemoto, Proc. Natl. Acad. Sci. USA 79: 5485-9 (1982); Tatemoto etal., Nature 296: 659-60 (1982)).

These three related peptides have been reported to exert variousbiological effects. Effects of PP include inhibition of pancreaticsecretion and relaxation of the gallbladder. Centrally administered PPproduces modest increases in feeding that may be mediated by receptorslocalized to the hypothalamus and brainstem (reviewed in Gehlert, Proc.Soc. Exp. Biol. Med. 218: 7-22 (1998)).

Release of PYY occurs following a meal. An alternate molecular form ofPYY is PYY(3-36) (Eberlein et al., Peptides 10: 797-803 (1989); Grandtet al., Regul. Pept. 51: 151-9 (1994)). This fragment constitutesapproximately 40% of total PYY-like immunoreactivity in human and canineintestinal extracts and about 36% of total plasma PYY immunoreactivityin a fasting state to slightly over 50% following a meal. It isapparently a dipeptidyl peptidase-IV (DPP4) cleavage product of PYY.PYY(3-36) is reportedly a selective ligand at the Y2 and Y5 receptors,which appear pharmacologically unique in preferring N-terminallytruncated (i.e., C-terminal fragments of) NPY analogs. Peripheraladministration of PYY reportedly reduces gastric acid secretion, gastricmotility, exocrine pancreatic secretion (Yoshinaga et al., Am. J.Physiol. 263: G695-701 (1992); Guan et al., Endocrinology 128: 911-6(1991); Pappas et al., Gastroenterology 91: 1386-9 (1986)), gallbladdercontraction and intestinal motility (Savage et al., Gut 28: 166-70(1987)). The effects of central injection of PYY on gastric emptying,gastric motility and gastric acid secretion, as seen after directinjection in or around the hindbrain/brainstem (Chen and Rogers, Am. J.Physiol. 269: R787-92 (1995); Chen et al., Regul. Pept. 61: 95-98(1996); Yang and Tache, Am. J. Physiol. 268: G943-8 (1995); Chen et al.,Neurogastroenterol. Motil. 9: 109-16 (1997)), may differ from thoseeffects observed after peripheral injection. For example, centrallyadministered PYY had some effects opposite to those described herein forperipherally injected PYY(3-36) in that gastric acid secretion wasstimulated, not inhibited. Gastric motility was suppressed only inconjunction with TRH stimulation, but not when administered alone, andwas indeed stimulatory at higher doses through presumed interaction withPP receptors. PYY has been shown to stimulate food and water intakeafter central administration (Morley et al., Brain Res. 341: 200-3(1985); Corp et al., Am. J. Physiol. 259: R317-23 (1990)).

Any PPF analog or derivative known in the art may be used in conjunctionwith a GIP component in the present invention. In one embodiment, thePPF analogs and derivatives have at least one hormonal activity of anative PPF polypeptide. In certain embodiments, the PPF analogs areagonists of a receptor which native PPF polypeptide is capable ofspecifically binding. Exemplary PPF analogs and derivatives includethose described in WO 03/026591 and WO 03/057235, which are hereinincorporated by reference in their entirety.

In one embodiment, preferred PPF analogs and derivatives that exhibit atleast one PPF hormonal activity generally comprise at least two PYYmotifs including a polyproline motif and C-terminal tail motif. Suchanalogs are generally described in U.S. Provisional Application No.60/543,406 filed Feb. 11, 2004, published as US 2006/013547A1 on Jun.22, 2006, which are herein incorporated by reference. Other preferredPPF analogs are disclosed in PCT/US2005/004351, entitled “PancreaticPolypeptide Family Motifs and Polypeptides Comprising the Same”,published as WO2005/077094 on Aug. 25, 2005, the contents of which arehereby incorporated by reference. Other preferred PPF analogs aredisclosed in PCT/US2005/045471, entitled “Pancreatic Polypeptide FamilyMotifs, Polypeptides and Methods Comprising the Same”, published asWO2006/066024 on Jun. 22, 2006, the contents of which are herebyincorporated by reference. By way of background, research has suggestedthat the differences in Y receptor binding affinities are correlatedwith secondary and tertiary structural differences. See, e.g., Keire etal., Biochemistry 2000, 39, 9935-9942. Native porcine PYY has beencharacterized as including two C-terminal helical segments from residues17 to 22 and 25 to 33 separated by a kink at residues 23, 24, and 25, aturn centered around residues 12-14, and the N-terminus folded nearresidues 30 and 31. Further, full-length porcine PYY has beencharacterized as including the PP fold, stabilized by hydrophobicinteractions among residues in the N- and C-termini. See id.

A “PYY motif” is generally a structural component, primary, secondary,or tertiary, of a native PP family polypeptide that is critical tobiological activity, i.e., biological activity is substantiallydecreased in the absence or disturbance of the motif. Preferred PYYmotifs include the N-terminal polyproline type II motif of a native PPfamily polypeptide, the type II β-turn motif of native PP familypolypeptide, the α-helical motif at the C-terminal end of native PPfamily polypeptide, and the C-terminal tail motif of native PP familypolypeptide. More particularly, in the N-terminal polyproline region,amino acids corresponding to residues 5 and 8 of a native PP familypolypeptide are generally conserved as a proline. The type II β-turnmotif will generally include amino acids corresponding to residues 12-14of a native PP family polypeptide. The α-helical motif can generallyextend from amino acids corresponding to approximately residue 14 of anative PP family polypeptide to any point up to and including theC-terminal end, so long as the α-helical motif includes a sufficientnumber of amino acid residues such that an α-helical turn is formed insolution. The α-helical motif can also include amino acid substitutions,insertions and deletions to the native PP family sequence, so long asthe α-helical turn is still formed in solution. The C-terminal tailmotif generally includes amino acids corresponding to approximately thelast 10 residues of a native PP family polypeptide, more preferably thelast 7, 6, or 5 residues of a native PP family polypeptide, and morepreferably amino acid residues 32-35.

Preferred PYY analogs include those with internal deletions, insertions,and substitutions in areas of the PYY molecule not corresponding to thepolyproline motif and/or the C-terminal tail motif. For instance,internal deletions at positions 4, 6, 7, 9, or 10 are envisioned.

In another embodiment of particular interest, the component hormone is aPPF polypeptide containing at least two PPF motifs including at leastthe N-terminal polyproline PPF motif and the C-terminal tail PPF motif.As used herein, “motif” refers to an amino acid sequence that ischaracteristic of a specific biochemical function or defines anindependently folded domain. Additional PPF motifs can correspond to amotif of any of the PP family polypeptides, including PP, PYY and NPY,for example the type II beta-turn region motif of PYY, or the α-helicalmotif at the C-terminal end of PYY.

In yet another embodiment the PPF family component module is a PPFchimeric polypeptide comprising a fragment of a PP, PYY or NPYpolypeptide covalently linked to at least one additional fragment of asecond PP, PYY or NPY polypeptide, wherein each PP, PYY or NPY fragmentincludes a PPF motif. Alternatively, the PPF chimeric can comprise afragment of a PP family polypeptide linked to one, two, three, or fourpolypeptides segments, wherein at least one of the linked polypeptidesegments is a fragment of a second PP family polypeptide. In certainembodiments, PPF polypeptides do not include an N-terminal PP fragmentwith a C-terminal NPY fragment. PPF chimeric polypeptide componentmodule will exhibit at least 50% sequence identity to a native PYY(3-36)over the entire length of the PYY(3-36). In some embodiments, such PPFchimeric polypeptide can exhibit at least 60%, at least 70%, at least80%, at least 90%, at least 92%, at least 94% or at least 97% sequenceidentity to a native PYY(3-36) over the entire length of the PYY(3-36).Such PPF chimeric polypeptides can exhibit at least 50%, at least 60%,at least 70%, at least 80%, at least 90%, at least 92%, at least 94% orat least 97% sequence identity to a native PP. In yet anotherembodiment, such PPF chimeric polypeptide can exhibit at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, at least 92%, atleast 94% or at least 97% sequence identity to a native NPY. In someembodiments, the PPF chimeric polypeptides can include at least theN-terminal polyproline PPF motif and the C-terminal tail PPF motif.These PPF chimeras as well as other PYY and PP analogs, are described inUS 2006/013547A1 published Jun. 22, 2006. In one embodiment, any of thePPF family peptides, if not contained as a hybrid component, can beprovided as a second agent, e.g. as a second anti-obesity agent, with ahybrid as described herein.

Again, the PPF chimeric polypeptide will generally retain, at least inpart, a biological activity of native human PP, PYY, or NPY. In someembodiments, the PPF chimeric polypeptide exhibits a biological activityin the treatment and prevention of metabolic conditions and disorders.

The polypeptide fragments of the PPF chimeras can be covalently linkedtogether in any manner known in the art, including but not limited todirect amide bonds or chemical linker groups. Chemical linker groups mayinclude peptide mimetics which induce or stabilize polypeptideconformation. PPF chimeric polypeptides include PYY-PP, PYY-NPY, PP-PYY,PP-NPY, NPY-PP, or NPY-PYY chimeras.

The PPF chimera can be at least 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,31, 32, 33, or 34 amino acids in length. In some embodiments, the PYYanalog polypeptides include only natural L amino acid residues and/ormodified natural L amino acid residues. In some embodiments, the PYYanalog polypeptides do not include unnatural amino acid residues.

In some embodiments, the PPF chimeric polypeptides include:hPP(1-7)-pNPY, hPP(1-17)-pNPY, hPP(19-23)-pNPY, hPP(19-23)-Pro³⁴pNPY,hPP(19-23)-His³⁴pNPY, rPP(19-23)-pNPY, rPP(19-23)-Pro³⁴pNPY,rPP(19-23)-His³⁴pNPY, hPP(1-17)-His³⁴pNPY, pNPY(1-7)-hPP, pNPY(1-7,19-23)-hPP, cPP(1-7)-pNPY(19-23)-hPP, cPP(1-7)-NPY(19-23)-His³⁴hPP,hPP(1-17)-His³⁴pNPY, hPP(19-23)-pNPY, hPP(19-23)-Pro³⁴pNPY,pNPY(1-7)-hPP, pNPY(19-23)-hPP, pNPY(19-23)-Gln³⁴hPP,pNPY(19-23)-His³⁴hPP, pNPY(19-23)-Phe⁶Gln³⁴hPP,pNPY(19-23)-Phe⁶His³⁴hPP, pNPY(1-7, 19-23)-hPP, pNPY(1-7,19-23)-Gln³⁴hPP, cPP(20-23)-Pro³⁴-pNPY, cPP(21-23)-Pro³⁴-pNPY,cPP(22-23)-Pro³⁴-pNPY, cPP(1-7)-Pro³⁴-pNPY, cPP(20-23)-Pro³⁴-pNPY,cPP(1-7, 20-23)-Pro³⁴-pNPY, cPP(1-7)-pNPY(19-23)-hPP,cPP(1-7)-pNPY(19-23)-His³⁴hPP, cPP(1-7)-gPP(19-23)-hPP,cPP(1-7)-pNPY(19-23)-Ala³¹Aib³²Gln³⁴-hPP,cPP(1-7)-pNPY(19-23)-Ala³¹Aib³²His³⁴-hPP hPP(1-7)-Ala³¹Aib³²-pNPY,hPP(1-17)-Ala³¹Aib³²-pNPY, pNPY(1-7)-Ala³¹Aib³²Gln³⁴-hPP, or pNPY(1-7,19-23)-Ala³¹Aib³²Gln³⁴-hPP.

In some embodiments, the PPF chimeric polypeptides can comprisefragments of PP family analog polypeptides. For instance, the PPFchimeric polypeptides may comprise PPF analog polypeptides describedherein, as well as PP analog polypeptides, and NPY analog polypeptides.

PYY analog polypeptide for use in the GIP hybrids of the invention, oradministered as a second agent with a GIP hybrid, are those having apotency in one of the assays described herein (including food intake,gastric emptying, pancreatic secretion, body composition or weightreduction assays) which is equal to or greater than the potency of NPY,PYY, or PYY(3-36) in that same assay. In some embodiments, the PPYanalog polypeptide for use in a GIP hybrid component may be useful inthe treatment of metabolic diseases, such as, for example, obesity,insulin resistance syndrome (Syndrome X) or diabetes mellitus. In someembodiments, the PYY analog polypeptide for use in a GIP hybrid mayexhibit improved ease of manufacture, stability, and/or ease offormulation, as compared to PP, NPY, PYY, or PYY(3-36).

In some embodiments, the PPF chimeric polypeptide component portionretains at least about 25%, or from about 30%, about 40%, about 50%,about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, orabout 99% percent of the biological activity of native human PYY withregard to the reduction of nutrient availability, the reduction of foodintake, the effect of body weight gain, and/or the treatment andprevention of metabolic conditions and disorders. In another embodiment,the PPF chimeric polypeptide for use in a GIP hybrid exhibits improvedPYY agonist activity. In some embodiments, the PPF chimeric polypeptidesexhibits at least about 110%, about 125%, about 130%, about 140%, about150%, about 200%, or more of the biological activity of native human PYYwith regard to the reduction of nutrient availability the reduction offood intake, the effect of body weight gain, and/or the treatment andprevention of metabolic conditions and disorders.

More particularly, in one aspect, the PPF chimeric polypeptides comprisea fragment of PP linked to a fragment of PYY. In one embodiment, the PPFchimeric polypeptides comprise an N-terminal fragment of PP or a PPanalog polypeptide linked at its C-terminal end to a C-terminal fragmentof PYY or a PYY analog polypeptide. In another embodiment, the PPFchimeric polypeptides comprise an N-terminal fragment of PYY, PYY(3-36),or a PYY analog polypeptide linked at its C-terminal end to a C-terminalfragment of PP or a PP analog polypeptide.

In some embodiments, the PPF chimeric polypeptides comprise a fragmentof PYY linked to a fragment of NPY. In one embodiment, the PPF chimericpolypeptides comprise an N-terminal fragment of PYY, PYY(3-36), or a PYYanalog polypeptide linked at its C-terminal end to a C-terminal fragmentof NPY or a NPY analog polypeptide. In another embodiment, the PPFchimeric polypeptides comprise an N-terminal fragment of NPY or a NPYanalog polypeptide linked at its C-terminal end to a C-terminal fragmentof PYY or a PYY analog polypeptide.

In some embodiments, the PPF chimeric polypeptides comprise a fragmentof PP linked to a fragment of NPY. In one embodiment, the PPF chimericpolypeptides comprise an N-terminal fragment of PP or a PP analogpolypeptide linked at its C-terminal end to a C-terminal fragment of NPYor a NPY analog polypeptide. In another embodiment, the PPF chimericpolypeptides comprise an N-terminal fragment of NPY or a NPY analogpolypeptide linked at its C-terminal end to a C-terminal fragment of PPor a PP analog polypeptide.

In some embodiments, a fragment of PP, a PP analog polypeptide, PYY,PYY(3-36), a PYY analog polypeptide, NPY, or an NPY analog polypeptideis a fragment comprising anywhere from 4 to 20 amino acid residues ofthe PP, PP analog polypeptide, PYY, PYY(3-36), PYY analog polypeptide,NPY, or NPY analog polypeptide. In some embodiments, the length offragment is selected so as to obtain a final PPF chimeric polypeptide ofat least 34 amino acids in length.

The PPF chimeric polypeptides when used in a GIP hybrid may alsocomprise further modifications including, but are not limited to,substitution, deletion, and insertion to the amino acid sequence of suchPPF chimeric polypeptides and any combination thereof. In someembodiments, the PPF chimeric polypeptides include one or moremodifications of a “non-essential” amino acid residue. A “non-essential”amino acid residue is a residue that can be altered, i.e., deleted orsubstituted, in the native human amino acid sequence without abolishingor substantially reducing the activity interest.

Derivatives of the PPF chimeric polypeptides are also useful in a GIPhybrid. Such derivatives include PPF chimeric polypeptides conjugated toone or more water soluble polymer molecules, such as polyethylene glycol(“PEG”) or fatty acid chains of various lengths (e.g., stearyl,palmitoyl, octanoyl, oleoyl etc.), or by the addition of polyaminoacids, such as poly-his, poly-arg, poly-lys, and poly-ala. Modificationsto the PPF chimeric polypeptides can also include small moleculesubstituents, such as short alkyls and constrained alkyls (e.g.,branched, cyclic, fused, adamantyl), and aromatic groups. In someembodiments, the water soluble polymer molecules will have a molecularweight ranging from about 500 to about 20,000 Daltons.

Such polymer-conjugations and small molecule substituent modificationsmay occur singularly at the N- or C-terminus or at the side chains ofamino acid residues, which are not involved in formation of the hybrid,within the sequence of the PPF chimeric polypeptides. Alternatively,there may be multiple sites of derivatization along the PPF chimericpolypeptide. Substitution of one or more amino acids with lysine,aspartic acid, glutamic acid, or cysteine may provide additional sitesfor derivatization. See, e.g., U.S. Pat. Nos. 5,824,784 and 5,824,778.In some embodiments, the PPF chimeric polypeptides may be conjugated toone, two, or three polymer molecules.

In some embodiments, the water soluble polymer molecules are linked toan amino, carboxyl, or thiol group, and may be linked by N or Cterminus, or at the side chains of lysine, aspartic acid, glutamic acid,or cysteine. Alternatively, the water soluble polymer molecules may belinked with diamine and dicarboxylic groups. In some embodiments, thePPF chimeric polypeptides are conjugated to one, two, or three PEGmolecules through an epsilon amino group on a lysine amino acid.

PPF chimeric polypeptides also include PPF chimeric polypeptides withchemical alterations to one or more amino acid residues. Such chemicalalterations include amidation, glycosylation, acylation, sulfation,phosphorylation, acetylation, and cyclization. The chemical alterationsmay occur singularly at the N- or C-terminus or at the side chains ofamino acid residues within the sequence of the PPF chimericpolypeptides. In one embodiment, the C-terminus of these peptides mayhave a free —OH or —NH₂ group. In another embodiment, the N-terminal endmay be capped with an isobutyloxycarbonyl group, an isopropyloxycarbonylgroup, an n-butyloxycarbonyl group, an ethoxycarbonyl group, anisocaproyl group (isocap), an octanyl group, an octyl glycine group(G(Oct)), or an 8-aminooctanic acid group. In some embodiments,cyclization can be through the formation of disulfide bridges.Alternatively, there may be multiple sites of chemical alteration alongthe PYY analog polypeptide.

In some embodiments, the PPF chimeric polypeptides include those havingan amino acid sequence of SEQ ID NOs. 238-347 of US2006/013547A1.

Exemplary PPF chimeric polypeptides include polypeptides of the Formula(VI):

(SEQ ID NO: 574) Xaa₁ Xaa₂ Xaa₃ Xaa₄ Pro Glu Xaa₇ Pro Xaa₉ GluAsp Xaa₁₂ Xaa₁₃ Xaa₁₄ Glu Xaa₁₆ Xaa₁₇ Xaa₁₈ Xaa₁₉Tyr Xaa₂₁ Xaa₂₂ Xaa₂₃ Leu Xaa₂₅ Xaa₂₆ Tyr Xaa₂₈ AsnXaa₃₀ Xaa₃₁ Thr Arg Gln Xaa₃₅ Xaa₃₆ wherein:

-   Xaa₁ is Tyr or absent;-   Xaa₂ is Ile, Pro, or absent;-   Xaa₃ is Ile, BH-modified Lys, Lys, Val, or Pro;-   Xaa₄ is Lys, BH-modified Lys, Ala, Ser, or Arg;-   Xaa₇ is Ala, Gly, or His;-   Xaa₉ is Gly or Ala;-   Xaa₁₂ is Ala or Pro;-   Xaa₁₃ is Ser or Pro;-   Xaa₁₄ is Pro, Ala, or Ser;-   Xaa₁₆ is Glu or Asp;-   Xaa₁₇ is Leu or Ile;-   Xaa₁₈ is Asn or Ala;-   Xaa₁₉ is Arg, Lys, BH-modified Lys, Gln, or N(Me)Ala;-   Xaa₂₁ is Tyr, Ala, Phe, Lys or BH-modified Lys;-   Xaa₂₂ is Ala or Ser;-   Xaa₂₃ is Ser, Ala, or Asp;-   Xaa₂₅ is Arg, Lys or BH-modified Lys;-   Xaa₂₆ is His, Ala, or Arg;-   Xaa₂₈ is Leu or Ile;-   Xaa₃₀ is Leu or Met;-   Xaa₃₁ is Val, Ile, or Leu;-   Xaa₃₅ is Lys, BH-modified Lys, or Arg; and-   Xaa₃₆ is Tyr, Trp, or Phe.

In one embodiment the PPF polypeptide of Formula VI can be a native PPFpolypeptide, PYY(2-36), Val3hPYY(3-36), Lys25hPYY(3-36),Lys25Ile28hPYY(3-36), Lys25Ile31hPYY(3-36), Lys25Leu31hPYY(3-36),Lys25Phe36hPYY(3-36), Ile28hPYY(3-36), Ile31hPYY(3-36), Leu31hPYY(3-36),Phe36hPYY(3-36), Leu31Phe36hPYY(3-36), or Pro13Ala14hPYY.

As will be recognized by one of skill in the art, the polypeptides ofFormula VI may be in the free acid form, or may be C-terminallyamidated.

In some embodiments, the PPF polypeptide may comprise an N-terminalfragment consisting essentially of the first 17 amino acid residues ofnative human PYY (Tyr Pro Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala SerPro Glu Glu Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu ValThr Arg Gln Arg Tyr) (SEQ ID NO:46) linked to a C-terminal fragmentconsisting essentially of amino acid residues 18-36 of native human NPY(Tyr Pro Ser Lys Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp Met AlaArg Tyr Tyr Ser Ala Leu Arg His Tyr Ile Asn Leu Ile Thr Arg Gln Arg Tyr)(SEQ ID NO:577), wherein one or more amino acid residues at theN-terminus of the PYY fragment may be deleted or absent, and whereinone, two, three, four, five, six, seven, eight, nine or ten amino acidsubstitutions may be made in each of the PYY and NPY fragments. In someembodiments, an N-terminal fragment consisting essentially of the first17 amino acids of the PPF polypeptide may exhibit at least 50%, at least60%, at least 70%, at least 80%, at least 90%, at least 92%, at least94% or at least 97% sequence identity to the first 17 amino acids of anative PYY. In some embodiments, a C-terminal fragment of the PPFpolypeptide consisting essentially of amino acid residues 18-36 mayexhibit at least 50%, at least 60%, at least 70%, at least 80%, at least90%, at least 92%, at least 94% or at least 97% sequence identity toamino acids 18-36 of a native NPY. In some embodiments, amino acids inthe N-terminal fragment of PYY (e.g., prolines at position 5 and 8,glutamates at positions 6, 10 and 15, or aspartate at position 11),and/or amino acids in the C-terminal fragment of NPY (e.g., tyrosines atpositions 20 and 27, leucine at position 24, asparagine at position 29,threonine at position 32, arginine at position 33, or glutamine atposition 34) are not substituted. In some embodiments, the PPFpolypeptides include those having an amino acid sequence of SEQ ID Nos.266, 267, 274, 282, 320, and 436 to 480 of US2006/013547A1. In someembodiments, the PPF polypeptides further comprise an N-terminal cap.Examples of these PPF polypeptides include SEQ ID NOs: 282, 320, 437,441, 444, 445-447, 452, 454-459, 461-464, 466, 468-470 and 472-480 ofUS2006/013547A1.

Other PPF polypeptides include polypeptides of the Formula (VII):

(SEQ ID NO: 575) Xaa₁ Xaa₂ Pro Xaa₄ Pro Xaa₆ His Pro Xaa₉ Xaa₁₀Xaa₁₁ Xaa₁₂ Xaa₁₃ Xaa₁₄ Xaa₁₅ Xaa₁₆ Xaa₁₇ Ala Xaa₁₉Tyr Xaa₂₁ Xaa₂₂ Xaa₂₃ Leu Xaa₂₅ Xaa₂₆ Xaa₂₇ Xaa₂₈Xaa₂₉ Xaa₃₀ Xaa₃₁ Thr Arg Gln Arg Tyr,wherein:

-   Xaa₁ is Tyr or absent;-   Xaa₂ is Ile, Pro, or absent;-   Xaa₄ is Lys, BH-modified Lys, Ala, Ser, or Arg;-   Xaa₆ is Glu, Gln, Ala, Asn, Asp, or Val;-   Xaa₉ is Gly or Ala;-   Xaa₁₀ is Glu, Ala, Asp, Asn, Gln, Gly, Pro, or Aib;-   Xaa₁₁ is Glu, Ala, Asp, Asn, Gln, Gly, Pro, or Aib;-   Xaa₁₂ is Ala or Pro;-   Xaa₁₃ is Ser or Pro;-   Xaa₁₄ is Pro, Ala, or Ser;-   Xaa₁₅ is Glu, Ala, Asp, Asn, Gln, Gly, Pro, or Aib;-   Xaa₁₆ is Glu or Asp;-   Xaa₁₇ is Leu or Ile;-   Xaa₁₉ is Arg, Lys, BH-modified Lys, Gln, or N(Me)Ala;-   Xaa₂₁ is Tyr, Ala, Phe, Lys, or BH-modified Lys;-   Xaa₂₂ is Ala or Ser;-   Xaa₂₃ is Ser, Ala, or Asp;-   Xaa₂₅ is Arg, Lys or BH-modified Lys;-   Xaa₂₆ is His, Ala, or Arg;-   Xaa₂₇ is Tyr, or Phe;-   Xaa₂₈ is Leu or Ile;-   Xaa₂₉ is Asn, or Gln;-   Xaa₃₀ is Leu or Met; and-   Xaa₃₁ is Val, Ile, or Leu.

As will be recognized by one of skill in the art, the polypeptides ofFormula VII may be in the free acid form, or may be C-terminallyamidated, depending on the linkage to the GIP or other peptide familycomponent in a GIP hybrid.

In some embodiments, the PPF polypeptide may comprise an N-terminalfragment consisting essentially of the first 17 amino acid residues ofnative human PYY (SEQ ID NO:2 of US2006/013547A1) linked to a C-terminalfragment consisting essentially of amino acid residues 18-36 of nativehuman NPY (SEQ ID NO:4 of US 2006/01354A1), wherein one or more aminoacid residues at the N-terminus of the PYY fragment may be deleted orabsent, and wherein one, two, three, four, five, six, seven, eight, nineor ten amino acid substitutions may be made in each of the PYY and NPYfragments. In some embodiments, an N-terminal fragment consistingessentially of the first 17 amino acids of the PPF polypeptide mayexhibit at least 50%, at least 60%, at least 70%, at least 80%, at least90%, at least 92%, at least 94% or at least 97% sequence identity to thefirst 17 amino acids of a native PYY. In some embodiments, a C-terminalfragment of the PPF polypeptide consisting essentially of amino acidresidues 18-36 may exhibit at least 50%, at least 60%, at least 70%, atleast 80%, at least 90%, at least 92%, at least 94% or at least 97%sequence identity to amino acids 18-36 of a native NPY. In someembodiments, amino acids in the N-terminal fragment of PYY (e.g.,prolines at positions 3, 5 and 8, or histidine 7), and/or amino acids inthe C-terminal fragment of NPY (e.g., alanine at position 18, tyrosinesat positions 20 and 36, leucine at position 24, threonine at position32, arginine at position 33, glutamine at position 34, or arginine atposition 35) are not substituted. In some embodiments, the PPFpolypeptides include those having an amino acid sequence of a PYY-NPYchimera such as SEQ ID Nos. 266, 437, 438, 439, 442, 462, 469, 470, 471and 472 of US 2006/013547A1, or a PYY-NPY chimera compound with theamino acid sequence Ile, Lys, Pro, Glu, His, Pro, Gly, Glu, Asp, Ala,Ser, Pro, Glu, Glu, Leu, Ala, Arg, Tyr, Tyr, Ala, Ser, Leu, Arg, Ala,Tyr, Ile, Asn, Leu, Ile, Thr, Arg, Gln, Arg, Tyr-NH2 (SEQ ID NO:456). Insome embodiments, the PPF polypeptides further comprise an N- terminalcap. Examples of these PPF polypeptides include SEQ ID NOs: 437, 462,469, 470 and 472 of US 2006/013547A1. For example sequence 438 ofUS2006/013547A1 is Pro Lys Pro Glu His Pro Gly Glu Asp Ala Ser Pro GluGlu Leu Ala Arg Tyr Tyr Ala Ser Leu Arg Ala Tyr Ile Asn Leu Ile Thr ArgGln Arg Tyr (SEQ ID NO:576). In one embodiment, a hybrid of the presentinvention includes as one component the sequence 438 of US2006/013547A1or a PYY-NPY chimera with the amino acid sequence Ile, Lys, Pro, Glu,His, Pro, Gly, Glu, Asp, Ala, Ser, Pro, Glu, Glu, Leu, Ala, Arg, Tyr,Tyr, Ala, Ser, Leu, Arg, Ala, Tyr, Ile, Asn, Leu, Ile, Thr, Arg, Gln,Arg, Tyr (SEQ ID NO:456), particularly in GIP hybrids useful to treatobesity, reduce weight, reduce or redistribute fat, and reduce caloricintake. Such a GIP hybrid can also further contain an amylinomimeticcomponent or a leptin component or both.

The GIP hybrids containing a PPF polypeptide or PPF chimera componentfind use in methods including, altering body composition of a subject,comprising administering to the subject the hybrid wherein the hybridalters the fat to lean ratio, thereby altering and improving bodycomposition. In one embodiment the PPF polypeptide can comprise an aminoacid sequence selected from the group consisting of a PYY-NPY chimeracompound with the amino acid sequence Ile, Lys, Pro, Glu, His, Pro, Gly,Glu, Asp, Ala, Ser, Pro, Glu, Glu, Leu, Ala, Arg, Tyr, Tyr, Ala, Ser,Leu, Arg, Ala, Tyr, Ile, Asn, Leu, Ile, Thr, Arg, Gln, Arg, Tyr (SEQ IDNO:456), and of the following sequences from US2006/013547A1: SEQ IDNOs: 266, 267, 274, 282, 320, 436, 437, 438, 439, 440, 441, 442, 443,444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457,458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471,472, 473, 474, 475, 476, 477, 478, 479 and 480. In one embodiment bodyfat is reduced and lean body mass is maintained or increased. In oneembodiment the body fat and lean body mass are measured as percent bodyfat and percent lean body mass, respectively. In one further embodimentbody weight is reduced. In another embodiment body weight is maintainedor increased. The compounds can be administered peripherally. The PPFpolypeptide or PPF chimera or PPF-containing GIP hybrid can be used in amethod that further comprises administering to the subject at least oneother agent selected from the group consisting of an amylin, amylinagonist or amylin analog agonist, salmon calcitonin, a cholecystokinin(CCK) or CCK agonist, a leptin (OB protein) or leptin agonist, anexendin or exendin analog agonist, a GLP-1, GLP-1 agonist or GLP-1analog agonist, a CCK or CCK agonist, calcitonin, a calcitonin agonist,a small molecule cannabinoid CB1 receptor antagonist, rimonabant, an 11beta-hydroxysteroid dehydrogenase-1 inhibitor, sibutramine, andphentermine In one embodiment the subject is overweight or obese. In yetanother embodiment the GIP hybrids containing a PPF polypeptide or PPFchimera component, find use in methods including a method forpreferentially lowering plasma triglyceride levels in a subject,comprising administering to the subject an amount of the compoundeffective to lower plasma triglyceride levels, wherein cholesterollevels are lowered to a lesser extent. In a further embodimenttriglyceride levels are lowered and cholesterol levels are not lowered.In a further embodiment triglyceride levels are lowered and LDLcholesterol levels are not lowered. In a further embodiment triglyceridelevels are lowered and LDL cholesterol levels are lowered to a lesserextent. In yet a further embodiment amylase levels are also lowered. Inyet another embodiment the GIP hybrids containing a PPF polypeptide orPPF chimera find use in methods including a method for reducing body fator body fat gain in a subject while maintaining or increasing lean bodymass, comprising administering to the subject an amount of the compoundeffective to reduce body fat or body fat gain while maintaining orincreasing lean body mass. In another embodiment the GIP hybridcontaining a PPF polypeptide or PPF chimera find use in methodsincluding a method of reducing visceral body fat in a subject,comprising administering to the subject an amount of the compoundeffective to reduce visceral body fat and preserve or increase lean bodymass. In another embodiment the GIP hybrid containing a PPF polypeptideor PPF chimera find use in methods including a method to alter fatdistribution in the subject. In one aspect, the alteration results froman increased metabolism of visceral or ectopic fat, or both in thesubject. In another embodiment the GIP hybrid containing a PPFpolypeptide or PPF chimera find use in methods including a method ofincreasing fatty acid β-oxidation while preserving or increasing leanbody mass in a subject comprising administering to the subject an amountof the compound effective to increase fatty acid β-oxidation whilepreserving or increasing lean body mass. In another embodiment the GIPhybrid containing a PPF polypeptide or PPF chimera find use in methodsincluding a method of treating nonalcoholic steatohepatitis orlipodystrophy in a subject comprising administering to the subject anamount of a compound effective to treat nonalcoholic steatohepatitis orlipodystrophy. GIP hybrids of particular interest in the above uses cancontain a PPF chimera as described herein in further combination with acomponent from the leptin family or the amylin family, such as anamylin-sCT-amylin hybrid, or both. A GIP/PPF-chimera/leptin hybrid or aGIP/PPF-chimera/amylin-sCT-amylin hybrid will provide an effect superiorto either parent compound alone. In yet further embodiments aGIP/PPF-chimera/leptin hybrid is administered with an amylinomimeticsuch as an amylin-sCT-amylin chimera, and alternatively aGIP/PPF-chimera/amylin-sCT-amylin hybrid is administered with a leptin.

Incretins and Incretin Mimetics. Component peptide hormones useful inthe present invention also include GLP-1 peptide hormones. Native GLP-1peptide hormones, including GLP-1(1-37), GLP-1(7-37), andGLP-1(7-36)amide, are known in art, as are functional peptide analogsand derivatives. As used herein, GLP-1 refers to all native forms ofGLP-1 peptide hormones. Certain exemplary native peptides, peptideanalogs and derivatives are described herein, however it should berecognized that any known GLP-1 peptides that exhibit hormonal activityknown in the art may be used in conjunction with the present invention.

Central to many metabolic diseases and disorders is the regulation ofinsulin levels and blood glucose levels. Insulin secretion is modulatedin part by secretagogue hormones, termed as incretins, which areproduced by enteroendocrine cells. The incretin hormone, glucagon-likepeptide-1 (“GLP-1”) is a peptide hormone secreted by intestinal cellsthat has been shown in multiple studies to produce an enhancing effecton insulin secretion. GLP-1 is processed from proglucagon in the gut andenhances nutrient-induced insulin release (Kreymann B., et al., Lancet,2:1300-1303 (1987)). Various truncated forms of GLP-1, are known tostimulate insulin secretion (insulinotropic action) and cAMP formation(see, e.g., Mojsov, S., Int. J. Pep. Pro. Res., 40:333-343 (1992)). Arelationship between various in vitro laboratory experiments andmammalian, especially human, insulinotropic responses to exogenousadministration of GLP-1, GLP-1(7-36) amide, and GLP-1(7-37) acid hasbeen established (see, e.g., Nauck, M. A., et al., Diabetologia,36:741-744 (1993); Gutniak, M., et al., New Eng. J. of Med.,326(20):1316-1322 (1992); Nauck, M. A., et al., J. Clin. Invest.,91:301-307 (1993); and Thorens, B., et al., Diabetes, 42:1219-1225(1993)).

GLP-1(7-36) amide exerts a pronounced antidiabetogenic effect ininsulin-dependent diabetics by stimulating insulin sensitivity and byenhancing glucose-induced insulin release at physiologicalconcentrations (Gutniak M., et al., New Eng. J. Med., 326:1316-1322(1992)). When administered to non-insulin dependent diabetics,GLP-1(7-36) amide stimulates insulin release, lowers glucagon secretion,inhibits gastric emptying and enhances glucose utilization (Nauck, 1993;Gutniak, 1992; Nauck, 1993). However, the use of GLP-1 type moleculesfor prolonged therapy of diabetes has been complicated because the serumhalf-life of such peptides is quite short.

More particularly, GLP-1 is a 30-amino acid peptide derived fromproglucagon, a 160-amino acid prohormone. Actions of differentprohormone convertases in the pancreas and intestine result in theproduction of glucagon and other ill-defined peptides, whereas cleavageof proglucagon results in the production of GLP-1 and GLP-2 as well astwo other peptides. The amino acid sequence of GLP-1 is 100% homologousin all mammals studied so far, implying a critical physiological role.GLP-1 (7-37) acid is C-terminally truncated and amidated to form GLP-1(7-36) NH2. The biological effects and metabolic turnover of the freeacid GLP-1 (7-37) OH, and the amide, GLP-1 (7-36) NH2, areindistinguishable. By convention, the numbering of the amino acids isbased on the processed GLP-1 (1-37) OH from proglucagon. Thebiologically active GLP-1 is the result of further processing: GLP-1(7-36) NH2. Thus the first amino acid of GLP-1 (7-37) OH or GLP-1(7-36)NH2 is 7His.

In the gastrointestinal tract, GLP-1 is produced by L-cells ofintestinal, colonic and rectal mucosa, in response to stimulation byintraluminal glucose. The plasma half-life of active GLP-1 is <5minutes, and its metabolic clearance rate is around 12-13 minutes(Holst, Gastroenterology 107(6):1848-55 (1994)). The major proteaseinvolved in the metabolism of GLP-1 is dipeptidyl peptidase (DPP) IV(CD26) which cleaves the N-terminal His-Ala dipeptide, thus producingmetabolites, GLP-1 (9-37) OH or GLP-1 (9-36) NH2 which are variouslydescribed as inactive, weak agonist or antagonists of GLP-1 receptor.The GLP-1 receptor (GLP-1R) is a G protein coupled receptor of 463 aminoacid and is localized in pancreatic beta cells, in the lungs, and to alesser extent in the brain, adipose tissue and kidneys. The stimulationof GLP-1R by GLP-1 (7-37) OH or GLP-1 (7-36)NH2 results in adenylatecyclase activation, cAMP synthesis, membrane depolarization, rise inintracellular calcium and increase in glucose-induced insulin secretion(Holz et al., J. Biol. Chem. 270(30):17749-57 (1995)).

GLP-1 is a potent insulin secretagogue that is secreted from theintestinal mucosa in response to food intake. The profound incretineffect of GLP-1 is underscored by the fact that GLP-1R knockout mice areglucose-intolerant. The incretin response of i.v. infused GLP-1 ispreserved in diabetic subjects, though the incretin response to oralglucose in these patients is compromised. GLP-1 administration byinfusion or sc injections controls fasting glucose levels in diabeticpatients, and maintains the glucose threshold for insulin secretion(Gutniak et al., N. Engl. J. Med. 326:1316-22 (1992); Nauck et al.,Diabet. Med. 13:(9 Suppl 5):S39-S43 (1996); Nauck et al., J. Clin.Endocrinol. Metab. 76:912-917 (1993)). GLP-1 has shown tremendouspotential as a therapeutic agent capable of augmenting insulin secretionin a physiological manner, while avoiding hypoglycemia associated withsulfonylurea drugs.

Other important effects of GLP-1 on glucose homeostasis are suppressionof glucagon secretion and inhibition of gastric motility. GLP-1inhibitory actions on pancreatic alpha cell secretion of glucagon leadsto decreases in hepatic glucose production via reduction ingluconeogenesis and glycogenolysis. This antiglucagon effect of GLP-1 ispreserved in diabetic patients.

The so-called ileal brake effect of GLP-1, in which gastric motility andgastric secretion are inhibited, is effected via vagal efferentreceptors or by direct action on intestinal smooth muscle. Reduction ofgastric acid secretion by GLP-1 contributes to a lag phase in nutrientavailability, thus obviating the need for rapid insulin response. Insummary, the gastrointestinal effects of GLP-1 contribute significantlyto delayed glucose and fatty acid absorption and modulate insulinsecretion and glucose homeostasis.

GLP-1 has also been shown to induce beta cell specific genes, such asGLUT-1 transporter, insulin (via the interaction of PDX-1 with insulingene promoter), and hexokinase-1. Thus GLP-1 could potentially reverseglucose intolerance normally associated with aging, as demonstrated byrodent experiments. In addition, GLP-1 may contribute to beta cellneogenesis and increase beta cell mass, in addition to restoring betacell function during states of beta cell insufficiency.

Central effects of GLP-1 include increases in satiety coupled withdecreases in food intake, effected via the action of hypothalamicGLP-1R. A 48 hour continuous SC infusion of GLP-1 in type II diabeticsubjects, decreased hunger and food intake and increased satiety. Theseanorectic effects were absent in GLP-1R knock out mice.

Thus a GIP hybrid comprising an incretin family hormone module canprovide the functions and uses associated with the incretin familymodule, e.g. exendin-4, GLP1, GLP2, as discussed, in addition to havinga GIP function.

Any GLP-1 peptide analog or derivative known in the art may be used inconjunction with the present invention. In one embodiment, the GLP-1peptide analogs and derivatives have at least one hormonal activity of anative GLP-1 peptide. In certain embodiments, the GLP-1 peptide analogsare agonists of a receptor which a native GLP-1 peptide is capable ofspecifically binding. Exemplary GLP-1 peptide analogs and derivativesinclude those described in, e.g., WO 91/11457, which is herebyincorporated by reference.

GLP-1 analogs known in the art include:

⁹Gln-GLP-1(7-37) D-⁹Gln-GLP-1(7-37) ¹⁶Thr-¹⁸Lys⁻GLP-1(7-37)¹⁸Lys-GLP-1(7-37) ⁸Gly-GLP-1 (7-36) ⁹Gln-GLP-1 (7-37) D-⁹Gln-GLP-1(7-37) acetyl-⁹Lys-GLP-1(7-37) ⁹Thr-GLP-1(7-37) D-⁹Thr-GLP-1 (7-37)⁹Asn-GLP-1 (7-37) D-⁹Asn-GLP-1 (7-37) ²²Ser²³Arg²⁴Arg²⁶Gln-GLP-1(7-37)¹⁶Thr¹⁸Lys-GLP-1(7-37) ¹⁸Lys-GLP-1(7-37) ²³Arg-GLP-1(7-37)²⁴Arg-GLP-1(7-37)

As known in the art, such GLP-1 analogs may preferably be amidated, butwithin the context of the present invention, may optionally be in theacid form unless otherwise specified.

Other GLP-1 analogs and derivatives are disclosed in U.S. Pat. No.5,545,618 which is incorporated herein by reference. A exemplary groupof GLP-1 analogs and derivatives include those disclosed in U.S. Pat.No. 6,747,006, which is herein incorporated by reference in itsentirety. The use in the present invention of a molecule described inU.S. Pat. No. 5,188,666, which is expressly incorporated by reference,is also contemplated. Another group of molecules for use in the presentinvention includes compounds described in U.S. Pat. No. 5,512,549, whichis expressly incorporated herein by reference. Another exemplary groupof GLP-1 compounds for use in the present invention is disclosed in WO91/11457, which is herein incorporated by reference.

In another embodiment useful with GIP or novel GIP analogs are GLP1analogs with Trp-Cage tails (e.g. exendin C-terminal sequence with orwithout the tryptophan (or similar residue) (which can be optionallyprovided as described, e.g. by the presence of a tryptophanadvantageously located in the hormone that is either naturallyoccurring, added as a substitution or as part of a linker.). Theseinclude:

GLP1(7-26)Gly8Ex-4(21-39): (SEQ ID NO: 74)HGEGTFTSDVSSYLEGQAAKLFIEWLKNGG PSSGAPPPS-NH2;GLP1(7-33)(G8,E30,K33)[Ex-4(28-39)]: (SEQ ID NO: 75)HGEGTFTSDVSSYLEGQAAKEFIEWLKNGGPSSGAPPPS-NH2;GLP1(7-33)(G8,K33)[EX4(28-39)]: (SEQ ID NO: 76)HGEGTFTSDVSSYLEGQAAKEFIAWLKNGGPSSGAPPPS-NH2; GLP1(7-33)G8[Ex-4(28-39)]:(SEQ ID NO: 77) HGEGTFTSDVSSYLEGQAAKEFIAWLVNGGPSSGAPPPS-NH2; andGLP1(7-35)G8[Ex-4(30-39)]: (SEQ ID NO: 78)HGEGTFTSDVSSYLEGQAAKEFIAWLVKGGPSSGAPPPS-NH2.

Component peptide hormones useful in the GIP hybrids of the presentinvention also include GLP-2 peptide hormones. Native GLP-2 peptidehormones, e.g., rat GLP-2 and its homologous including ox GLP-2, porcineGLP-2, degu GLP-2, bovine GLP-2, guinea pig GLP-2, hamster GLP-2, humanGLP-2, rainbow trout GLP-2, and chicken GLP-2, are known in art, as arefunctional peptide analogs and derivatives. Certain exemplary nativepeptides, peptide analogs and derivatives are described herein, howeverit should be recognized that any known GLP-2 peptides that exhibithormonal activity known in the art may be used in conjunction with thepresent invention.

Any GLP-2 peptide analog or derivative known in the art may be used inconjunction with the present invention. In one embodiment, the GLP-2peptide analogs and derivatives have at least one hormonal activity of anative GLP-2 peptide. In certain embodiments, the GLP-2 peptide analogsare agonists of a receptor which a native GLP-2 peptide is capable ofspecifically binding. Exemplary GLP-2 peptide analogs and derivativesinclude those described in, e.g., U.S. Ser. No. 08/669,791 and PCTApplication PCT/CA97/00252, both of which are hereby incorporated byreference. Specific GLP-2 analogs known in the art include: rat or humanGLP-2 altered at position 2 to confer DPP-IV resistance by substitutinga Gly for an Ala.

Component peptide hormones useful in the present invention also includeoxyntomodulin (OXM) peptide hormones. Native OXM peptide hormones areknown in art, as are functional peptide analogs and derivatives. Certainexemplary native peptides, peptide analogs and derivatives are describedherein, however it should be recognized that any known OXM peptides thatexhibit hormonal activity known in the art may be used in conjunctionwith the present invention.

Any OXM peptide analog or derivative known in the art may be used inconjunction with the present invention. In one embodiment, the OXMpeptide analogs and derivatives have at least one hormonal activity of anative OXM peptide. In certain embodiments, the OXM peptide analogs areagonists of a receptor which a native OXM peptide is capable ofspecifically binding.

Component peptide hormones useful in the present invention also includeexendin peptide hormones. Native exendin peptide hormones are known inart, as are functional peptide analogs and derivatives. Certainexemplary native peptides, peptide analogs and derivatives are describedherein, however it should be recognized that any known exendin peptidesthat exhibit hormonal activity known in the art may be used inconjunction with the present invention.

Exendins are another family of peptides implicated in insulin secretion.Exendins are found in the saliva of the Gila-monster, a lizardendogenous to Arizona, and the Mexican Beaded Lizard. Exendin-3 ispresent in the saliva of Heloderma horridum, and exendin-4 is present inthe saliva of Heloderma suspectum (Eng, J., et al., J. Biol. Chem.,265:20259-62, 1990; Eng., J., et al., J. Biol. Chem., 267:7402-05(1992)). The exendins have some sequence similarity to several membersof the glucagon-like peptide family, with the highest identity, 53%,being to GLP-1 (Goke, et al., J. Biol. Chem., 268:19650-55 (1993)).

Exendin-4 binds the GLP-1 receptors on insulin-secreting TC1 cells, atdispersed acinar cells from guinea pig pancreas, and at parietal cellsfrom stomach; the peptide also stimulates somatostatin release andinhibits gastrin release in isolated stomachs (Goke, et al., J. Biol.Chem., 268:19650-55 (1993); Schepp, et al., Eur. J. Pharmacol.,69:183-91 (1994); Eissele, et al., Life Sci., 55:629-34 (1994)).Exendin-3 and exendin-4 were found to bind the GLP-1 receptors on, tostimulating cAMP production in, and amylase release from, pancreaticacinar cells (Malhotra, R., et al., Relulatory Peptides, 41:149-56(1992); Raufman, et al., J. Biol. Chem., 267:21432-37 (1992); Singh, etal., Regul. Pept., 53:47-59 (1994)). The use of the insulinotropicactivities of exendin-3 and exendin-4 for the treatment of diabetesmellitus and the prevention of hyperglycemia has been proposed (Eng,U.S. Pat. No. 5,424,286).

Truncated exendin peptides such as exendin[9-39], a carboxyamidatedmolecule, and fragments 3-39 through 9-39 have been reported to bepotent and selective antagonists of GLP-1 (Goke, et al., J. Biol. Chem.,268:19650-55 (1993); Raufman, J. P., et al., J. Biol. Chem.,266:2897-902 (1991); Schepp, W., et al., Eur. J. Pharm., 269:183-91(1994); Montrose-Rafizadeh, et al., Diabetes, 45(Suppl. 2):152A (1996)).Exendin[9-39] blocks endogenous GLP-1 in vivo, resulting in reducedinsulin secretion (Wang, et al., J. Clin. Invest., 95:417-21 (1995);D'Alessio, et al., J. Clin. Invest., 97:133-38 (1996)). The receptorapparently responsible for the insulinotropic effect of GLP-1 has beencloned from rat pancreatic islet cells (Thorens, B., Proc. Natl. Acad.Sci. USA 89:8641-8645 (1992)). Exendins and exendin[9-39] bind to thecloned GLP-1 receptor (rat pancreatic-cell GLP-1 receptor: Fehmann H C,et al., Peptides, 15 (3): 453-6 (1994); human GLP-1 receptor: Thorens B,et al., Diabetes, 42 (11): 1678-82 (1993)). In cells transfected withthe cloned GLP-1 receptor, exendin-4 is an agonist, i.e., it increasescAMP, while exendin[9-39] is an antagonist, i.e., it blocks thestimulatory actions of exendin-4 and GLP-1. Id.

More particularly, exendin-4 is a 39 amino acid C-terminal amidatedpeptide found in the saliva of the Gila Monster (Heloderma suspectum),with a 53% amino acid sequence identity to the GLP-1 peptide sequence.See, e.g., Eng, J., et al. “Isolation and Characterization of Exendin-4,and Exendin-3 Analogue from Heloderma suspectum Venom,” J. Bio. Chem.,267:11, p. 7402-7405 (1992), Young, A. A., et al., “Glucose-Lowering andInsulin-Sensitizing Actions of Exendin-4,” Diabetes, Vol. 48, p.1026-1034, May, 1999. In terms of its activity, exendin-4 is a highlyspecific agonist for the GLP-1 receptor, and, like GLP-1, is able tostimulate insulin secretion. Therefore, like GLP-1, exendin-4 isregarded as an insulinotropic peptide.

However, unlike GLP-1, exendin-4 has a relatively long half-life inhumans, because of its resistance to the dipeptidyl peptidase IV whichrapidly degrades the GLP-1 sequence in vivo. Furthermore, it has beenshown that, as compared to GLP-1, exendin-4 has a stronger capability tostimulate insulin secretion, and that a lower concentration of exendin-4may be used to obtain such stimulating activity. See, e.g., U.S. Pat.No. 5,424,286, herein incorporated by reference. Therefore exendin-4peptides or derivatives thereof (for examples of such derivatives, see,e.g., U.S. Pat. No. 6,528,486, herein incorporated by reference, and itscorresponding international application WO 01/04156) have a greaterpotential utility for the treatment of conditions involving thedysregulation of insulin levels (e.g., conditions such as diabetes) thaneither insulin or GLP-1. Thus a GIP hybrid comprising an exendin familyhormone module can provide the functions and uses associated with theexendin family module, e.g. exendin-4, exendin tail, as discussed, inaddition to having a GIP function.

Any exendin peptide analog or derivative known in the art may be used inconjunction with the present invention. In one embodiment, the exendinpeptide analogs and derivatives have at least one hormonal activity of anative exendin peptide. In certain embodiments, the exendin peptideanalogs are agonists of a receptor which a native exendin peptide iscapable of specifically binding.

Exemplary exendin analogs include:

¹⁴Leu, ²⁵Phe-exendin-4 ⁵Ala, ¹⁴Leu, ²⁵Phe-exendin-4 ¹⁴Leu, ²²Ala,²⁵Phe-exendin-4

As known in the art, such exendin analogs are preferably amidated, butwithin the context of the present invention, may optionally be in theacid form unless otherwise specified.

Additional exemplary exendin analogs and derivatives are described inPCT Application Serial No. PCT/US98/16387 filed Aug. 6, 1998, entitled“Novel Exendin Agonist Compounds,” which claims the benefit of U.S.patent application Ser. No. 60/055,404, filed Aug. 8, 1997, both ofwhich are herein incorporated by reference. Other exendin analogs andderivatives are described in PCT Application Serial No. PCT/US98/24210,filed Nov. 13, 1998, entitled “Novel Exendin Agonist Compounds,” whichclaims the benefit of U.S. Provisional Application No. 60/065,442 filedNov. 14, 1997, both of which are herein incorporated by reference. Stillother exendin analogs and derivatives are described in PCT ApplicationSerial No. PCT/US98/24273, filed Nov. 13, 1998, entitled “Novel ExendinAgonist Compounds,” which claims the benefit of U.S. ProvisionalApplication No. 60/066,029 filed Nov. 14, 1997, both of which are hereinincorporated by reference. Still other exendin analogs and derivativesare described in PCT Application Serial No. PCT/US97/14199, filed Aug.8, 1997, entitled “Methods for Regulating Gastrointestinal Activity,”which is a continuation-in-part of U.S. patent application Ser. No.08/694,954 filed Aug. 8, 1996, both of which are hereby incorporated byreference. Still other exendin analogs and derivatives are described inPCT Application Serial No. PCT/US98/00449, filed Jan. 7, 1998, entitled“Use of Exendins and Agonists Thereof for the Reduction of Food Intake,”which claims priority to U.S. Provisional Application No. 60/034,905filed Jan. 7, 1997, both of which are hereby incorporated by reference.Yet other exendin analogs and derivatives are described in US2004/0209803 A1, filed Dec. 19, 2003, entitled “Compositions for theTreatment and Prevention of Neuropathy,” which is hereby incorporated byreference.

Catestatin Family. The catestatin fragment of chromogranin A is anendogenous inhibitor of nicotinic cholinergic transmission, functioningin negative feedback control of catecholamine secretion. We explorednaturally occurring polymorphisms in the amino acid sequence ofcatestatin. Three human variants were identified: Gly364Ser, Pro370Leu,and Arg374Gln.

Sequence variants in human catestatin (human chromogranin A352-372) andinterspecies homologies in humans and other mammals are shown below.Amino acids at positions variant in human catestatin are shown in boldtype. The typical dibasic proteolytic cleavage site at thecarboxy-terminal side of catestatin is given in brackets, [RR]. Forhuman chromogranin A, this [RR] site is Arg373Arg374. In furtherembodiments, variants absent either or both arginines are included. GIPhybrids containing catestatin family members, analogs, derivatives orfragments thereof, find use in the treatment methods of the invention.For example, such hybrids will find use in treating cardiovasculardiseases and conditions as discussed herein, including hypertension andcongestive heart failure and related conditions. Combined with an activeGIP hormone module, the compounds will find use in the critical careconditions described herein. Catestatin species variants include:

(SEQ ID NO: 79) Mouse RSMRLSFRTRGYGFRDPGLQL[RR] CGA364-384(SEQ ID NO: 80) Rat RSMRLSFRARGYGFRDPGLQL[RR] CGA367-387 (SEQ ID NO: 81)Cow RSMRLSFRARGYGFRGPGLQL[RR] CGA344-364 (SEQ ID NO: 82) PigRSMRLSFRAPAYGFRGPGLQL[RR] CGA343-363 (SEQ ID NO: 83) HorseRSMKLSFRARAYGFRGPGLQL[RR] CGA343-363 (SEQ ID NO: 84) ChimpSSMKLSFRARAYGFRGPGPQL[RR] CGA354-374 Human: (SEQ ID NO: 85) Wild-typeSSMKLSFRARAYGFRGPGPQL[RR] CGA352-372 (SEQ ID NO: 86) VariantSSMKLSFRARAYSFRGPGPQL[RR] (SEQ ID NO: 87) VariantSSMKLSFRARAYGFRGPGLQL[RR] (SEQ ID NO: 88) VariantSSMKLSFRARAYGFRGPGPQL[RQ]

Natriuretic Peptides. Natriuretic peptides are a family of hormones thatconsist of atrial natriuretic peptide (ANP), brain natriuretic peptide(BNP), and C-type natriuretic peptide (CNP). They are synthesized andstored as 3 distinct precursor prohormones, which are the 126 amino acidANP, 108 amino acid BNP, and 104 amino acid CNP. They are each encodedby separate genes and have distinct sites of synthesis and mechanisms ofregulation. Parental natriuretic peptide sequences include:

SEQ ID No: Description Sequence 89 151 amino acidMSSFSTTTVSFLLLLAFQLLGQTRANPMYNAVS human ANPNADLMDFKNLLDHLEEKMPLEDEVVPPQVLSD preprohormonePNEEAGAALSPLPEVPPWTGEVSPAQRDGGALG RGPWDSSDRSALLKSKLRALLTAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY 90 134 amino acid MDPQTAPSRALLLLLFLHLAFLGGRSHPLGSPGhuman BNP SASDLETSGLQEQRNHLQGKLSELQVEQTSLEP preprohormoneLQESPRPTGVWKSREVATEGIRGHRKMVLYTLR APRSPKMVQGSGCFGRKMDRISSSSGLGCKVLR RH91 126 amino acid MHLSQLLACALLLTLLSLRPSEAKPGAPPKVPR human CNPTPPAEELAEPQAAGGGQKKGDKAPGGGGANLKG preproCNPDRSRLLRDLRVDTKSRAAWARLLQEHPNARKY KGANKKGLSKGCFGLKLDRIGSMSGLGC

The main site of synthesis of the ANP prohormone is the atrial myocytewhere it is synthesized as a 151-amino acid preprohormone. Removal of a25-amino acid signal peptide from its N terminal end occurs in theendoplasmic reticulum, leaving a 126-amino acid ANP prohormone (ProANP),the main storage form of ANP within the heart. The prohormone consistsof 4 biologically active peptide segments: amino acids 1-30 (ProANF1-30, also known as long acting Na stimulator), 31-67 (ProANF 31-67,also known as vessel dilator), 79-98 (ProANF 79-98, also known aspotassium excreter), and 99-126 (ANF, also known as atrial natriureticfactor).

BNP was originally isolated from porcine brain but in humans it issynthesized and secreted from the left ventricle. Sequence analysisreveals that preproBNP consists of 134 residues and is cleaved to a108-amino acid ProBNP. Cleavage of a 32-amino acid sequence from theC-terminal end of ProBNP results in human BNP (77-108), which is thephysiologically active form in plasma.

CNP is the third member of the natriuretic peptide system and isprimarily found in human vascular endothelial cells, kidney, and porcinebrain. High concentrations of CNP are also found in human hypothalamusand midbrain. In humans, preproCNP is a 126-amino acid precursorprocessed into proCNP by cleavage of 23 residues from its N-terminalend. This 23-amino acid sequence serves as a signal peptide. Theterminal 22 (105-126) amino acids are cleaved from proCNP to yield abiologically active form of CNP.

Urodilatin is a kidney-derived member of the natriuretic peptide familyand is formed from the same ANP prohormone and consists of amino acids95-126. Except for the 4 amino acid N terminal extension, it isidentical to ANF (99-126). Urodilatin appears to be an importantregulator of sodium and water handling in the kidney, as well as amediator of sodium excretion in patients with congestive heart failure(CHF).

Natriuretic peptides exert their biologic effects by binding tohigh-affinity receptors on the surface of target cells. Three subtypesof NPRs—NPR-A, NPR-B, and NPRC—have been isolated. Consequently, in oneembodiment is provided a method to screen hybrids for natriureticreceptor binding and/or activation. Natriuretic peptides includingprohormone variants can impart numerous natriuretic peptide hormoneactivities to hybrids of the invention. In other embodiments of interestare natriuretic antagonist hybrids. Natriuresis is the excretion of anexcessively large amount of sodium into the urine. Natriuresis issimilar to diuresis (the excretion of an unusually large quantity ofurine), except that in natriuresis the urine is exceptionally salty.Natriuresis occurs with some diuretics and diseases (as of the adrenal)and can lead to the salt-losing syndrome characterized by dehydration,vomiting, low blood pressure, and the risk of sudden death. Exogenousadministration of the 4 independent circulating peptides of the ANPprohormone (1-30, 31-67, 79-98, and 99-126) produce in vivovasodilation, diuresis, suppression of the renin-angiotensin-aldosteronesystem and enhanced natriuresis and/or kaliuresis. ProANF 1-30, ProANF31-67 and ANF 99-126 each have natriuretic, blood pressure lowering anddiuretic properties with ProANF 31-67 and ANF 99-126 having the greatestimpact on blood pressure. There are varying effects of the ANP peptideson potassium homeostasis: ProANF 79-98 stimulates potassium excretion,whereas ProANF 31-67 spares potassium loss by inhibiting Na/K ATPase inthe medullary collecting duct cells. Specific to ANF 99-126 is adose-dependent inhibition of angiotensin II-mediated aldosteronesecretion, whereas proANF 31-67 has the property of inducing natriuresisthrough generation of prostaglandin.

BNP produces similar biologic effects as ANF in normal humans. Infusionsof BNP in normal men produced a 2-fold increase in sodium excretion, 50%reduction in plasma renin, angiotensin II and aldosterone secretion aswell as a reduction in plasma volume.

CNP induces cardiovascular effects similar to the other natriureticpeptides but does not appear to mediate any renal effects. When CNP isinfused in anesthetized dogs at equivalent doses of ANF, plasma cGMProse with a concomitant reduction in mean arterial pressure, rightatrial pressure and cardiac output, but glomerular filtration rate,renal blood flow and sodium excretion decreased.

Natriuretic peptides can provide therapeutic benefit in heart failure.Congestive heart failure (CHF) is associated with increases invasopressin, endothelin, and with activation of therenin-angiotensin-aldosterone system, and sympathetic nervous systems,mediating vasoconstriction, sodium and water retention, and negativevascular and cardiac remodeling. These effects occur despite theelevated levels of the natriuretic peptides in patients with heartfailure. In one embodiment of the invention are hybrids that provideincreased or therapeutic serum levels of natriuretic peptide activityfor treatment or prevention of cardiac related diseases and conditions,including CHF. Although ANF infusion in normal individuals can result ina sustained increase in sodium excretion and urine flow rates, in theheart failure patient a marked beneficial reduction in renal responsecan be obtained. BNP infusion markedly increases sodium excretion inpatients with heart failure and exerts significant beneficialhemodynamic effects. As compared with ANP, the diuretic and natriureticeffects of BNP are significantly greater. BNP is cleared more slowlythan ANP and exerts other effects including suppressing aldosteronesecretion and increasing serum levels of ANP. BNP peptides can alsoprovide a beneficial decrease in pulmonary capillary wedge pressure,systemic vascular resistance, right atrial pressure and systolic bloodpressure, with an increase in cardiac index in patients hospitalized forsymptomatic CHF. In patients with decompensated heart failure,natriuretic peptide hybrids can provide a beneficial decrease inpulmonary capillary wedge pressure and an improved dyspnea score.(Dyspnea is an unpleasant sensation of difficulty in breathing,typically associated with early stages of cardiac heart failure.) Thehybrids containing one, two or three natriuretic hormone functionsprovide methods of administration of pharmaceutically activecompositions that are useful for both the prophylactic and therapeutictreatment of CHF patients, preferably CHF patients that aredecompensated, patients with chronic CHF, and patients withhypertension. The natriuretic portion(s) of a hybrid is sufficient toprovide a therapeutically effective amount of a natriurertic peptide tosuch patient when administered in a therapeutically effective dose overa therapeutically effective period.

As discussed herein any of the family of therapeutically effectivenatriuretic peptides or their analogs can be used as a component of aGIP hybrid. Useful natriuretic peptides include, for example, atrialnatriuretic peptide (ANP), brain natriuretic peptide (BNP or B-typenatriuretic peptide) and C-type natriuretic peptide (CNP). Sequences ofuseful forms of natriuretic peptides are disclosed in U.S. PatentPublication 20010027181, which is incorporated herein by reference.Examples of ANPs include human ANP (Kangawa et al., BBRC 118:131 (1984))or that from various species, including pig and rat ANP (Kangawa et al.,BBRC 121:585 (1984)). Such ANPs comprise 28 amino acids. Such ANPs maybe administered as a peptide having a ring structure of ANP (formationof a disulfide bond based on Cys), and a C-terminal portion succeedingthe ring structure. An example of such a peptide is a peptide havingamino acid residues at the 7-position to the 28-position of ANP isprovided in U.S. Patent Application Publication No. 20010027181. Anotherexample is frog ANP. Specific examples of BNPs that can be used in themethods of the invention include human BNP (hBNP). Human BNP comprises32 amino acids and involves the formation of a disulfide bond (Sudoh etal., BBRC 159:1420 (1989)) and U.S. Pat. Nos. 5,114,923, 5,674,710,5,674,710, and 5,948,761, each of which is incorporated by reference.Various BNP's of origin other than human, including as pig BNP and ratBNP, are also known, and can be used. A further example is chicken BNP.Examples of CNPs that can be used in the methods of the inventioninclude pig CNP. Pig CNP comprises 22 amino acids and involves theformation of a disulfide bond, like the above-described ANP and BNP(Sudoh et al., BBRC 168:863 (1990)) (human and rat have the same aminoacid sequence), chicken CNP (Arimura et al., BBRC 174:142 (1991)). FrogCNP (Yoshihara et al., BBRC 173:591 (1990) can also be used. Asdiscussed herein, one skilled in the art can apply modifications, suchas a deletion, substitution, addition or insertion, and/or chemicalmodification to amino acid residues in the amino acid sequence of aknown natriuretic peptide as desired, by known methods. The resultingcompound has the activity of acting on a receptor of the starting ANP,BNP or CNP. Analogs having this activity, therefore, are included in thehybrids for use in accordance with the methods of the present invention.

In another embodiment, the hybrids containing one or more natriureticfunctions can be used in treating hypertension. In one embodiment anatriuretic hybrid will have no deleterious effect on heart rate and isnot associated with arrhythmias. In one embodiment the hybrid willcomprise at least one, two or three natriuretic peptide functions, forexample, both ANP and BNP activity. One or more natriuretic hormonefunctions can be combined with any other hormone function or peptidicenhancer, as described herein. In another embodiment the natriureticportion(s) is a more stable analog having an extended in vivo half-lifewhen compared with that of a native natriuretic peptide. Analogs thatprevent undesirable cleavage by endogenous enzymes such as NEP are alsoenvisioned. The natriuretic containing hybrids are also further directedto hypertension reduction, diuresis inducement, natriuresis inducement,vascular conduct dilatation or relaxation, natriuretic peptide receptors(such as NPR-A) binding, renin secretion suppression from the kidney,aldostrerone secretion suppression from the adrenal gland, treatment ofcardiovascular diseases and disorders, reducing, stopping or reversingcardiac remodeling in congestive heart failure, treatment of renaldiseases and disorders; treatment or prevention of ischemic stroke, andtreatment of asthma. Hybrids can be administered to patients that wouldbenefit from inducing natriuresis, diuresis and vasodilatation. Hybridscan be administered alone or in combination with one or more of thefollowing types of compounds: ACE inhibitors, beta-blockers, diuretics,spironolactone, digoxin, anticoagulation and antiplatelet agents, andangiotensin receptor blockers. Additional diseases or conditions includerenal disorders and diseases, asthma, hypertension and pulmonaryhypertension. Hybrids are also useful to treat inflammatory-relateddiseases, erectile dysfunction and hypercholesterolemia.

Peptide Module Selection Considerations, Spacers, and Linking Groups.

The GIP hybrid polypeptides of the present invention generally compriseat least two bio-active peptide hormone modules of the invention,wherein at least one of the bio-active peptide hormone modules,typically a GIP module, exhibits at least one hormonal activity. Withinthe context of the present invention, at least one of the bio-activepeptide hormone modules will be comprised from a GIP peptide hormone,analog, derivative, fragment, or peptidic enhancer. The bio-activepeptide hormone module that exhibits the at least one hormonal activitymay be located at the N-terminal end of the hybrid polypeptide, theC-terminal end of the hybrid polypeptide, or in the event that thehybrid polypeptide comprises more than two bio-active peptide hormonemodules, may be located in the internal portion of the hybridpolypeptide.

In certain embodiments, it may be preferable to locate the bio-activepeptide hormone module exhibiting the at least one hormonal activitysuch that the C-terminal end of the bio-active peptide hormone module isamidated. Amidation of the C-terminal end of the bio-active peptidehormone module may be accomplished by locating the module at theC-terminal end of the hybrid peptide, or by configuring the module inthe C-terminal-to-N-terminal direction at the N-terminal end of thehybrid polypeptide. In both configurations, the C-terminal end of thebio-active peptide hormone module is available for amidation. Specificcomponent peptide hormones where C-terminal amidation may preferablyinclude amylin family peptide hormones, CCK, PYY, hGLP-1(7-36) andhGLP-2. Specific component peptide hormones where C-terminal amidationis not necessarily exemplary (stated otherwise, where elongation at theC-terminal end of the module is easily tolerated) include exendin-4,exendin-4(1-28), GIP, GLP-1(7-37), frog GLP-1(7-36), and frog GLP-2.However, if these component peptide hormones are located at theC-terminal end of the hybrid polypeptide, they may still be optionallyamidated, and in fact may preferably be optionally amidated.

The bio-active peptide hormone modules may be covalently linked in anymanner known in the art. Stable linkages may be used, or cleavablelinkage may be used. In one embodiment, the carboxy of a first modulemay be directly linked to the amino of a second module. In anotherembodiment, linking groups may be used to attached modules. Further, ifdesired, spacers or turn inducers known in the art may be employed tostabilize the linkage. By way of example, where amidation of theC-terminal end of the N-terminally located bio-active peptide hormonemodule is not desired, the module may be attached to a second moduledirectly, or using any appropriate linking group known in the art, suchas, an alkyl; PEG; amino acid, e.g., Lys, Glu, beta-Ala; polyaminoacids,e.g., poly-his, poly-arg, poly-lys, poly-ala, Gly-Lys-Arg (GKR) etc.;bifunctional linker (see, e.g., Pierce catalog, Rockford, Il);aminocaproyl (“Aca”), beta-alanyl, 8-amino-3,6-dioxaoctanoyl, or othercleavable and non-cleavable linker known in the art. Specificallydescribed herein, as if each were explicitly drawn, are embodiments ofspecific hybrids in which the linker in each exemplifiedlinker-containing hybrid is replaced by a Gly linker, particularlyembodiments where the Gly linker is Gly-Gly-Gly. As an example, forexemplifiedYAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTYPRTNTGSETF(SEQ ID NO: 92)(see tables herein) its Gly linker species analog is alsospecifically intended and disclosed: this species isYAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Gly-Gly-Gly-KCNTATCVLGRLSQELHRLQTYPRTNTGSETF(SEQ ID NO: 92). In one embodiment a linker or spacer is 1 to 30residues long, in another embodiment 2 to 30 residues, and in yetanother 3-30 residues long, and any integer length from 2 to 30inclusive; each integer unit is contemplated, e.g. 2, 3, 4, 5, 6, 7,etc. In one embodiment a Gly linker is used, and in a particularembodiment a three residue linker Gly-Gly-Gly.

In one embodiment the linker is an K(N-epsilon) linker, as used forexample in 0601GIP4619:

In one embodiment as discussed herein the GIP is attached to the secondbio-active hormone module in a C-terminus to C-terminus orientation. TheC-terminus of a GIP is linked to the C-terminus of a second bio-activehormone module, optionally with a linker. Orthogonal chemistries can beused to ligate functionalized peptide modules, optionally with linkersas described herein. For example, native chemical ligation chemistriescan be used. As shown below, where R is a good leaving group, a hybridcan be generated with a Cys-Lys linkage:

In a further example the hybrid can be prepared using functionalizedmodules:

to generate:

Using a similar approach, a hybrid having a lysine linker can becreated:

Additional linkers are shown in FIG. 24. The linkers are particularlyuseful for N-terminal to N-terminal linking, however either or both endsof these linkers can be readily adapted to react to the C-terminus of aGIP compound. The C-terminus of a GIP compound is the preferred terminalfor linking a GIP analog or derivative to another peptide component of aGIP-containing hybrid, because as shown herein, linking a peptide moduleto the N-terminus of GIP resulted in lack of receptor activation, unlessthe module was cleaved off in vivo. Such N-terminal extensions are knownthat act to extend plasma half life of the GIP compound and prevent orreduce receptor activation until removed by a serum or membraneprotease.

Of particular interest are GIP-exendin family hybrids that are linkedC-terminus to C-terminus, keeping their respective receptor activationN-termini unhindered. The receptor activation regions of both moleculesare present in such hybrids, for example using any of the GIP and theexendin and GLP1 family peptides and analogs, active fragments andderivatives herein. For example a dAla(2)-GIP(1-30) analog can be linkedto exendin-4, in a tail to tail manner, via suitable linking chemistry.

Further, as will be recognized by those of skill in the art, thepeptides of the invention may be C-terminally amidated, or may exist asa free acid. In an exemplary embodiment the peptides of the inventionare C-terminally amidated. Where amidation of the C-terminal end ofN-terminally located bio-active peptide hormone module is desired, themodule may again be attached to a second module using any appropriatelinking group known in the art. More specifically, in the event that abio-active peptide hormone module exhibiting at least one hormonalactivity has been configured in the C-terminal-to-N-terminalorientation, resulting in an amino to amino linkage, exemplary linkinggroups include dicarboxylic acids, alkyls, PEGs, and amino acids such asLys, Cys, and Glu.

As mentioned above, the hybrid polypeptides may also preferably includespacer to further stabilize the linkage of the bio-active peptidehormone modules. Any spacer or turn inducer known in the art may beused. By way of example, referred beta-turn mimetics include mimic A andmimic B illustrated herein, also Ala-Aib and Ala-Pro dipeptides. TheirIUPAC names are Mimic A:N-(3S,6S,9S)-2-oxo-3-amino-1-azabicyclo[4.3.0]-nonane-9-carboxylic acid.Mimic B:N-(3S,6S,9R)-2-oxo-3-amino-7-thia-1-azabicyclo[4.3.0]-nonane-9-carboxylicacid.

By agonist is meant a compound which elicits a biological activity ofnative human hormone. In a exemplary embodiment, the terms refer to acompound which elicits a biological effect in glucose lowering or otheractivity of native human GIP. Novel GIP analogs for example haveactivity in a glucose lowering assay, gastric secretion inhibitionassay, dP/dt assay, blood pressure assay, insulin secretion assay, bonedensity assay, or plasma stability assay, preferably similar to orbetter than native human GIP and/or which binds specifically in a GIPreceptor assay or in a competitive binding assay with labeled GIP. Inone embodiment, the agonists will bind in such assays with an affinityof greater than 1 μM, and more preferably with an affinity of greaterthan 1-5 nM. In another embodiment the agonist (or antagonist as thecase may be) IC50 will be less than or about 100 micromolar, less thanor about 50 micromolar, less than about 20 micromolar, and less than orabout 10 micromolar. Such agonists may comprise a polypeptide having aGIP sequence with a Trp-cage motif (e.g. exendin tail PSSGAPS (SEQ IDNO: 93) or variant) or frog GLP-1 tail or analog or derivative of thetail.

By “amino acid” and “amino acid residue” is meant natural amino acids,unnatural amino acids, and modified amino acid. Unless stated to thecontrary, any reference to an amino acid, generally or specifically byname, includes reference to both the D and the L stereoisomers if theirstructure allow such stereoisomeric forms. Natural amino acids includealanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp),cysteine (Cys), glutamine (Gln), glutamic acid (Glu), glycine (Gly),histidine (His), isoleucine (Ile), leucine (Leu), Lysine (Lys),methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser),threonine (Thr), tryptophan (Trp), tyrosine (Tyr) and valine (Val).Unnatural amino acids include, but are not limited to homolysine,homoarginine, azetidinecarboxylic acid, 2-aminoadipic acid,3-aminoadipic acid, beta-alanine, aminopropionic acid, 2-aminobutyricacid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid,2-aminoisobutyric acid, 3-aminoisbutyric acid, 2-aminopimelic acid,tertiary-butylglycine, 2,4-diaminoisobutyric acid, desmosine,2,2′-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine,N-ethylasparagine, homoproline, hydroxylysine, allo-hydroxylysine,3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine,N-methylalanine, N-methylglycine, N-methylisoleucine,N-methylpentylglycine, N-methylvaline, naphthalanine, norvaline,norleucine, ornithine, pentylglycine, pipecolic acid, thioproline,sarcosine and citrulline. Additional unnatural amino acids includemodified amino acid residues which are chemically blocked, reversibly orirreversibly, or chemically modified on their N-terminal amino group ortheir side chain groups, as for example, N-methylated D and L aminoacids or residues wherein the side chain functional groups arechemically modified to another functional group. For example, modifiedamino acids include methionine sulfoxide; methionine sulfone; asparticacid-(beta-methyl ester), a modified amino acid of aspartic acid;N-ethylglycine, a modified amino acid of glycine; or alaninecarboxamide, a modified amino acid of alanine. Additional residues thatcan be incorporated are described in Sandberg et al., J. Med. Chem. 41:2481-91, 1998.

By “Ahx” is meant 6-amino hexanoic acid. As used herein: “5 Apa” means 5amino-pentanoyl, “12 Ado” means 12-amino dodecanoyl, “PEG(8)” mean3,6,-dioxyoctanoyl, and “PEG(13)” means1-amino-4,7,10-trioxa-13-tridecanamine succinimoyl. In addition are thefollowing abbreviations: “ACN” or “CH3CN” refers to acetonitrile. “Boc”,“tBoc” or “Tboc” refers to t-butoxy carbonyl. “DCU” refers toN,N′-dicyclohexylcarbodiimide. “Fmoc” refers tofluorenylmethoxycarbonyl. “HBTU” refers to2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluroniumhexafluorophosphate. “HOBt” refers to 1-hydroxybenzotriazolemonohydrate. “HomoP” or “HPro” refers to homoproline. “MeAla” or “Nme”refers to N-methylalanine. “Naph” refers to naphthylalanine. “pG” or“pGly” refers to pentylglycine. “tBuG” refers to tertiary-butylglycine.“ThioP” or “tPro” refers to thioproline. “3Hyp” refers to3-hydroxyproline. “4Hyp” refers to 4-hydroxyproline. “NAG” refers toN-alkylglycine. “NAPG” refers to N-alkylpentylglycine. “Norval” refersto norvaline. “Norleu” refers to norleucine. “OctGly” refers tooctyl-glycine in which the glycine amino acid side group His replacedwith an eight carbon saturated aliphatic chain.

Further Exemplary Combinations and Specific Embodiments.

Exemplary combinations of bio-active peptide hormone modules to form theGIP hybrid polypeptides of the invention include combinations of two ormore bio-active peptide hormone modules selected from: native peptidehormones, analogs and derivatives of peptide hormones that exhibit atleast one hormonal activity, fragments of native peptide hormones thatexhibit at least one hormonal activity, fragments of analogs andderivatives of peptides hormones that exhibit at least one hormonalactivity, and peptidic enhancers, with the proviso that at least onemodule exhibit at least one hormonal activity.

The hybrid polypeptides of the invention will include at least twobio-active peptide hormone modules, wherein at least one module iscomprised from a GIP peptide hormone, analog, derivative, fragment orpeptidic enhancer. In one embodiment, at least two of the componentpeptide hormones are from different peptide hormone families, e.g., theamylin family, CCK, the leptin family, PPF, the proglucagon family, thenatriuretic peptide family, and the exendin family. For example, a GIPhybrid can comprise a GIP portion, with or without a tail sequence,combined with a bio-active module that comprises two or more hormonemodules (a non-GIP hormone hybrid) such as an exendin-amylin/sCT hybridor a hormone chimera such as an amylin-sCT chimera.

In certain embodiments, the hybrid polypeptides of the invention maycomprise two or more modules that exhibit at least one hormonalactivity. For instance, the hybrid polypeptide may comprise a fragmentof a first peptide hormone or analog that exhibits at least one hormonalactivity covalently, linked to a fragment of at least one additionalpeptide hormone analog. The additional fragment(s) may optionallyexhibit at least one hormonal activity. The first peptide hormone may bethe same or different from the additional peptide hormone(s), with theproviso that at least one of the additional peptide hormones aredifferent from the first peptide hormone, and the first hormonalactivity may be the same or different from the optional additionalhormonal activity.

In other embodiments, the hybrid polypeptides of the invention maycomprise one or more modules that exhibit at least one hormonal activityin combination with one or more peptidic enhancer modules. For instance,a fragment of a first peptide hormone that exhibits a at least onehormonal activity may be covalently linked to a peptidic enhancer, or afragment of a first peptide hormone that exhibits at least one hormonalactivity may be covalently linked to a second peptide hormone thatexhibits at least one hormonal activity, which is in turn linked to apeptidic enhancer. Alternatively, a peptidic enhancer may be locatedbetween two peptide hormone modules as a stabilizing spacer. Again, thefirst peptide hormone may be the same or different from the secondpeptide hormone, and the first hormonal activity may be the same ordifferent from the second hormonal activity.

In another embodiment, the hybrid polypeptides of the invention maycomprise two, three, four, or more bio-active peptide hormone modules.Exemplary combinations include a module with a hormonal activity incombination with one, two, or three peptidic enhancers; two modules witha hormonal activity in combination with one or two peptidic enhancers;three modules with a hormonal activity in combination with one peptidicenhancer, etc.

The component peptide hormones are preferably selected from amylin,adrenomedullin, calcitonin, calcitonin gene related peptide, intermedin,cholecystokinin, leptin peptide YY, glucagon-like peptide-1,glucagon-like peptide 2, oxyntomodulin, ANP, BNP, CNP, urodilatin, GIP,GLP1 or exendin-4.

More particularly, exemplary module combinations include those involvingcombinations of at least GIP and amylin (and/or sCT), BNP, CGRP, CT,CCK, leptin, PYY, GLP1, and exendin-4.

In exemplary embodiments, a first module comprising a GIP peptide islinked to a second bio-active peptide hormone module comprising anamylin peptide that exhibits at least one hormonal activity. In anotherembodiment, the second module is further linked to a third bio-activepeptide hormone module comprising a calcitonin peptide that exhibits atleast one hormonal activity. In yet another embodiment, the third modulemay be further linked to a fourth bio-active peptide hormone modulecomprising a peptidic enhancer selected from amylin peptides. In oneembodiment, the first module may be located at the C-terminal end of thehybrid polypeptide. Alternatively, the first module may be located atthe N-terminal end of the hybrid polypeptide. In certain embodiments,spacers or linkers such as betaAla or Gly may be inserted if desired tolink the modules.

Exemplary exendin-4 peptides include: exendin-4, exendin-4(1-27),exendin-4(1-28), ¹⁴Leu,²⁵Phe-exendin-4(1-28), and⁵Ala,¹⁴Leu,²⁵Phe-exendin-4(1-28). Also useful are exendin(7-15) and itsSer2 analog, HSEGTFTSD (SEQ ID NO:94). Exemplary amylin peptides thatexhibit at least one hormonal activity include amylin, amylin fragmentssuch as amylin(1-17), amylin (1-16), amylin(1-15), and amylin(1-7), andamylin analogs such as pramlintide, ²Ala-h-amylin, ^(2, 7)Ala-h-amylin,and fragments thereof Exemplary calcitonin peptides that exhibit atleast one hormonal activity sCT, sCT fragments such as sCT(8-10),sCT(8-27), and, and calcitonin analogs such as ^(11, 18)Arg-sCT,¹⁸Arg-sCT, ¹⁴G1u,¹⁸Arg-sCT, ¹⁴G1u,^(11,18)Arg- sCT, and fragmentsthereof. Exemplary amylin peptidic enhancers include amylin(32-37),amylin(33-37), and amylin(34-37), and analogs thereof Amylin/sCTcombinations useful in connection with the present invention includethose disclosed in PCT/US2005/004631 Amylin Family Agonist, which isherein incorporated by reference. An amylin/sCT chimera particularlyuseful for creating hybrids of the invention with GIP is anamylin-sCT-amylin chimera, for examplehAmylin(1-7)-^(11,18)Arg-sCT(8-27)-Amylin(33-37), which has the sequenceKCNTATCVLGRLSQELHRLQTYPRTNTGSNTY (SEQ ID NO:95), and is preferably inits C-terminal amide form and analogs and derivatives thereof (describedherein and in PCT/US2005/004631).

In one aspect, module combinations include those involving a firstmodule comprising GIP, a fragment of GIP that exhibits at least onehormonal activity, a GIP analog or derivative that exhibits at least onehormonal activity, or a fragment of an GIP analog that exhibits at leastone hormonal activity in combination with a second module comprisingCCK, a fragment of CCK that exhibits at least one hormonal activity, aCCK analog or derivative that exhibits at least one hormonal activity,or a fragment of a CCK analog that exhibits at least one hormonalactivity. Exemplary CCK compounds include: CCK-8, andCCK-8(Phe(CH₂SO₃)). In one embodiment, the first module is located atthe C-terminal end of the hybrid polypeptide and the second module islocated at the N-terminal end of the hybrid polypeptide. Alternatively,the first module may be located at the N-terminal end of the hybridpolypeptide and second located at the C-terminal end of the hybridpolypeptide. In certain embodiments, spacers or linkers such as beta-Alaor Gly may be inserted if desired to attach the modules.

In one aspect, exemplary module combinations include those involving afirst module comprising GIP, a fragment of GIP that exhibits at leastone hormonal activity, a GIP analog or derivative that exhibits at leastone hormonal activity, or a fragment of an GIP analog that exhibits atleast one hormonal activity in combination a second module comprisingamylin, a fragment of amylin that exhibits at least one hormonalactivity, an amylin analog or derivative that exhibits at least onehormonal activity, or a fragment of an amylin analog that exhibits atleast one hormonal activity. The amylin module can be an Amylin/sCTchimera as disclosed herein. In one embodiment, the first module islocated at the C-terminal end of the hybrid polypeptide and the peptidicenhancer is located at the N-terminal end of the hybrid polypeptide.Alternatively, the first module may be located at the N-terminal end ofthe hybrid polypeptide and second located at the C-terminal end of thehybrid polypeptide. In certain embodiments, spacers or linkers such asbetaAla or Gly may be inserted if desired to attach the modules.

Yet other exemplary module combinations include those involvingcombinations of GIP, amylin and calcitonin as tertiary and tetra-hybridmolecules. Exemplary combinations include GIP/amylin/calcitonin;GIP/amylin/calcitonin/amylin; amylin/calcitonin/GIP; andamylin/calcitonin/amylin/GIP combinations, with and without spacers orlinking groups. Each module may independently be a peptidic enhancer ormay exhibit a hormonal activity, depending on the desired properties ofthe hybrid polypeptide.

In another embodiment, one of the bio-active peptide hormone module(s)that exhibits at least one hormonal activity is GLP-1 or an analog orfragment thereof, and a second bio-active peptide hormone modulecomprises GIP. In yet another such hybrid, the hybrid polypeptidecomprises a third bio-active peptide hormone module. Exemplary thirdbio-active peptide hormone modules include amylin (including analogs,derivatives and fragments thereof) and amylin-sCT chimeras, PYY(including analogs, derivatives and fragments thereof) and CCK(including analogs, derivatives and fragments thereof).

Exemplary compounds of GIP-Neuromedin peptide hybrids include

YaGIP(1-30)-beta-Ala-beta-Ala-FN-38:YAEGTFISDYSIAMDKIHQQDFVNWLLAQK-beta-Ala-beta-Ala-FLFHYSKTQKLGKSNVVEELQSPFASQSRGYFLFRPRN-NH2(SEQ ID NO: 96);

YaGIP(1-30)-beta-Ala-beta-Ala-Neuromedin(U25):YAEGTFISDYSIAMDKIHQQDFVNWLLAQK-beta-Ala-beta-Ala-FRVDEEFQSPFASQSRGYFLFRPRN-NH2(SEQ ID NO: 97); and

YaGIP(1-30)-beta-Ala-beta-Ala-Neuromedin(U-9):YAEGTFISDYSIAMDKIHQQDFVNWLLAQK-beta-Ala-beta-Ala-GYFLFRPRN-NH2 (SEQ IDNO: 98).

The beta-Ala-beta-Ala spacer is optional, and can be replaced withGly-Gly-Gly, a mini-PEG group, or other linker known in the art,particularly those described herein.

Exemplary compounds of GIP and a natriuretic peptide include GIP-hBNPpeptide hybrids, including YaGIP(1-30)-beta-Ala-beta-Ala-hBNP where hBNPis SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH (SEQ ID NO: 99) andYaGIP(1-30)-exendin(31-39)-beta-Ala-beta-Ala-hBNP, where hBNP isSPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH (SEQ ID NO: 99). The beta-Ala-beta-Alaspacer is optional, and can be replaced with Gly-Gly-Gly, a mini-PEGgroup, or other linker known in the art, particularly those describedherein.

Embodiments include:

SEQ ID NO: Sequence 100 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGKLSQELHRLQTYPRTNTGSNTY 101YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLSQELHRLQTLPRTNTGSNTY102 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTYPPTNTGSNTY 103YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLSQELHRLQTYPRTNVGSNTY104 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTLPPTNVGSNTY 105YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLANFLHRLQTYPRTNTGSNTY106 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-ACNTATCVLGRLSQELHRLQTYPRTNTGSNTY 107YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNAATCVLGRLSQELHRLQTYPRTNTGSNTY108 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTAACVLGRLSQELHRLQTYPRTNTGSNTY 109YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- CANLSTCVLGRLSQELHRLQTYPRTNTGSNTY110 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-CSNASTCVLGRLSQELHRLQTYPRTNTGSNTY 111YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- CSNLATCVLGRLSQELHRLQTYPRTNTGSNTY112 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-CSNLSACVLGRLSQELHRLQTYPRTNTGSNTY 113YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLSQELHKLQTYPRTNTGSNTY114 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTYPRTNTGSGTP 115YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- CSALSTCVLGRLSQELHRLQTYPRTNTGSNTY116 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCLLQQLQKLLQKLKQYPRTNTGSNTY 117YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTASCVLGRLSQELHRLQTYPRTNTGSNTY118 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTAVCVLGRLSQELHRLQTYPRTNTGSNTY 119YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLSQELHRYPRTNTGSNTY 120YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGK(For)LSQELHK(For)LQTYPRTNTGSNTY 457YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTA(d-Thr)CVLGRLSQELHRLQTYPRTNTGSNTY 458YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTA(dAh)CVLGRLSQELHRLQTYPRTNTGSNTY 121YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-ACNTATCVLGRLSQELHK(PEG5000)LQTYPRTNTGSNTY 122YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTLQTYPRTNTGSNTY 123YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTLLQTYPRTNTGSNTY 124YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGKLSQELHKLQTYPRTNTGSNTY125 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTSTCVLGRLSQELHRLQTYPRTNTGSNTY 126YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCATQRLSQELHRLQTYPRTNTGSNTY127 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCATQRLSQELHRLQTYPRTNVGSNTY 128YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTSTCATQRLANELVRLQTYPRTNVGSNTY129 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTA(Hse)CVLGRLSQELHRLQTYPRTNTGSNTY 130YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTA(Ahb)CVLGRLSQELHRLQTYPRTNTGSNTY 131YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTA(Ahp)CVLGRLSQELHRLQTYPRTNTGSNTY 132YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTAT(OPO3H2)CVLGRLSQELHRLQTYPRTNTGSNTY 133YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLG(Orn)LSQELH(Orn)LQTYPRTNTGSNTY 134YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLG(Cit)LSQELH(Cit)LQTYPRTNTGSNTY 135YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLG(homoK)LSQELH(homoK)LQTYPRTN TGSNTY 136YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCMLGRYTQDFHRLQTYPRTNTGSNTY137 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-DSNLSTKVLGRLSQELHRLQTYPRTNTGSNTY 138YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KDNTATKVLGRLSQELHRLQTYPRTNTGSNTY139 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-CNTATCVLGRLSQELHRLQTYPRTNTGSNTY 140YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTYPRTNTGSNTY(9Anc) 141YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTYPRTNTGSNTY(L- octylglycine) 142YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLG(homoR)LSQELH(homoR)LQTYPRTN TGSNTY 143YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- FCNTATCVLGRLSQELHRLQTYPRTNTGSNTY144 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELH(Cit)LQTYPRTNTGSNTY 145YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELH(Orn)LQTYPRTNTGSNTY 146YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- ICNTATCVLGRLSQELHRLQTYPRTNTGSNTY147 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLG(Cit)LSQELHRLQTYPRTNTGSNTY 148YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTYPRTNTGSNTY(4ABU) 149YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTSTCATQRLANELVRLQTYPRTNVGSEAF150 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTYPTNVGSEAF 151YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLSRSLHRLQTYPRTNTGSNTY152 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVTHRLSQELHRLQTYPRTNTGSNTY 153YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLADFLHRLQTYPRTNTGSNTY154 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-CNTATCVLGRLSQELHRLQTYPRTNTGSNT 155YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLSQELHRLQNFVPRTNTGSNTY156 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTYPRTNTGSETF 157YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- ACDTATCVLGRLSQELHRLQTYPRTNTGSNTY158 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTYPRTNTGSKAF 159YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCDTATCVTHRLAGLLSRSQTYPRTNTGSNTY160 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLADALHRLQTYPRTNTGSNTY 161YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLAAFLHRLQTYPRTNTGSNTY162 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-SCNTATCVLGRLADFLHRLQTYPRTNTGSNTY 163YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLSQELHRLQTMPRTNTGSNTY164 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTVPRTNTGSNTY 165YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLNEYLHRLQTYPRTNTGSNTY166 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-SCNTATCVLGRLSQELHRLQTYPRTNTGSNTY 167YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLTEFLHRLQTYPRTNTGSNTY168 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLAEFLHRLQTYPRTNTGSNTY 169YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLTDYLHRLQTYPRTNTGSNTY170 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLAQFLHRLQTYPRTNTGSNTY 171YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLADFLHRFQTFPRTNTGSNTY172 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLADFLHRFHTFPRTNTGSNTY 173YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLADFLHRFQTFPRTNTGSGTP174 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-CNTATCVLGRLADFLHRLQTYPRTNTGSNTY 175YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCDTATCVLGRLSQELHRLQTYPRTNTGSNTY176 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLFDFLHRLQTYPRTNTGSNTY 177YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- KCNTATCVLGRLAAALHRLQTYPRTNTGSNTY178 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-TCDTATCVLGRLSQELHRLQTYPRTNTGSNTY 179YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- CSNLSTCATQRLANELVRLQTYPRTNVGSNTY180 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCATQRLANELVRLQTYPRTNVGSNTY 181YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker- CSNLSTCVLGRLSQELHRLQTYPRTNTGSNTY182 YAEGTFISDYSIAMDKIRQQDFVNWLLAQK-Linker-KCNTATCVLGRLSQELHRLQTYPRTNTGSNTYGIP(1-30)-(12 Ado)-hAmylin(1-7)-^(11,18)Arg-sCt(8-27)-hAmylin(33-37)GIP(1-30)-(12 Ado)-¹des-Lys-hAmylin(1-7)-^(11,18)Arg-sCt(8-27)-hAmylin(33-37)GIP(1-30)-(3,6-dioxaoctanoyl)-hAmylin(1-7)-^(11,18)Arg-sCt(8-27)-hAmylin(33-37)GIP(1-30)-(3,6-dioxaoctanoyl)-¹des-Lys-hAmylin(1-7),^(11,18)Arg-sCt(8-27)-hAmylin(33-37)GIP(1-30)-(5 Apa)-hAmylin(1-7)-^(11,18)Arg-sCt(8-27)-hAmylin(33-37)GIP(1-30)-(5 Apa)-¹des-Lys-hAmylin(1-7)-^(11,18)Arg-sCt(8-27)-hAmylin(33-37)GIP(1-30)-betaAla-betaAla-hAmylin(1-7)-^(11,18)Arg-sCt(8-27)-hAmylin(33-37)GIP(1-30)-betaAla-betaAla-¹des-Lys-hAmylin(1-7)-^(11,18)Arg-sCt(27)-hAmylin(33-37) GIP(1-30)-(4,7,10-trioxa-13-tridecanamine succinimidy1)-hAmylin(1-7) ^(11,18)Arg-sCt(8-27)-hAmylin(33-37)GIP(1-30)-(4,7,10-trioxa-13-tridecanamine succinimidy1)-¹des-Lys-hAmylin(1-7)-^(11,18)Arg-sCt(8-27)-hAmylin(33-37)GIP(1-30)-(Gly-Gly-Gly)-hAmylin(1-7)-^(11,18)Arg-sCt(8-27)-hAmylin(33-37)GIP(1-30)-(Gly-Gly-Gly)-¹des-Lys-hAmylin(1-7))^(11,18)Arg-sCt(27)-hAmylin(33-37) GIP(1-30)-(4,7,10-trioxa-13-tridecanamine succinimidy1)-hAmylin(1-7) ^(11,18)Arg-sCt(8-27)-hAmylin(33-37)GIP(1-30)-(4,7,10-trioxa-13-tridecanamine succinimidy1)-¹des-Lys-hAmylin(1-7)-^(11,18)Arg-sCt(8-27)-hAmylin(33-37)

Further exemplary GIP hybrids include GIP and neuromedin hybrids, forexample dAla2-GIP(1-30)-beta-Ala-beta-Ala-FN-38:

-   YaEGTFISDYSIAMDKIHQQDFVNWLLAQK-beta-Ala-beta-Ala-FLFHYSKTQKLGKSNVVEELQSPFASQSRGYFLFRPRN-NH2    (SEQ ID NO:459);-   dAla2-GIP(1-30)-beta-Ala-beta-Ala-Neuromedin(U25):-   YaEGTFISDYSIAMDKIHQQDFVNWLLAQK-beta-Ala-beta-Ala-FRVDEEFQSPFASQSRGYFLFRPRN-NH2    (SEQ ID NO:460); and-   dAla2-GIP(1-30)-beta-Ala-beta-Ala-Neuromedin(U-9):-   YaEGTFISDYSIAMDKIHQQDFVNWLLAQK-beta-Ala-beta-Ala-GYFLFRPRN-NH2 (SEQ    ID NO:461). The beta-Ala-beta-Ala spacer is optional, and can be    replaced with Gly-Gly-Gly, a mini-PEG group, or other linker known    in the art, particularly those described herein.

Exemplary GIP and natriuretic peptide hybrids include GIP-hBNP peptidehybrids, including dAla2-GIP(1-30)-beta-Ala-beta-Ala-hBNP:

-   YaEGTFISDYSIAMDKIHQQDFVNWLLAQK-beta-Ala-beta-Ala-SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH    (SEQ ID No.462); and-   dAla2-GIP(1-30)-beta-Ala-beta-Ala-hBNP:    YaEGTFISDYSIAMDKIHQQDFVNWLLAQK-beta-Ala-beta-Ala-SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH    (SEQ ID NO:463).

As has been discussed throughout, in any of the embodiments herein,including the above hybrids, additional changes as discussed can beincluded. For example, in any of the embodiments herein, including theabove hybrids, positions 1 (including the N-terminus), 2 or 3 can bemodified to impart DPP-IV resistance. For example, specificallyexemplified herein are each of the D-Ala2 analogs of each embodimentherein as well as of the above species.

GIP and Peptidic Enhancer Hybrid

In one hybrid embodiment GIP is C-terminally extended by a peptidicenhancer, e.g., a tail or C-terminal portion of another hormone, such asexendin or GLP-1, which provide analogs that have enhanced in vivoefficacy. Exendin-4 (FIG. 1) is a potent incretin mimetic that shares a53% homology with GLP-1, and mirrors many of the key biological actionsof GLP-1. Unlike GLP-1, exendin-4 is much more resistant to proteolyticcleavage to DPP-IV peptidase and NEP. This confers greater enhancedpharmacokinetics and improved in vivo efficacy in humans compared toGLP-1. Circular dichroism (CD) and NMR studies of Exendin-4 in aqueousmedia and in media containing organic cosolvents reveal that theC-terminal segment containing the sequence LFIEWLKNGGPSSGAPPPS (SEQ IDNO: 183) (residues 21-39) forms a unique hydrophobic Trp-cage clusterresulting from interactions of Pro37 with Phe22 and Pro38 with Trp25(29-31). This Trp-cage cluster motif is the first example of aprotein-like tertiary structure displayed by a peptide, and could beresponsible for imparting greater metabolic stability by maskingprotease-sensitive sites in the molecule in vivo (32).

Accordingly, in one aspect, exemplary module combinations include thoseinvolving a first module comprising GIP, a fragment of GIP that exhibitsat least one hormonal activity, a GIP analog or derivative that exhibitsat least one hormonal activity, or a fragment of an GIP analog thatexhibits at least one hormonal activity in combination with a peptidicenhancer. Useful peptidic enhancers are the exendin-4 and frog GLPtails, as described herein, as well as PYY(25-36), PYY(30-36) andPYY(31-36). In one embodiment, the first module is located at theC-terminal end of the hybrid polypeptide and the peptidic enhancer islocated at the N-terminal end of the hybrid polypeptide. Alternatively,the first module may be located at the N-terminal end of the hybridpolypeptide and the peptidic enhancer may be located at the C-terminalend of the hybrid polypeptide. In certain embodiments, spacers orlinkers such as betaAla or Gly may be inserted if desired to attach themodules.

A particular compound of interest isYaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (Compound 0601GIP3794; whichhas a D-Ala at position 2, and is in amide form). Exemplary compoundshaving a modification at position 2 (i.e. residue 2) or positions 2 and3 (e.g. Ser at 2 with Asp at 3), and their GIP Receptor binding andreceptor activation activities includeY-Residue2-EGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 where Residues 2and/or 3 are shown in the table (and see FIG. 12):

Residue 2 or Cmpd# Residues 2 + 3 GIP RBA GIPR Cyclase 0601GIP3794 dAla3.8 38 0601GIP4189 V 12 >1000 0601GIP4145 dnorV 83 10000 0601GIP4146dSer 20 171 0601GIP4147 Abu 7.4 126 0601GIP4148 dAbu 34 248 0601GIP4186homo-Ser 20 >1000 0601GIP4195 d-homoSer 52 10000 0601GIP4164 dPro 50110000 0601GIP4187 cyclopropyl Ala 67 >1000 0601GIP4188 d-cyclopropyl Ala214 10000 0601GIP4181 cycloHexyl Ala 35.3151 (% Inh 10000 10 nM)0601GIP4182 d-cyclohexyl Ala 37.42591 (% Inh 10000 10 nM) 0601GIP4237A(NMe) 28 10000 0601GIP4324 Aib 104.7129 (% Inh 13.4 10 nM) CCcyclpropGly 0601GIP4458 betaAla 51.122 (% Inh 10 nM) 0601GIP4215 Ser +Asp 4.5 57.6 0601GIP4389 Asp 66.554 (% Inh 128 10 nM) 0601GIP4703 dGlu71.4 (% Inh 10 nM)

Further exemplary compounds having a modification at the N-terminus andtheir GIP Receptor binding and receptor activation activity, includeN-Terminus-YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO:186)where the N-terminus modification is shown in the table (and see FIG.12):

Cmpd# N-Terminus GIP RBA Cyclase 0601GIP3794 H 3.8 38 0601GIP4196 Isocap11 10000 0601GIP4180 isoBuOCO 88.0407 386 (% Inh 10 nM) 0601GIP4178Octylglycine 1.5 96 0601GIP4238 Y(NMe) 4.2 144 0601GIP4291 Succinoyl 17910000

Further exemplary compounds with various linkers or fatty acidmodifications, or combinations of modifications, as described herein andtheir GIP Receptor binding and receptor activation activity, are shownin the table (and see FIG. 12). Note that Ocg and OctG both designateoctvlglvcine. DNaI indicates D-2-Nanhthvlalanine amino acid.

Cmpd # Sequence GIP RBA Cyclase 0601GIP 3794YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP   3.8 38 SSGAPPPS-NH2 (SEQ ID NO: 186)0601GIP4290 YaEGTFISDYSIALDKIRQQEFVNWLLAQK-   0.35 14bAla-PSSGAPPPS-NH2 (SEQ ID NO: 464) 0601GIP4178 OctG-  1.5 RIN, 0.170 IC50 36.2 YAEGTFISDYSIAMDKIHQQDFVNWLL in HEK-GIPRAQKPSSGAPPPS-NH2 (SEQ ID NO: 391) 0601GIP4293 octG-   0.12 20YAEGTFISDYSIAMDKIRQQDFVNWLL AQKPSSGAPPPS-NH2 (SEQ ID NO: 392)0601GIP4292 octG-   0.17 3.46 YAEGTFISDYSIALDKIRQQEFVNWLLAQHPSSGAPPPS-NH2 (SEQ ID NO: 393) 0601GIP4806 OctG- 101.3(% Inh 10 nM)YAEGTFISDYSIAMDKIRQQEFVNWLLAQ HPKKIRYS-NH2 (SEQ ID NO: 620) 0601GIP4670OctG-  96.9324(% Inh, 10 nM) YAEGTFISDYSIAMDKIRQQEFVNWLLAQHPSSGAPPPS-NH2 (SEQ ID NO: 621) 0601GIP4635 OctG-  87.7032(% Inh, 10 nM)YaEGTFISDYSIAMDKIHQQDFVNWLLAQ KPSSGAPPPS-NH2 (SEQ ID NO: 622)0601GIP4636 OctG-  92.8656(% Inh, 10 nM) YaEGTFISDYSIAMDKIRQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 623) 0601GIP4637 OctG-  95.7634(% Inh, 10 nM)YaEGTFISDYSIALDKIRQQEFVNWLLAQH PSSGAPPPS-NH2 (SEQ ID NO: 624)0601GIP4543 OctG-  85.4306(% Inh, 10 nM) YAPGTFISDYSIALDKIRQQEFVNWLLAQHPSSGAPPPS-NH2 (SEQ ID NO: 395) 0601GIP OctG-  81.7225(% Inh, 10 nM)YaPGTFISDYSIALDKIRQQEFVNWLLAQH PSSGAPPPS-NH2 (SEQ ID NO: 618)0601GIP4712 OctG-  94.7(% Inh, 10 nM) YaEGTFISDYSIALDKIAQQEFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 625) 0601GIP4194YaEGTFISDYSIAMD(OctG)IHQQDFVNWLL  68 933AQKPSSGAPPPS-NH2 (SEQ ID NO: 591) 0601GIP4252YaEGTFISDYSIAMDKIHQQDFVNWLLAQ   5.6 154KPSS(OctG)APPPS-NH2 (SEQ ID NO: 599) 0601GIP4548YAEGTFISDYSIAMDKIHQQDFVNWLLAQ  93.9341(% Inh, 10 nM)KPSS(OctG)APPPS-NH2 (SEQ ID NO: 396) 0601GIP4549YSEGTFISDYSIAMDKIHQQDFVNWLLAQ  87.5173(% Inh, 10 nM)KPSS(OctG)APPPS-NH2 (SEQ ID NO: 397) 0601GIP4550YSDGTFISDYSIAMDKIHQQDFVNWLLAQ  78.9341(% Inh, 10 nM)KPSS(OctG)APPPS-NH2 (SEQ ID NO: 398) 0601GIP4606YaEGTFISDYSIALDKIHQQDFVNWLLAQK  79.8162(% Inh, 10 nM)PSS(OctG)APPPS-NH2 (SEQ ID NO: 626) 0601GIP4607YaEGTFISDYSIALDKIRQQEFVNWLLAQK  84.6962(% Inh, 10 nM)PSS(OctG)APPPS-NH2 (SEQ ID NO: 627) 0601GIP4325YAEGTFISDYSIA(Ocg)DKIHQQDFVNWLL 106.9993 219 AQK-NH2 (SEQ ID NO: 399)(% Inh, 10 nM) 0601GIP4326 YaEGTFISDYSIA(OctG)DKIHQQDFVNWLL 97.448(% Inh, 10 nM) 53 AQKPSSGAPPPS)-NH2 (SEQ ID NO: 611) 0601GIP4671YaEGTFISDYSIA(OctG)DKIHQQDFVNWLL  97.4262(% Inh, 10 nM)AQKPKKIRYS-NH2 (SEQ ID NO: 628) 0601GIP4693YaEGTFISDYSIA(OctG)DKIHQQDFVNWLL  91.6712(% Inh,10 nM)AQK(beta-A) (beta-A)PSSGAPPPS-NH2 (SEQ ID NO: 629) 0601GIP4755YaEGTFISDYSIA(OctG)DKIAQQEFVNWLL  96.3(% Inh, 10 nM)AQKPSSGAPPPS-NH2 (SEQ ID NO: 630) 0601GIP4547YaEGTFISDYSIA(K(Oct))DKIHQQDFVNWL  41.3078(% Inh 10 nM)LAQKPSSGAPPPS-NH2 (SEQ ID NO: 619) 0601GIP4461YAEGTFISDYSIAMDKIHQQDFVNWLLAQ  95.785(% Inh 10 nM)KPSSGAPPPS(OctG)-NH2 (SEQ ID NO: 401) 0601GIP4581YaEGTFISDYSIAMDKIHQQDFVNWLLAQ  97.512(% Inh 10 nM)KPSSGAPPPS(OctG)-NH2 (SEQ ID NO: 631) 0601GIP4583K(epsilon-NH-Octanoyl)-  85.4997(% Inh 10 nM)YaEGTFISYDSIAMDKIHQQDFVNWLLAQ KPSSGAPPPS(OctG)-NH2 (SEQ ID NO: 632)0601GIP4585 K(epsilon-NH-Octanoyl)-  85.1781(% Inh 10 nM)YaEGTFISDYSIAMDKIHQQDFVNWLLAQ KPSSGAPPPS-NH2 (SEQ ID NO: 633)0601GIP4584 K(epsilon-NH-(2-(2-  26.5178(% Inh 10 nM)(2methoxyetoxy)ethoxy)acetoyl))- YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS(OctG)-NH2 (SEQ ID NO: 634) 0601GIP4833YaEGTFISDYSIAKDKIHQQDFVNWLLAQK PKKK(epsilon-NH-(palmitoyl))RYS-NH2(SEQ ID NO: 635) 0601GIP4586 K(epsilon-NH-(2-(2-  19.2602(% Inh 10 nM)(2methoxyetoxy)ethoxy)acetoyl))- YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 636) 0601GIP4647YaEGTFISDYSIAMDKIHQQDFVNWLLAQ  76.6236(% Inh, 10 nM)K(beta-A)(beta-A)PSSGAPPPS-NH2 (SEQ ID NO: 637) 0601GIP4179YaEGTFISDYSIALDKIHQQDFVNWLLAQK   3.3 RIN, 0.700 IC50  55.9(beta-A)(beta-A)PSSGAPPPS-NH2 in HEK-GIPR (SEQ ID NO: 587) 0601GIP4649OctG-  87.3376(% Inh, 10 nM) YaEGTFISDYSIAMDKIHQQDFVNWLLAQK(beta-A)(beta-A)PSSGAPPPS-NH2 (SEQ ID NO: 638) 0601GIP4642YAEGTFISDYSIAMDKIHQQDFVNWLLAQ  82.0796(% Inh, 10 nM)K(beta-A)(beta-A)PSSGAPPPS-NH2 (SEQ ID NO: 639) 0601GIP4643YaEGTFISDYSIAMDKIRQQEFVNWLLAQK  84.7142(% Inh, 10 nM)(beta-A)(beta-A)PSSGAPPPS-NH2 (SEQ ID 640) 0601GIP4644YaEGTFISDYSIAMDKIRQQDFVEWLLAQK  70.8009(% Inh, 10 nM)(beta-A)(beta-A)PSSGAPPPS-NH2 (SEQ ID NO: 641) 0601GIP4645 OctG- 82.1831(% Inh, 10 nM) YaEGTFISDYSIAMDKIRQQEFVNWLLAQH(beta-A)(beta-A)PSSGAPPPS-NH2 (SEQ ID NO: 642) 0601GIP4646YaEGTFISDYSIAMDKIAQQEFVNWLLAQK  82.1763(% Inh, 10 nM)(beta-A)(beta-A)PSSGAPPPS-NH2 (SEQ ID NO: 643) 0601GIP4294 octG-   0.92282 YaEGTFISDYSIALDKIHQQDFVNWLLAQK (beta-A)(beta-A)PSSGAPPPS-NH2(SEQ ID NO: 610) 0601GIP4542 OctG-  19.1733(% Inh, 10 nM)YaPGTFISDYSIALDKIHQQDFVNWLLAQK (beta-A)(beta-A)PSSGAPPPS-NH2(SEQ ID NO: 617) 0601GIP4541 OctG-  14.3806(% Inh, 10 nM)YAPGTFISDYSIALDKIHQQDFVNWLLAQK (beta-A)(beta-A)PSSGAPPPS-NH2(SEQ ID NO: 403) 0601GIP4191 YaEGTFISDYSIAMDKIHQQDFVNWLLAQ  10 81K-8-amino 3,6-dioxaoctanoyl-PSSGAPPPS- NH2 (SEQ ID NO: 589) 0601GIP4756YaEGTFISDYSIAMDKIHQQDFVNWLLAQ  60.5(% Inh, 10 nM)K(Aca)PSSGAPPPS-NH2 (SEQ ID NO: 644) 0601GIP4562 YaEGT(D-Nal2]ISDYSIAMDKIHQQDFVNWLLAQKPS SGAPPPS-NH2 (SEQ ID NO: 645) 0601GIP4572YaEGTFISD(D-  33.6497(% Inh, 10 nM) Nal2)SIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 646) 0601GIP4573 YaEGTFISDYSIA(D- 57.9293(% Inh, 10 nM) Nal2)DKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 647) 0601GIP4595 YaEGTFISDYSIAMDKIHQQD(D-Nal2)VNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 648) 0601GIP4605YaEGTFISDYSIAMDKIHQQDFVN(D-   9.4012(% Inh, 10 nM)Nal2)LLAQKPSSGAPPPS-NH2 (SEQ ID NO: 649) 0601GIP4609YaEGTFISDYSIAMDK-(epsilon-NH-(Aun- Aun-(2-(2methoxyethoxy)-acetoyl)))-IHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 650)

Alternative representations of some of the above compounds are asfollows:

In other embodiments GIP compounds incorporate one or more modificationsor derivatizations. For example, 0601 GIP4294 contains both anoctylglycyl N-terminus modification and a beta-Ala linker. Furtherexemplary compounds include:

0601GIP4399 N-octylglycine- 104.3139YADGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (% Inh (SEQ ID NO: 376)10 nM) 0601GIP4390 YADGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIRYS-NH2  90.281(SEQ ID NO: 377) (% Inh 10 nM) 0601GIP4395YSDGTFISDYSIAMDKIHQQDFVNWLLAQK(beta-  74.626A)PSSGAPPPS-NH2 (SEQ ID NO: 378) (% Inh 10 nM) 0601GIP4387N-octylglycine-  97.011 YSDGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2(% Inh (SEQ ID NO: 379) 10 nM) 0601GIP4386YSDGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIRYS-NH2(SEQ ID NO: 406) (SEQ ID NO: 380)

Further exemplary compounds depict incorporation of modifications fromother (non-human) species, or combinations of modifications as describedherein, and their GIP Receptor binding and receptor activation activity,are shown in the table (changes from Compound 0601GIP3794 arehighlighted in bold italic; and see also FIG. 12).

Cmpd# Sequence GIP RBA Cyclase 0601GIP3794YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS- 3.8 38 NH2 (SEQ ID NO: 186)0601GIP4190 YaEGTFISDYSIALDKIHQQDFVNWLLAQKPSSGAPPPS- 2.4 31NH2 (SEQ ID NO: 588) 0601GIP4151YaEGTFISEYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS- 20 10000 NH2 (SEQ ID NO: 581)0601GIP4152 YaEGTFISDYSIAMDKIHQQEFVNWLLAQKPSSGAPPPS- 2.3 22NH2 (SEQ ID NO: 582) 0601GIP4150YaEGTFISDYSIAMDKIAQQDFVNWLLAQKPSSGAPPPS- 1.6 14 NH2 (SEQ ID NO: 580)0601GIP4153 YaEGTFISDYSIAMDKIRQQDFVNWLLAQKPSSGAPPPS- 0.53 11.4NH2 (SEQ ID NO: 583) 0601GIP4149YaEGTFISDYSIAMDKIKQQDFVNWLLAQKPSSGAPPPS- 1.5 36 NH2 (SE ID NO: 579)0601GIP4165 YaEGTFISDYSIAMDKIHQQDFVNWLLAQAPSSGAPPPS- 21 40NH2 (SEQ ID NO: 584) 0601GIP4176YaEGTFISDYSIAMDKIHQQDFVNWLLAQRPSSGAPPPS- 4.8 28 NH2 (SEQ ID NO: 585)0601GIP4177 YaEGTFISDYSIAMDKIHQQDFVNWLLAQHPSSGAPPPS- 2.9 11NH2 (SEQ ID NO: 586) 0601GIP4213YaEGTFISDYSITMDKIHQQDFVNWLLAQKPSSGAPPPS- 44 NH2 (SEQ ID NO: 592)0601GIP4214 YaEGTFISDYSIAMDKIHQQDFVNWLLSQKPSSGAPPPS- 145NH2 (SEQ ID NO: 593) 0601GIP4694YaEGTFISDYSIAMDKIRQQDFVNWLEAQEPSSGAPPPS- 8.1305 NH2 (SEQ ID NO: 651)(% Inh, 10 nM)

In one embodiment the GIP hybrids or GIP portions thereof have one ormore of the following modifications (for reference only to formulaN-terminus-YaEGTFISDYSIAMDKIHQQDFVNWLLAQK-Linker-PSSGAPPPS-NH2) (SEQ IDNO:652):

dAla2 to Abu, Ala, Gly, or Ser; Met14 to Leu; His18 to Ala, Arg, or Lys;Asp21 to Glu; Lys30 to Arg or His; an N-terminus as Gly(Oct); and/or abAla-bAla or Gly-Gly-Gly linker. In a further embodiment one or more ofsuch changes are made to compound 0601GIP3794.

In one embodiment the GIP analogs or GIP portions of hybrids do not havea substitution, modification and/or substitution at any one or more ofthe following positions: Tyr1 , Ty10, Va123, Leu27 and/or Phe22. Asdemonstrated in the following table, substitution by alanine at one ormore of these positions in 0601GIP3794 result in an analog having lessthan 25% inhibition of receptor binding (at 10 nM peptideconcentration). In yet another embodiment, the GIP analogs and hybridsdo not contain an alanine substitution at one or more of Tyr1, Ty10,Va123, Leu27and/or Phe22.

0601GIP4958 AaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-  9.4 (% Inh NH210 nM) 0601GIP4964 YaEGTFISDASIAMDKIHQQDFVNWLLAQKPSSGAPPPS- 15.7 (% InhNH2 10 nM) 0601GIP4940 YaEGTFISDYSIAMDKIHQQDAVNWLLAQKPSSGAPPPS-21.9 (% Inh NH2 10 nM) 0601GIP4941YaEGTFISDYSIAMDKIHQQDFANWLLAQKPSSGAPPPS- −2.5′ (% Inh NH2 10 nM)0601GIP4945 YaEGTFISDYSIAMDKIHQQDFVNWLAAQKPSSGAPPPS- 26.6 (% Inh NH210 nM)

In yet a further embodiment, a GIP analog or hybrid can have an alaninesubstitution at one or more of the positions as compared to 0601GIP3794and retain receptor binding as indicated in the following table. Thedata also indicate that these positions of GIP are tolerant tosubstitution and modification, as described herein.

0601GIP4959 YaAGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS- 72.2 (% InhNH2 (SEQ ID NO:818) 10 nM) 0601GIP4960YaEGAFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS- 55.9 (% Inh NH2 (SEQ ID NO:819)10 nM) 0601GIP4961 YaEGTAISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS- 47 (% InhNH2 (SEQ ID NO:820) 10 nM) 0601GIP4962YaEGTFIADYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS- 72 (% Inh NH2 (SEQ ID NO:821)10 nM) 0601GIP4963 YaEGTFISAYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS- 82.1 (% InhNH2 (SEQ ID NO:822) 10 nM) 0601GIP4967YaEGTFISDYAIAMDKIHQQDFVNWLLAQKPSSGAPPPS- 90.2 (% Inh NH2 (SEQ ID NO:823)10 nM) 0601GIP4968 YaEGTFISDYSAAMDKIHQQDFVNWLLAQKPSSGAPPPS- 82 (% InhNH2 (SEQ ID NO:824) 10 nM) 0601GIP4969YaEGTFISDYSIAADKIHQQDFVNWLLAQKPSSGAPPPS- 62.9 (% Inh NH2 (SEQ ID NO:825)10 nM) 0601GIP4970 YaEGTFISDYSIAMAKIHQQDFVNWLLAQKPSSGAPPPS- 86.7 (% InhNH2 (SEQ ID NO:826) 10 nM) 0601GIP4935YaEGTFISDYSIAMDAIHQQDFVNWLLAQKPSSGAPPPS- 61.4 (% Inh NH2 (SEQ ID NO:827)10 nM) 0601GIP4936 YaEGTFISDYSIAMDKAHQQDFVNWLLAQKPSSGAPPPS- 84.6 (% InhNH2 (SEQ ID NO:828) 10 nM) 0601GIP4937YaEGTFISDYSIAMDKIHAQDFVNWLLAQKPSSGAPPPS- 85.4 (% Inh NH2 (SEQ ID NO:829)10 nM) 0601GIP4938 YaEGTFISDYSIAMDKIHQADFVNWLLAQKPSSGAPPPS- 79.3 (% InhNH2 (SEQ ID NO:830) 10 nM) 0601GIP4939YaEGTFISDYSIAMDKIHQQAFVNWLLAQKPSSGAPPPS- 91.9 (% Inh NH2 (SEQ ID NO:831)10 nM) 0601GIP4942 YaEGTFISDYSIAMDKIHQQDFVAWLLAQKPSSGAPPPS- 78.8 (% InhNH2 (SEQ ID NO:832) 10 nM) 0601GIP4943YaEGTFISDYSIAMDKIHQQDFVNALLAQKPSSGAPPPS- 49 (% Inh NH2 (SEQ ID NO:833)10 nM) 0601GIP4944 YaEGTFISDYSIAMDKIHQQDFVNWALAQKPSSGAPPPS- 65.7 (% InhNH2 (SEQ ID NO:834) 10 nM) 0601GIP4946YaEGTFISDYSIAMDKIHQQDFVNWLLAAKPSSGAPPPS- 73.9 (% Inh NH2 (SEQ ID NO:835)10 nM)

Further exemplary modifications (compared to 0601GIP3794) which can beused in the GIP portions of the compounds of the invention, andexemplary compounds containing them, are shown in the table (and seeFIG. 12):

Cmpd # Sequence GIP RBA Cyclase 0601GIP4263YaEGTFISDYSIALDKIAQQEFVNWLLAQRPSSGAPPPS- 0.66 6.2 NH2 (SEQ ID NO: 600)0601GIP4278 YaEGTFISDYSIALDKIRQQEFVNWLLAQRPSSGAPPPS- 0.24 3.5NH2 (SEQ ID NO: 601) 0601GIP4264YaEGTFISDYSIALDKIKQQEFVNWLLAQRPSSGAPPPS- 2.1 14 NH2 (SEQ ID NO: 653)0601GIP4279 YaEGTFISDYSIALDKIAQQEFVNWLLAQHPSSGAPPPS- 2.1 14NH2 (SEQ ID NO: 602) OO YaEGTFISDYSIALDKIRQQEFVNWLLAQHPSSGAPPPS-NH2 (SEQ ID NO: 654) PP YaEGTFISDYSIALDKIKQQEFVNWLLAQHPSSGAPPPS-NH2 (SEQ ID NO: 655) 0601GIP4235YaEGTFISDYSIAMDKIHQVKFVNWLLAQKPSSGAPPPS- NH2 (SEQ ID NO: 597)0601GIP4283 YaEGTFISDYSIALDKIRQQEFVNWLLAQKPSSGAPPPS- 0.41NH2 (SEQ ID NO: 603) 0601GIP4284YaEGTFISDYSIALDKIKQQEFVNWLLAQKPSSGAPPPS- 1.8 NH2 (SEQ ID NO: 604)0601GIP4285 YaEGTFISDYSIALDKIAQQEFVNWLLAQKPSSGAPPPS- 0.58NH2 (SEQ ID NO: 605) 0601GIP4286YaEGTFISDYSIALDKIRQQEFVNWLLAQHPSSGAPPPS- 1000 NH2 (SEQ ID NO: 606)0601GIP4287 YaEGTFTADYSKALDKIHQQDFVNWLLAQKPSSGAPPP 27S-NH2 (SEQ ID NO: 607) VV YaEGTFTSDYSKALDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 656) WW YaEGTFISDYSKAMDKIRQQEFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 657) XX YaEGTFISDYSIALEKIRQQKFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 658) 0601GIP4289YaEGTFISDYSIALDKIRQQDFVEWLLAQKPSSGAPPPS- 0.58 22 NH2 (SEQ ID No 609) ZZYaEGTFISDYSIALDKIRQQEFVNWLLAQK-bAla- PSSGAPPPS-NH2 (SEQ ID NO: 659) AAAYaEGTFISDYSIALDKIRQQEFVNWLLAQK-bAla- PSSGAPPPS-NH2 (SEQ ID NO: 660)0601GIP4215 YaEGTFISDYSIAMDKIHQQLFIEWLKNGGPSSGAPPPS-NH2 (SEQ ID NO: 374) 0601GIP4288YaEGTFISDYSIAMDKIRQQEFVNWLLAQKPSSGAPPPS- NH2 (SEQ ID NO: 608) AAAAYaEGTFISDYSIAMDKIHQQDFVNFLLAQKPSSGAPPPS- NH2 (SEQ ID NO: 661) BBBBYAEGTFISDYSIAMDKIHQQDFVNFLLAQKPSSGAPPPS- NH2 (SEQ ID NO: 185)0601GIP4696 YaEGTFISDYSIAMDKILQQDFVNWLSAQQPSSGAPP 17.0923PS-NH2 (SEQ ID NO: 662) (% Inh, 10 nM)

Exemplary analogs also include amino acid modifications that eliminateor reduce oxidation. Such replacements include a deletion or replacementof methionine 14 with leucine and/or the tryptophan 25 withphenylalanine. Accordingly, specific exemplary analogs include a variantof each analog described herein by having one or more such replacements.As an example are compounds AAAA and BBBB which are the D-Ala2 andL-Ala2 analogs of 0601GIP3794 having a Phe for Trp replacement atposition 25.

Further exemplary “tail” modifications (compare to 0601GIP3794 (SEQ IDNO:186)), for example those having a frog GLP-1 tail (PKKIRYS) (SEQ IDNO:421) alone or in combination with other modifications andderivatizations, and exemplary compounds having them, are depicted inthe table below (and see FIG. 12), along with receptor binding andactivation data. Ado is 8-Amino 3,6 dioxaoctanoic acid and Aun is11-amino undecanoic acid.

GIPR Cmpd # Sequence GIP RBA Cyclase 0601GIP3794YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPP   3.8 38 PS-NH2 (SEQ ID NO: 186)0601GIP4216 YaEGTFISDYSIAMDKIHQQLFIEWLKNGGPSSGAPPP  12 122 Trp cageS-NH2 (SEQ ID NO: 594) “Leu21-Pro38” 0601GIP4233YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIRYS-   0.1 31 fGLP1 tailNH2 (SEQ ID NO: 595) 0601GIP4234 YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSKEIIS-  3.4 83 fGLP1 tail NH2 (SEQ ID NO: 596) 0601GIP4236YaEGTFISDYSIAMDKIHQQDFVNWLLAQKTSPRPPS-   0.62 29 Helospectin IINH2 (SEQ ID NO: 598) tail 0601GIP4798LYaEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIR  82.3 YS-NH2 (SEQ ID NO: 663)(% Inh 10 nM) 0601GIP4799 LYAEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKI  91.6RYS-NH2 (SEQ ID NO: 664) (% Inh 10 nM) 0601GIP4801IYaEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIR  88.8 YS-NH2 (SEQ ID NO: 665)(% Inh 10 nM) 0601GIP4802 LYaEGTFISDYSIALDKIAQQEFVNWLLAQKPKKIR  87.3YS-NH2 (SEQ ID NO: 666) (% Inh 10 nM) 0601GIP4803LYAEGTFISDYSIALDKIAQQEFVNWLLAQKPKKIR  89.9 YS-NH2 (SEQ ID NO: 667)(% Inh 10 nM) 0601GIP4804 IYaEGTFISDYSIALDKIAQQEFVNWLLAQKPKKIR  85.3YS-NH2 (SEQ ID NO: 668) (% Inh 10 nM) 0601GIP4766 Methyl-  94.5YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIR (% Inh, YS-NH2 (SEQ ID NO: 669)10 nM) HaEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIR YS-NH2 (SEQ ID NO: 670)HGEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIR YS-NH2 (SEQ ID NO: 671)HAEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIR YS-NH2 (SEQ ID NO: 672)HGEGTFISDYSIALDKIAQQEFVNWLLAQKPKKIRY S-NH2 (SEQ ID NO: 673)HGEGTFISDYSIALDKIRQQEFVNWLLAQKPKKIRY S-NH2 (SEQ ID NO: 674)HGEGTLISDYSIAMDKIHQQDFVNWLLAQKPKKIR YS-NH2 (SEQ ID No, 675)YAibEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKI RYS-NH2 (SEQ ID NO: 676)0601GIP4192 YaEGTFISDYSIAMDKIHQQDFVNWLLAQKSGAPP   7 135PS-NH2 (SEQ ID NO: 590) 0601GIP4807 YaEGTFISDYSIALDKIHQQDFVNWLLAQKPKKIRY 96.1 S-NH2 (SEQ ID NO: 677) (% Inh 10 nM) 0601GIP4233YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIR 0.1 RIN, 31 YS-NH2 (SEQ ID NO: 678)0.210, IC50 HEK- GIPR 0601GIP4327 YAEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIR 96.504 92.6 YS-NH2 (SEQ ID NO: 405) (% Inh, 10 nM) 0601GIP4762YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIR  79.1 YS-OH (SEQ ID NO: 679) (% Inh,10 nM) 0601GIP4386 YSDGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIR IC50 = 156 56YS-NH2 (SEQ ID NO: 406) nM RIN, 93.58 8 (% Inh 10 nM) 0601GIP4698Guanido-  78.3 YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIR (% InhYS-NH2 (SEQ ID NO: 680) 10 nM) 0601GIP4791 Guanido-YaEGTFISDYSIALDKIRQQEFVNWLLAQKPKKIRY S-NH2 (SEQ ID NO: 681) 0601GIP4538YSEGTFISDYSIAMDKIHQQDFVNWLLAQKPKKIR  94.2371 YS-NH2 (SEQ ID NO: 407)(% Inh 10 nM) 0601GIP4539 YaEGTFISDYSIALDKIRQQEFVNWLLAQKPKKIRY  98.6752S-NH2 (SEQ ID NO: 615) (% Inh 10 nM) 0601GIP4540YaEGTFISDYSIALDKIRQQDFVEWLLAQKPKKIRY  92.2169 S-NH2 (SEQ ID NO: 616)(% Inh 10 nM) 0601GIP4648 YaEGTFISDYSIAMDKIHQQDFVNWLLAQK(beta-  85.1034A)(beta-A)PKKIRYS-NH2 (SEQ ID NO: 682) (% Inh 10 nM) 0601GIP4631YaEGTFISDYSIALDKIAQQEFVNWLLAQKPKKIRY  79.031 S-NH2 (SEQ ID NO: 683)(% Inh 10 nM) 0601GIP4805 OctG-  83.5YAEGTFISDYSIALDKIAQQEFVNWLLAQKPKKIRY (% Inh S-NH2 (SEQ ID NO: 684)10 nM) 0601GIP4561 OctG- YaEGTFISDYSIAMDKIRQQEFVNWLLAQKPKKIRYS-NH2 (SEQ ID NO: 685) 0601GIP4673 OctG-  94.9197YaEGTFISDYSIALDKIAQQEFVNWLLAQKPKKIRY (% Inh S-NH2 (SEQ ID NO: 686)10 nM) 0601GIP4672 OctG-  91.9031 YaEGTFISDYSIALDKIAQQDFVEWLLAQKPKKIRY(% Inh S-NH2 (SEQ ID NO: 687) 10 nM) 0601GIP4713 Guan-  86.7YaEGTFISDYSIALDKIAQQEFVNWLLAQKPKKIRY (% Inh S-NH2 (SEQ ID NO: 688)10 nM) 0601GIP4711 Guan-  95 (% Inh YaEGTFISDYSIALDKIAQQDFVEWLLAQKPKKIRY10 nM) S-NH2 (SEQ ID NO: 689) 0601GIP83YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSKEII   3.4 S-NH2 (SEQ ID NO: 690)0601GIP4710 YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSKEII  79.2H-OH (SEQ ID NO: 691) (% Inh 10 nM) 0601GIP4765YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSKEII  67 (% Inh S-OH (SEQ ID NO: 692)10 nM) 0601GIP4236 YaEGTFISDYSIAMDKIHQQDFVNWLLAQKTSPRPP   0.62 29S-NH2 (SEQ ID NO: 598) 0601GIP4328 YAEGTFISDYSIAMDKIHQQDFVNWLLAQKTSPRP104.7575 46.8 PS-NH2 (SEQ ID NO: 408) (% Inh, 10 nM) 0601GIP4345YaEGTFISDYSIAMDKIHQQDFVNWLLAQKTSPPP-  76.134(% 103 NH2 (SEQ ID NO: 612)Inh, 10 nM) 0601GIP4401 YAEGTFISDYSIAMDKIHQQDFVNWLLAQKTSPRP 102.8819PSS-NH2 (SEQ ID NO: 409) (% Inh, 10 nM) 0601GIP4346YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPKLIKL  91.004(% 235IKS-NH2 (SEQ ID NO: 613) Inh, 10 nM) 0601GIP4700YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPKGKG  86.6(% Inh, KS-NH2 (SEQ ID NO: 693)10 nM) 0601GIP4400 YAEGTFISDYSIAMDKIHQQDFVNWLLAQK-Ado-  98.3705 Aun(% Inh, (SEQ ID NO: 410) 10 nM) 0601GIP4402YAEGTFISDYSIAMDKIHQQDFVNWLLAQ-K(N- 103.3047epsilon)-PSSGAPPPS-NH2 (SEQ ID NO: 614) (% Inh, 10 nM) 0601GIP4619YaEGTFISDYSIAMDKIHQQDFVNWLLAQKGFVLW  84.5725 KGIQ-NH2 (% Inh, 10 nM)

Even further exemplary “tail” modifications (compare to 0601GIP4233which incorporates a frog GLP1 tail PKKIRYS (SEQ ID NO:421)) which canbe used alone or in combination with other modifications andderivatizations, and the exemplary GIP compounds containing them, aredepicted in the following table along with various activities. Analog0601GIP4233 is an example of a GIP analog having surprisingly highsolubility (e.g., solubility greater than 5mg/m1 in 30 mM histidinebuffer at pH 4 to 8) and contains a frog GLP-1 C-terminal tail. Afurther such tail modification that improves solubility of a GIP analogor hybrid into which it is incorporated is a chimera of the frog tailand the exendin tail: PKKIPPPS (SEQ ID NO:836) as found in 0601GIP4951.This chimeric tail can be incorporated into other GIP analogs andhybrids as disclosed herein to improve solubility. Further modificationand derivatizations as shown in the table below can also improveduration of action, e.g. as tested in a rat IVGTT assay, and plasmastability, when incoprotaed into a GIP analog or hybrid. In in vitrostudies, the main cleavage site of an analog having the frog tail was atthe Ile34-Arg35 peptide bond. Accordingly, in one embodiment is a GIPanalog or hybrid having a modification, substitution or derivitizationat one or both of these two positions to reduce in vitro cleavage ascompared to the parent peptide. Examples of such modifications (ascompared to 0601GIP4233) are shown in the table below, and arecontemplated to be used with any of the other GIP analogs and hybridsshown herein.

Basal (% Inh Gluc. Duration In 10 nm, GIP- OGTT/ Low. 80 The RatLF Assay) GL (%) nmol/Kg Solubility IVGTT Assay 0601GIP4233YaEGTFISDYSIA 89 (% Inh −22 −8 to >5 mg/ml <794 @ −120 MDKIHQQDFVN10 nM); 350 nmol/kg, −19%, min WLLAQKPKKIR 0.12, 0.41, −17 AUC240YS-NH2 (SEQ ID  0.21 IC50 30 nmol/kg NO: 595) HEK-GIPR 0601GIP4807YaEGTFISDYSIA 96.1 (% Inh −27, −26%, <794 @ −120 LDKIHQQDFVN 10 nM)30 nmol/kg AUC240 min WLLAQKPKKIR YS-NH2 (SEQ ID 677) 0601GIP4798LYaEGTFISDYSI 82.3 (% Inh −27, −8%, <3794 @ −120 AMDKIHQQDFV 10 nM)30 nmol/kg AUC240 min NWLLAQKPKKI RYS- NH20601GIP (SEQ ID NO: 663)0601GIP4799 LYAEGTFISDYS 91.6 (% Inh −10, IAMDKIHQQDF 10 nM) 30 nmol/kgVNWLLAQKPK KIRYS-NH2 (SEQ ID NO: 664) 0601GIP4801 IYaEGTFISDYSI88.8(% Inh −23, −1%, AMDKIHQQDFV 10 nM) 30 nmol/kg AUC240 NWLLAQKPKKIRYS-NH2 (SEQ ID NO: 665) 0601GIP4802 LYaEGTFISDYSI 87.3 (% Inh −28,−15%, <794 @ −120 ALDKIAQQEFV 10 nM) 30 nmol/kg AUC240 min NWLLAQKPKKIRYS-NH2 (SEQ ID NO: 666) 0601GIP4803 LYAEGTFISDYS 89. 9(% Inh −16,IALDKIAQQEFV 10 nM) 30 nmol/kg NWLLAQKPKKI RYS-NH2 (SEQ ID NO: 667)0601GIP4804 IYaEGTFISDYSI 85.3 (% Inh −15, ALDKIAQQEFV 10 nM) 30 nmol/kgNWLLAQKPKKI RYS-NH2 (SEQ ID NO: 668) 0601GIP4951 YaEGTFISDYSIA102.6(% Inh, −25, −17%, >5 mg/ml <794 @ −120 MDKIHQQDFVN 10 nM)30 nmol/kg AUC240 min WLLAQKPKKIP PPS-NH2 (SEQ ID NO: 837) 0601GIP4838HaEGTFISDYSIA 34.3 (% Inh MDKIHQQDFVN 10 nM) WLLAQKPKKIR YS-NH2(SEQ ID NO: 838) 0601GIP4839 HGEGTFISDYSI 23.9(% Inh AMDKIHQQDFV 10 nM)NWLLAQKPKKI RYS-NH2 (SEQ ID NO: 839) 0601GIP4840 HAEGTFISDYSI 44.1(% InhAMDKIHQQDFV 10 nM) NWLLAQKPKKI RYS-NH2 (SEQ ID NO: 840) 0601GIP4841HGEGTFISDYSI 56.6(% Inh ALDKIAQQEFV 10 nM) NWLLAQKPKKI RYS-NH2(SEQ ID NO: 841) 0601GIP4842 HGEGTFISDYSI 40.8 (% Inh ALDKIRQQEFV 10 nM)NWLLAQKPKKI RYS-NH2 (SEQ ID NO: 842) 0601GIP4843 HGEGTLISDYSI 3(% InhAMDKIHQQDFV 10 nM) NWLLAQKPKKI RYS-NH2 (SEQ ID NO: 843) 0601GIP4845YaEGTFISDYSIA 69.5 (% Inh, −21, −14%, MDKIHQQDFVN 10 nM) 30 nmol/kgAUC240 QLLAQKPKKIR YS-NH2 (SEQ ID NO: 844) 0601GIP4865 YaEGTFISDYSIA85.6 (% Inh, −17, MDKIHQQDFVQ 10 nM) 30 nmol/kg WLLAQKPKKIR YS-NH2(SEQ ID NO: 845) 0601GIP4865 Y(Aib)EGTFISD 91.2 (% Inh −13, YSIAMDKIHQQ10 nM) 30 nmol/kg DFVNWLLAQKP KKIRYS-NH2 (SEQ ID NO: 846) 0601GIP4814YaEGTFISDYSIA 88 (% Inh −22, −16%, MDKIHQQDFVN 10 nM) 30 nmol/kg AUC240WLLAQKAKKIR YS-NH2 (SEQ ID NO: 695) 0601GIP4815 YaEGTFISDYSIA 89 (% Inh−23, −14%, <794@ −120 MDKIHQQDFVN 10 nM) 30 nmol/kg AUC240 minWLLAQKPAKIR YS-NH2 (SEQ ID NO: 696) 0601GIP4816 YaEGTFISDYSIA87.3 (% Inh −19, −9%, <794@ −120 MDKIHQQDFVN 10 nM) 30 nmol/kg AUC240min WLLAQKPKAIR YS-NH2 (SEQ ID NO: 697) 0601GIP4856 YaEGTFISDYSIA83.7 (% Inh −29, −3%, <794@ −120 MDKIHQQDFVN 10 nM) 30 nmol/kg AUC240min WLLAQKPKKA RYS-NH2 (SEQ ID NO: 847) 0601GIP4817 YaEGTFISDYSIA80.5 (% Inh −20, −4%, <794@ −120 MDKIHQQDFVN 10 nM); 30 nmol/kg AUC240min WLLAQKPKKIA 0.45IC50Hek YS-NH2 GIPR (SEQ ID NO: 698) 0601GIP4818YaEGTFISDYSIA 76.1 (% Inh −23, −9%, MDKIHQQDFVN 10 nM) 30 nmol/kg AUC240WLLAQKPKKIR AS-NH2 (SEQ ID NO: 699) 0601GIP4819 YaEGTFISDYSIA80.4 (% Inh −26, −15%, MDKIHQQDFVN 10 nM) 30 nmol/kg AUC240 WLLAQKPKKIRYA-NH2 (SEQ ID NO: 700) 0601GIP4820 YaEGFISDYSIA 46 (% Inh MDKIHQQDFVN10 nM) WLLAQKPSPKK IRYS-NH2 (SEQ ID NO: 701) 0601GIP4823 YaEGTFISDYSIA94.1 (% Inh −23, −23%, <794@ −120 MDKIHQQDFVN 10 nM) 30 nmol/kg AUC240min WLLAQKPSPKK IRYS-NH2 (SEQ ID NO: 702) 0601GIP4821 YaEGTFISDYSIA93.5 (% Inh −28, −5%, <794@ −120 MDKIHQQDFVN 10 nM) 30 nmol/kg AUC240min WLLAQKPKSAR PS-NH2 (SEQ ID NO: 703) 0601GIP4822 YaEGTFISDYSIA95.4 (% Inh −23, −11%, <794@ −120 MDKIHQQDFVN 10 nM) 30 nmol/kg AUC240min WLLAQKPKKLK PS-NH2 (SEQ ID NO: 704) 0601GIP4914 YaEGTFISDYSIA96.3 (% Inh MDKIHQQDFVN 10 nM) WLLAQKPKKQ RYS-NH2 (SEQ ID NO: 848)0601GIP4913 YaEGTFISDYSIA 92.1 (% Inh MDKIHQQDFVN 10 nM) WLLAQKPKKIQYS-NH2 (SEQ ID NO: 849) 0601GIP4906 YaEGTFISDYSIA −28, −15%, MDKIHQQDFVN30 nmol/kg AUC240 WLLAQKPSSGR YS-NH2 (SEQ ID NO: 850) 0601GIP4851YaEGTFISDYSIA 87 (% Inh MDKIHQQDFVN 10 nM) WLLAQKPNKIR YS-NH2(SEQ ID NO: 851) 0601GIP4852 YaEGTFISDYSIA 90 (% Inh MDKIHQQDFVN 10 nM)WLLAQKPKNIR YS-NH2 (SEQ ID NO: 852) 0601GIP4855 YaEGTFISDYSIA78.8 (% Inh −21, <794@ −120 MDKIHQQDFVN 10 nM); 30 nmol/kg minWLLAQKPQQIR IC50 = 0.72H YS-NH2 EKGIPR (SEQ ID NO: 853) 0601GIP4853YaEGTFISDYSIA 91 (% Inh −25, −20%, <794@ −120 MDKIHQQDFVN 10 nM)30 nmol/kg AUC240 min WLLAQKPQKIR YS-NH2 (SEQ ID NO: 854) 0601GIP4854YaEGTFISDYSIA 93.5 (% Inh −14, <794@ −120 MDKIHQQDFVN 10 nM) 30 nmol/kgmin WLLAQKPKQIR YS-NH2 (SEQ ID NO: 855) 0601GIP4898 YaEGTFISDYSIA −23,MDKIHQQDFVN 30 nmol/kg WLLAQKPKSIR YS-NH2 (SEQ ID NO: 856) 0601GIP4899YaEGTFISDYSIA −26, MDKIHQQDFVN 30 nmol/kg WLLAQKPSKIR YS-NH2 (SEQ ID NO:857) 0601GIP4900 YaEGTFISDYSIA −29, MDKIHQQDFVN 30 nmol/kg WLLAQKPQKIQYS-NH2 (SEQ ID NO: 858) 0601GIP4904 YaEGTFISDYSIA −35, MDKIHQQDFVN30 nmol/kg WLLAQKPKGKI RYS-NH2 (SEQ ID NO: 859) 0601GIP4824YaEGTFISDYSIA 92.9 (% Inh −15, MDKIHQQDFVN   10 nM) 30 nmol/kg WLLAQKPKK(OctG)RYS-NH2 (SEQ ID NO: 709) 0601GIP4825 YaEGTFISDYSIA 77.5 (% Inh30 nmol/kg −15%, MDKIHQQDFVN 10 nM) AUC240 WLLAQKPKKIR YS(OctG)-NH2(SEQ ID NO: 710) 0601GIP4806 OctG- 101.3 (% Inh −14, −5% YAEGTFISDYSI10 nM) 30 nmol/kg AUC240 AMDKIRQQEFV NWLLAQHPKKI RYS-NH2 (SEQ ID NO:620) 0601GIP4805 OctG- 83.5 (% Inh −13, YAEGTFISDYSI 10 nM) 30 nmol/kgALDKIAQQEFV NWLLAQKPKKI RYS-NH2 (SEQ ID NO: 684)

Accordingly, in one embodiment are GIP analogs having a potency loss ofless than 25%, less than 15%, less than 10% or less than about 5%, at pH4 to 9, at pH 5 to 7, or further at pH 6 to 7, under acceleratedstability of 40 degrees C. for at least 1, at least 3 or at least 7days. In yet a further embodiment, the GIP analog has a solubilitygreater than about at least 1 mg/ml, at least 2 mg/ml, at least 3 mg/ml,at least 4 mg/ml or greater than at least 5 mg/ml, at at least one ormore of about pH 4, 5, 6, 7, 8, or 9, and further at at least three ormore of these pHs, and even further at all of these pHs. In oneembodiment the GIP compound has a solubility of at least about 2.0 mg/mlin 30 mM histidine buffer at pH 6 and/or at least about 5.0 mg/ml in 30mM histidine buffer at pH 6. In yet a further embodiment, the GIPcompound retains at least about 80% activity, at least about 90%activity or at least about 95% activity in 30 mM histidine buffer at pH6 for at least 7 days at 40 degrees C.

Further exemplary “tail” modifications (compare to 0601GIP4285 (SEQ IDNO:605) which has Leu14, A1a18 and Glu21 substitutions compared to0601GIP3794) that increase solubility of GIP analogs, improve theirduration of action and/or increase glucose lowering, as compared to0601GIP4285, and that can be used alone or combined with othermodifications and derivatizations, and the exemplary GIP compoundscontaining them, are depicted in the following table along with theirreceptor binding and activation data. For example, the N for Psubstitution in the tail region of 0601GIP4974 as compared to0601GIP4285, and more specifically the modified tail region, are suchmodifications that can be incorporated into other GIP compounds. (“Ocg”below stands for octylglycine).

Basal Duration (% Inh Gluc. In The Rat 10 nm, GIP- OGTT/ Low. 80 IVGTTLF Assay) GL(%) nmol/kg Solubility Assay 0601GIP4285 YaEGTFISDYSIALDKIAQIC50 = 0.110, −17 −2%, <1 mg/ = 794 at QEFVNWLLAQKPSSGAPP 0.22 HEK-30 nmol/ AUC240 ml −120 min PS-NH2 (SEQ ID NO: GIPR) kg 605) 0601GIP4974YaEGTFISDYSIALDKIAQ IC50 HEK- −21, −19%, <1 mg/ QEFVNWLLAQKPSSGAPPGIPR 0.18; 30 nmol/ AUC240 ml >794 at NS-NH2 (SEQ ID NO: kg; −120 min860) ED50 ~0.4 nmol/kg 0601GIP4992 YaEGTFISDYSIALDKIAQ  85.8(% Inh −18,−17%, QEFVNWLLAQKPSSGAPP 10 nM) 30 nmol/ AUC240 QS-NH2 (SEQ ID NO: kg861) 0601GIP4979 YaEGTFISDYSIALDKIAQ −20, −19%, <1 mg/ = 794 atQEFVNWLLAQKPSSGAPP  84.5(% Inh 30 nmol/ AUC240 ml −120 minQSK-NH2 (SEQ ID NO: 10 nM) kg 862) 0601GIP5074 YaEGTFISDYSIALDKIAQ 95.8(% Inh −37, QEFVNWLLAQKPSSGAPP 10 nM) 30 nmol/ PSK-NH2 (SEQ ID NO:kg 863) 0601GIP5083 YaEGTFISDYSIALDKIAQ  98.9(% Inh −23,QEFVNWLLKQKPSSGAPP 10 nM) 30 nmol/ PSNH2 (SEQ ID NO: kg 864) 0601GIP5084YaEGTFISDYSIALDKIAQ  99.4(% Inh, −22, QEFVNWLLAQKPSSGKPP 10 nM) 30 nmol/PS-NH2 (SEQ ID NO: kg 865) 0601GIP5085 YaEGTFISDYSIALDKIAQ  98.1(% Inh−26, QEFVNWLLAQKPSSGAK 10 nM) 30 nmol/ PPS-NH2 (SEQ ID NO: kg 866)0601GIP5095 YaEGTFISDYSIALDKIAQ  98.9(% Inh, −22, QEFVNWLLAQKPSSGAP10 nM) 30 nmol/ KPS-NH2 (SEQ ID NO: kg 867) 0601GIP5096YaEGTFISDYSIALDKIAQ  98.2(% Inh −18, QEFVNWLLAQKPSSGAPP 10 nM) 30 nmol/KS-NH2 (SEQ ID NO: kg 868) 0601GIP5097 YaEGTFISDYSIALDKIAQ 100.9% Inh,−21, QEFVNWLLAQKPSSGAPP 10 nM) 30 nmol/ KSK-NH2 (SEQ ID NO: kg 869)

Further exemplary tail modifications are described in the followingtable. The modifications provide increased plasma stability. In oneembodiment the frog GLP-1 tail region is substituted or modified at ornear the “KK” sequence to prevent or reduce proteolytic cleavage. Whilesuch modified tail region is depicted in the context of specific GIPanalogs in the table below, it is intended that such a modified tailsequence that increases plasma stability of the attached GIP portion, isto be used with any GIP analog or derivative, including those disclosedherein, to provide enhanced plasma stability and longer half-life. Themodified tail can be combined with one or more other GIP modificationsor derivatizations as discussed herein. Further,modified-frog-tail-containing GIP compounds are particularly usefulcomponents of GIP hybrids. In a further embodiment the frog GLP1 tailand analogs and derivatives thereof that enhance stability are ofparticular interest as an alternative to the exendin tail as used withGIP, exendin, GLP1 or other peptide hormones, as discussed herein.

0601GIP4814 YaEGTFISDYSIAMDKIHQQDFVNWLLAQKA 88KKIRYS-NH2 (SEQ ID NO: 695) (% Inh 10 nM) 0601GIP4815YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP 89 AKIRYS-NH2 (SEQ ID NO: 696) (% Inh10 nM) 0601GIP4816 YaEGTFISDYSIAMDKIHQQDFVNWLLAQKR 87.3PKAIYS-NH2 (SEQ ID NO: 697) (% Inh 10 nM) 0601GIP4817YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP 80.5 KKIAYS-NH2 (SEQ ID NO: 698) (% Inh10 nM) 0601GIP4818 YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP 76.1KKIRAS-NH2 (SEQ ID NO: 699) (% Inh 10 nM) 0601GIP4819YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP 80.4 KKIRYA-NH2 (SEQ ID NO: 700) (% Inh10 nM) 0601GIP4820 YaEGFISDYSIAMDKIHQQDFVNWLLAQKPS 46PKKIRYS-NH2 (SEQ ID NO: 701) (% Inh 10 nM) 0601GIP4823YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP 94.1 SPKKIRYS-NH2 (SEQ ID NO: 702)(% Inh 10 nM) 0601GIP4821 YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP 93.5KSARPS-NH2 (SEQ ID NO: 703) (% Inh 10 nM) 0601GIP4822YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP 95.4 KKLKPS-NH2 (SEQ ID NO: 704) (% Inh10 nM) YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP NKIRYS-NH2 (SEQ ID NO: 705)YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP KNIRYS-NH2 (SEQ ID NO: 706)YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP RQKIYS-NH2 (SEQ ID NO: 707)YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP KQIRYS-NH2 (SEQ ID NO: 708) 0601GIP4824YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP 92.9 KK(OctG)RYS-NH2 (SEQ ID NO: (% Inh709) 10 nM) 0601GIP4825 YaEGTFISDYSIAMDKIHQQDFVNWLLAQKP 77.5KKIRYS(OctG)-NH2 (SEQ ID NO: (% Inh 710) 10 nM)

Further exemplary “tail” modifications (compare to 0601GIP4288 (SEQ IDNO:608) which has Leu14, Glu15 and Arg18 and Glu21 substitutionscompared to 0601GIP3794), that improve solubility, duration of action orglucose lowering of GIP analogs compared to human GIP or to 0601GIP4288,and that can be used alone or combined with other modifications andderivatizations disclosed herein, and the exemplary compounds containingthem, are depicted in the following table along with various activities.(“Ocg” below stands for octylglycine).

Duration (% Inh Basal Gluc. In The 10 nm, Low. at Rat GIP-LF OGTT/Peptide Conc. IVGTT Assay) GL(%) of 80 nmol/Kg Solubility Assay0601GIP4288 YaEGTFISDYSIALE HEK- −19  −9 to −22%, <1 mg/ml >794 atKIRQQEFVNWLLA GIPR 350 nmol/kg, AUC240 −240 min QKPSSGAPPPS-NH2 IC50 =−24 (SEQ ID NO:   0.16 30 nmol/kg 608) ED50-0.8 nmol/kg 0601GIP5040YaEGTFISDYSIAME  91.3(% Inh −24, −16%, AUC240 KIRQQEFVNWLLA 10 nM)30 nmol/kg QKPSSGAPPPS-NH2 (SEQ ID NO: 870) 0601GIP4975 YaEGTFISDYSIALEGIPR- −14 and  −3% to −14%, >794 at KIRQQEFVNWLLA HEK IC50 -24 AUC240−240 min QKPSSGAPPNS-NH2 = 0.1 30 nmol/kg (SEQ ID NO: 871) 0601GIP5070YaEGTFISDYSIALE  97.3 −30, KIRQQEFVNWLLA (% Inh 30 nmol/kgQKPSSGARPPS-NH2 10 nM) (SEQ ID NO: 872) 0601GIP5071 YaEGTFISDYSIALE 97.8 −31, KIRQQEFVNWLLA (% Inh 30 nmol/kg QKPSSGAKPPS-NH2 10 nM)(SEQ ID NO: 873) 0601GIP5072 YaEGTFISDYSIALE  98.8 −22, KIRQQEFVNWLLA(% Inh 30 nmol/kg QKPSSGAPKPS-NH2 10 nM) (SEQ ID NO: 874) 0601GIP5073YaEGTFISDYSIALE  91.1 −32, KIRQQEFVNWLLA (% Inh 30 nmol/kgQKPSSGAPDPS-NH2 10 nM) (SEQ ID NO: 875) 0601GIP5080 YaEGTFISDYSIALE 95.3 −32, KIRQQEFVNWLLA (% Inh 30 nmol/kg QKPSSGAPPKSK- 10 nM)NH2 (SEQ ID NO:  876) 0601GIP5081 YaEGTFISDYSIALE 100(% Inh −28,KIRQQEFVNWLLK 10 nM) 30 nmol/kg QKPSSGAPPPS-NH2 (SEQ ID NO: 877)0601GIP5082 YaEGTFISDYSIALE  99.7(% Inh −24, KIRQQEFVNWLLK 10 nM)30 nmol/kg QKPSSGAPPKS-NH2  97(% Inh −20, (SEQ ID NO: 878) 0601GIP5098YaEGTFISDYSIALE 10 nM) 30 nmol/kg KIRQQEFVNWLLA QKPSSGAPPNSK-NH2 (SEQ ID NO:  879) 0601GIP4996 YaEGTFISDYSIALD  88.2 −14,KIKQQEFVNWLLA (% Inh 30 nmol/kg QKPSSGAPPQS-NH2 10 nM) (SEQ ID NO: 880)

Yet even further exemplary “tail” modifications (compare to 0601GIP3794which incorporates the exendin tail PSSGAPPPS (SEQ ID NO:1)) that canimprove solubility, duration of action and/or glucose lowering activity,and which can be used alone or in combination with other modificationsand derivatizations as disclosed herein, and exemplary GIP compoundshaving them, are depicted in the following table. For example, in oneembodiment a GIP analog or hybrid will incorporate (at its C-terminus)any one of the tail sequences, such as PSSGAPPNS (SEQ ID NO:881), in thefollowing table, to achieve greater solubility, improved duration ofaction or improved glucose lowering as compared to the parent compound.In another embodiment, a GIP analog or hybrid can incorporate any one ormore of the non-tail amino acid substitutions from the table below (ascompared to 0601GIP3794) to improve solubility, duration of action orglucose lowering activity.

Basal Gluc. (% Inh Lowering 10 nm, at GIP- 80 Duration In LF OGTT/ nmol/Solub- The Rat Assay) GL(%) Kg ility IVGTT Assay 0601GIP4844YaEGTFISDYSIAMDKI 27(% Inh, −4, duration < HQQDFVNQLLAQKPSS 10 nM);30 nmol/ 0601GIP3794 GAPPPS-NH2 (SEQ ID IC5011 @ −120 min NO: 882)HEKGIPR 0601GIP4846 YaEGTFISDYSIAMDKI 79.6(% Inh, −25, −6%,HQQDFVQWLLAQKPSS 10 nM) 30 nmol/ AUC240 GAPPPS-NH2 (SEQ ID kg NO: 694)0601GIP4866 YaEGTFISDYSIAMDKI 47.9(% Inh, +7, HQQDFVNNLLAQKPSS 10 nM);30 nmol/ GAPPPS-NH2 (SEQ ID IC50 = 39 kg NO: 694) HEKGIPR 0601GIP4901YaEGTFISDYSIAMDKI −10, HQQDFVNSLLAQKPSS 30 nmol/ GAPPPS-NH2 (SEQ ID kgNO: 694) 0601GIP4867 YaEGTFISDYSIAMDKI 0.3(% Inh, HQQDFVNWLNAQKPS 10 nM)SGAPPPS-NH2 SEQ ID NO: 694) 0601GIP4868 YaEGTFISDYSIAMDKI 8.1(% Inh,HQQDFVNWLSAQKPSS 10 nM) GAPPPS-NH2 (SEQ ID NO: 694) 0601GIP4869YaEGTFISDYSIAMDKI 18.9(% Inh, HQQDFVNWLQAQKPS 10 nM) SGAPPPS-NH2 (SEQ IDNO: 694) 0601GIP4858 YaEGTFISDYSIAMDKI 11.4(% Inh, HQQDFVNWNLAQKPS10 nM) SGAPPPS-NH2 (SEQ ID NO: 694) 0601GIP4859 YaEGTFISDYSIAMDKI4.5(% Inh, HQQDFVNWSLAQKPSS 10 nM) GAPPPS-NH2 (SEQ ID NO: 694)0601GIP4860 YaEGTFISDYSIAMDKI −1.8(% Inh, HQQDFVNWQLAQKPS 10 nM)SGAPPPS-NH2 (SEQ ID NO: 694) 0601GIP4861 YaEGTFISDYSIAMDKI 17.4(% Inh,HQQDFVEWLKAQKPSS 10 nM) GAPPPS-NH2 (SEQ ID NO: 694) 0601GIP4862YaEGTFISDYSIAMDKI −14.3(% Inh, HQQDFVNNLNAQKPSS 10 nM)GAPPPS-NH2 (SEQ ID NO: 694) 0601GIP4902 YaEGTFISDYSIAMDKI −19, −28,HQQDFVNWLLKQKPSS 30 nmol/ AUC240 GAPPPS-NH2 (SEQ ID kg NO: 694)0601GIP4909 YaEGTFISDYSIAMDKI 55(% Inh, HQQDFVNWLLHQKPSS 10 nM)GAPPPS-NH2 (SEQ ID NO: 694) 0601GIP4911 YaEGTFISDYSIAMDKI 79(% Inh,HQQDFVNWLLGQKPSS 10 nM) GAPPPS-NH2 (SEQ ID NO: 694) 0601GIP4910YaEGTFISDYSIAMDKI 78.8(% Inh, HQQDFVNWLLAQKPSS 10 nM) GHPPPS-NH2 (SEQ IDNO: 694) 0601GIP4847 YaEGTFISDYSIAMDKI 70(% Inh, −20, −1 to −15%, =794@−120 HQQDFVNWLLAQKPSS 10 nM); 30 nmol/ AUC240 min GNPPPS-NH2 (SEQ IDIC50 = 1.3 kg NO: 694) HEKGIPR 0601GIP4971 YaEGTFISDYSIAMDKI 97.1(% Inh,−22, −15, HQQDFVNWLLAQKPSS 10 nM) 30 nmol/ AUC240 GQPPPS-NH2 (SEQ ID kgNO: 694) 0601GIP4848 YaEGTFISDYSIAMDKI 75(% Inh, 10 −22, <794@ −120HQQDFVNWLLAQKPSS nM); 30 nmol/ min GANPPS-NH2 (SEQ ID IC50 = 0.93 kgNO: 900) HEKGIPR 0601GIP4849 YaEGTFISDYSIAMDKI 66, 81.4(% −19, = 794@−120 HQQDFVNWLLAQKPSS Inh, 10 nM); 30 nmol/ min GAPNPS-NH2 (SEQ IDIC50 = 0.79 kg NO: 901) HEKGIPR 0601GIP4850 YaEGTFISDYSIAMDKI 69(% Inh,−21, −21% ~1 mg/ = 794@ −120 HQQDFVNWLLAQKPSS 10 nM); 30 nmol/ to 2%, mlmin GAPPNS-NH2 (SEQ ID IC50 = 0.64, kg, AUC240 NO: 902) 0.5, ED50 ~ 60.41 HEKGIPR nmol/kg 0601GIP4957 YaEGTFISDYSIAMDKI  99.4(% −13 and −8%,= 794@ −120 HQQDFVNWLLAQKPSS Inh, −22, AUC240 min GAPPQS-NH2 (SEQ ID10 nM); 30 nmol/ NO: 903) IC50 kg HEK- GIPR 0.51; 0601GIP5029YaEGTFISDYSIAMDKI GIPR- −22, −1%, HQQDFVNWLLAQKPSS HEK 30 nmol/ AUC240GAPPDS-NH2 (SEQ ID IC50 = 2.2 kg NO: 904) 0601GIP4972 YaEGTFISDYSIALDKIH101(% Inh, 10 −17, QQDFVNWLLAQKPSSG nM) 30 nmol/ APPNS-NH2 (SEQ ID kgNO: 905) 0601GIP4973 YaEGTFISDYSIALDKIH 102.3 −19, −17, QQDFVNWLLAQKPSSG(% Inh, 10 30 nmol/ AUC240 APPQS-NH2 (SEQ ID nM) kg NO: 906) 0601GIP5075YaEGTFISDYSIAMDKI 83.7(% −30, HQQDFVNWLLAQKPSS Inh, 10 nM) 30 nmol/GQPPQSK-NH2 (SEQ ID kg NO: 907) 0601GIP5076 YaEGTFISDYSIAMSKI 90.9(%−30, HQQDFVNWLLAQKPSS Inh, 10 nM) 30 nmol/ GAPPQSK-NH2 (SEQ ID kgNO: 908) 0601GIP4952 YaEGTFISDYSIAMDKI 96.1(% −21, −1, HQQDFVNWLLAQKPSSInh, 10 nM) 30 nmol/ AUC240 GAPGPS-NH2 (SEQ ID kg NO: 909) 0601GIP4948YaEGTFISDYSIAMDKI  93.7(% −32, −14, >5 mg/ <794 @ −120 HQQDFVNWLLAQKPSSInh, 30 nmol/ AUC240 ml min GKPPPS-NH2 (SEQ ID 10 nM); kg NO: 910) GIPR-HEK IC50 =   0.42 0601GIP4947 YaEGTFISDYSIAMDKI  90.9(% −29, −19, >5 mg/<794 @ −120 HQQDFVNWLLAQKPSS Inh, 30 nmol/ AUC240 ml minGAPPKS-NH2 (SEQ ID 10 nM), kg NO: 911) GIPR-   HEK IC50 =   0.590601GIP4949 YaEGTFISDYSIAMDKI −26, −16, HQQDFVNWLLAQKPSS 30 nmol/ AUC240GKPPKS-NH2 (SEQ ID kg NO: 912) 0601GIP4912 YaEGTFISDYSIAMDKI  82.7(%−23, HQQDFVNWLLAQKPSS Inh, 30 nmol/ GAQPPS-NH2 (SEQ ID 10 nM) kgNO: 913) 0601GIP4905 YaEGTFISDYSIAMDKI −29, −11%, HQQDFVNWLLAQKPSS30 nmol/ AUC240 GAPGGS-NH2 (SEQ ID kg NO: 914) 0601GIP4903YaEGTFISDYSIAMDKI −27, −15%, HQQDFVNWLLAQKGK 30 nmol/ AUC240KPSSGAPPPS-NH2 kg (SEQ ID NO: 915)

In yet other embodiments are the modifications and the specific GIPcompounds described in the following table to provide increasedsolubility, particularly when combined with the exendin tailmodification. Modifications to the FVNWLLA region are of particularinterest to improve solubility as are changes to the exendin tailitself. In other embodiments solubility is enhanced by addition of awater soluble polymer, e.g. PEG, either to either terminal or to aninternal amino acid, e.g. lysine, as shown herein.

0601GIP4767 YaEGTFISDYSIAMDKIHQQDFVEWLLAQKPKKIRYS-NH2 82.4(%(SEQ ID NO: (711) Inh, 10 nM) 0601GIP4768YaEGTFISDYSIAMDKIHQQDFVPWLLAQKPKKIRYS-NH2 17.9(% (SEQ ID NO: 712) Inh,10 nM) 0601GIP4769 YaEGTFISDYSIAMDKIHQQDFVNELLAQKPKKIRYS-NH2 42.8(%(SEQ ID NO: 713) Inh, 10 nM) 0601GIP4770YaEGTFISDYSIAMDKIHQQDFVNPLLAQKPKKIRYS-NH2 10.8(% (SEQ ID NO: 714) Inh,10 nM) 0601GIP4771 YaEGTFISDYSIAMDKIHQQDFVNWLEAQKPKKIRYS-NH2 17.8(%(SEQ ID NO: 715) Inh, 10 nM) 0601GIP4772YaEGTFISDYSIAMDKIHQQDFVNWLPAQKPKKIRYS-NH2  0.2(% (SEQ ID NO: 716) Inh,10 nM) 0601GIP4289 YaEGTFISDYSIALDKIRQQDFVEWLLAQKPSSGAPPPS-NH2  0.58(SEQ ID NO: 609) 0601GIP4708 Ado-Ado- 19.2(%YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 Inh, (SEQ ID NO: 717) 10 nM)0601GIP4709 YaEGTFISYDSIAMDK-(epsilon-NH-(Ado-Ado-Ado-(2-(2- 42.9 (%methoxyetoxy)-acetoyl)))-IHQQDFVNWLLAQKPSSGAPPPS- Inh,NH2 (SEQ ID NO: 718) 10 nM) 0601GIP4763((2-(2-methoxyethoxy)-acetoyl)-Ado-Ado)- 14.6(%YaEGTFISYDSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 Inh, (SEQ ID NO: 719) 10 nM)0601GIP4761 YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-Ado- 87.3(%Ado-NH2 (SEQ ID NO: 720) Inh, 10 nM) 0601GIP4832YaEGTFISDYSIAK(epsilon-NH-(Ado-(2-(2-methoxyethoxy)-acetyol)))DKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 721)YaEGTFISDYSIAMDKIHQQDFVNQLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 722)YaEGTFISDYSIAMDKIHQQDFVNQLLAQKPKKIRYS- NH2 (SEQ ID NO: 723)YaEGTFISDYSIAMDKIHQQDFVQWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 724)YaEGTFISDYSIAMDKIHQQDFVQWLLAQKPKKIRYS- NH2 (SEQ ID NO: 725)YaEGTFISDYSIAMDKIHQQDFVNNLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 726)YaEGTFISDYSIAMDKIHQQDFVNWLNAQKPSSGAPPPS-NH2 (SEQ ID NO: 727)YaEGTFISDYSIAMDKIHQQDFVNWLSAQKPSSGAPPPS-NH2 (SEQ ID NO: 728)YaEGTFISDYSIAMDKIHQQDFVNWLQAQKPSSGAPPPS-NH2 (SEQ ID NO: 729)YaEGTFISDYSIAMDKIHQQDFVNWNLAQKPSSGAPPPS-NH2 (SEQ ID NO: 730)YaEGTFISDYSIAMDKIHQQDFVNWSLAQKPSSGAPPPS-NH2 (SEQ ID NO: 731)YaEGTFISDYSIAMDKIHQQDFVNWQLAQKPSSGAPPPS-NH2 (SEQ ID NO: 732)YaEGTFISDYSIAMDKIHQQDFVEWLKAQKPSSGAPPPS-NH2 (SEQ ID NO: 733)YaEGTFISDYSIAMDKIHQQDFVNNLNAQKPSSGAPPPS-NH2 (SEQ ID NO: 734)YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGNPPPS-NH2 (SEQ ID NO: 735)YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGANPPS-NH2 (SEQ ID NO: 736)YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPNPS-NH2 (SEQ ID NO: 737)YaEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPNS-NH2 (SEQ ID NO: 738)

Alternative representations of some of the above compounds are asfollows:

Yet further embodiments contain modifications and specific GIP sequencesdescribed in the following table that may provide increased solubility,glucose lowering or duration of action as compared to human GIP, and insome embodiments, greater than or equal to 0601GIP3794. Modificationscan be in the tail region (PSSGAPPPS) or elsewhere in the compound orboth, as shown in the following table. The modified GIP sequences andmodified tail sequences can be used in other GIP analogs or hybrids.Receptor binding and glucose lowering activity via OGTT are shown.

0601GIP4997 YaEGTFISDYSIALDKIRQQEFVNWLL  94 (% Inh 10 nM)−17, 30 nmol/kg AQHPSSGAPPQS-NH2 (SEQ ID NO: 916) 0601GIP4998YaEGTFISDYSIALDKIRQQKFVNWLL  84.9 (% Inh −11, 30 nmol/kgAQKPSSGAPPQS-NH2 (SEQ ID NO: 10 nM) 917) 0601GIP4995YaEGTFISDYSIALDKIRQQKFVNWLL  87.8(% Inh −7, 30 nmol/kgAQKPSSGAPPNS-NH2 (SEQ ID NO: 10 nM) 918) 0601GIP4994YaEGTFISDYSIALDKIRQQEFVNWLL 101.9(% Inh −16, 30 nmol/kgAQHPSSGAPPNS-NH2 (SEQ ID NO: 10 nM) 919) 0601GIP5078YaEGTFISDYSIALDKIRQQEFVNWLL 100.2 (% Inh −33, 30 nmol/kgAQKPSSGAPPKS-NH2 (SEQ ID NO: 10 nM) 920) 0601GIP5079YaEGTFISDYSIALDKIKQQEFVNWLL  98.6 (% Inh −28, 30 nmol/kgAQKPSSGAPPKS-NH2 (SEQ ID NO: 10 nM) 921) 0601GIP5077YaEGTFISDYSIALDKIHQQEFVNWLL  81.3 (% Inh −34, 30 nmol/kgAQKPSSGQPPQS-NH2 (SEQ ID NO: 10 nM) 922) 0601GIP4993YaEGTFISDYSIALDKIKQQEFVNWLL  91.7 (% Inh −19, 30 nmol/kgAQKPSSGAPPNS-NH2 (SEQ ID NO: 10 nM) 923) 0601GIP4950YaEGTFISDYSIAMDKIKQQDEVNWL   4.7(% Inh, 10 nM)LAQKPSSGAPPPS-NH2 (SEQ ID NO: 924)

In one embodiment are GIP analogs with surprisingly high solubility, andin a further embodiment, surprisingly greater solubility than either orboth 0601GIP3794 and 0601GIP4850, as measured at about pH 5 to 7, whileretaining glucose lowering (e.g. OGTT or glucose lowering assay) greaterthan human GIP or about equal to or better than either or both0601GIP3794 and 0601GIP4850, as shown in the following table. In oneembodiment the analog has greater solubility than either or both0601GIP3794 and 0601GIP4850 at pH 6.0 buffered with 30 mM histidine orpH 7.0 buffered with 30 mM histidine. In one embodiment are GIP analogsor hybrids that contain one or more or all of the modifications in eachof analogs 0601GIP5075, 0601GIP5076, 0601GIP5080, 0601GIP5081,0601GIP5082 and 0601GIP4850 as compared to 0601GIP3794 that providesolubility and bioactivity. In one embodiment are GIP analogs or hybridsthat contain one or more or all of the modifications in each of analogs0601GIP5070, 165071, 0601GIP5072, 0601GIP5073 as compared to 0601GIP4288that provide solubility and bioactivity. In one embodiment are GIPanalogs or hybrids that contain one or more or all of the modificationsin analog 0601GIP4904 as compared to 0601GIP4233 that provide solubilityand bioactivity. In one embodiment the analog has a solubility ofgreater than or about 5 mg/ml, and further retains glucose loweringgreater than or about that of human GIP, 0601GIP3794 and/or 0601GIP4850.In one embodiment the GIP analog or hybrid is or comprises 0601GIP4904,0601GIP5072, 0601GIP5075, 0601GIP5080, 0601GIP5081, 0601GIP5082,0601GIP5070, 0601GIP5071, 0601GIP5073, or 0601GIP5076. In anotherembodiment the GIP analog is or comprises 0601GIP4904, 0601GIP5072,0601GIP5075, 0601GIP5080, 0601GIP5081, 0601GIP5082, which analogs alsodemonstrate superior stability in solution, for example as determined byan accelerated stability study at 40 degrees C. for at least 3 days orat least 7 days. In one such embodiment are analogs 0601GIP5080,0601GIP5081, 0601GIP5082 or 0601GIP5072, or analogs or hybridscontaining these sequences. (In the table herein, “794” means0601GIP3794.)

solubility/ OGTT GL DOA stability 0601GIP3794 YaEGTFISDYSIAMDKIHQQD  =794 = 794 = 794 <1 mg/ml FVNWLLAQKPSSGAPPPS- NH2 (SEQ ID NO: 186)0601GIP4850 YaEGTFISDYSIAMDKIHQQD  = 794 = 794 = 794 ~1 mg/mlFVNWLLAQKPSSGAPPNS- NH2 (SEQ ID NO: 902) 0601GIP5075YaEGTFISDYSIAMDKIHQQD  = 794 <794@ >5 mg @ FVNWLLAQKPSSGQPPQSK- −120 minpH 5-9 NH2 (SEQ ID NO: 907) 0601GIP5076 YaEGTFISDYSIAMDKIHQQD  = 794=794@  1 mg/ml FVNWLLAQKPSSGAPPQSK- −120 min NH2 (SEQ ID NO: 908)0601GIP5080 YaEGTFISDYSIALEKIRQQEF  = 794 = 794 submitted >5VNWLLAQKPSSGAPPKSK- mg/ml NH2 (SEQ ID NO: 876) 0601GIP5081YaEGTFISDYSIALEKIRQQEF  = 794 = 794 = 794@ >5 VNWLLKQKPSSGAPPPS-NH2−120 min mg/ml (SEQ ID NO: 877) 0601GIP5082 YaEGTFISDYSIALEKIRQQEF  =794 = 794 = 794@ >5 VNWLLKQKPSSGAPPKS- −120 min mg/mlNH2 (SEQ ID NO: 878) 0601GIP5070 YaEGTFISDYSIALEKIRQQEF  = 794  1 mg/mlVNWLLAQKPSSGARPPS- NH2 (SEQ ID NO: 872) 0601GIP5071YaEGTFISDYSIALEKIRQQEF  = 794  1 mg/ml VNWLLAQKPSSGAKPPS-NH2 (SEQ ID NO: 873) 0601GIP5072 YaEGTFISDYSIALEKIRQQEF  = 794 >5VNWLLAQKPSSGAPKPS- mg/ml NH2 (SEQ ID NO: 874) 0601GIP5073YaEGTFISDYSIALEKIRQQEF  = 794  1 mg/ml VNWLLAQKPSSGAPDPS-NH2 (SEQ ID NO: 875) 0601GIP4904 YaEGTFISDYSIAMDKIHQQD >= 794 <794@ >5FVNWLLAQKPKGKIRYS- −120 min mg/ml NH2 (SEQ ID NO: 859)

In a further embodiment are analogs or derivatives, or hybrids thereof,of the GIP compounds in the above table, and further in each of thetables and figures herein, having no more than 5, no more than 4, nomore than 3, no more than 2 or no more than 1 substitution, modificationand/or derivatization as described herein and/or that exhibits at least50%, at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90%, at least 95% or at least 98% sequenceidentity to the parent GIP analog of the above table, or other table orfigure herein, over the entire length of the parent GIP compound.

FIGS. 12.15 to 12.65 depict further exemplary analogs and referencepeptides of the invention. It is intended that the various modificationsand variants shown are to be used in the present invention, and may becombined as discussed herein. For example, the terms exendin tail orexendin trp-cage motif includes any of the exendin tail variantsdepicted, which are useful as shield sequences (peptidic enhancers). Offurther interest are the frog GLP1 C-terminal extensions as shown in thefigures, which are yet another example of a shield sequence that can beused in place of an exendin tail. For example, in one embodiment the GIPcompounds of the invention comprise a frog GLP1 “tail” sequence as apeptidic enhancer as described herein (and see FIG. 12). Of particularinterest are compounds 0601GIP4179, 0601GIP4233, 0601GIP4285,0601GIP4178, and 0601GIP4467. In other embodiment, the “S” or shieldregion or C-terminal tail can be any of the tails depicted herein,including for example PSSGQPPQSK (SEQ ID NO:925), PSSGAPPQSK (SEQ IDNO:926), PSSGAPPKSK (SEQ ID NO:927), PSSGAPPPS (SEQ ID NO:1), PSSGAPPKS(SEQ ID NO:928), PSSGARPPS (SEQ ID NO:929), PSSGAKPPS (SEQ ID NO:930),PSSGAPKPS (SEQ ID NO:931), PSSGAPDPS (SEQ ID NO:932) or PKGKIRYS (SEQ IDNO:933). Further the the “S” or shield region or C-terminal tail can beany of the tails found in any of theGIP analogs depicted hereinincluding those from GIP compounds 0601GIP3794, 0601GIP4850,0601GIP5075, 0601GIP5076, 0601GIP5080, 0601GIP5081, 0601GIP5082,0601GIP5070, 0601GIP5071, 0601GIP5072, 0601GIP5073 or 0601 GIP4904.

In yet a further embodiment of any of the GIP modules herein, is aSerine-2, Aspartic acid3 (i.e. S2,D3), double substitution at positions2 and 3 at the N-terminus of a GIP. Thus it is expressly intended thatfor each of the species and formulas depicted herein, that each S2,D3analog is explicitly disclosed herein as if it had been written. As withthe other DPP-IV resistance modifications described herein, the S2,D3can be combined with one or two or more other modifications, for examplea fatty acyl derivatization to decrease plasma (e.g. renal clearance)and/or increase duration of action, and/or with a C-terminal shieldsequence, and/or with a GIP species amino acid substitution. Of coursethese GIP analogs can be used directly or as the GIP portion of a GIPhybrid.

Exemplary compounds (see FIG. 12 for example) showing exceptional GIPReceptor binding activity at less than about 10 nm include 0601GIP3794at 3.8 nM, 0601GIP4283 0.41 nM, 0601GIP4284 1.8 nM, 0601GIP4285 0.58 nM,0601GIP4288 0.28 nM, 0601GIP4289 0.58 nM, 0601GIP4290 0.35 nM,0601GIP4147 at 7.4 nM, 0601GIP4178 1.5 nM, 0601GIP4293 0.12 nM,0601GIP4292 0.17 nM, 0601GIP4238 4.2 nM, 0601GIP4179 3.3 nM, 0601GIP42940.92 nM, 0601GIP4252 5.6 nM, 0601GIP3794 3.8 nM, 0601GIP4190 2.4 nM,0601GIP4152 2.3 nM, 0601GIP4150 1.6 nM, 0601GIP4153 0.53 nM, 0601GIP41491.5 nM, 0601GIP4176 4.8 nM, 0601GIP4177 2.9 nM, 0601GIP4213 7.9 nM,0601GIP4215 4.5 nM, 0601GIP4263 0.66 nM, 0601GIP4278 0.24 nM,0601GIP4264 0.4 nM, 0601GIP4279 2.1 nM, 0601GIP4233 0.1 nM, 0601GIP42343.4 nM, 0601GIP4236 0.62 nM. These compounds also display GIP Receptoractivation and appropriate receptor specificity (e.g., lack of bindingto GLP1-R or glucagon receptor in absence of appropriate hybrid module).

As demonstrated herein, DPP-IV resistant hybrids of the invention haveincreased plasma stability compared to native GIP. For example,0601GIP3796 amide form is essentially 100% present after 5 hours inhuman plasma, in contrast to about 60% for GIP(1-42) acid form.

The following table further demonstrates that GIP peptides of theinvention and their analogs and derivatives have in vivo activities thatare directly related to desirable therapeutic effects as discussedherein. Compounds marked in bold are of particular interest, as are themodifications and/or derivatizations, which can be combined or used withother modifications or derivatives herein. These compounds findparticular use in the GIP hybrids of the invention. Bolded compoundsdemonstrate very effective activity.

Basal Glucose IVGTT Basal Glucose Lowering IVGTT Lowering OGTT BasalGlucose AUC Change AUC Change > = < Basal Glucose OGTT/GL(%) Lowering inInsulin in Insulin Compared Lowering Cmpd # 350 nmol/Kg at 80 nmol/KgPre IVGTT Post IVGTT to 0601GIP3794 in db/db 0601GIP3757 −22 −2%, t =120 0601GIP4044  −2%, AUC180 0601GIP4045 no data 0601GIP3794 −21% 350nmol/kg, −7 to −20%,  28.8 +− 10.7 173.1 +− 29.4 = −33%, 80 nmol/kg,−17% 10 nmol/kg, AUC240, t = 120 ED50 ~2 nmol/kg −9%, AUC180 0601GIP4046−5%, AUC180, −2%, AUC240 0601GIP3793 −26 −2%, t = 120 0601GIP3756 −120601GIP3974 8%, AUC240, 10%, (80 nmol/Kg) and 0% (100 nmol/kg) t = 1200601GIP4429 −8, 30 nmol/kg 0601GIP4283 −14 0601GIP4284 −21  −7%, AUC2400601GIP4405 −19, 30 nmol/kg  −0%, AUC240 0601GIP4406 −21, 30 nmol/kg −0%, AUC240 0601GIP4403 −12, 30 nmol/kg 0601GIP4404 −15, 30 nmol/kg0601GIP4285 −10 350 nmol/kg,  −2%, AUC240  22.1 +− 10.7 206.2 +− 11.8 =−17 30 nmol/kg 0601GIP4286 −22, 30 nmol/kg 0601GIP4313 −5, 30 nmol/kg0601GIP4288 −19 0601GIP4344 −24, 30 nmol/kg 0601GIP4290 −17 0601GIP4456−3, 30 nmol/kg 0601GIP4457 4, 30 nmol/kg 0601GIP4460 −12, 30 nmol/kgAC1540 −19% 80 nmol/kg Human t = 60 and 120 0601GIP3300 −2%, AUC240 at800 nmol/kg 0601GIP3943  −8%, AUC180 chicken −7, 30 nmol/kg 0601GIP3794−21% 350 nmol/kg, −7 to −20%,  28.8 +− 10.7 173.1 +− 29.4 = −33%, 80nmol/kg, −17% 10 nmol/kg, AUC240, t = 120 ED50 ~2 nmol/kg −9%, AUC1800601GIP4190 −14 0601GIP4152 −20 0601GIP4150 −13 0601GIP4153 −140601GIP4149    −16% 0601GIP4176 −10 0601GIP4177 −19 0601GIP4213 −170601GIP4263 −17 0601GIP4278 −12 0601GIP4264 −12 0601GIP4279  −70601GIP4306 −20, 30 nmol/kg  −5%, AUC240 Xenopus −3, 30 nmol/kg0601GIP4503 −4, 30 nmol/kg 0601GIP4504 −2, 30 nmol/kg 0601GIP4505 +9, 30nmol/kg 0601GIP4506 −14, 30 nmol/kg 0601GIP4753 −22, 30 nmol/kg −13%,AUC240 0601GIP4754 −20, 30 nmol/kg −13%, AUC240 0601GIP4596 −7, 30nmol/kg 0601GIP4465 −16, 30 nmol/kg 0601GIP4466 −20, 30 nmol/kg −26%,AUC240 17.3 +− 3.3 113.9 +− 18.9 < 0601GIP4478 −7, 30 nmol/kg0601GIP4467 −18, 30 nmol/kg  −7%, AUC240 0601GIP4479 −16, 30 nmol/kg0601GIP4480 −12, 30 nmol/kg 0601GIP4571 −23, 30 nmol/kg −11%, AUC2400601GIP4551 −14, 30 nmol/kg 0601GIP4407 −9, 30 nmol/kg 0601GIP4650 −11,30 nmol/kg 0601GIP4651 −7, 30 nmol/kg 0601GIP4576 −22, 30 nmol/kg  −2%,AUC240 0601GIP4507 −5, 30 nmol/kg 0601GIP4536 −15, 30 nmol/kg0601GIP4537 −7, 30 nmol/kg 0601GIP4627 −17, 30 nmol/kg 0601GIP4391 −12,30 nmol/kg 0601GIP4459 −7, 30 nmol/kg 0601GIP4147 −9 0601GIP4324 BB −23,30 nmol/kg −23%, AUC240 0601GIP4458 −14, 30 nmol/kg 0601GIP4215 −23 −0%, AUC240 0601GIP4389 −6, 30 nmol/kg 0601GIP4399 −3, 30 nmol/kg0601GIP4390  1, 30 nmol/kg 0601GIP4395 −11, 30 nmol/kg  −0%, AUC2400601GIP4387 −7, 30 nmol/kg 0601GIP4386 −0, 30 nmol/kg 0601GIP4703 −18,30 nmol/kg 0601GIP4180 −11, 30 nmol/kg 0601GIP4238 −25  −6%, AUC2400601GIP4392 −20, 30 nmol/kg  −9%, AUC240 0601GIP4577 −27, 30 nmol/kg −8%, AUC240 0601GIP4790 −24, 30 nmol/kg 0601GIP4588 −8 to −20, 30nmol/kg 0601GIP4331 −25 and −16, −13%, AUC240 17.4 +− 6.5 131.3 +− 15.5= 30 nmol/kg 0601GIP4580 −17, 30 nmol/kg  −2%, AUC240 0601GIP4582 −23,30 nmol/kg  −5%, AUC240 0601GIP4699 −18, 30 nmol/kg 0601GIP4764 −18, 30nmol/kg 0601GIP4620 −8, 30 nmol/kg 0601GIP4359 −11, 30 nmol/kg0601GIP4347 −10, 30 nmol/kg 0601GIP4384 −12, 30 nmol/kg 0601GIP4385 −8,30 nmol/kg 0601GIP4608 −8, 30 nmol/kg 0601GIP4798 −27, 30 nmol/kg0601GIP4799 −10, 30 nmol/kg 0601GIP4801 −23, 30 nmol/kg 0601GIP4766 −25,30 nmol/kg 0601GIP4178 −20 −13%, AUC240 18.5 +− 6.7 106.6 +− 23.8 <0601GIP4293 −22 −13%, AUC240 0601GIP4292 −24 −10%, AUC240 35.6 +− 5.4183.9 +− 26.6 = 0601GIP4806 −14, 30 nmol/kg 0601GIP4670 −24, 30 nmol/kg−14%, AUC240 27.3 +− 5.7 175.9 +− 19.0 = 0601GIP4635 −17, 30 nmol/kg0601GIP4636 −19, 30 nmol/kg −16%, AUC240 0601GIP4637 −11, 30 nmol/kg0601GIP4543 −0, 30 nmol/kg 0601GIP4544 −13, 30 nmol/kg 0601GIP4712 −10,30 nmol/kg 0601GIP4252 −18  −7%, AUC240  11.9 +− 11.7 1218.1 +− 12.7  =0601GIP4548 −12, 30 nmol/kg 0601GIP4549 −13, 30 nmol/kg 0601GIP4550 −3,30 nmol/kg 0601GIP4606 −18, 30 nmol/kg  −9%, AUC240 0601GIP4607 −4, 30nmol/kg 0601GIP4326 −18 and −25,  −8%, AUC240 37.6 +− 7.0 154.9 +− 17.3= 30 nmol/kg 0601GIP4671 −24, 30 nmol/kg −14%, AUC240 29.1 +− 4.5 243.7+− 20.6 = 0601GIP4693 −17, 30 nmol/kg 0601GIP4755 −21, 30 nmol/kg  −7%,AUC240 0601GIP4547 +5, 30 nmol/kg 0601GIP4461 −20, 30 nmol/kg +12%,AUC240 0601GIP4581 −20, 30 nmol/kg −12%, AUC240 0601GIP4585 −15, 30nmol/kg  −4%, AUC240 0601GIP4586 −15, 30 nmol/kg  −9%, AUC2400601GIP4179 −23 350 nmol/kg, −17%, AUC240 52.4 +− 9.6 206.8 +− 30.1 =−24 30 nmol/kg 0601GIP4649 −14, 30 nmol/kg 0601GIP4642 −17, 30 nmol/kg0601GIP4645 −24, 30 nmol/kg 0601GIP4294 −27 −10%, AUC240 0601GIP4756−21, 30 nmol/kg  −1%, AUC240 0601GIP4562 −10, 30 nmol/kg 0601GIP4572 +1,30 nmol/kg 0601GIP4573 +10, 30 nmol/kg 0601GIP4609 −5, 30 nmol/kg0601GIP3794 −21% 350 nmol/kg, −7 to −20%,  28.8 +− 10.7 173.1 +− 29.4 =−33%, 80 nmol/kg, −17% 10 nmol/kg, AUC240, t = 120 ED50 ~2 nmol/kg −9%,AUC180 0601GIP4414 +3, 30 nmol/kg 0601GIP4415 +10, 30 nmol/kg0601GIP4416 −0, 30 nmol/kg 0601GIP4417 +9, 30 nmol/kg 0601GIP4192 −160601GIP4807 −27, 30 nmol/kg 0601GIP4233 −22 350 nmol/kg, −11 to −18%, 53.8 +− 14.7 234.5 +− 25.5 = −17 30 nmol/kg AUC240 0601GIP4327 −7, 30nmol/kg 0601GIP4386 −0, 30 nmol/kg 0601GIP4698 −14, 30 nmol/kg0601GIP4538 −9, 30 nmol/kg 0601GIP4539 −12, 30 nmol/kg  −5%, AUC2400601GIP4540 −16, 30 nmol/kg −12%, AUC240 0601GIP4648 −20, 30 nmol/kg−8%, AUC240 0601GIP4631 −14, 30 nmol/kg 0601GIP4805 −13, 30 nmol/kg0601GIP4561 −15, 30 nmol/kg  −8%, AUC240 0601GIP4673 −23, 30 nmol/kg−21%, AUC240 51.9 +− 8.1 205.5 +− 21.0 = 0601GIP4672 −21, 30 nmol/kg −9%, AUC240 0601GIP4713 −21, 30 nmol/kg −12%, AUC240 0601GIP4711 −22,30 nmol/kg −11%, AUC240 0601GIP4234 −17 −11%, AUC240 0601GIP4710 −12, 30nmol/kg 0601GIP4765 −12, 30 nmol/kg 0601GIP4236 −16 −12%, AUC2400601GIP4328 −2, 30 nmol/kg 0601GIP4345 −14 @ 30 nmol/kg, −11%, AUC240−25 @ 250 nmol/kg 0601GIP4401  1, 30 nmol/kg 0601GIP4346 −20, 30 nmol/kg−10%, AUC240 0601GIP4700 −21, 30 nmol/kg  −6%, AUC240 0601GIP4400 −2, 30nmol/kg 0601GIP4402 −8, 30 nmol/kg 0601GIP4619 −19, 30 nmol/kg −10%,AUC240 16.6 +− 1.5 151.2 +− 19.0 < 0601GIP4767 −24, 30 nmol/kg0601GIP4289 −24  −4%, AUC240 0601GIP4708 −14, 30 nmol/kg 0601GIP4709 +4,30 nmol/kg 0601GIP4761 −17, 30 nmol/kg

Embodiments of the invention further include the following. Thefollowing also provides in shorthand notation a description of eachspecies and sub-genus derivable therefrom.

In one embodiment, the novel GIP analog or a GIP hybrid comprises apolypeptide comprising the formula D-L-C-S, wherein

-   D comprises a dipeptidyl peptidase IV resistant GIP N-terminal    region,-   L comprises a linker,-   C comprises a GIP C-terminal region, and-   S comprises a shield region; and    wherein L is optionally present and at least one of D or C are    present, and wherein when C is present then C-S comprises a Trp-cage    motif, or when C is absent then L-S further comprises a Trp-cage    motif, and the polypeptide has GIP receptor binding and/or    activating activity. When at least one of D or C is present, the at    least one present D or C has GIP receptor activation and/or binding    activity. In another embodiment both D and C are present. Either or    both D and C can have GIP receptor activation and/or binding    activity. In one embodiment the polypeptide can specifically bind a    GIP receptor. Typically this binding will be at least two-fold    greater than binding to another receptor such as an incretin    receptor, e.g., GLP1R. The binding can be at least 5-, 10-, 50-, or    even 100-fold greater than binding to another receptor such as an    incretin receptor, e.g., GLP1R. In one embodiment the novel GIP    analog comprises GIP agonist activity. In one embodiment the    polypeptide can specifically activate a GIP receptor. Typically this    activation will be at least two-fold greater than activation of    another receptor such as an incretin receptor, e.g., GLP1R. The    activation can be at least 3-, 4-, 5-, 10-, 50-, or even 100-fold    greater than activation of another receptor such as an incretin    receptor, e.g., GLP1R.

In another embodiment the polypeptide comprises at least one desiredactivity of a native GIP. When a desired activity of a novel GIP hybridis greater than that of the native form, the activity can be at leasttwo-fold greater. In further embodiments the desired activity is atleast 3-, 4-, 5-, 10-, 50-, or even 100-fold greater than the activitycompared to a native GIP. The activity may be receptor binding, receptoractivation, receptor antagonism, glucose lowering, inhibition orreduction of gastric secretion, or any other activity, in vitro, ex vivoor in vivo, that may be known in the art or that is provided herein.

In further embodiments the D region of a novel GIP analog or hybridcomprises an 11 N-terminal amino acid sequence of a native GIP or a 14N-terminal amino acid sequence of native GIP. In other embodiments the Dregion comprises the N-terminal portion of a modified or substitutedGIP, e.g. see WO 00/58360, EP1171465 or published United States PatentApplication 20030232761.

In further embodiments region C comprises C-terminal amino acids 19-26of native GIP, C-terminal amino acids 19-30 of native GIP, C-terminalamino acids 19-39 of native GIP or C-terminal amino acids 19-42 of anative GIP. In one such embodiment region C can comprise amino acids19-26, 19-30, 19-39 or 19-42 of human, mouse, porcine or rat GIP. Inother embodiments the C region comprises the C-terminal portion of amodified or substituted GIP, e.g. see published United States PatentApplication 20030232761.

In one embodiment L comprises a sequence from native GIP, including DKIHor DKIH. In a further such embodiment the D-L-C portion of a novel GIPanalog comprises amino acids 1-26, 1-30, 1-39, or 1-42 of a native GIP.In one such embodiment regions D-L-C comprise amino acids 1-26, 1-30,1-39 or 1-42 of human, mouse, porcine or rat GIP (see for example Li etal., Regulatory Peptides 121(1-3) pages 107-112 (2004)). In yet afurther such embodiment the D-L-C portion of a novel GIP analogcomprises amino acids 1-26, 1-30, 1-39, or 1-42 of an N-terminallymodified or substituted GIP (in any of positions 1-4) that comprisesDPP-IV resistance, e.g. see WO 00/58360, EP1171465 or published UnitedStates Patent Application 20030232761.

Novel GIP compounds of the formula D-L-C-S can comprise the sequence

(SEQ ID NO: 186) YAEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS,(SEQ ID NO: 187) (Tyr1-glucitol)AEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS,(SEQ ID NO: 188)(Tyr1-pyroglutamyl)AEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS,(SEQ ID NO: 187) (Tyr1-glucitol)AEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS,(SEQ ID NO: 189)(Tyr1-9-fluorenylmethoxycarbonyl)AEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS,(SEQ ID NO: 190) (Tyr1-palmitate)AEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS,(SEQ ID NO: 191) YSEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS, or(SEQ ID NO: 192) YGEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS.

In another embodiment novel GIP compounds comprise the sequence

(SEQ ID NO: 193) YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS,(SEQ ID NO: 194)(Tyr1-glucitol) AEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS,(SEQ ID NO: 195)(Tyr1-pyroglutamyl) AEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS,(SEQ ID NO: 194)(Tyr1-glucitol) AEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS,(SEQ ID NO: 196) (Tyr1-9-fluorenylmethoxycarbonyl)AEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS, (SEQ ID NO: 197)(Tyr1-palmitate) AEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS,(SEQ ID NO: 198) YSEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS, or(SEQ ID NO: 199) YGEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS.

Novel GIP compounds can also comprise the sequence

(SEQ ID NO: 186) Y(D-Ala)EGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS,(SEQ ID NO: 200) YAbuAEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS, or(SEQ ID NO: 201) YSarAEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS.

In yet another embodiment novel GIP compounds comprise the sequence

(SEQ ID NO: 193)Y(D-Ala)EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS,(SEQ ID NO: 202) YAbuAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS,or (SEQ ID NO: 203)YSarAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS.

In one embodiment of novel GIP analog or hybrid, D comprises thesequence X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14 (SEQ ID NO:465),wherein at least one of X1, X2, and X3 is an amino acid substitution ormodification providing DPP-IV resistance. In a further such embodimentDPP-IV resistance is provided by a modification comprising a peptidemimetic bond between X2 and X3. Such a bond can be provided as a reducedpeptide bond of the formula Ψ(CH2NH), for example as when X1-X2-X3 isTyrl-AlaΨ(CH2NH)-Glu. In a further embodiment any bond of the novel GIPanalog is a reduced peptide bond of the formula Ψ(CH2NH), particularlyone that is identified as susceptible to protease or peptidasedegradation. In a further embodiment the substitution or modificationcomprises a D-amino acid substitution in X1, X2 and/or X3 and/orglycation, alkylation, acetylation or acylation of the N-terminus.Positions Xl-X14 can be independently selected. In other embodiments anyor more of X12-X14 are optionally absent.

Of interest are novel GIP analogs or hybrids wherein X2 and X3 areindependently Lys, Ser, 4-amino butyric amino acid, Aib, D-Ala,Sarcosine or Pro. The N-terminal modification can be selected from thegroup of glycation, alkylation, acetylation, alkyloxycarbonylation orarylalkoxycarbonylation.

In yet another embodiment X1 is Tyr, desamino-Tyr, D-Tyr, Ala, a D-aminoacid, Tyr-glucitol, an N-methylated amino acid, and/or comprises anN-terminal glycation, alkylation, acetylation, alkyloxycarbonylation,arylalkoxycarbonylation or acylation. In a further embodiment when X1 isTyr then the N-terminus of the tyrosine residue can be modified byalkylation, alkyloxycarbonylation, arylalkoxycarbonylation,sulphonylation, glycation, homoserine formation, pyroglutamic acidformation, acylation, methylation, t-butylation,t-butyloxycarbonylation, 4-methylbenzylation, benzyloxymethylation,benzyloxycarbonylation, 4-toluenesulphonylation, diphenylmethylation,2-bromobenzyloxycarbonylation, 9-fluorenylmethyloxycarbonylation,acylation, formylation, acetylation, benzylation, benzoylation,phosphorylation, sulphation, glycolysation with pentoses, deoxyhexoses,glucosamines, or N-acetylglucosamines, farnesylation, biotinylation,palmitoylation, stearoylation, geranylgeranylation, glutathionylation,and modification with lipoic acid. In yet a further embodiment theN-terminus of the X1 residue can be modified by alkylation,alkyloxycarbonylation, arylalkoxycarbonylation, sulphonylation,glycation, homoserine formation, pyroglutamic acid formation, acylation,methylation, t-butylation, t-butyloxycarbonylation, 4-methylbenzylation,benzyloxymethylation, benzyloxycarbonylation, 4-toluenesulphonylation,diphenylmethylation, 2-bromobenzyloxycarbonylation,9-fluorenylmethyloxycarbonylation, acylation, formylation, acetylation,benzylation, benzoylation, phosphorylation, sulphation, glycolysationwith pentoses, deoxyhexoses, glucosamines, or N-acetylglucosamines,farnesylation, biotinylation, palmitoylation, stearoylation,geranylgeranylation, glutathionylation, and modification with lipoicacid.

In yet another embodiment X2 is Ala, AlaΨ(CH2NH), Ser, D-amino acid,Lys, 4-amino butyric amino acid, Aib, D-Ala, Sarcosine, Pro, Gly,phosphorylated Ser, Val, Leu, Ile, Thr, or an N-methylated amino acid.

In a further embodiment X2 is a conservative amino acid change from anative residue or from an X2 residue provided herein. In yet anotherembodiment X2 is any naturally occurring amino acid. In a still furtherembodiment X2 is any non-proteinogenic amino acid.

In yet another embodiment X3 is Glu, D-Glu, L-Pro, (N-Me)Glu, Pro,D-amino acid, Lys, Ser, 4-amino butyric amino acid, Aib, D-Ala,Sarcosine, Pro, or an N-methylated amino acid. In a further embodimentX3 is a conservative amino acid change from a native residue or from anX3 residue provided herein. In yet another embodiment X3 is anynaturally occurring amino acid. In a still further embodiment X3 is anynon-proteinogenic amino acid.

In yet another embodiment X4 is Gly or Ala. In a further embodiment X4is a conservative amino acid change from a native residue or from an X4residue provided herein.

In yet another embodiment X5 is Thr or Ser.

In yet another embodiment X6 is Phe or Ala. In a further embodiment X6is a conservative amino acid change from a native residue or from an X6residue provided herein.

In yet another embodiment X7 is Ile or Ala. In a further embodiment X7is a conservative amino acid change from a native residue or from an X7residue provided herein.

In yet another embodiment X8 is Ser or Ala. In a further embodiment X8is a conservative amino acid change from a native residue or from an X8residue provided herein.

In yet another embodiment X9 is Asp or Ala. In a further embodiment X9is a conservative amino acid change from a native residue or from an X9residue provided herein.

In yet another embodiment X10 is Tyr or Ala. In a further embodiment X10is a conservative amino acid change from a native residue or from an X10residue provided herein.

In yet another embodiment X11 is Ser or Ala. In a further embodiment X11is a conservative amino acid change from a native residue or from an X11residue provided herein.

In yet another embodiment X12 is Ile, Ala, Ser, or Lys. In a furtherembodiment X12 is a conservative amino acid change from a native residueor from an X12 residue provided herein. In yet another embodiment X12 isany naturally occurring amino acid. In a still further embodiment X12 isabsent.

In yet another embodiment X13 is Ala, Tyr, Glutamine, or Asp. In afurther embodiment X13 is a conservative amino acid change from a nativeresidue or from an X13 residue provided herein. In yet anotherembodiment X13 is any naturally occurring amino acid. In a still furtherembodiment X13 is absent.

In yet another embodiment X14 is Met, Ala, or Leu. In a furtherembodiment X14 is a conservative amino acid change from a native residueor from an X14 residue provided herein. In yet another embodiment X14 isany naturally occurring amino acid. In a still further embodiment X14 isabsent.

In certain embodiments a modified D region of a novel GIP analog and ahybrid comprises the sequenceTyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-11e-Tyr-Met (SEQ ID NO:204).

In certain embodiments D comprises the sequence

(SEQ ID NO: 205) Ala-Ala-Glu-Gly-Thr-Phe-lIe-Ser-Asp-Tyr-Ser-Ile-Ala-Met; (SEQ ID NO: 206)Tyr-Ala-Ala-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile- Ala-Met;(SEQ ID NO: 207) Tyr-Ala-Glu-Ala-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met; (SEQ ID NO: 208)Tyr-Ala-Glu-Gly-Ala-Phe-Ile-Ser-Asp-Tyr-Ser-Ile- Ala-Met;(SEQ ID NO: 209) Tyr-Ala-Glu-Gly-Thr-Ala-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met; (SEQ ID NO: 210)Tyr-Ala-Glu-Gly-Thr-Phe-Ala-Ser-Asp-Tyr-Ser-Ile- Ala-Met;(SEQ ID NO: 211) Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ala-Asp-Tyr-Ser-Ile-Ala-Met; (SEQ ID NO: 212)Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Ala-Tyr-Ser-Ile- Ala-Met;(SEQ ID NO: 213) Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Ala-Ser-Ile-Ala-Met; (SEQ ID NO: 214)Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ala-Ile- Ala-Met;(SEQ ID NO: 215) Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ala-Ala-Met; or (SEQ ID NO: 216)Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile- Ala-Ala.

In still further embodiments D comprises the sequence

(SEQ ID NO: 217) TyrSerGluGlyThrPheIleSerAspTyrSerIleAlaMet;(SEQ ID NO: 218) TyrGlyGluGlyThrPheIleSerAspTyrSerIleAlaMet; orTyr-DAla-GluGlyThrPheIleSerAspTyrSerIleAlaMet.

In further embodiments D comprises the sequence

(SEQ ID NO: 14) YAEGTFISDYSIAM, (SEQ ID NO: 219)(Tyr1-glucitol)AEGTFISDYSIAM, (SEQ ID NO: 220)(Tyr1-pyroglutamyl)AEGTFISD, (SEQ ID NO: 219)(Tyr1-glucitol)AEGTFISDYSIAM, (SEQ ID NO: 221)(Tyr1-9-fluorenylmethoxycarbonyl)AEGTFISDYSIAM, (SEQ ID NO: 222)(Tyr1-palmitate)AEGTFISDYSIAM, (SEQ ID NO: 223) YSEGTFISDYSIAM, or(SEQ ID NO: 224) YGEGTFISDYSIAM.

In yet other embodiments D comprises the sequence

Y(D-Ala)EGTFISDYSIAM, (SEQ ID NO: 225) YAbuAEGTFISDYSIAM, or(SEQ ID NO: 226) YSarAEGTFISDYSIAM.

In a still further embodiment a novel GIP analog or hybrid region D mayexhibit at least 60%, 65%, 70%, 80%, 85%, 90%, 95%, 98% or 100% sequenceidentity to a corresponding region of a native GIP, for example aminoacids 1-11, 1-12, 1-13 or 1-14 of a native GIP, preferably a human GIP,over the entire length of each corresponding sequence. Furthermore, aregion D of a novel GIP analog may also exhibit at least 50%, 60%, 65%,70%, 80%, 85%, 90%, 95% or even 100% sequence identity to a modified orsubstituted GIP, e.g. see WO 00/58360, EP1171465 or published UnitedStates Patent Application 20030232761. Percent identity can bedetermined manually or by analysis with the AlignX module in Vector NTI(Invitrogen; Carlsbad Calif.) or the ClustalW algorithm for globalalignment. Native region D GIP sequences include those derived fromhuman, mouse, rat, porcine or bovine GIP. Native GIP sequences includehuman GIP(1-42) (YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ; SEQ ID NO:2), mouse GIP(1-42) (YAEGTFISDYSIAMDKIRQQDFVNWLLAQRGKKSDWKHNITQ; SEQ IDNO: 10), rat GIP(1-42) (YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKNDWKHNLTQ; SEQID NO: 11), pig GIP(1-42) (YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWKHNITQ;SEQ ID NO: 12), or bovine GIP(1-42)(YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWIHNITQ; SEQ ID NO: 13). In yetother embodiments region D comprises amino acids 1-11, 1-12, 1-13 or1-14 of human, mouse, rat, pig or bovine GIP, e.g. wherein region Dcomprises YAEGTFISDYS (SEQ ID NO: 227), YAEGTFISDYSI (SEQ ID NO: 228),YAEGTFISDYSIA (SEQ ID NO: 229) or YAEGTFISDYSIAM (SEQ ID NO: 14). Instill further embodiments a region D amino acid sequence furthercomprises a modified or substituted amino acid in addition to any one ofpositions X1, X2 or X3.

In some embodiments of the novel GIP analog or hybrid L can be absent.In other embodiments L comprises

-   a) Aha,-   b) Aha-Aha,-   c) Aha-Aha-Aha,-   d) Amino alkanoic acid (C5-C12),-   e) Glu-Lys-Glu-Lys (SEQ ID NO: 230),-   f) Ala-Ala-Ala-Ala (SEQ ID NO: 231),-   g) a linker peptide comprising 12 amino acid residues selected from    the group consisting of amino acid residues, D-amino acids and    non-proteinogenic amino acids,-   h) Glu-Lys-Glu-Glu-Lys-Glu-Lys-Glu-Glu-Lys-Glu-Lys (SEQ ID NO: 232),-   i) an omega-amino fatty acids (saturated and unsaturated) of    omega—NH2—(CHx)n—COOH where n=10 to 34; or-   j) the sequence X15-X16-X17-X18 (SEQ ID NO:466) wherein each of    X15-X18 is independently any naturally-occurring amino acid,    non-proteinogenic amino acid, D-amino acid or is absent.

In further embodiments X15 is D, E, or a conservative amino acid changethereof or of a native X15 residue. In further embodiments X16 is K, G,E, or a conservative amino acid change thereof or of a native X16residue. In further embodiments X17 is I, Q, E, or a conservative aminoacid change thereof or of a native X17 residue. In further embodimentsX18 is H, R, A or a conservative amino acid change thereof or of anative X18 residue. In novel GIP analogs L can comprise the sequenceD-K-I-H or D-K-I-R. In further embodiments L comprises a modified orsubstituted amino acid. In one such embodiment L comprises in a firstposition (e.g. X16) a (hetero)aryl (both optionally substituted) or 3-7Ccycloalkyl, 1-10C (hetero)alkylene, 2-10C (hetero)alkenylene, 2-10C(hetero)alkynylene or phenyl, and in a second C-terminally adjacentposition (e.g. X17) a 1-10C (hetero)alkylene, 2-10C (hetero)alkenylene,2-10C (hetero)alkynylene, or phenyl linked via a —CO— to the nextresidue in the amino acid backbone. In still further embodiments aregion L amino acid sequence further comprises a modified or substitutedamino acid.

In one embodiment of the invention region C comprises the sequenceX19-X20-X21-X22-X23-X24-X25-X26-X27-X28-X29-X30 (SEQ ID NO:467), eachposition being independently selected, wherein

-   X19 is Q or a conservative amino acid substitution thereof,-   X20 is Q or a conservative amino acid substitution thereof,-   X21 is D or a conservative amino acid substitution thereof,-   X22 is F, Y or a conservative amino acid substitution thereof,-   X23 is V, I, A, or a conservative amino acid substitution thereof,-   X24 is N, Q or a conservative amino acid substitution thereof,-   X25 is W, F, Y, napthylalanine or a conservative amino acid    substitution thereof,-   X26 is L, A or a conservative amino acid substitution thereof,-   X27 is L, K, R, V, A, I or a conservative amino acid substitution    thereof, or is absent-   X28 is A, N, D, K, R, E or a conservative amino acid substitution    thereof, or is absent-   X29 is Q, G or a conservative amino acid substitution thereof or is    absent, and-   X30 is K, G, R, G, P, R or a conservative amino acid substitution    thereof or is absent.

In a further aspect any one, two, or three of X26 to X30 is absent inregion C.

In yet another embodiment a novel GIP analog region C comprises 8 to 24C-terminal amino acids of a GIP (beginning at a position in the GIPcorresponding to position X19 (Gln) in human GIP), at least the firstsuch 8 amino acids (e.g., comprising positions X19-X26, such as X19-27,X19-X28, X19-29), at least the first 12 such amino acids (e.g.,comprising positions X19 to X30, such as X19-X31, X19-X32, X19-X33,X19-X34, X19-X35, X19-X36, X19-X37, X19-X38), at least the first 21 suchamino acids (e.g. comprising positions X19 to X39, such as X19-X40,X19-X41) or at least 24 such amino acids. Notably in these embodimentsX27-X30 may be independently present or absent. For example, region Ccan further comprise residues 31 to 39 of a GIP or a native GIP, and X27to X30 may be optionally absent.

In a still further embodiment a novel GIP analog or hybrid region C mayexhibit at least 60%, 65%, 70%, 80%, 85%, 90%, 95%, 98% or 100% sequenceidentity to a corresponding region of a native GIP, for example aminoacids 19-30, 19-26, 19-26 or 19-42 of a native GIP over the entirelength of each corresponding sequence. Furthermore, a region C of anovel GIP analog may also exhibit at least 50%, 60%, 65%, 70%, 80%, 85%,90%, 95%, 98% or even 100% sequence identity to a modified orsubstituted GIP, e.g. see WO 00/58360, EP1171465 or published UnitedStates Patent Application 20030232761. Native region C GIP sequencesinclude those derived from human, mouse, rat, porcine or bovine GIP.Native GIP sequences include human GIP(1-42)(YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ; SEQ ID NO: 2), mouseGIP(1-42) (YAEGTFISDYSIAMDKIRQQDFVNWLLAQRGKKSDWKHNITQ; SEQ ID NO: 10),rat GIP(1-42) (YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKNDWKHNLTQ; SEQ ID NO:11), pig GIP(1-42) (YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWKHNITQ; SEQ IDNO: 12), or bovine GIP(1-42)(YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWIHNITQ; SEQ ID NO: 13). In yetother embodiments region C comprises amino acids 19-30, 19-26, 19-26 or19-42 of human, mouse, rat, pig or bovine GIP, e.g. region C comprisesGlnGlnAspPheValAsnTrpLeuLeuAlaGlnLys (SEQ ID NO: 233) orGlnGlnAspPheValAsnTrpLeuLeuAlaGlnArg (SEQ ID NO: 234). In still furtherembodiments a region C amino acid sequence further comprises a modifiedor substituted amino acid.

In one embodiment of the novel GIP analog or hybrid region S comprisesthe sequence X31-X32-X33-X34-X35-X36-X37-X38-X39 (SEQ ID NO:468), eachindependently selected, wherein X31 is Pro, homoproline, 3Hyp, 4Hyp,thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine, G,S;

-   X32 is Ser, Pro, His, homoproline, 3Hyp, 4Hyp, thioproline,    N-alkylglycine, N-alkylpentylglycine or N-alkylalanine;-   X33 is Ser, Arg, Thr, Trp, Lys;-   X34 is Gly, Ser;-   X35 is Ala, Arg, Asp, Glu, Lys, Gly;-   X36 is Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine,    N-alkylpentylglycine or N-alkylalanine, A, absent;-   X37 is Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine,    N-alkylpentylglycine or N-alkylalanine, A, absent;-   X38 is Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine,    N-alkylpentylglycine or N-alkylalanine, Ala, Arg, Lys, His, or is    absent; and-   X39 is Ser, Thr, Tyr, Leu, Ala, Lys, His, Pro, Lys, Arg, Gly, or    absent, wherein if an amino acid is absent then all subsequent    positions are absent.

In a further embodiment at least one of X31-X39 contains a conservativesubstitution of an amino acid listed herein for the embodiments ofregion S. In further embodiments region S comprisesProSerSerGlyAlaProProProSer (SEQ ID NO: 1), ProSerSerGlyAlaProProPro(SEQ ID NO: 235), ProSerSerGlyAlaProPro (SEQ ID NO: 236),ProSerSerGlyAlaPro (SEQ ID NO: 237), ProSerSerGlyAla (SEQ ID NO: 238),ProSerSerGly (SEQ ID NO: 239), or ProSerSer. In yet a further embodimentregion S comprises a C-terminal amide. In still a further embodimentregion S comprises a sequence wherein X37 is Pro, homoproline, 3Hyp,4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine orN-alkylalanine that is capable of interacting with a Trp or Trp-likeresidue in region C to form a Trp-cage. In still another embodimentregion S comprises a sequence wherein X31 is Pro, homoproline, 3Hyp,4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine orN-alkylalanine that is capable of interacting with a Trp or Trp-likeresidue in region C to form a Trp-cage. In yet a further embodimentregion S comprises a sequence wherein X31 and X37 are both Pro,homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine,N-alkylpentylglycine or N-alkylalanine and that is capable ofinteracting with a Trp or Trp-like residue in region C to form aTrp-cage. In some embodiments region S comprises a sequence of 5 to 14amino acids, 5 to 10 amino acids, or 6 to 9 amino acids that is capableof forming a Trp cage with the region C.

In other embodiments the S region contains or alternatively comprises afrog GLP1 tail region. GIP analog 0601GIP4673 is an example of such acompound, which also has a DPPP-IV resistant N-terminus andmodifications that reduce hydrophobicity to increase solubility.Accordingly, in a further embodiment, the GLP-1 frog tail containing GIPcompounds and hybrids further include at least one, two or threemodifications that increase solubility of the parent compound, asdiscussed and exemplified herein. Of particular interest are embodimentswherein the frog GLP-1 tail is PKKIRYS (SEQ ID NO:421) or an analog orderivative thereof. In one embodiment, GIP analogs and derivatives, andGIP hybrids containing such GIP compounds do not include the frog GLP-1tails specifically exemplified in PCT/US2006/005020 of Levy et al., butwould include the novel analogs and derivatives thereof disclosedherein. It is expressly intended that for each GIP analog and derivativeexemplified herein, a second compound is expressly intended wherein anovel frog GLP-1 tail region as disclosed herein is substituted or addedto the C-terminal region of the GIP compound as taught herein. Accordingto this aspect, for example, the C-terminal PSSGAPPPS region of0601GIP4645 would be replaced with PKKIRYS (SEQ ID NO:421) or a novelanalog or derivative thereof to generate a new GIP compound usefuleither alone or as a GIP hybrid component. Such specific molecules arehereby expressly intended and described as if each was individuallylisted herein.

In one embodiment are GIP compounds having an anolog or derivative ofthe PKKIRYS tail (SEQ ID NO:421) wherein any one of the positions in thetail is substituted with an alanine, e.g. PAKIRYS (SEQ ID NO:422). Inone embodiment the PKKIRYS tail (SEQ ID NO:421)analog has serine-prolinedipeptide is inserted between the proline and lysine. In one embodimentGIP compounds have a PKKIRYS tail (SEQ ID NO:421) analog wherein anyone, two or three of positions 3, 4 and 6 are substituted with serine,alanine and proline, respectively. In one embodiment the PKKIRYS tail(SEQ ID NO:421) analog has any one, two or three of positions 4, 5 and 7substituted with lysine, leucine, and proline, respectively. In oneembodiment having the PKKIRYS tail (SEQ ID NO:421) is an tail analogwherein any one or two of positions 2 and 3 are substituted with eitherasparagine, glutamine or both, which effectively reduces proteolyticcleavage at the 2-3 bond. In one embodiment having the PKKIRYS tail (SEQID NO:421) is a tail analog wherein any one or two of positions 2 and 3are substituted or derivatized to effectively reduce proteolyticcleavage at the 2-3 bond. Such substitutions or derivatives includethose known to prevent cleavage of a KK bond, and will maintain peptidefunction as is readily determined as taught herein. In one embodimenthaving the PKKIRYS tail (SEQ ID NO:421) is a tail analog wherein any oneor two of positions 4 and 7 are substituted with an octylglycine, whicheffectively reduces proteolytic cleavage at the 2-3 bond. In yet otherembodiments, a PKKIRYS tail (SEQ ID NO:421) or analog or derivativethereof is combined with a modification that increases thehydrophilicity of the GIP analog. In one such embodiment at least anyone, two or three of positions N24, W25, L26 or L27 are substituted witha more hydrophilic amino acid. In one such embodiment the morehydrophilic amino acid is selected from with E, P, N, S, T, K , R or Q.In one such embodiment the N24 is substituted with E, P or Q. In onesuch embodiment the W25 is substituted with E, P, N or Q. In one suchembodiment either or both L26 or L27 is substituted with E, P, Q, N, S,T or K. In one such embodiment the W25 is substituted with E, P, N, S,T, K or Q.

In one embodiment the novel GIP analog or hybrid is modified. The novelGIP hybrid can comprise a modification by fatty acid addition at anepsilon amino group of at least one lysine residue.

In one embodiment a novel GIP analog or hybrid is a GIP-receptoragonist. The novel GIP hybrid can potentiate cyclic AMP production. Inanother embodiment a novel GIP hybrid is a GIP-receptor antagonist. Theapplicant appreciates that GIP compounds and hybrids as disclosed hereinmay bind but not significantly activate the GIP receptor. Such GIPreceptor antagonists are useful, for example, as in chronicadministration to treat obesity-related diabetes, possibly by increasinginsulin resistance (see for example, Gault et al. Diabetes (2005)54(8):2436-3446).

In one embodiment a novel GIP analog or hybrid comprises a sequence ofthe formula D-L-C—S where D comprises a D-amino acid alanine at X2 andwherein D, L, C and S are as defined herein and is any of the otherembodiments herein. For example, in a further such embodiment region Ccomprises amino acids 19-30 of a GIP, particularly a human GIP, evenmore particularly comprises the sequence QQDFVNWLLAQK (SEQ ID NO: 15).In a further such embodiment L is naturally occurring sequence X15-X18from a native GIP, particularly human GIP. In a further exemplaryembodiment S is a sequence comprising PSSGAPPPS (SEQ ID NO: 1), PSSGAPPP(SEQ ID NO: 235), PSSGAPP (SEQ ID NO: 236), PSSGAP (SEQ ID NO: 237),PSSGA (SEQ ID NO: 238), or PSSG (SEQ ID NO: 239). In yet anotherembodiment a novel GIP hybrid comprise the sequence:

(SEQ ID NO: 469) Y(D-Ala)EGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS;(SEQ ID NO: 470) Y(D-Ala)EGTFISDYSIAMDKIRQQDFVNWLLAQRPSSGAPPPS;(SEQ ID NO: 471) Y(D-Ala)EGTFISDYSIAMDKIRQQDFVNWLLAQKPSSGAPPPS;(SEQ ID NO: 472) Y(D-Ala)EGTFISDYSIAMDKIRQQDFVNWLLAQKPSSGAPPPS; or(SEQ ID NO: 473) Y(D-Ala)EGTFISDYSIAMDKIRQQDFVNWLLAQKPSSGAPPPS.

In a further example, an embodiment of such a novel D-Ala2-containingGIP analog or hybrid can exhibit at least 50% sequence identity to oneof the above analogs and comprises a D-Ala at position X2. In additionalembodiments, the embodiment can further comprise the sequence PSSGAPPPS(SEQ ID NO: 1) or KNGGKPSSGAPPPS (SEQ ID NO: 240).

In one embodiment of a novel GIP analog or hybrid region D comprises theformula X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14 (SEQ ID NO:474)wherein X1 and X2 are absent. In a further embodiment region D comprisesthe formula X1; -X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14 (SEQ IDNO:578) wherein X1 and X2 are absent and at least one of X3, X4 or X5 isan amino acid substitution or modification providing DPP-IV resistance,for example with a modification or substitution or reduced bond asdefined herein. Other amino acid positions are as defined herein.Typically such embodiment of a novel GIP analog or hybrid has GIPantagonist activity.

In one embodiment D is absent. In another embodiment when D is absent, anovel GIP analog can comprise L-C-S or C-S where region L or C comprisesan N-terminal modification, substitution or modification providingprotease resistance, particularly DPP-IV resistance. In yet a furtherembodiment is X18-X19-C-S wherein one or both of X18 and X19 are absent,such that for X18-X19-X20, X19-X20-X21, and X20-X21-X22, an amino acidsubstitution or modification or N-terminal modification of at least oneof X18, X19, X20, X21 or X22 provides DPP-IV resistance.

Additional embodiments include compounds comprising the sequence

(SEQ ID NO: 186) Y(DAla)EGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS,(SEQ ID NO: 241) Y(pSer)EGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS,(SEQ ID NO: 242) YA(N-MeGlu)EGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS,(SEQ ID NO: 243) YPEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS,(SEQ ID NO: 244) YVEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS,(SEQ ID NO: 475) (D-Tyr)AEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS, or(SEQ ID NO: 245) YAPGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS.

Further embodiments include compounds comprising the sequence

(SEQ ID NO: 193)Y(DAla)EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS,(SEQ ID NO: 246)Y(pSer)EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS,(SEQ ID NO: 247)YA(N-MeGlu)EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS,(SEQ ID NO: 248) YPEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS,(SEQ ID NO: 249) YVEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS,(SEQ ID NO: 476)(D-Tyr)AEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS, or(SEQ ID NO: 250) YAPGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS.

In a further embodiment any of the GIP polypeptides comprises anN-terminal His, D-histidine, desamino-histidine, 2-amino-histidine,beta-hydroxy-histidine, homohistidine, alpha-fluoromethyl-histidine,alpha-methyl histidine. Additional embodiments include compoundscomprising the sequence

(SEQ ID NO: 251) HGEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS or(SEQ ID NO: 252) HGEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS.

In one embodiment of a novel GIP analog or hybrid, region L and/or Ccomprises a modified or substituted amino acid. In certain embodimentsthe novel GIP analog comprises Cys, D-Cys, HomoCys or Penicillamine 1n afurther embodiment the linker L and/or region C comprises Cys, D-Cys,homoCys or penicillamine. These amino acids are inserted as a site formodification to add peg molecules, lipids or link to other SH containingmolecules such as other peptides or reactive molecules. In anotherembodiment at least one Cys, D-Cys, HomoCys or Penicillamine is modifiedwith a lipid or a peg molecule or a reactive group. Typically 0, 1, 2 or3 such residues are present.

In one such embodiment region L and/or C comprises at least one Cys,D-Cys, homocys or penicillamine residue. In one such embodiment of thenovel GIP analog at least one of X15 to X18 or X31 to X40 is Cys, D-Cys,homocys or penicillamine. In a further such embodiment, no more than twoof X15 to X18 or X31 to X40 is Cys, D-Cys, homocys or penicillamine 1n afurther embodiment no more than one of X15 to X18 or X31 to X40 is Cys,D-Cys, homocys or penicillamine 1n a further such embodiment at leastone of X15 to X18 or X31 to X40 is Cys, D-Cys, homocys or penicillamineand at least one of said residues is modified by a lipid.

In an embodiment a novel GIP analog or hybrid comprises a pegylatedamino acid. At least one PEG molecule can be attached to thepolypeptide. In one such embodiment each peg molecule is attached to thecompound at a D-Cys, homocys or penicillamine or Lys amino acid or tothe carboxy terminal amino acid. In a further such embodiment the atleast one PEG molecule is attached to an amino acid in region L and/orC. In a further embodiment a pegylated novel GIP analog has anelimination half-life of at least one hour. Further a novel GIP analogor hybrid can comprise 1, 2, or 3 peg molecules. In a further embodimentat least one of X15 to X18 or X31 to X40 is Cys, D-Cys, homocys orpenicillamine and at least one of said residues is attached to a pegmolecule. Furthermore at least one, two or three of X15 to X18 or X31 toX40 is Cys, D-Cys, homocys or penicillamine and at least one, two orthree of said residues are attached to a peg molecule.

A GIP compound of the present invention can be modified by attaching orcoupling a reactive group. A GIP compound is thereby capable ofcovalently binding to a blood component through the reactive group. Thereactive group typically will covalently bond with an amino group, ahydroxyl group, or a thiol group on a blood component, therebycovalently linking the GIP peptide to the blood component. In oneembodiment, the reactive group will react with a thiol group on a bloodcomponent. More preferably, the reactive group will react with a thiolgroup on blood serum albumin. The reactive group may contain any of anumber of chemically reactive entities that are capable of forming acovalent bond. In one embodiment, the reactive group will be capable ofreacting with a thiol group on a blood component to form a disulfidebond. Such reactive groups are found for example in U.S. Pat. No.6,593,295. In one embodiment of particular interest, the GIP compound isreacted ex vivo with along-lived blood component such as albumin to forma composition suitable for sustained release. Other suitable long-livedcomponents of the blood include immunoglobulin, human serum albumin, redblood cells and platelets.

Reactive groups that are capable of forming disulfide bonds with thiolgroups include those having an activated disulfide bond or anS-sulfonate. Reactive groups having an activated disulfide bond can bederived by coupling a GIP peptide cysteine (or cysteine analog) with anactivating group, such as 2,2′-dithiodipyridine (DTDP),2,2′-dithiobis(5-Nitropyridine) (NPYS), 5,5′-dithiobis(2-nitrobenzoicacid) (Ellman's reagent), or 6,6′-dithiodinicotinic acid. Reactivegroups containing an activated disulfide bond are herein referred to asactivated disulfide bond groups. In addition, an activated disulfidebond group can be derived by acylating a lysine side chain of a GIPpeptide with a mercapto-activated carboxylic acid. Another exemplaryembodiment of the present invention is to utilize a reactive group thatis capable of reacting with a thiol group on a blood component to form athioether linkage. In one embodiment, such a reactive group will bederived by coupling a GIP peptide with a chemically reactive entity froma maleimido-containing group, such as gamma-maleimide-butyrylamide(GMBA), maleimide-benzoyl-succinimide (MBS), gamma-maleimido-butyryloxysuccinimide ester (GMBS), and maleimidopropionic acid (MPA). These andother maleimide containing groups are herein referred to as maleimidogroups. In an alternative embodiment of the present invention, thereactive group of a GIP compound will be capable of covalently bondingto a primary amine on a blood component to form an amide bond. In oneembodiment, such reactive groups will be derived by coupling a GIPpeptide with N-hydroxysuccinimide (NHS) or N-hydroxysulfosuccinimide(sulfo-NHS) to form an NHS or sulfo-NHS ester. These succinimidyl groupsmay potentially react with alpha-amine groups on the N-termini of bloodcomponent proteins, provided that such amine groups are accessible oravailable to the reactive group. In one embodiment, these succinimidylgroups will react with the epsilon-amine of lysine in blood componentproteins, since the epsilon-amine of lysine is the only amino acid sidechain that reacts significantly with NHS esters. In yet anotherembodiment, GIP compounds of the present invention contain reactivegroups that are designed to covalently bond with thiol groups on bloodcomponents. Binding to thiol groups is exemplary over binding to aminogroups, because thiol groups are less abundant in vivo than are aminogroups. Fewer blood components are thereby targeted through binding tothiol groups compared to binding to amino groups, resulting in greaterspecificity of binding. Accordingly, the exemplary GIP compounds willcontain GIP peptides modified with a maleimido group or more In oneembodiment, an S-sulfonate or an activated disulfide bond group. Whilethe GIP compounds of the present invention may bind to any of severalblood components that contain a free thiol group, the GIP compoundspreferably will covalently bond with the thiol group on serum albumin.Serum albumin is the most abundant blood protein, and contains a singlethiol group, located at amino acid residue 34 in the protein (Cys34),which is highly conserved among species. The binding of GIP compounds toserum albumin not only provides specificity of binding, but alsoprovides a reproducible formation of conjugates having a 1:1 binding ofGIP compound to serum albumin. The reproducibility of this 1:1 ratio isdesirable for use of a GIP compound as a therapeutic, since reproducibleconjugates of GIP compound and serum albumin will result uponadministration of the GIP compound. Furthermore, the reproducibility of1:1 conjugates of GIP compound and serum albumin is desirable for exvivo or in vitro approaches to form conjugates for therapy. Conjugatescan be formed ex vivo by combining GIP compounds of the presentinvention with blood, allowing formation of the conjugates, and thenadministering the conjugate-containing blood to the host. Alternatively,GIP compound-serum albumin conjugates can also be formed in vitro, bycombining GIP compound with recombinant serum albumin to form conjugateswhich can be administered. The reproducibility of 1:1 conjugates of GIPcompound and serum albumin provides for reproducible conjugates from exvivo administration or in vitro batch to batch preparation.

In another embodiment provided are GIP compounds covalently attached toone or more molecules of polyethylene glycol (peg), or a derivativethereof wherein each peg is attached at a Cys or Lys amino acid or thecarboxy terminus of the peptide, resulting in pegylated GIP compoundwith a half-life of at least one hour, at least 4, 6, 10, 15, 20 or 24.In one embodiment a pegylated GIP compound comprises any of the novelGIP compound sequences taught herein with a peg molecule covalentlyattached at 1, 2 or 3 residues.

In yet further contemplated embodiments the embodiments presented aboveor herein are combined in any consistent combination. For exampleembodiments describing region D can be combined with embodimentsdescribing region L to describe novel GIP analog embodiments having thecombined changes in region D and in region L. The analogs can be furthercombined with a second hormone module to form a GIP hybrid.

In another embodiment, the novel GIP analog or hybrid polypeptides ofthe invention are at least amino acids 25 amino acids in length. Inother embodiments, the polypeptides may be at least 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, and each integer up to 54 amino acids inlength (e.g. GIP(1-42)+long exendin tail (27-39)). Further, in oneembodiment, the polypeptides of the invention include only natural Lamino acid residues and/or modified natural L amino acid residues.Alternatively, in another embodiment, the polypeptides of the inventiondo not include unnatural amino acid residues.

In yet another embodiment, the novel GIP analog or hybrid may exhibit atleast 60%, 65%, 70%, 80%, 85%, 90%, 95% or 98% sequence identity to anative GIP(1-42), GIP(1-30), GIP(1-26), GIP(1-39), GIP(19-30),GIP(19-26), GIP(19-39), GIP(19-42), GIP(1-11), or GIP(1-14) over theentire length of each corresponding sequence. Such polypeptides of theinvention may also exhibit at least 50%, 60%, 65%, 70%, 80%, 85%, 90%,95% or 98% sequence identity to a modified or substituted GIP, e.g. seeWO 00/58360, EP1171465 or published United States Patent Application20030232761. In yet another embodiment the D-L-C region of a novel GIPanalog may exhibit at least 60%, 65%, 70%, 80%, 85%, 90%, 95% or 98%sequence identity to a native GIP(1-42), GIP(1-30), GIP(1-26),GIP(1-39), GIP(19-30), GIP(19-26), GIP(19-39), GIP(19-42), GIP(1-11), orGIP(1-14) over the entire length of each corresponding sequence. NativeGIP sequences include those derived from human GIP(1-42)(YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ; SEQ ID NO: 2), humanGIP(1-26)(YAEGTFISDYSIAMDKIRQQDFVNWL; SEQ ID NO: 253), humanGIP(1-30)(YAEGTFISDYSIAMDKIHQQDFVNWLLAQK; SEQ ID NO: 3), humanGIP(1-39)(YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHN; SEQ ID NO: 254),mouse GIP(1-42)(YAEGTFISDYSIAMDKIRQQDFVNWLLAQRGKKSDWKHNITQ; SEQ ID NO:10), mouse GIP(1-26) (YAEGTFISDYSIAMDKIRQQDFVNWL; SEQ ID NO: 255), mouseGIP(1-30) (YAEGTFISDYSIAMDKIRQQDFVNWLLAQR; SEQ ID NO: 256), mouseGIP(1-39) (YAEGTFISDYSIAMDKIRQQDFVNWLLAQRGKKSDWKHN; SEQ ID NO: 257)),rat GIP(1-42) YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKNDWKHNLTQ (SEQ ID NO:11), rat GIP(1-26) YAEGTFISDYSIAMDKIRQQDFVNWL (SEQ ID NO: 258), ratGIP(1-30) YAEGTFISDYSIAMDKIRQQDFVNWLLAQK (SEQ ID NO: 259), rat GIP(1-39)YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKNDWKHN (SEQ ID NO: 260), pig GIP(1-42)YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWKHNITQ (SEQ ID NO: 12), pigGIP(1-26) YAEGTFISDYSIAMDKIRQQDFVNWL (SEQ ID NO: 261), pig GIP(1-30)YAEGTFISDYSIAMDKIRQQDFVNWLLAQK (SEQ ID NO: 262), pig GIP(1-39)YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWKHN (SEQ ID NO: 263), bovineGIP(1-42) YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWIHNITQ (SEQ ID NO: 13),bovine GIP(1-26) YAEGTFISDYSIAMDKIRQQDFVNWL (SEQ ID NO: 264), bovineGIP(1-30) YAEGTFISDYSIAMDKIRQQDFVNWLLAQK (SEQ ID NO: 265), or bovineGIP(1-39) YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWIHN (SEQ ID NO: 266).

In yet another embodiment, the S region of a novel GIP analog or hybridof the invention may exhibit at least 50%, 60%, 65%, 70%, 80%, 85%, 90%,95% or 98% sequence identity to a native Trp-cage sequence, such asPSSGAPPPS (SEQ ID NO: 1).

In a further embodiment a novel GIP analog or hybrid polypeptide of theinvention comprises a sequence comprising at least 60%, 65%, 70%, 80%,85%, 90%, 95% or 98% sequence identity to a novel GIP analog sequencedisclosed herein. Such novel GIP analog or hybrid sequences, which arealso useful for the sequence comparison, include:

(SEQ ID NO: 267)YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPPSGAPPPS (human GIP(1-42) core),(SEQ ID NO: 186)YAEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS (human GIP(1-30) core),(SEQ ID NO: 268)YAEGTFISDYSIAMDKIRQQDFVNWLLAQRGKKSDWKHNITQPSSGAPPPS (mouse GIP(1-42) core),(SEQ ID NO: 269)YAEGTFISDYSIAMDKIRQQDFVNWLLAQRPSSGAPPPS (mouse GIP(1-30) core),(SEQ ID NO: 270)YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKNDWKHNLTQPSSGAPPPS (rat GIP(1-42) core),(SEQ ID NO: 271)YAEGTFISDYSIAMDKIRQQDFVNWLLAQKPSSGAPPPS (rat GIP(1-30) core),(SEQ ID NO: 272)YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWKHNITQPSSGAPPPS (pig GIP(1-42) core),(SEQ ID NO: 273)YAEGTFISDYSIAMDKIRQQDFVNWLLAQKPSSGAPPPS (pig GIP(1-30) core),(SEQ ID NO: 274)YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWIHNITQPPSGAPPPS (bovine GIP(1-42) core),or (SEQ ID NO: 275)YAEGTFISDYSIAMDKIRQQDFVNWLLAQKPPSGAPPPS (bovine GIP(1-30) core).

Further novel GIP analog or hybrid sequences, which are also used in thesequence comparisons mentioned above, include:

(SEQ ID NO: 276) YAEGTFISDYSIAMDKIHQQDFVNWLKNGGPSSGAPPPS (human GIP(1-26) core), (SEQ ID NO: 277)YAEGTFISDYSIAMDKIRQQDFVNWLKNGGPSSGAPPPS (mouse GIP (1-26) core),(SEQ ID NO: 278) YAEGTFISDYSIAMDKIRQQDFVNWLKNGGPSSGAPPPS (rat GIP(1-26) core), (SEQ ID NO: 279)YAEGTFISDYSIAMDKIRQQDFVNWLKNGGPSSGAPPPS (pig GIP (1-26) core), or(SEQ ID NO: 280) YAEGTFISDYSIAMDKIRQQDFVNWLKNGGPPSGAPPPS (bovineGIP(1-26) core).

Further novel GIP analog or hybrid sequences, which are also used in thesequence comparisons mentioned above, include:

(SEQ ID NO: 281) YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNPPSGAPPPS(human GIP(1-39) core), (SEQ ID NO: 282)YAEGTFISDYSIAMDKIRQQDFVNWLLAQRGKKSDWKHNPSSGAPPPS (mouse GIP(1-39) core),(SEQ ID NO: 283) YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKNDWKHNPSSGAPPPS(rat GIP(1-39) core), (SEQ ID NO: 284)YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWKHNPSSGAPPPS (pig GIP(1-39) core),or (SEQ ID NO: 285) YAEGTFISDYSIAMDKIRQQDFVNWLLAQKGKKSDWIHNPPSGAPPPS(bovine GIP(1-39) core).Further Applicable Considerations and Intentions.

Within each of the combinations described herein, it is understood thatreference to a component peptide hormone or module includes reference toanalogs, derivatives, fragments, as well as peptidic enhancers relatedthereto.

As mentioned, the novel GIP analogs are preferably C-terminallyamidated, but need not be for the purposes of the instant invention. Inother words, the C-terminus of these peptides, may have a free —OH or—NH2 group. These peptides may also have other post-translationalmodifications. One skilled in the art will appreciate that the novel GIPanalog polypeptides of the present invention may also be constructedwith an N-terminal methionine residue.

In yet other embodiments envisioned are variants of each of thesequences where the GIP portion is modified by one, two or threemodifications as described herein. Exemplary modifications are those atthe first (including the terminal NH2), second or third N-terminal aminoacid of GIP that impart DPP-IV resistance superior to that of nativeGIP. Of particular interest are GIP compounds as described herein havingat least a D-Ala substitution at position 2.

More particularly, in one aspect, the present invention relates to novelGIP analog polypeptides including one or more amino acid sequencemodifications. Such modifications include substitutions, insertions,and/or deletions, alone or in combination. In one aspect the GIP analogor hybrid polypeptide includes one or more modifications of a“non-essential” amino acid residue. In the context of the invention, a“non-essential” amino acid residue is a residue that can be altered,i.e., deleted or substituted, in the native human amino acid sequencewithout abolishing or substantially reducing the GIP or componentpeptide hormone receptor agonist activity of the GIP analog or hybrid.

Substitutions. In one embodiment, the GIP analog or hybrid polypeptidesof the invention may have one or more substitutions in the amino acidsequence of native GIP, GIP(1-30), GIP(1-14), GIP(1-26), GIP(1-39),GIP(19-26), GIP(19-30), GIP(19-39) or GIP(19-42) or a region S, alone orin combination with one or more insertions or deletions. In oneembodiment, the substitution does not abolish or substantially reducethe GIP agonist activity of the GIP analog polypeptide. In one aspect,the present invention relates to GIP analog polypeptides that have asingle substitution, or consecutive or non-consecutive substitution ofmore than one amino acid residues in the amino acid sequence of nativehuman GIP. In one embodiment, the GIP analog polypeptides of theinvention include one, two, or three amino acid substitutions. In oneembodiment the native GIP is human, rat, mouse, porcine or bovine.

Particularly useful substitutions include conservative amino acidsubstitutions. A “conservative amino acid substitution” is one in whichthe amino acid residue is replaced with an amino acid residue having asimilar side chain, or physicochemical characteristics (e.g.,electrostatic, hydrogen bonding, isosteric, hydrophobic features).Families of amino acid residues having similar side chains are known inthe art. These families include amino acids with basic side chains(e.g., lysine, arginine, histidine), acidic side chains (e.g., asparticacid, glutamic acid), uncharged polar side chains (e.g., glycine,asparagine, glutamine, serine, threonine, tyrosine, methionine,cysteine), nonpolar side chains (e.g., alanine, valine, leucine,isoleucine, proline, phenylalanine, tryptophan), beta-branched sidechains (e.g., threonine, valine, isoleucine) and aromatic side chains(e.g., tyrosine, phenylalanine, tryptophan, histidine). In yet otherembodiments exemplary conservative substitutions are shown in thefollowing table under the column “Exemplary Substitutions”. In stillother embodiments conserved substitutions are selected from the aminoacids listed in the column labeled “Preferred Substitutions.”

Original Exemplary Preferred Residue Substitutions Substitutions Ala (A)val; leu; ile val Arg (R) lys; gln; asn lys Asn (N) gln; his; asp; lys;arg gln Asp (D) glu; asn glu Cys (C) ser; ala ser Gln (Q) asn; glu asnGlu (E) asp; gln asp Gly (G) ala ala His (H) asn; gln; lys; arg arg Ile(I) leu; val; met; ala; phe; norleucine leu Leu (l) norleucine; ile;val; met; ala; phe ile Lys (K) arg; gln; asn arg Met (M) leu; phe; ileleu Phe (F) leu; val; ile; ala; tyr tyr Pro (P) ala ala Ser (S) thr thrThr (T) ser ser Trp (W) tyr; phe tyr Tyr (Y) trp; phe; thr; ser phe Val(V) ile; leu; met; phe; ala; norleucine leu

Optionally, a novel GIP analog or hybrid will have no more than oneconservative amino acid substitution as compared to the sequence againstwhich is being compared, alternatively no more than 2, 3, 4, 5, 6, 7, 8,9, or 10 conservative amino acid substitution as compared to thesequence against which is being compared.

In another embodiment, the GIP analog or hybrid polypeptides of theinvention may include substitutions of one or more unnatural and/ornon-amino acids, e.g., amino acid mimetics, into the sequence of GIP. Ina exemplary embodiment, the non-amino acids inserted into the sequenceof GIP may be beta-turn mimetics or linker molecules, such as —NH—X—CO—,wherein X=(CH₂)—_(n) (where n can be 2-20) or—NH—CH₂CH₂(—O—CH₂CH₂—O—)_(m)—CH₂—CO— (where m=1-5). Exemplary linkermolecules include aminocaproyl (“Aca”), beta-alanyl, and8-amino-3,6-dioxaoctanoyl. beta-turn mimetics are available commercially(BioQuadrant Inc, Quebec, Canada) and have been described in literature(Hanessian et al., Tetrahedron 12789-854 (1997); Gu et al., TetrahedronLetters 44: 5863-6 (2003); Bourguet et al., Bioorganic & MedicinalChemistry Letters 13: 1561-4 (2003); Grieco et al., Tetrahedron Letters43: 6297-9 (2002); Souers et al., Tetrahedron 57: 7431-48 (2001); Tsaiet al., Bioorganic & Medicinal Chemistry 7: 29-38 (1999); Virgilio etal., Tetrahedron 53: 6635-44 (1997)). Exemplary beta-turn mimeticsinclude mimic A and mimic B illustrated herein. Their IUPAC names areMimic A:N-(35,65,95)-2-oxo-3-amino-1-azabicyclo[4.3.0]-nonane-9-carboxylic acid.Mimic B:N-(3S,6S,9R)-2-oxo-3-amino-7-thia-1-azabicyclo[4.3.0]-nonane-9-carboxylicacid.

Exemplary GIP analog or hybrid polypeptides comprising amino acidsequence beta-turn mimetic substitutions include native human GIP,wherein amino acids at positions x and x+1 are substituted withbeta-turn mimetics selected from the group consisting of mimic A andmimic B, wherein x is selected from the amino acids at amino acidpositions 8 to 14 of native human GIP. (In addition to mimic A and B,Ala-Aib and Ala-Pro dipeptides are good turn inducers). These linkersare particularly useful to comprise region the region “L” of the D-L-C-Snovel GIP analogs of the invention.

Deletions and Truncations. In another embodiment, the GIP analog orhybrid polypeptides of the invention may have one or more amino acidresidues deleted from the amino acid sequence of native GIP, or a regionS, alone or in combination with one or more insertions or substitutions.In one aspect, the GIP analog or hybrid polypeptides of the inventionmay have one or more amino acid residues deleted from the N-terminus orC-terminus of a native GIP. In another embodiment, the GIP analog orhybrid polypeptides of the invention may have one or more amino acidresidues deleted at amino acid positions 1 through 42 of a native GIP,GIP(1-14), GIP(1-26), GIP(1-30), GIP(1-39), GIP(19-26), GIP(19-30),GIP(19-39) or GIP(19-42) or a region S. Such deletions may include morethan one consecutive or non-consecutive deletion. In a exemplaryembodiments no more than 1, no more than 2, no more than 3, no more than4, or no more than 5 amino acids are deleted from a native GIP, fromGIP(1-30), GIP(1-14), GIP(1-26), GIP(1-39), GIP(19-30), GIP(19-26),GIP(19-39) or GIP(19-42) or from a region S as when region isexendin(31-39) or exendin(27-39) for example. In one embodiment thenative GIP is human, rat, mouse, porcine or bovine.

In one embodiment the GIP compound, either analog, derivative or hybrid,when intended for use as an agonist, does not include a deletion at anyone of positions 1-15, corresponding to positions YAEGTFISDYSIAMD (SEQID NO:477), of the C-terminal sequence of GIP. In other words, each ofthe corresponding 1-15 positions of GIP will be present, although theymay be substituted or derivatized. In a further embodiment the agonistGIP compound does not include a deletion at any one of positions 4-15,corresponding to positions GTFISDYSIAMD (SEQ ID NO:478), of theC-terminal sequence of GIP. In other words, each of the corresponding4-15 positions of GIP will be present, although they may be substitutedor derivatized. Accordingly, in embodiments of an agonist GIP compound,each of the positions 1-15 or 4-15 will be present and occupied by theamino acid present in that position of a naturally-occurring GIP speciesor by a substitution or derivative thereof In yet another embodiment ofagonist GIP compounds, excluded from the various embodiments describedherein are the GIP compounds that did not demonstrate adequate receptorbinding activity or receptor activation activity as shown.

In one embodiment the GIP compound, either analog, derivative or hybrid,when intended for use as an agonist, does not include a deletion at anyone of positions 1-15, corresponding to positions YAEGTFISDYSIAMD (SEQID NO:477), of the C-terminal sequence of GIP. In other words, each ofthe corresponding 1-15 positions of GIP will be present, although theymay be substituted or derivatized. In a further embodiment the agonistGIP compound does not include a deletion at any one of positions 4-15,corresponding to positions GTFISDYSIAMD (SEQ ID NO:478), of theC-terminal sequence of GIP. In other words, each of the corresponding4-15 positions of GIP will be present, although they may be substitutedor derivatized.

Insertions. In another embodiment, the GIP analog or hybrid polypeptidesof the invention may have one or more amino acid residues inserted intothe amino acid sequence of native GIP from GIP(1-30), GIP(1-14),GIP(1-26), GIP(1-39), GIP(19-30), GIP(19-26), GIP(19-39) or GIP(19-42)or region S, alone or in combination with one or more deletions and/orsubstitutions. In one aspect, the present invention relates to GIPanalog or hybrid polypeptides that have a single insertion, orconsecutive or non-consecutive insertions of more than one amino acidresidues into the amino acid sequence of native GIP, GIP(1-30),GIP(1-14), GIP(1-26), GIP(1-39), GIP(19-30), GIP(19-26), GIP(19-39) orGIP(19-42), or region S, for example exendin(27-39) and exendin(31-39).In one embodiment the native GIP is human, rat, mouse, porcine orbovine.

In another embodiment, the GIP analog or hybrid polypeptides of theinvention may include insertions of one or more unnatural amino acidsand/or non-amino acids into the sequence of GIP, GIP(1-30), GIP(1-14),GIP(1-26), GIP(1-39), GIP(19-30), GIP(19-26), GIP(19-39) or GIP(19-42),or a region S, for example exendin(27-39) and exendin(31-39). In aexemplary embodiment, the unnatural amino acids inserted into thesequence of GIP, GIP(1-30), GIP(1-14), GIP(1-26), GIP(1-39), GIP(19-30),GIP(19-26), GIP(19-39) or GIP(19-42) or region S, for exampleexendin(27-39) and exendin(31-39) may be beta-turn mimetics or linkermolecules. In further such embodiments the native GIP can be human, rat,mouse, porcine or bovine. In some embodiments region S retains at leastProline (or proline analog) at X37 in order to interact with a Trp (orTrp analog) to favor Trp cage formation. In further exemplaryembodiments a Pro is retained at position X31 to also interact with Trpat X25. In the case of N-terminally truncated exendin-4 analogs(Trp-cages), it has been established that the helix is not significantlypopulated unless it is capped by either a Trp25/Pro31 hydrophobic stapleor the complete formation of the Trp-cage. The latter, complete Trp-cageformation, serves as a very effective helix C-cap. There is alsoevidence for the contribution of the half-cage structure, with the Proat X36, X37, X38 unit undocked, in partially melted Trp-cage species.

Accordingly, while compounds are shown with optional linking groups, inone embodiment of the sequences herein, the linker is a Gly linker, forexample Gly-Gly-Gly, or a betaAla linker, for example betaAla-betaAla;all of which are specifically envisioned. Linker molecules of particualrinterest include aminocaproyl (“Aca”), beta-alanyl, and8-amino-3,6-dioxaoctanoyl. Further in other embodiments a beta-turnmimetic is used, which includes mimic A:N-(3S,6S,9S)-2-oxo-3-amino-1-azabicyclo[4.3.0]-nonane-9-carboxylic acid,mimic B:N-(3S,6S,9R)-2-oxo-3-amino-7-thia-1-azabicyclo[4.3.0]-nonane-9-carboxylicacid, and also Ala-Aib and Ala-Pro dipeptides.

In another embodiment, GIP analog or hybrid polypeptides of theinvention may include insertions of polyamino acid sequences (e.g.,poly-his, poly-arg, poly-lys, poly-ala, etc.) at either terminus of thepolypeptide, known as “extensions” or “tails.”

In some embodiments novel GIP analog or hybrid polypeptides comprisingamino acid sequence insertions include an alanine substitution at eachamino acid position along the length of native GIP, GIP(1-30),GIP(1-14), GIP(1-26), GIP(1-39), GIP(19-30), GIP(19-26), GIP(19-39) orGIP(19-42), or region S, for example exendin(27-39) and exendin(31-39).

Derivatives. The present invention also relates to derivatives of theGIP analogs and hybrid polypeptides. Such derivatives include GIP analogand hybrid polypeptides conjugated to one or more water soluble polymermolecules, such as polyethylene glycol (“PEG”) or fatty acid chains ofvarious lengths (e.g., stearyl, palmitoyl, octanoyl, etc.), or by theaddition of polyamino acids, such as poly-his, poly-arg, poly-lys, andpoly-ala. Modifications to the polypeptides can also include smallmolecule substituents, such as short alkyls and constrained alkyls(e.g., branched, cyclic, fused, adamantyl), and aromatic groups. Thewater soluble polymer molecules will preferably have a molecular weightranging from about 500 to about 20,000 Daltons.

Such polymer-conjugations and small molecule substituent modificationsmay occur singularly at the N- or C-terminus or at the side chains ofamino acid residues within the sequence of the GIP analog and hybridpolypeptides. Alternatively, there may be multiple sites ofderivatization along the GIP analog and hybrid polypeptide. Substitutionof one or more amino acids with lysine, aspartic acid, glutamic acid, orcysteine may provide additional sites for derivatization. See, e.g.,U.S. Pat. Nos. 5,824,784 and 5,824,778. In one embodiment, the GIPanalog and hybrid polypeptides may be conjugated to one, two, or threepolymer molecules.

The water soluble polymer molecules are preferably linked to an amino,carboxyl, or thiol group, and may be linked by N or C termini, or at theside chains of lysine, aspartic acid, glutamic acid, or cysteine.Alternatively, the water soluble polymer molecules may be linked withdiamine and dicarboxylic groups. In a exemplary embodiment, GIP analogand hybrid polypeptides of the invention are conjugated to one, two, orthree PEG molecules through an epsilon amino group on a lysine aminoacid.

GIP analog and hybrid polypeptide derivatives of the invention alsoinclude GIP analog and hybrid polypeptides with chemical alterations toone or more amino acid residues. Such chemical alterations includeamidation, glycosylation, acylation, sulfation, phosphorylation,acetylation, and cyclization. The chemical alterations may occursingularly at the N- or C-terminus or at the side chains of amino acidresidues within the sequence of the GIP analog and hybrid polypeptides.In one embodiment, the C-terminus of these peptides may have a free —OHor —NH2 group. In another embodiment, the N-terminal end may be cappedwith an isobutyloxycarbonyl group, an isopropyloxycarbonyl group, ann-butyloxycarbonyl group, an ethoxycarbonyl group, an isocaproyl group(isocap), an octanyl group, an octyl glycine group (G(Oct)), or an8-aminooctanic acid group or a Fmoc group. In a exemplary embodiment,cyclization can be through the formation of disulfide bridges.Alternatively, there may be multiple sites of chemical alteration alongthe GIP analog and hybrid polypeptide.

A number of pseudopeptide bonds have been described that in general donot affect peptide structure and biological activity. One example ofthis approach is to substitute retro-inverso pseudopeptide bonds(“Biologically active retroinverso analogues of thymopentin”, Sisto A.et al in Rivier, J. E. and Marshall, G. R. (eds) “Peptides, Chemistry,Structure and Biology”, Escom, Leiden (1990), pp. 722-773) and Dalpozzo,et al. (1993), Int. J. Peptide Protein Res., 41:561-566, incorporatedherein by reference). According to this modification, the amino acidsequences of the peptides may be identical to the sequences of a GIPdescribed herein, except that one or more of the peptide bonds arereplaced by a retro-inverso pseudopeptide bond. Preferably the mostN-terminal peptide bond is substituted, since such a substitution willconfer resistance to proteolysis by exopeptidases acting on theN-terminus. Further modifications also can be made by replacing chemicalgroups of the amino acids with other chemical groups of similarstructure. Another suitable pseudopeptide bond that is known to enhancestability to enzymatic cleavage with no or little loss of biologicalactivity is the reduced isostere pseudopeptide bond (Couder, et al.(1993), Int. J. Peptide Protein Res., 41:181-184, incorporated herein byreference in its entirety).

Thus, the amino acid sequences of these peptides may be identical to thesequences of a novel GIP analog and hybrid peptide, except that one ormore of the peptide bonds are replaced by an isostere pseudopeptidebond. Preferably the most N-terminal peptide bond is substituted, sincesuch a substitution would confer resistance to proteolysis byexopeptidases acting on the N-terminus. The synthesis of peptides withone or more reduced isostere pseudopeptide bonds is known in the art(Couder, et al. (1993), cited above). Other examples include theintroduction of ketomethylene or methylsulfide bonds to replace peptidebonds.

In another embodiment the bond between the second and third residuesthat is a target for cleavage by DPP-IV is replaced to apeptidase-resistant bond as disclosed herein.

Peptoid derivatives of GIP analog and hybrid peptides represent anotherclass of peptide mimetics that retain the important structuraldeterminants for biological activity, yet eliminate the peptide bonds,thereby conferring resistance to proteolysis (Simon, et al., Proc. Natl.Acad. Sci. USA, 89:9367-9371 (1992), incorporated herein by reference inits entirety). Peptoids are oligomers of N-substituted glycines. Anumber of N-alkyl groups have been described, each corresponding to theside chain of a natural amino acid (Simon, et al. (1992), cited above).Some or all of the amino acids of the GIP peptides may be replaced withthe N-substituted glycine corresponding to the replaced amino acid.

In one embodiment the novel GIP analog or hybrid polypeptides includecombinations of the above-described modifications, i.e., deletion,insertion, and substitution.

Also included within the scope of the invention are GIP analog or hybridpolypeptides of the formulas wherein the indicated amino acid residue ischemical modified or derivitized (e.g., through fatty acidderivatization, PEGylation, amidation, glycolization, etc.). Exemplaryembodiments include derivatization of a lysine residue, particularly atposition 16 or 30. Also contemplated within the scope of the inventionare D-amino acid residues of the indicated amino acids. In anotherembodiment, exemplary GIP analog or hybrid polypeptides include thepolypeptides of the formulas with internal deletions, particularly inareas not corresponding to the active sites as described herein.

Exemplary GIP analog or hybrid polypeptides comprising substitutions ofunnatural amino acids. Exemplary derivatives of the GIP analog or hybridpolypeptides of the invention include polymer-conjugated GIP analog orhybrid polypeptides, wherein the GIP analog or hybrid polypeptideincludes any of the above-described insertions, deletions,substitutions, or combinations thereof, and the polymer molecule isconjugated at a lysine residue. Thus in one embodiment, the GIP analogor GIP-containing hybrid is a derivative or substitution of themethionine at position 14 and having a longer duration of actioncompared to human GIP or to the patent analog. For example, anoctyl-glycine at the methionine position 14, as in 0601GIP4755,increases the duration of action of the compound in vivo. Duration ofaction was increased to at least 4 hours by this modification.Accordingly, in one embodiment are GIP analog and hybrid polypeptidesconjugated at this position to one or more water soluble polymermolecules, such as polyethylene glycol (“PEG”) or fatty acid chain ofvarious lengths (e.g., stearyl, palmitoyl, octanoyl, etc.), or by theaddition of polyamino acids, such as poly-his, poly-arg, poly-lys,poly-glu and poly-ala. Modifications to the polypeptides can alsoinclude small molecule substituents, such as short alkyls andconstrained alkyls (e.g., branched, cyclic, fused, adamantyl), andaromatic groups.

Further specifically envisioned are D-Ala2 variants of each GIP sequenceherein (e.g., see tables). In yet other embodiments envisioned arevariants of each of the above sequences where the GIP portion ismodified by one, two or three modifications as described herein.Exemplary modifications are those at the first, second or thirdN-terminal amino acid of GIP that impart DPP-IV resistance superior tothat of native GIP. In yet a further embodiment the novel GIP compoundscomprise a C-terminal amide.

In a further embodiment the novel GIP analog or a GIP hybrid comprises ahalf-life at least twice that of human GIP(1-30)amide. Further thehalf-life can be at least 6 hours.

In another embodiment is a pharmaceutically acceptable salt of a novelGIP analog or hybrid. The novel GIP analogs and hybrids can beformulated in a composition comprising a pharmaceutically acceptablecarrier.

In one embodiment an analog of exenatide with leucine substituted forMet at position 14 is used either as a hybrid component or in adjuncttherapy with a GIP hybrid:

(SEQ ID NO: 286) HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPPS-NH2.

In one embodiment, the GIP analog or hybrid polypeptides of theinvention retain at least about 25%, preferably about 30%, 40%, 50%,60%, 70%, 80%, 90%, 95%, 98%, or 99% percent of the biological activityof native human GIP with regard to glucose lowering. In anotherembodiment, the GIP analog or hybrid polypeptides of the inventionexhibit improved GIP agonist activity. In one embodiment, the GIP analogor hybrid polypeptides of the invention exhibits at least about 110%,125%, 130%, 140%, 150%, 200%, or more of the biological activity ofnative human GIP. Conversely, the novel GIP analog or hybrids can beantagonists.

Exemplary GIP analog or hybrid polypeptide are those having a potencywhich is equal to or greater than the potency of GIP(1-42) or GIP(1-30)in that same assay. Alternatively, exemplary GIP analog or hybridpolypeptides of the invention may exhibit improved ease of manufacture,stability, and/or ease of formulation, as compared to GIP(1-42) orGIP(1-30).

It is also contemplated that the novel GIP analogs of the invention, aswell as GIP analogs, can be administered with agents such as smallmolecules or antibodies that are agonists or antagonists, as may be thecase, for the peptide hormones and growth factors mentioned herein.

In further embodiments and uses of the GIP hybrids having thenaturally-occurring C-terminal amino acid sequence of exendin-4,particularly PSSGAPPPS (SEQ ID NO: 1) sequence, described herein,specifically excluded are those having a modification at the “P′1”position as described in WO2004/103390.

Further examples of the analog and hybrid polypeptides of the presentinvention are provided in the Sequence Listing, Tables and in theExamples section.

Further Uses of Hybrid Polypeptides in the Treatment or PreventionDisease Conditions or Disorders.

Metabolic diseases and disorders take on many forms, including obesity,diabetes, dyslipidemia, insulin resistance, cellular apoptosis, etc.Obesity and its associated disorders are common and very serious publichealth problems in the United States and throughout the world. Upperbody obesity is the strongest risk factor known for type 2 diabetesmellitus, and is a strong risk factor for cardiovascular disease.Obesity is a recognized risk factor for hypertension, atherosclerosis,congestive heart failure, stroke, gallbladder disease, osteoarthritis,sleep apnea, reproductive disorders such as polycystic ovarian syndrome,cancers of the breast, prostate, and colon, and increased incidence ofcomplications of general anesthesia (see, e.g., Kopelman, Nature 404:635-43 (2000)). It reduces life-span and carries a serious risk ofco-morbidities above, as well disorders such as infections, varicoseveins, acanthosis nigricans, eczema, exercise intolerance, insulinresistance, hypertension hypercholesterolemia, cholelithiasis,orthopedic injury, and thromboembolic disease (Rissanen et al., Br. Med.J. 301: 835-7 (1990)). Obesity is also a risk factor for the group ofconditions called insulin resistance syndrome, or “Syndrome X.” Recentestimate for the medical cost of obesity and associated disorders is$150 billion worldwide. The pathogenesis of obesity is believed to bemultifactorial but the basic problem is that in obese subjects nutrientavailability and energy expenditure do not come into balance until thereis excess adipose tissue. Obesity is currently a poorly treatable,chronic, essentially intractable metabolic disorder. A therapeutic druguseful in weight reduction of obese persons could have a profoundbeneficial effect on their health.

Diabetes is a disorder of carbohydrate metabolism characterized byhyperglycemia and glucosuria resulting from insufficient production orutilization of insulin. Diabetes severely affects the quality of life oflarge parts of the populations in developed countries. Insufficientproduction of insulin is characterized as type 1 diabetes andinsufficient utilization of insulin is type 2 diabetes. However, it isnow widely recognized that there are many distinct diabetes relateddiseases which have their onset long before patients are diagnosed ashaving overt diabetes. Also, the effects from the suboptimal control ofglucose metabolism in diabetes gives rise to a wide spectrum of relatedlipid and cardiovascular disorders.

Dyslipidemia, or abnormal levels of lipoproteins in blood plasma, is afrequent occurrence among diabetics. Dyslipidemia is typicallycharacterized by elevated plasma triglycerides, low HDL (High DensityLipoprotein) cholesterol, normal to elevated levels of LDL (Low DensityLipoprotein) cholesterol and increased levels of small dense, LDL (LowDensity Lipoprotein) particles in the blood. Dyslipidemia is one of themain contributors to the increased incidence of coronary events anddeaths among diabetic subjects. Epidemiological studies have confirmedthis by showing a several-fold increase in coronary deaths amongdiabetic subjects when compared with non-diabetic subjects. Severallipoprotein abnormalities have been described among diabetic subjects.

Insulin resistance is the diminished ability of insulin to exert itsbiologically action across a broad range of concentrations. In insulinresistance, the body secretes abnormally high amounts of insulin tocompensate for this defect and a state of impaired glucose tolerancedevelops. Failing to compensate for the defective insulin action, theplasma glucose concentration inevitable rises, resulting in the clinicalstate of diabetes. It is being recognized that insulin resistance andrelative hyperinsulinemia have a contributory role in obesity,hypertension, atherosclerosis and type 2 diabetes. The association ofinsulin resistance with obesity, hypertension and angina has beendescribed as a syndrome, Syndrome X, having insulin resistance as thecommon pathogenic link.

Apoptosis is an active process of cellular self-destruction that isregulated by extrinsic and intrinsic signals occurring during normaldevelopment. It is well documented that apoptosis plays a key role inregulation of pancreatic endocrine beta cells. There is increasingevidence that in adult mammals the beta-cell mass is subject to dynamicchanges to adapt insulin production for maintaining euglycemia inparticular conditions, such as pregnancy and obesity. The control ofbeta cell mass depends on a subtle balance between cell proliferation,growth and programmed cell death (apoptosis). A disturbance of thisbalance may lead to impairment of glucose homeostasis. For example, itis noteworthy that glucose intolerance develops with aging when betacell replication rates are reduced and human autopsy studies repeatedlyshowed a 40-60% reduction of beta cell mass in patients withnon-insulin-dependent-diabetes mellitus compared with nondiabeticsubjects. It is generally agreed that insulin resistance is aninvariable accompaniment of obesity but that normoglycemia is maintainedby compensatory hyperinsulinemia until the beta cells become unable tomeet the increased demand for insulin, at which point type 2 diabetesbegins.

Attempts to treat the multiple abnormalities associated with diabeteshave prompted for the administration of several anti-diabeticmedicaments in order to address these abnormalities in the differentpatients. However, the GIP analogs, GIP hybrids and GIPR agonists asdiscussed herein find use, when administered at therapeuticallyeffective amounts, either in monotherapy or in adjunct therapy, intreating or preventing these and other diseases and conditions discussedthroughout.

Gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1)are gut peptide hormones that exert potent glucoregulatory actionthrough their glucose-dependant stimulation of insulin secretion.Studies have shown that GIP and GLP-1 act in concert to exert theirincretin effects [1-3]. Consequently, these incretin hormones haveattracted considerable interest as potential anti-diabetic agents withreduced risk for hypoglycemia. Whereas GLP-1, GLP-1 analogs and mimeticssuch as exenatide have been shown to be efficacious in controllingglucose levels in type 2 diabetic patients, the insulinotropic effect ofGIP is significantly reduced in diabetic subjects, compared to normalindividuals [4-6]. The preservation of insulinotropic action of GLP-1but not of GIP in the same diabetic subjects suggests that GIP signaltransduction is impaired in type 2 diabetes. Reduced GIP receptorexpression in pancreatic beta cells has been proposed to contribute tooverall reduced incretin effects in diabetic subjects [7]. Thishypothesis is supported by rodent studies showing decreased GIP receptorexpression on beta-cells in diabetic fatty Zucker rats and reduced GIPincretin effect seen in first-degree relatives of patients with type 2diabetes [8-9]. However, a recent study has shown significant increasesin plasma insulin levels in type 2 diabetics to a bolus intravenousadministration of GIP, that is in marked contrast to weak increase ininsulin secretion with continuous GIP infusion [10]. The similarrelative beta-cell sensitivity towards GIP bolus in type 2 diabeticpatients and healthy control subjects suggest that a specific GIPreceptor defect appears unlikely [10]. Rather, the differences ininsulin secretion after acute and during continuous GIP administrationindicate an impaired amplification of the late phase insulin response toglucose by GIP in type 2 diabetic patients, whereas the response in theearly phase is almost preserved [11-12]. While not to be bound bytheory, it is believed that while GIP's incretin effect is attenuatedduring persistent hyperglycemia, there is potential for GIP or itsanalogs to act with a similar potency in diabetic patients as theiraction in normal subjects once glucose control is improved in theseindividuals.

Amylin Pharmaceuticals, Inc. has conducted three pivotal clinicalstudies to evaluate the effects of exenatide in patients with type 2diabetes not achieving target blood glucose concentrations usingmetformin alone, sulfonylureas alone, or using a combination ofmetformin and a sulfonylurea. All three studies met the primary glucosecontrol endpoint as measured by HbA1c. The average reduction in HbA1cacross the Phase 3 program in patients completing the studies on thehighest dose of exenatide (10 μg twice daily) was approximately onepercent. Additionally, approximately 40 percent of these patientsachieved HbA 1c measurements of 7 percent or less. The clinical dataindicate that despite the efficacy of exenatide, some diabeticindividuals fail to attain normal glucose concentrations.

In an embodiment of the invention, reduction of hyperglycemia (e.g., asby exenatide) in treated diabetic patients sets the stage for GIPintervention. Whereas the chronic hyperglycemic condition in type 2diabetes patients attenuates GIP's insulinotropic response, improvedglycemic control resulting from exenatide treatment would restoreresponsiveness of the pancreatic beta-cell to GIP stimulation. Thereforeadjunct therapy, e.g. co-administration, GIP phybrids, ofpharmacological doses of GIP or novel GIP analog or hybrids withexenatide (or other glucose lowering agents or agents or methods thatreduce or inhibit gastric emptying) will lead to desired normoglycemiain diabetic patients or patients suffering from conditions associatedwith elevated glucose. Of note, GIP lacks the gastric emptying effect ofGLP-1 [13-14] that is a possible contributing factor to the incidence ofnausea during GLP-1 treatment and which limits the peptide's therapeuticwindow [15]. Thus, it should permit the use of higher GIP dosingregimens.

Since currently prescribed anti-diabetic agents (metformin,sulfonyureas, TZDs, etc) are able to achieve various degrees of glycemiccontrol, the combination of GIP or novel GIP analog or hybrids with anyof these therapies should also elicit an improved response that leads tonormalization of glucose levels.

Accordingly, in one embodiment the methods of the present invention arebased on the notion that patients can be primed for GIP therapy throughprior glucose lowering with other anti-diabetic agents, such as GLP-1, aGLP-1 analog or exendin-4 or other agents, e.g. metformin, sulfonyureas,thiazolidinediones (TZDs), pramlintide, insulin, acarbose, dipeptidylpeptidase (DPP-IV) inhibitors. DPP-IV inhibitors are well-known anddescribed for example in published application US20050004117, U.S. Pat.No. 6,710,040, and U.S. Pat. No. 6,645,995, which are incorporatedherein by reference for their compounds. As example of a sulfonylureas(SFUs), which acts on the pancreatic tissue to produce insulin, isGlimepiride.

Adjunct therapy of a metabolically stable GIP analog or hybrid or novelGIP analog or hybrid with exenatide (or other antidiabetics) willprovide for increased insulinotropic responses than either alone, inpatients with conditions associated with elevated glucose, such aspatients with type 2 diabetes. Such a treatment regimen leads tonormalization of glucose concentrations, improvement in beta-cellfunction, and through their trophic activity on the β cells slowsdisease progression to obviate or lesson the need for insulin therapy.

GIP hybrids of the invention can be useful for reducing food intake,reducing appetite, reducing caloric intake, inducing satiety, reducingnutrient availability, causing weight loss, affecting body composition,altering body energy content or energy expenditure, improving lipidprofile (including reducing LDL cholesterol and triglyceride levelsand/or changing HDL cholesterol levels), slowing gastrointestinalmotility, delay gastric emptying, moderating the postprandial bloodglucose excursions, preventing or inhibiting glucagon secretion, anddecreasing blood pressure. In one embodiment such GIP hybrids contain anexendin, GLP1, amylin and/or sCT portion.

Of particular interest as anti-obesity, weight reduction, foodreduction, metabolic rate increasing, and body fat reduction and/or fatredistribution hybrids are those GIP-containing hybrids that contain anexendin, amylin (e.g. amylin-sCT-amylin chimera), leptin or PYY (e.g.PYY-NPY chimera) family module that can effectively reduce food intake,change body composition, redistribute fat and/or reduce body weight. Inembodiments of particular interest for treating obesity and relateddiseases and conditions (body fat reduction) as discussed herein, areGIP hybrids comprising an exendin-4 or analog or derivative thereof, anamylin component such as pramlintide or an amylin-sCT-amylin chimera, anFN38 family member such as FN38 or an analog or derivative thereof, aPYY member such as a PYY-NPY chimera as described herein such as SEQ IDNos. 266, 437, 438, 439, 442, 462, 469, 470, 471 and 472 of US2006/013547A1 or the PYY-NPY chimera compound with the amino acidsequence Ile, Lys, Pro, Glu, His, Pro, Gly, Glu, Asp, Ala, Ser, Pro,Glu, Glu, Leu, Ala, Arg, Tyr, Tyr, Ala, Ser, Leu, Arg, Ala, Tyr, Ile,Asn, Leu, Ile, Thr, Arg, Gln, Arg, Tyr (SEQ ID NO:456), for example. Inanother embodiment, the GIP hybrid can have at least one, preferably twocomponents, which act on the CNS. Particular areas of the forebrain(telencephalonic- and diencephalonic-derived constituents of the brain)and hindbrain or brainstem (including the midbrain, pons and medulla)have been identified as being involved in controlling energy balance.Forebrain structures or nuclei residing in the hypothalamus involved infood intake and/or body weight modulation include, for example, thearcuate nucleus (ARC), the paraventricular nucleus (PVN), thedorsomedial hypothalamus (DMH), the ventromedial nucleus (VMH), and thelateral hypothalamus nucleus (LHA). Hindbrain structures or nucleiresiding in the brainstem involved in food intake and/or body weightmodulation include, for example, the nucleus of the solitary tract(NST), the area postrema (AP), and the lateral parabrachial nucleus(lPBN). Brainstem nuclei that control the elements of the consummatorymotor control system are likely controlled by primary or second orderprojections from brainstem regions like the NST, AP, and lPBN. It isnoteworthy that the AP, NST and lPBN have all been shown to(collectively and independently) possess their own integrativeabilities.

A variety of CNS-directed anti-obesity agents act upon these forebrainstructures residing in the hypothalamus involved in food intake and/orbody weight modulation. In addition, CNS-directed anti-obesity agentsact upon hindbrain structures residing in the brainstem involved in foodintake and/or body weight modulation. Examples of such anti-obesityagents are described herein. See the table below for further examples ofpeptide family modules that can be combined with a GIP compound to forman anti-obesity agent hybrid, and can be combined to form ananti-obesity hybrid with activity on both the forebrain and hindbrain.Such components include, for example, neuropeptide Y1 (NPY1) receptorantagonists, NPY5 receptor antagonists, leptin and leptin agonists,ciliary neurotrophic factor (CNTF) and CNTF agonists, peptide YY (PYY)and PYY agonists, exendin and exendin agonists, GLP-1 and GLP-1 agonist,ghrelin and ghrelin antagonists, cholecystokinin (CCK) and CCK agonists,and amylin and amylin agonists, including those described herein.Further peptide family components and clinical guidance can be found inapplicant's co-pending patent application PCT/US06/17529, which isincorporated herein by reference.

Individual anti-obesity targets and location Anti-obesity SignalingSystem CNS Region Food Intake Role agents Neuropeptide Y ForebrainIncreases intake NPY1 and (NPY) (ARC/PVN) NPY5 receptor antagonistsLeptin Forebrain (ARC) Decreases intake Leptin, or agonists Ciliaryneurotrophic Forebrain (ARC) Decreases intake CNTF factor (CNTF) PeptideYY (PYY) Forebrain (ARC) Decrease intake PYY(3-36) agonistsGlucagon-like Forebrain (PVN) Decrease intake Exenatide peptide-1(GLP-1) and other GLP-1 ligands, DPP-IV inhibitors Ghrelin Forebrain(ARC) Increase intake Ghrelin antagonists Cholecystokinin Hindbrain (AP)Decrease intake CCK (CCK) agonists Amylin Hindbrain (AP) Decrease intakeAmylin agonists, Pramlintide, amylin analogs Melanocortins ForebrainAgonists decrease MC4 (MC) (PVN/ARC) intake agonists

In certain embodiments, the GIP hybrid is an anti-obesity agent that caninclude one or more predominantly forebrain acting peptide familycomponents in addition to a GIP compound. In other embodiments, thehybrid is an anti-obesity agent that can include one or morepredominantly hindbrain acting anti-obesity agents. Exemplary peptidefamilies and components are an NPY1 receptor antagonist, an NPY5receptor antagonist, a leptin or a leptin agonist or analog, a CNTF, anNPY2 receptor agonist (e.g., a PYY(3-36) or a PYY(3-36) agonist), anexendin or an exendin agonist or analog, a GLP-1 or a GLP-1 agonist oranalog, a ghrelin antagonist, a CCK or a CCK agonist or analog, and anamylin or an amylin agonist or analog.

In certain embodiments, the GIP hybrid and method for it use include afirst component that predominantly targets the energy balance centers ofthe hypothalamus, such as the ARC, PVN, VM, and LH. In one embodimentthe GIP hybrid further contains one or more other peptide familycomponent that also target the hypothalamus but at a different locationor via a different mechanism of action than the first component. Whenthe GIP hybrid contains more than one other peptide family component andthese also target the hypothalamus, the more than one other peptidefamily components may target the same location via the same mechanism ofaction as each other, or they may target different locations and/ordifferent mechanisms of action. In another embodiment, the GIP hybridthen contains one or more other peptide family components that provideone or more additional beneficial therapeutic effects as desired,including an anti-obesity effect via a location or mechanism of actiondifferent than the first component and each other, control of bloodglucose, cardioprotection, and/or control of hypertension. In certainembodiments, the additional peptide family component is one thatpredominantly targets the energy balance centers of the hindbrain suchas the NST, the AP and the lPBN.

In certain embodiments, the GIP hybrid and method for it use include afirst component that predominantly targets the energy balance centers ofthe hindbrain such as the NST, the AP and the lPBN. In one embodimentthe GIP hybrid further contains one or more other peptide familycomponent that also target the hypothalamus but at a different locationor via a different mechanism of action than the first component and eachother. In another embodiment, the GIP hybrid then contains one or moreother peptide family components that provide one or more additionalbeneficial therapeutic effects as desired, including an anti-obesityeffect via a location or mechanism of action different than the firstcomponent and each other, control of blood glucose, cardioprotection,and/or control of hypertension. In certain embodiments, the additionalpeptide family component is one that predominantly targets the energybalance centers of the hypothalamus, such as the ARC, PVN, VM, and LH.

As used herein, an anti-obesity agent that “acts on a forebrainstructure involved in food intake and/or body weight modulation”stimulates or suppresses activity of a particular region, e.g.,particular nuclei and/or neuronal circuits, in the forebrain. Thisforebrain stimulation or suppression leads to a reduction in nutrientavailability to the body. An anti-obesity agent that “acts on ahindbrain structure involved in food intake and/or body weightmodulation” stimulates or suppresses activity of a particular region,e.g., particular nuclei and/or neuronal circuits, in the hindbrain. Thishindbrain stimulation or suppression results in a reduction in nutrientavailability to the body.

In another aspect, methods for reducing fat mass by increasing themetabolic rate in a subject are provided, where the methods compriseadministering an anti-obesity GIP hybrid in amounts effective to reducefat mass by increasing the subject's metabolic rate. Fat mass can beexpressed as a percentage of the total body mass. In some aspects, thefat mass is reduced by at least 1%, at least 5%, at least 10%, at least15%, at least 20%, or at least 25% over the course of treatment. In oneaspect, the subject's lean mass is not decreased over the course of thetreatment. In another aspect, the subject's lean mass is maintained orincreased over the course of the treatment. In another aspect, thesubject is on a reduced calorie diet or restricted diet. By “reducedcalorie diet” is meant that the subject is ingesting fewer calories perday than compared to the same subject's normal diet. In one instance,the subject is consuming at least 50 fewer calories per day. In otherinstances, the subject is consuming at least 100, 150, 200, 250, 300,400, 500, 600, 700, 800, 900, or 1000 fewer calories per day.

In one embodiment, methods of use in altering fat distribution, reducingfat mass, or both in a subject are provided. Accordingly, subjects forwhom altering body composition is of benefit can also benefit from thepresent methods. Altered body composition, as intended herein, includesloss or maintenance of body fat, with minimization of loss, maintenance,or gain of lean body mass. In such situations, weight may increase aswell as decrease. Accordingly, subjects may be lean, overweight, orobese as these terms are generally used in the art. Methods provided mayalso include reducing fat in non-adipose tissue while sparing lean mass.Uses for this method include treating diseases such as nonalcoholicsteatohepatitis (NASH) or lipodystrophy.

In one embodiment, a method for altering the fat distribution in asubject is provided where the method comprises administering ananti-obesity GIP hybrid in amounts effective to alter fat distributionin the subject. In one aspect, the alteration results from an increasedmetabolism of visceral or ectopic fat, or both in the subject. By “fatdistribution” is meant the location of fat deposits in the body. Suchlocations of fat deposition include, for example, subcutaneous, visceraland ectopic fat depots. By “subcutaneous fat” is meant the deposit oflipids just below the skin's surface. The amount of subcutaneous fat ina subject can be measured using any method available for the measurementof subcutaneous fat. Methods of measuring subcutaneous fat are known inthe art, for example, those described in U.S. Pat. No. 6,530,886, theentirety of which is incorporated herein by reference. By “ectopic fatstorage” is meant lipid deposits within and around tissues and organsthat constitute the lean body mass (e.g., skeletal muscle, heart, liver,pancreas, kidneys, blood vessels). Generally, ectopic fat storage is anaccumulation of lipids outside classical adipose tissue depots in thebody. By “visceral fat” is meant the deposit of fat as intra-abdominaladipose tissue. Visceral fat surrounds vital organs and can bemetabolized by the liver to produce blood cholesterol. Visceral fat hasbeen associated with increased risks of conditions such as polycysticovary syndrome, metabolic syndrome and cardiovascular diseases. In someembodiments, the method involves the metabolism of visceral or ectopicfat or both at a rate of at least about 5%, 10%, 15%, 20%, 25%, 30%,40%, or 50% greater than for subcutaneous fat. In one aspect, themethods result in a favorable fat distribution. In one embodiment,favorable fat distribution is an increased ratio of subcutaneous fat tovisceral fat, ectopic fat, or both. In one aspect, the method involvesan increase in lean body mass, for example, as a result of an increasein muscle cell mass.

In another embodiment, methods for reducing the amount of subcutaneousfat in a subject are provided, wherein the method comprisesadministering, to a subject in need thereof, an anti-obesity GIP hybridin amounts effective to reduce the amount of subcutaneous fat in thesubject. In one instance, the amount of subcutaneous fat is reduced in asubject by at least about 5%. In other instances, the amount ofsubcutaneous fat is reduced by at least about 10%, 15%, 20%, 25%, 30%40%, or 50% compared to the subject prior to administration of theanti-obesity hybrid.

The methods described herein can be used to reduce the amount ofvisceral fat in a subject. In one instance, the visceral fat is reducedin a subject by at least about 5%. In other instances, the visceral fatis reduced in the subject by at least about 10%, 15%, 20%, 25%, 30% 40%,or 50% compared to the subject prior to administration of theanti-obesity GIP hybrid. Visceral fat can be measured through any meansavailable to determine the amount of visceral fat in a subject. Suchmethods include, for example, abdominal tomography by means of CTscanning and MRI. Other methods for determining visceral fat aredescribed, for example, in U.S. Pat. Nos. 6,864,415, 6,850,797, and6,487,445.

In one embodiment, a method for preventing the accumulation of ectopicfat or reducing the amount of ectopic fat in a subject is provided,wherein the method comprises administering, to a subject in needthereof, an anti-obesity GIP hybrid in amounts effective to preventaccumulation of ectopic fat or to reduce the amount of ectopic fat inthe subject. In one instance, the amount of ectopic fat is reduced in asubject by at least about 5% compared to the subject prior toadministration of the anti-obesity hybrid. In other instances, theamount of ectopic fat is reduced in a subject by at least about 10%, orby at least about 15%, 20%, 25%, 30% 40%, or 50%. Alternatively, theamount of ectopic fat is proportionally reduced 5%, 10%, 15%, 20%, 25%,30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% in comparison to subcutaneousfat in a subject. Ectopic fat can be measured in a subject using anymethod available for measuring ectopic fat.

In another embodiment, methods are provided for producing a morefavorable fat distribution in a subject, where the method comprisesadministering to a subject a GIP hybrid that is effective as ananti-obesity agent in an amount effective to produce a favorable fatdistribution. In one embodiment, administration of an anti-obesity GIPhybrid reduces the amount of visceral fat or ectopic fat, or both, in asubject. In one embodiment is administered an anti-obesity hybrid thatcomprises at least one family module that acts upon forebrain structuresinvolved in food intake or body weight modulation or both in combinationwith at least one family module that acts upon hindbrain structuresinvolved in food intake or body weight modulation or both. In oneembodiment, the methods preferentially reduce the amount of visceral orectopic fat, or a combination of both, over the reduction insubcutaneous fat. Such methods result in a higher ratio of subcutaneousfat to visceral fat or ectopic fat. Such improved ratios may result in areduced risk of the development of cardiovascular diseases, polycysticovary syndrome, metabolic syndrome, or any combinations thereof. In oneembodiment, ectopic or visceral fat is metabolized at a rate 5% greaterthan subcutaneous fat. In other embodiments, ectopic or visceral fat ismetabolized at a rate at least 10% 15%, 20%, 25%, 30% 50%, 60%, 70%,80%, 90%, or 100% greater than subcutaneous fat.

Of particular interest for anti-obesity, body weight and fat compositionrelated treatments as discussed herein are GIP hybrids containing anexendin, amylin (e.g. amylin-sCT-amylin chimera), leptin and/or PPF(e.g. PYY analogs or PPY/NPY chimera) family modules. In yet a furtherembodiment a GIP hybrid contains at least two of these peptide familymodules. The GIP hybrid can be administered either alone or incombination with a second anti-obesity agent such as an amylin. Leptin,PYY or exendin family peptide.

In still another aspect, provided is a method for the administration ofa therapeutically effective amount of a GIP hybrid effective as ananti-obesity agent administered in combination withglucocorticosteroids. Glucocorticosteroids have the adverse effect ofincreasing fat mass and decreasing lean mass. Accordingly, it iscontemplated that the anti-obesity agent combination can be used inconjunction with glucocorticosteroids under conditions whereglucocorticosteroid use is beneficial, in order to counteract theadverse effect of the glucocoriticosteroid.

As discussed herein, a GIP hybrid of the invention can be administeredseparately or together with one or more other agents in order to obtainadditional benefits or to enhance the effect of either the hybrid or theother agent. For example, an anti-obesity GIP hybrid can be administeredwith an anti-obesity agent or a cardioprotective or anti-hypertensionagent, depending on the risk factors pertinent to the subject in need oftreatment and desired treatment outcome. Exemplary anti-obesity agentsfor administration (either separately or mixed; either prior to,concomitantly or after) with a hybrid include serotonin (5HT) transportinhibitors, including, but not limited to, paroxetine, fluoxetine,fenfluramine, fluvoxamine, sertraline, and imipramine Anti-obesityagents also include selective serotonin reuptake inhibitors, including,but not limited to dexfenfluramine, fluoxetine, sibutramine (e.g.,MERIDIA®) and those described in U.S. Pat. No. 6,365,633 and PCT PatentApplication Publication Nos. WO 01/27060 and WO 01/162341, which arehereby incorporated by reference in their entirety. Such 5HT transportinhibitors and serotonin reuptake inhibitors, analogs, derivatives,preparations, formulations, pharmaceutical compositions, doses, andadministration routes have previously been described.

Anti-obesity agents also include selective serotonin agonists andselective 5-HT2C receptor agonists, including, but not limited to, U.S.Pat. No. 3,914,250; and PCT Application Publication Nos. WO 02/36596, WO02/48124, WO 02/10169, WO 01/66548, WO 02/44152; WO 02/51844, WO02/40456, and WO 02/40457, which are hereby incorporated by reference intheir entirety. Such selective serotonin agonists and 5-HT2C receptoragonists, compositions containing such agonists, and administrationroutes appropriate for use in the methods provided are known in the art.See, for example, Halford et al. (2005) Curr. Drug Targets 6:201-213 andWeintraub et al. (1984) Arch. Intern. Med. 144:1143-1148.

Anti-obesity agents also include antagonists/inverse agonists of thecentral cannabinoid receptors (the CB-1 receptors), including, but notlimited to, rimonabant (Sanofi Synthelabo), and SR-147778 (SanofiSynthelabo). CB-1 antagonists/inverse agonsits, derivatives,preparations, formulations, pharmaceutical compositions, doses, andadministration routes have previously been described, for example, inU.S. Pat. Nos. 6,344,474, 6,028,084, 5,747,524, 5,596,106, 5,532,237,4,973,587, 5,013,837, 5,081,122, 5,112,820, 5,292,736, 5,624,941;European Patent Application Nos. EP-656 354 and EP-658546; and PCTApplication Publication Nos. WO 96/33159, WO 98/33765, WO98/43636,WO98/43635, WO 01/09120, WO98/31227, WO98/41519, WO98/37061, WO00/10967,WO00/10968, WO97/29079, WO99/02499, WO 01/58869, and WO 02/076949, whichare hereby incorporated by reference in their entirety.

Anti-obesity agents also include melanocortins and melanocortinagonists. The receptor MC4R appears to play a role in energy balance andobesity. See, for example, Anderson et al., Expert Opin. Ther. Patents11:1583-1592 (2001), Speake et al., Expert Opin. Ther. Patents12:1631-1638 (2002), Bednarek et al., Expert Opin. Ther. Patents14:327-336 (2004). Melanocortin agonists, including, but not limited to,MC4R agonists, and composition containing such agonist appropriate foruse in the methods provided are known in the art. MCR agonists, MC4Ragonists, derivatives, preparations, formulation, pharmaceuticalcompositions, doses, and administration routes have previously beendescribed, for example, in the following PCT patent applications, whichare hereby incorporated by reference in their entirety: WO 03/007949, WO02/068388, WO 02/068387, WO 02/067869, WO 03/040117, WO 03/066587, WO03/068738, WO 03/094918, and WO 03/031410.

Anti-obesity agents also include metabotropic glutamate subtype 5receptor (mGluR5) antagonists, including, but are not limited to,compounds such as 2-methyl-6-(phenylethynyl)-pyridine (MPEP) and(3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine) (MTEP) and thosecompounds described in Anderson et al. J. Eur. J. Pharmacol. 473:35-40(2003); Cosford et al. Bioorg. Med. Chem. Lett. 13(3):351-4 (2003); andAnderson et al. J. Pharmacol. Exp. Ther. 303:1044-1051 (2002).

Anti-obesity agents also include topiramate (TOPIMAX® (Ortho McNeilPharmaceuticals), indicated as an anti-convulsant and ananti-convulsant, but also shown to increase weight loss.

Anti-obesity agents also include neuropeptide Y1 (NPY1) antagonists andNPY5 antagonists. NPY1 and NPY5 antagonists are known in the art. See,for example Duhault et al. (2000) Can. J. Physiol. Pharm. 78:173-185,and U.S. Pat. Nos. 6,124,331, 6,214,853, and 6,340,683. NPY1 and NPY5antagonists, derivatives, preparations, formulation, pharmaceuticalcompositions, doses, and administration routes have previously beendescribed. NPY1 antagonists useful in the compositions and methodsprovided include: U.S. Pat. No. 6,001,836; and PCT ApplicationPublication Nos. WO 96/14307, WO 01/23387, WO 99/51600, WO 01/85690, WO01/85098, WO 01/85173, and WO 01/89528, which are hereby incorporated byreference in their entirety. NPY5 antagonists useful in compositions andmethods of use provided herein, include, but are not limited to, thecompounds described in: U.S. Pat. Nos. 6,140,354, 6,191,160, 6,258,837,6,313,298, 6,337,332, 6,329,395, 6,340,683, 6,326,375, and 6,335,345;European Patent Nos. EP-01010691, and EP-01044970; and PCT PatentPublication Nos. WO 97/19682, WO 97/20820, WO 97/20821, WO 97/20822, WO97/20823, WO 98/27063, WO 00/64880, WO 00/68197, WO 00/69849, WO01/09120, WO 01/85714, WO 01/85730, WO 01/07409, WO 01/02379, WO01/02379, WO 01/23388, WO,01/23389, WO 01/44201, WO 01/62737, WO01/62738, WO 01/09120, WO 02/22592, WO 0248152, WO 02/49648, and WO01/14376.

Anti-obesity agents also include melanin-concentrating hormone (MCH)antagonists including melanin-concentrating hormone 1 receptor (MCH1R)antagonists, such as T-226296 (Takeda) and melanin-concentrating hormone2 receptor (MCH2R) antagonists. MCH receptor antagonists, derivatives,preparations, formulation, pharmaceutical compositions, doses, andadministration routes have previously been described, for example, inU.S. Patent Application Publication Nos. 2005/0009815, 2005/0026915,2004/0152742, 2004/0209865; PCT Patent Application Publication Nos. WO01/82925, WO 01/87834, WO 02/06245, WO 02/04433, and WO 02/51809; andJapanese Patent Application No. JP 13226269, which are herebyincorporated by reference in their entirety.

Anti-obesity agents also include opioid antagonists, including, but notlimited to those described in PCT Application No. WO 00/21509. Specificopioid antagonists useful in compositions and methods of use providedherein include, but are not limited to, nalmefene (REVEX®),3-methoxynaltrexone naloxone, naltrexone, naloxonazine,beta-funaltrexamine, delta 1 ([D-Ala2,Leu5,Cys6]-enkephalin (DALCE),naltrindole isothiocyanate, and nor-binaltorphamine

Anti-obesity agents also include orexin antagonists, including, but notlimited to, those described in PCT Patent Application Nos. WO 01/96302,WO 01/68609, WO 02/51232, and WO 02/51838. Specific orexin antagonistsuseful in compositions and methods of use provided include, but are notlimited to, SB-334867-A.

Anti-obesity agents also include neuropeptide Y2 (NPY2) agonists,including, but not limited to, compounds such as PYY3-36 (e.g.,Batterham et al. (2003) Nature 418:650-654), NPY3-36 and other Y2agonists such as N acetyl [Leu(28,31)] NPY 24-36 (White-Smith et al.(1999) Neuropeptides 33:526-533, TASP-V (Malis et al. (1999) Br. J.Pharmacol. 126:989-996), cyclo-(28/32)-Ac-[Lys28-Glu32]-(25-36)-pNPY(Cabrele et al. (2000) J. Pept. Sci. 6:97-122), which can be either ahybrid component as discussed or administered separately. Anti-obesityagents provided also include neuropeptide Y4 (NPY4) agonists including,but not limited to, compounds such as pancreatic peptide (PP) (e.g.,Batterham et al. (2003) J. Clin. Endocrinol. Metab. 88:3989-3992) andother Y4 agonists such as 1229U91 (Raposinho et al. (2000)Neuroendocrinology 71:2-7). NPY2 agonists and NPY4 agonsits,derivatives, preparations, formulations, pharmaceutical compositions,doses, and administration routes have previously been described, forexample, in U.S. Pat. Publication No. 2002/0141985 and PCT ApplicationPublication No. WO 2005/077094.

Anti-obesity agents also include histamine 3 (H3) antagonist/inverseagonists including but not limited to, those described in PCTApplication No. WO 02/15905, O-[3-(1H-imidazol-4-yl)propanol]carbamates(Kiec-Kononowicz et al. (2000) Pharmazie 55:349-355),piperidine-containing histamine H3-receptor antagonists (Lazewska et al.(2001) Pharmazie 56:927-932), benzophenone derivatives and relatedcompounds (Sasse et al. (2001) Arch. Pharm.(Weinheim) 334:45-52),substituted N-phenylcarbamates (Reidemeister et al. (2000) Pharmazie55:83-86), and proxifan derivatives (Sasse et al. (2000) J. Med. Chem.43:3335-3343). Specific H3 antagonists/inverse agonists useful incompositions and methods of use provided include, but are not limitedto, thioperamide, 3-(1H-imidazol-4-yl)propyl N-(4-pentenyl)carbamate,clobenpropit, iodophenpropit, imoproxifan, and GT2394 (Gliatech).

Anti-obesity agents also include cholecystokinin (CCK) and CCK agonists.Cholecystokinin-A (CCK-A) agonists of use include, but are not limitedto, those described in U.S. Pat. No. 5,739,106. Specific CCK-A agonistsinclude, but are not limited to, AR-R 15849, GI 181771, JMV-180,A-71378, A-71623 and SR146131.

Anti-obesity agents also include ghrelin antagonists such as thosedescribed in PCT Application Publication Nos. WO 01/87335 and WO02/08250. Ghrelin antagonists are also known as GHS (growth hormonesecretagogue receptor) antagonists. The compositions and methodsprovided therefore contemplate the use GHS antagonists in place ofghrelin antagonists.

Anti-obesity agents include obestatin and obestatin analogs andagonists. Obestatin is a peptide derived from the same precursor fromwhich ghrelin is derived, preproghrelin. See, for example, Zhang et al.(2005) Science 310: 996-999; Nogueiras et al. (2005) Science 310:985-986; Pan et al. (2006) Peptides 27:911-916. In contrast to theactivity of ghrelin, obestatin appears to act as an anorexic hormone bydecreasing food intake, gastric emptying activities, jejunal motility,and body weight gain. Obestatin peptides of use include, but are notlimited to those described in Zhang et al. (2005) Science 310: 996-999.

And the amylinomimetics, e.g. pramlintide, amylin-sCT-amylin, incretins,e.g. exendin-4, and PYY analogs, are anti-obesity agents that also canbe administered as an anti-obesity agents with a GIP hybrid. Forexample, a GIP-leptin hybrid may be administered with exendin-4, a PYYanalog, and/or an amylin analog.

Thus, in certain embodiments, the hybrids of the invention are usefulfor treating or preventing conditions or disorders which can bealleviated by reducing nutrient availability comprising administering tosaid subject a therapeutically or prophylactically effective amount of acompound of the invention. Such conditions and disorders include, butare not limited to, eating disorders, insulin-resistance, obesity,abnormal postprandial hyperglycemia, diabetes of any kind, includingType I, Type II, and gestational diabetes, Metabolic Syndrome, DumpingSyndrome, hypertension, dyslipidemia, cardiovascular disease,hyperlipidemia, sleep apnea, cancer, pulmonary hypertension,cholecystitis, and osteoarthritis. In one embodiment such hybridscontain an exendin, GLP1, amylin and/or sCT portion.

Non-limiting examples of a cardiovascular condition or disease arehypertension, myocardial ischemia, and myocardial reperfusion. Compoundsof the invention may also be useful in treating or preventing otherconditions associated with obesity including stroke, cancer (e.g.,endometrial, breast, prostate, and colon cancer), gallbladder disease,sleep apnea, reduced fertility, and osteoarthritis, (see Lyznicki et al,Am. Fam. Phys. 63:2185, 2001). In other embodiments, compounds of theinvention may be used to alter body composition for aesthetic reasons,to enhance one's physical capabilities, or to produce a leaner meatsource. Hybrids are useful to change body composition by decreasing fatwithout significant decrease in muscle mass, thus producing a desirableloss of body fat while preserving lean body mass. In one embodiment suchhybrids contain an exendin, GLP1, amylin and/or sCT portion.

In another aspect of the invention, methods for treating or preventingobesity are provided, wherein the method comprises administering atherapeutically or prophylactically effective amount of a hybridpolypeptide to a subject in need thereof. In a exemplary embodiment, thesubject is an obese or overweight subject. While “obesity” is generallydefined as a body mass index over 30, for purposes of this disclosure,any subject, including those with a body mass index of less than 30, whoneeds or wishes to reduce body weight is included in the scope of“obese.” Subjects who are insulin resistant, glucose intolerant, or haveany form of diabetes mellitus (e.g., type 1, 2 or gestational diabetes)can benefit from these hybrids. In one embodiment such GIP hybridscontain an exendin, PYY, GLP1, amylin and/or sCT portion.

In other aspects of the invention, methods of reducing food intake,reducing nutrient availability, causing weight loss, affecting bodycomposition, and altering body energy content or increasing energyexpenditure, treating diabetes mellitus, and improving lipid profile(including reducing LDL cholesterol and triglyceride levels and/orchanging HDL cholesterol levels) are provided, wherein the methodscomprise administering to a subject an effective amount of a hybridpolypeptide of the invention. In a exemplary embodiment, the methods ofthe invention are used to treat or prevent conditions or disorders whichcan be alleviated by reducing nutrient availability in a subject in needthereof, comprising administering to said subject a therapeutically orprophylactically effective amount of a hybrid polypeptide of theinvention. Such conditions and disorders include, but are not limitedto, hypertension, dyslipidemia, cardiovascular disease, eatingdisorders, insulin-resistance, obesity, and diabetes mellitus of anykind. In one embodiment such hybrids contain an exendin, PYY, GLP1,amylin and/or sCT portion.

In one embodiment in which a PPF or PYY family member comprises aGIP-hybrid component, and without intending to be limited by theory, itis believed that the effects of such peripherally-administered GIPhybrid polypeptides in the reduction of food intake, in the delay ofgastric emptying, in the reduction of nutrient availability, and in thecausation of weight loss are determined by interactions with one or moreunique receptor classes in, or similar to, those in the PP family. Moreparticularly, it appears that a receptor or receptors similar to thePYY-preferring (or Y7) receptors are involved.

Additional assays useful to the invention include those that candetermine the effect of GIP hybrid compounds, particularly thosecontaining an exendin, PPF, PYY, GLP1, amylin and/or sCT portion, onbody composition. An exemplary assay can be one that involvesutilization of a diet-induced obese (DIO) mouse model for metabolicdisease. Prior to the treatment period, male C57BL/6J mice can be fed ahigh-fat diet (#D12331, 58% of calories from fat; Research Diets, Inc.,)for 6 weeks beginning at 4 weeks of age. During the study, the mice cancontinue to eat their high-fat diet. Water can be provided ad libitumthroughout the study. One group of similarly-aged non-obese mice can befed a low-fat diet (#D12329, 11% of calories from fat) for purposes ofcomparing metabolic parameters to DIO groups.

DIO mice can be implanted with subcutaneous (SC) intrascapular osmoticpumps to deliver either vehicle (50% dimethylsulfoxide (DMSO) in water)or a compound of the invention. The pumps of the latter group can be setto deliver any amount, e.g., 1000 μg/kg/d of a compound of the inventionfor 7-28 days. Body weights and food intake can be measured over regularintervals throughout the study periods. Respiratory quotient (RQ,defined as CO₂ production÷O₂ consumption) and metabolic rate can bedetermined using whole-animal indirect calorimetry (Oxymax, ColumbusInstruments, Columbus, Ohio). The mice can be euthanized by isofluraneoverdose, and an index of adiposity (bilateral epididymal fat padweight) measured. Moreover, prior to determination of epididymal weight,body composition (lean mass, fat mass) for each mouse can be analyzedusing a Dual Energy X-ray Absorptiometry (DEXA) instrument permanufacturer's instructions (Lunar Piximus, GE Imaging System). In themethods of the invention, GIP hybrids, particularly those comprising anexendin, PPF, PYY, GLP1, amylin and/or sCT portion having a potency inone of the assays described herein (preferably food intake, gastricemptying, pancreatic secretion, weight reduction or body compositionassays) which is greater than the potency of a component peptide hormonein that same assay, can be identified.

In addition to the amelioration of hypertension in subjects in needthereof as a result of reduced food intake, weight loss, or treatingobesity, compounds of the invention may be used to treat hypotension.

In another general aspect, hybrids of the invention may be used toinhibit the secretion of ghrelin. Accordingly, compounds of theinvention may be utilize this mechanism to treat or prevent ghrelinrelated disorders such as Prader-Willi syndrome, diabetes of all typesand its complications, obesity, hyperphagia, hyperlipidemia, or otherdisorders associated with hypernutrition. In one embodiment such hybridscontain an exendin, GLP1, amylin and/or sCT portion.

Compounds of the invention may also be useful for potentiating,inducing, enhancing or restoring glucose responsivity in pancreaticislets or cells. These actions may be useful for treating or preventingconditions associated with metabolic disorders such as those describedabove and in U.S. patent application no. US2004/0228846. Assays fordetermining such activity are known in the art. For example, inpublished U.S. patent application no. US2004/0228846 (incorporated byreference in its entirety), assays are described for islet isolation andculture as well as determining fetal islet maturation. In the examplesof patent application US2004/0228846, intestine-derived hormone peptidesincluding pancreatic polypeptide (PP), neuropeptide Y (NPY),neuropeptide K (NPK), PYY, secretin, glucagon-like peptide-1 (GLP-1) andbombesin were purchased from Sigma. Collagenase type XI was obtainedfrom Sigma. RPMI 1640 culture medium and fetal bovine serum wereobtained from Gibco. A radioimmunoassay kit containing anti-insulinantibody ([¹²⁵I]-RIA kit) was purchased from Linco, St Louis.

Post-partem rat islets were obtained from P-02 year old rats. Adult ratislets were obtained from 6-8 week old rats. Fetal rat islets wereobtained as follows. Pregnant female rats were sacrificed on pregnancyday E21. Fetuses were removed from the uterus. 10-14 pancreata weredissected from each litter and washed twice in Hanks buffer. Thepancreata were pooled, suspended in 6 ml 1 mg/ml collagenase (Type XI,Sigma) and incubated at 37° C. for 8-10 minutes with constant shaking.The digestion was stopped by adding 10 volumes of ice-cold Hanks bufferfollowed by three washes with Hanks buffer. The islets were thenpurified by Ficoll gradient and cultured in 10% fetal bovine serum(FBS)/RPMI medium with or without addition of 1 μM IBMX. At the end offive days, 20 islets were hand picked into each tube and assayed forstatic insulin release. Generally, islets were first washed with KRPbuffer and then incubated with 1 ml of KRP buffer containing 3 mM (low)glucose for 30 minutes at 37° C. with constant shaking. After collectingthe supernatant, the islets were then incubated with 17 mM (high)glucose for one hour at 37° C. The insulin released from low or highglucose stimulation were assayed by radioimmunoassay (RIA) using the[¹²⁵I]-RIA kit. E21 fetal islets were cultured for 5 days in thepresence of 200 ng/ml PYY, PP, CCK, NPK, NPY, Secretin, GLP-1 orBombesin.

An exemplary in vivo assay is also provided using the Zucker DiabeticFatty (ZDF) male rat, an inbred (>F30 Generations) rat model thatspontaneously expresses diabetes in all fa/fa males fed a standardrodent diet Purina 5008. In ZDF fa-fa males, hyperglycemia begins todevelop at about seven weeks of age and glucose levels (fed) typicallyreach 500 mg/DL by 10 to 11 weeks of age. Insulin levels (fed) are highduring the development of diabetes. However, by 19 weeks of age insulindrops to about the level of lean control litter mates. Triglyceride andcholesterol levels of obese rats are normally higher than those ofleans. In the assay, three groups of 7-week old ZDF rats, with 6 ratsper group, received the infusion treatment by ALZA pump for 14 days: 1)vehicle control, 2) and 3), PYY with two different doses, 100 pmol/kg/hrand 500 pmol/kg/hr respectively. Four measurements were taken before theinfusion and after the infusion at day 7 and day 14: 1) plasma glucoselevel, 2) plasma insulin level, and 3) plasma triglycerides (TG) level,as well as oral glucose tolerance (OGTT) test. Accordingly, these assayscan be used with compounds of the invention to test for desiredactivity.

Hybrids are also useful for the therapeutic and prophylactic treatmentof neurological and nervous system disorders associated with neuronalloss or dysfunction, including, but not limited to, Parkinson's Disease,Alzheimer's Disease, Huntington's Disease, ALS, stroke, ADD, andneuropsychiatric syndromes, and to enhance or facilitate learning,memory and cognition in mammals. Particularly useful in this regard areGIP hybrids containing an exendin or GLP1 active portion, morespecifically comprising at least the N-terminal 7-15 amino acids oranalog thereof, for example HSEGTFTSD (SEQ ID NO:94).

Other uses contemplated for the hybrid polypeptides include methods forreducing aluminum (Al) concentrations in the central nervous system (seeU.S. Pat. No. 6,734,166, incorporated by reference in its entirety) fortreating, preventing, or delay the onset of Alzheimer's disease. Assaysfor determining effects on Al are known in the art and can be found inU.S. Pat. No. 6,734,166 using diploid and Ts mice. These mice wereindividually housed in Nalgene® brand metabolism or polypropylene cagesand given three days to adjust to the cages before experimentation. Micehad free access to food (LabDiet® NIH Rat and Moust/Auto 6F5K52, St.Louis, Mo.) and water during the experiment except for the 16 hoursprior to euthanasia when no food was provided. Mice were given dailysubcutaneous injections of either active compound or saline. Mice weresacrificed at the end of day 13 for one experiment and day 3 foranother, and samples were collected. Mice brain samples were weighted inclean teflon liners and prepared for analysis by microwave digestion inlow trace element grade nitric acid. Samples were then analyzed for Alcontent using Inductively Coupled Plasma Mass Spectrometry (Nuttall etal., Annals of Clinical and Laboratory Science 25, 3, 264-271 (1995)).All tissue handling during analysis took place in a clean roomenvironment utilizing HEPA air filtration systems to minimize backgroundcontamination.

Hybrids of the invention are useful for prevention and treatment ofnephropathy, including hypertensive and diabetic nephropathy, andnephropathy associated with insulin resistance and metabolic syndrome.Hybrids achieve these ends by, among other things, improving orpreventing worsening of hypertension, endothelial function, renalfunction, and glomerulosclerosis. In one embodiment, the inventionprovides a method for preventing or treating nephropathy, includinghypertensive and diabetic nephropathy, or that related to insulinresistance, comprising administering a compound of the invention.Hybrids find further use for improving endothelial function in a patienthaving reduced vasodilatory capacity, or having glomerulosclerosis orany other reduction in glomerular flow. Such improvement in endothelialfunction serves both to reduce hypertension and to improve the functionof the capillaries of the glomeruli. In additional embodiments, themolecules of the invention are useful to prevent progression ofnephropathy to ESRD, to prevent, slow the progression of, treat orameliorate proteinuria and/or glomerulosclerosis.

Hybrids are useful for reducing the risk of suffering from, preventing,or treating cardiac arrhythmias. Hybrids can provide anti-arrhythmiceffects in patients with cardiac ischemia, cardiac ischemia-reperfusion,and congestive heart failure. For example, incretin GLP-1 has been foundto reduce cardiac injury and enhance recovery in patients with thesedisorders. Incretins, including GLP-1, are glucose-dependentinsulinotropic hormones. GLP-1 and exendin effectively enhanceperipheral glucose uptake without inducing dangerous hypoglycemia. Theyalso strongly suppress glucagon secretion, independent of itsinsulinotropic action, and thereby powerfully reduce plasma free fattyacid (FFA) levels substantially more than can be accomplished withinsulin. High FFA levels have been implicated as a major toxic mechanismduring myocardial ischemia. In another embodiment hybrids are useful forpreventing and treating cardiac arrhythmias that reliably reduce injuryassociated with reperfusion and ischemia, and enhance patient recovery.In yet a further embodiment hybrid treatment after acute stroke orhemorrhage, preferably intravenous administration, provides a means foroptimizing insulin secretion, increasing brain anabolism, enhancinginsulin effectiveness by suppressing glucagon, and maintainingeuglycemia or mild hypoglycemia with no risk of severe hypoglycemia orother adverse side effects. In one embodiment such GIP hybrids contain aGLP1 or exendin portion.

In yet a further embodiment, hybrids that are capable of loweringinsulin resistance or increasing insulin sensitivity are useful to treatpolycystic ovary syndrome (PCOS). Administering hybrids of the inventioncan reduce or prevent insulin resistance in a subject suffering fromPCOS. In yet another embodiment hybrids prevent the onset of type-2diabetes in a subject suffering from PCOS. Further hybrids can restoreregular menses, ovulation, or fertility in a subject suffering fromPCOS. In one embodiment such GIP hybrids contain a GLP1 or an exendinportion for binding and activating a GLP1 receptor.

By selection of hormone component modules the compounds of the inventioncan exhibit a broad range of biological activities, some related totheir antisecretory and antimotility properties. The compounds maysuppress gastrointestinal secretions by direct interaction withepithelial cells or, perhaps, by inhibiting secretion of hormones orneurotransmitters which stimulate intestinal secretion. Anti-secretoryproperties include inhibition of gastric and/or pancreatic secretionsand can be useful in the treatment or prevention of diseases anddisorders including gastritis, pancreatitis, Barrett's esophagus, andGastroesophageal Reflux Disease, as well as conditions associatedtherewith including heartburn, heartburn accompanied by regurgitation ofgastric/intestinal contents into the mouth or the lungs, difficulty inswallowing, coughing, intermittent wheezing and vocal cord inflammation(conditions associated with GERD), esophageal erosion, esophageal ulcer,esophageal stricture, Barrett's metaplasia (replacement of normalesophageal epithelium with abnormal epithelium), Barrett's espohagealadenocarcinoma, and pulmonary aspiration. In another embodiment GIPhybrids containing amylin and/or sCT portions can be useful for treatingor preventing these diseases and conditions, such as Barrett'sesophagus, Gastroesophageal Reflux Disease (GERD) and conditionsassociated therewith as disclosed herein. Such hybrids have particularlyeffective anti-secretory properties, such as inhibition of gastricacids, inhibition of bile acids, and inhibition of pancreatic enzymes.Moreover, such hybrids can have a gastroprotective effect, which rendersthem particularly useful in the treatment or prevention of intestinaldiseases and conditions and of Barrett's esophagus, and/or GERD andrelated or associated conditions as described herein.

Compounds of the invention are useful in the treatment of any number ofgastrointestinal disorders (see e.g., Harrison's Principles of InternalMedicine, McGraw-Hill Inco, N.Y., 12th Ed.) that are associated withexcess intestinal electrolyte and water secretion as well as decreasedabsorption, e.g., infectious diarrhea, inflammatory diarrhea, shortbowel syndrome, or the diarrhea which typically occurs followingsurgical procedures, e.g., ileostomy. Examples of infectious diarrheainclude, without limitation, acute viral diarrhea, acute bacterialdiarrhea (e.g., salmonella, campylobacter, and clostridium or due toprotozoal infections), or traveller's diarrhea (e.g., Norwalk virus orrotavirus). Examples of inflammatory diarrhea include, withoutlimitation, malabsorption syndrome, tropical sprue, chronicpancreatitis, Crohn's disease, diarrhea, and irritable bowel syndrome.It has also been discovered that the peptides of the invention can beused to treat an emergency or life-threatening situation involving agastrointestinal disorder, e.g., after surgery or due to cholera.

Compounds of the invention may also be useful for treating or preventingintestinal, including gastrointestinal, damage as opposed to merelytreating the symptoms associated with the intestinal damage (forexample, diarrhea). Such damage to the intestine may be, or a result of,ulcerative colitis, inflammatory bowel disease, bowel atrophy, lossbowel mucosa, and/or loss of bowel mucosal function (see WO 03/105763,incorporated herein by reference in its entirety). Assays for suchactivity, as described in WO 03/105763, include 11 week old male HSDrats, ranging 250-300 grams housed in a 12:12 light:dark cycle, andallowed ad libitum access to a standard rodent diet (Teklad LM 485,Madison, Wis.) and water. The animals were fasted for 24 hours beforethe experiment. A simple and reproducible rat model of chronic colonicinflammation has been previously described by Morris G P, et al.,“Hapten-induced model of chronic inflammation and ulceration in the ratcolon.” Gastroenterology. 1989; 96:795-803. It exhibits a relativelylong duration of inflammation and ulceration, affording an opportunityto study the pathophysiology of colonic inflammatory disease in aspecifically controlled fashion, and to evaluate new treatmentspotentially applicable to inflammatory bowel disease in humans.

Rats were anesthetized with 3% isofluorane and placed on a regulatedheating pad set at 37° C. A gavage needle was inserted rectally into thecolon 7 cm. The hapten trinitrobenzenesulfonic acid (TNBS) dissolved in50% ethanol (v/v) was delivered into the lumen of the colon through thegavage needle at a dose of 30 mg/kg, in a total volume of 0 0.4-0.6 mL,as described in Mazelin, et al., “Protective role of vagal afferents inexperimentally-induced colitis in rats.” Juton Nerv Syst. 73:38-45(1998). Control groups received saline solution (NaCl 0.9%)intracolonically. Four days after induction of colitis, the colon wasresected from anesthetized rats, which were then euthanized bydecapitation. Weights of excised colon and spleen were measured, and thecolons photographed for scoring of gross morphologic damage.Inflammation was defined as regions of hyperemia and bowel wallthickening.

In another aspect, GIP hybrids can be useful for treating or preventingpancreatitis, pancreatic carcinoma, and gastritis, particularly in thetreatment and prevention of pancreatitis in patients who have undergoneendoscopic retrograde cholangiopancreatography (ERCP). Amylin and/or sCTcontaining GIP hybrid agonists can have a surprisingly superiortherapeutic effect when combined with somatostatin. Accordingly, incertain embodiments, methods for treating or preventing pancreatitiscomprise administering such hybrids and administering somatostatin andsomatostatin agonists to a subject. Hybrid polypeptides of the inventionmay also be used to treat or prevent Barrett's esophageal adenocarcinomaor pancreatic tumors (e.g., inhibit the proliferation of pancreatictumors). Methods of the invention include reducing the proliferation oftumor cells. The types of benign pancreatic tumor cells which may betreated in accordance with the present invention include serous cystadenomas, microcystic tumors, and solid-cystic tumors. The method isalso effective in reducing the proliferation of malignant pancreatictumor cells such as carcinomas arising from the ducts, acini, or isletsof the pancreas. Particularly useful GIP hybrids in this regard arethose comprising a hormone module component of the PYY or PPF family.U.S. Pat. No. 5,574,010 (incorporated by reference in its entirety)provides exemplary assays for testing anti-proliferative properties. Forexample, the '010 patent provides that PANC-1 and MiaPaCa-2 are twohuman pancreatic adenocarcinoma cancer cell lines which are availablecommercially from suppliers such as American Type Culture Collection,ATCC (Rockville, Md.). The two tumor cells were grown in RPMI-1640culture media supplemented with 10% fetal bovine serum, 29.2 mg/L ofglutamine, 25 μg gentamicin, 5 ml penicillin, streptomycin, andfungizone solution (JRH Biosciences, Lenexa, Kans.) at 37 degreesCelcius in a NAPCO water jacketed 5% CO₂ incubator. All cell lines weredetached with 0.25% trypsin (Clonetics, San Diego, Calif.) once to twicea week when a confluent monolayer of tumor cells was achieved. Cellswere pelleted for 7 minutes at 500g in a refrigerated centrifuge at 4degrees Celcius, and resuspended in trypsin free fortified RPMI 1640culture media. Viable cells were counted on a hemocytometer slide withtrypan blue.

Ten thousand, 20,000, 40,000 and 80,000 cells of each type were added to96 well microculture plates (Costar, Cambridge, Mass.) in a total volumeof 200 ul of culture media per well. Cells were allowed to adhere for 24hours prior to addition of the PYY or test peptide. Fresh culture mediawas exchanged prior to addition of peptides. In vitro incubation ofpancreatic tumor cells with either PYY or test compound was continuedfor 6 hours and 36 hours in length. PYY was added to cells at doses of250 pmol, 25 pmol, and 2.5 pmol per well (N=14). Test compound was addedto cells cultures at doses of 400 pmol, 40 pmol, and 4 pmol per well.Control wells received 2 ul of 0.9% saline to mimic the volume andphysical disturbance upon adhered tumor cells. Each 96 well platecontained 18 control wells to allow for comparison within each plateduring experimentation. Ninety-six (96) well plates were repeated 6times with varying concentrations of PYY and test compound in both thePANC-1 and MiaPaCa-2 cells.

At the end of the incubation period,3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium bromide, MTrtetrazolium bromide (Sigma, St. Louis, Mo.) was added to fresh culturemedia at 0.5 mg/ml. Culture media was exchanged and tumor cells wereincubated for 4 hours with MTT tetrazolium bromide at 37° C. At the endof incubation, culture media was aspirated. Formazon crystalprecipitates were dissolved in 200 μl of dimethyl sulfoxide (Sigma, St.Louis, Mo.). Quantitation of solubilized formazon was performed byobtaining absorption readings at 500 nm wavelength on an ELISA reader(Molecular Devices, Menlo Park, Calif.). The MTT assay measuresmitochondrial NADH dependent dehydrogenase activity, and it has beenamong the most sensitive and reliable method to quantitative in vitrochemotherapy responses of tumor cells. (Alley, M. C., et al., CancerRes., 48:589-601, 1988; Carmichael, J., et al., Cancer Res., 47:936-942,1987; McHale, A. P., et al., Cancer Lett., 41:315-321, 1988; and Saxton,R. E., et al., J. Clin. Laser Med. and Surg., 10(5):331-336, 1992.)Analysis of absorption readings at 550 nm were analyzed by groupingwells of the same test conditions and verifying differences occurringbetween control and the various peptide concentration treatments byone-way ANOVA.

An exemplary in vivo assay is also provided. The human pancreatic ductaladenocarcinoma Mia Paca-2 was examined for in vivo growth inhibition bypeptide YY and test compound. Seventy thousand to 100,000 human MiaPaCa-2 cells were orthotopically transplanted into 48 male athymic mice.After one week, the animals were treated with either PYY or testcompound at 200 pmol/kg/hr via mini-osmotic pumps for four weeks. Thepaired cultures received saline. At sacrifice, both tumor size and masswere measured. Control mice had significant human cancer growth withinthe pancreas as evidenced by histologic sections. At 9 weeks, ninetypercent (90%) of control mice had substantial metastatic disease. Tumormass was decreased by 60.5% in test treated mice and 27% in PYY treatedmice.

In another general aspect, hybrids are useful for decreasing boneresorption, decreasing plasma calcium, and/or inducing an analgesiceffect, particularly to treat bone disorders such as osteopenia andosteoporosis. In yet other embodiments, hybrids are useful to treat painand painful neuropathy. In one embodiment such hybrids contain anexendin, GLP1, amylin and/or sCT portion. For example, a GIP-sCT orGIP-amylin/sCT hybrid compound of the invention can have a selectableproperty of a salmon calcitonin or amylin/sCT/Amylin chimera, such asdecreasing bone loss and bone resorption or reducing cartilage turnover(chondroprotection), and a property of a GIP, such as plasma glucoselowering (concomitant with an anti-catabolic aspect as described herein)and/or inhibiting bone resorption and maintaining or increasing bonedensity. A GIP hybrid with such selectable properties can enhancetreatment of osteoporosis or conditions of high cartilage turnover,particularly in those who can also benefit from glycemic control, suchas subjects with diabetes or under going critical care.

GIP compounds, particularly GIP analogs, extended half-life GIP hybrids(e.g. DPP-IV cleavage resistant (such as a D-Ala2, N-Acetyl orN-pyroglutamyl analogs) optionally further comprising a peptidicenhancer such as a heterologous C-terminal tail, and GIP hybridscomprising other hormone modules known to provide beneficialcardiovascular effects, are useful to treat cardiovascular disease andrelated conditions. As demonstrated herein GIP compounds increasecardiac contractility (dP/dt), decrease blood pressure (for example byacute vasodilatation), decrease systolic pressure, decrease diastolicpressure, and can provide a direct beneficial action on cardiac cells.GIP compounds also improve cardiac function via metabolic actions, e.g.glucose lowering, insulin secretion, beta cell proliferation. By alsoproviding direct effects on the cardiovascular system, the GIP compoundsare surprisingly even more therapeutically beneficial.

Accordingly, provided herein are methods to treat, prevent or alleviatecardiovascular diseases and conditions by administering atherapeutically effective amount of a GIP compound, either alone or withanother agent that provides cardiovascular benefit, to a patient in needof such treatment. As with the other conditions discussed throughoutthis specification, a GIP compound can be administered concurrently,sequentially or alternately with another agent.

Accordingly, in one embodiment the cardiovascular disease or conditionis hypertension (including stage 1, stage 2 and stage 3 hypertension,diastolic or systolic), pulmonary hypertension, congestive heartfailure, cardiac insufficiency, reduced stroke volume, cardiomyopathy(dilated, hypertrophic or restrictive), decreased cardiac contractility,pulmonary congestion associated with cardiovascular conditions,pulmonary and systemic edema, decreased cardiac output, abnormal leftventricular function, diastolic blood pressure abnormalities, renalfailure associated with decreased cardiac contractility, increasedcardiovascular risk (e.g. associated with elevated systolic pressureaccompanied by normal diastolic pressure, associated with elevateddiastolic pressure accompanied by normal systolic pressure, associatedwith elevated diastolic and systolic pressure, associated with elevatedmean arterial blood pressure) and non-ischemic or ischemic heart tissuedegeneration (such as from myocardial infarction). In one embodimenteither or both the mortality or the morbidity associated with thesediseases and conditions are reduced.

The patient in need of treatment includes those who are diabetic (e.g.suffering from diabetic cardiomyopathy), obese, undergoing intensivecare, undergoing surgery, or a combination thereof, or who are otherwisenormal. The patient may have had or be at risk of having such a diseaseor condition. For example, patients post myocardial infarction that arein need of preventing further heart failure can benefit from the methodsherein.

Preventing a disease or condition, e.g., a cardiovascular disease orcondition, includes preventing the initiation of, delaying theinitiation of, preventing the progression or advancement of, slowing theprogression or advancement of, delaying the progression or advancementof, and reversing the progression of the disease or condition from anadvanced to a less advanced stage.

In one embodiment the method provides treating or delaying the onset ofsuch diseases or conditions. For example, impaired contractility candecrease stroke volume which in turn can precipitate congestive heartfailure. Thus in one embodiment treating heart failure refers totreating any one or more of the conditions underlying heart failure,including, without limitation, decreased cardiac contractility, abnormaldiastolic compliance, reduced stroke volume, high blood pressure,pulmonary congestion, and decreased cardiac output.

In one embodiment is provided a method for inducing an inotropicresponse, for reducing blood pressure, for reducing diastolic pressure,for reducing diastolic pressure, increasing vasodilation, or a anycombination of the above, with or without a concomitant beneficialmetabolic action of a GIP such as glucose lowering, insulin secretion,or beta cell proliferation, comprising administration of atherapeutically effective amount of a GIP compound to provide suchdesired beneficial action. These methods are useful for treatingconditions or disorders that can be alleviated by an increase in cardiaccontractility, a reduction in blood pressure, a reduction in diastolicpressure, a reduction in diastolic pressure, an increase invasodilation, or a combination of the above, in patients in need of suchbenefits.

Inotropic compounds are compounds that induce inotropic effects (e.g.,increase of force of contraction of the heart) have been recognized asbeing useful for the treatment of, for example, congestive heartfailure. Congestive heart failure, which is one of the most commoncauses of death and disability in industrialized nations, has amortality rate of about 50% at five years (Goodman and Gilman s ThePharmacological Basis of Therapeutics, 9th Ed. McGraw Hill, N.Y., pp.809-838). Criteria, testing and guidelines as established by theAmerican Heart Association (AHA) are suitable for diagnosing thecardiovascular diseases and conditions discussed herein.

GIP compounds display a desired positive inotropic effect without asubstantial, concomitant increase in blood pressure. Such blood pressurechanges in subjects experiencing heart failure or cardiovascular diseaseor condition could cause further deterioration in heart function. Infact as demonstrated herein, GIP compounds can function to reduce bloodpressure or the rate of change in blood pressure.

Issues with available inotropic agents illustrates the need for, anddesirability of, therapies that are inotropic, with rapid onset ofaction, with prolonged duration of action (including a persistenteffect, with absence of tachyphylaxis), with low toxicity (a high ratioof toxic to therapeutic dose), with absent or low nausea effect, andwith a convenient (non-intravenous) route of administration. GIPcompounds can provide these benefits.

Further beneficial action of GIP compounds of the invention,particularly the GIP hybrids comprising a DPP-IV resistant GIP analogwith a peptidic enhancer such as an exendin tail (e.g. Compound G),arises from a lack of or reduced anorectic effect and an absence of orrelatively insignificant nausea effect, which can be important in thepatient populations discussed throughout.

Also provided is a method for treating critically ill patients,exemplified as those sufficiently ill to warrant admission to anintensive care unit (ICU) and that find benefit from anti- ornon-catabolic therapy, which comprises administering a therapeuticallyeffective amount of a GIP analog or hybrid to a patient in need of suchtreatment, alone or with another beneficial agent. Without being limitedby theory, the methods are intended to benefit those patients in whichthe effect of GIP agonist analogs and hybrids to stimulate insulinsecretion and incur the benefits associated with intensive insulintherapy (GIK therapy; glucose-insulin-potassium), without the hazardsand complexity associated with insulin/glucose infusion and without theside effects reportedly associated with the use of some glucagon-likepeptide-1 agonists. Further, it is now observed that GIP can favorablyaffect a patient's metabolic state in addition to simply indirectlyregulating glucose levels in response to digestion of food. AccordinglyGIP compounds are useful to reduce the mortality and morbidity thatoccurs in critically ill patients.

As demonstrated herein GIP compounds provide beneficial metaboliceffects such as glucose lowering, insulin secretion and/or beta cellproliferation. GIP compounds also improve cardiac function by increasingcardiac contractility (dP/dt), decreasing blood pressure (for example byacute vasodilatation), and decreasing systolic pressure, decreasingdiastolic pressure, and providing a direct beneficial action on cardiaccells. Since many critically ill patients have or are at risk for or arecomplicated by cardiovascular diseases or conditions, thesecardiovascular effects can provided additional benefit. By alsoproviding direct effects on the cardiovascular system, the GIPcompounds, surprisingly, have added therapeutic value.

Accordingly, provided herein are methods to treat, prevent or alleviateconditions and diseases of critical care by administering atherapeutically effective amount of a GIP compound, either alone or withanother agent that provides desired benefits, to a critically illpatient in need of such treatment. As with the other conditionsdiscussed throughout this specification, a GIP compound can beadministered concurrently, sequentially or alternately with anotheragent.

The “intensive care unit” can be a part of a hospital where criticallyill patients are treated, and of course may not officially bear the name“Intensive Care Unit”. ICU also includes a nursing home a clinic, forexample, a private clinic, or the like if the same or similar activitiesare performed there.

The term a “critically ill patient” can be a patient who has sustainedor are at risk of sustaining acutely life-threatening single or multipleorgan system failure due to disease or injury, a patient who is beingoperated and where complications supervene, and a patient who has beenoperated in a vital organ within the last week or has been subject tomajor surgery within the last week. A critically ill patient can be apatient who needs vital organ support (either mechanically such as withmechanical ventilation or dialysis etc., or pharmacologically such aswith inotropes or vasopressors) without which they would not survive.Expressions “critical care”, “intensive care” and “critically ill” areused interchangeably. Critically ill patients are those who generallyexperience an unstable metabolic state. This unstable metabolic state,e.g. catabolic state, can be a result of changes in substrate metabolismwhich may lead to relative deficiencies in some nutrients and/orincreased oxidation (e.g. wasting) of both fat and muscle, undesirableaccelerated protein breakdown, hyperglycemia and high concentrations ofserum triglycerides and other lipids. Non-limiting examples of acritically ill patient is a patient in need of cardiac surgery, cerebralsurgery, thoracic surgery, abdominal surgery, vascular surgery, ortransplantation, or a patient suffering from cerebral trauma,respiratory insufficiency, critical illness polyneuropathy, multipletraumas or severe burns, or a patient being mechanically ventilated.

Accordingly, in one embodiment the critical care disease or condition isclassified as medical, surgical (e.g. trauma) or coronary care, andfurther can be classified as sepsis and respiratory care. Of particularinterest are those classifications, such as septic shock or myocardialinfarction, for which GIK therapy would be warranted.

Catabolic change (e.g., loss of body weight) is an adverse risk factorfor the critically ill patient. Although most admissions to the ICUreceive intravenous lines that deliver calories in some form, a Canadianstudy of nutritional support in ICU reported that typically only 58% ofdaily requirements were supplied and only 26% received parenteralnutrition. Thus a method is provided in which a critically ill patientin need of prevention or alleviating catabolic effects, such as weighloss, is administered a therapeutically effective amount of a GIPcompound as provided herein to prevent or alleviate the catabolism. Thecritically ill patient in need of treatment includes patients who arenon-diabetic patient (not diagnosed as having diabetes or prediabetes),diabetic, prediabetic, and/or obese. The patient may have had or be atrisk of having the disease or conditions indicated.

The use of GIP compounds can minimize or avoid risks associated withGLP-1 in invoking a GIK-like benefit. Slowing of gastric emptying cancomplicate the delivery of oral medicines, for example, by alteringtheir kinetics, and decrease nutrient uptake; GLP-1 agonists, amylinagonists, CCK agonists, and secretin agonists, for example, slow gastricemptying. As shown herein, within therapeutic ranges, doses of GIPcompounds do not slow gastric emptying or show only a weak effect, andin any event much less so than GLP1 and exendin 4. Typically such effectwas blocked with a selective amylin antagonist, e.g. pramlintide,indicating that the effect was an indirect consequence of augmentedbeta-cell secretion of amylin, the latter being the most potentendogenous inhibitor of gastric emptying thus far identified. GIPadministration is thus unassociated with a direct inhibition of gastricemptying. Importantly, it has been shown herein that GIP itself does notacutely inhibit food intake in mice. Neither does GIP cause weight lossin diet-induced-obese mice. Nor does the GIP analog hybrid 0601GIP3794.Further GIP was reported to exert a fat-sparing effect relative to GLP-1agonists which are associated with a loss of body weight and adiposity.This fat-sparing effect is possibly attributable to an antilipolyticeffect in adipocytes or to such effects as promotion of lipoproteinlipase, amplification of insulin signaling, and/or an increase of fattyacid incorporation into adipocyte lipid. Interestingly, 0601GIP3794provided a slight decrease in percentage body fat with an increase inbody protein without a concomitant reduction in body weight, indicatingthat body composition was affected. It is well recognized that loss ofbody energy stores predicts adverse outcomes in critical care whereaspreservation of body energy stores promotes beneficial outcomes. Theabsence of or decreased anorexigenic effects, the absence of ordecreased nausea and/or the absence of or reduction of weight loss, withor without the improvement in body composition, are advantageous inpatients experiencing catabolic effects, such as critically illpatients. Although GIP receptor mRNA has been detected in heart tissue,hormone binding in heart has not been detected to date. However, asshown herein GIP binds to and activates cardiac myocytes and displays apositive inotropic effect in vivo. With regard to treatment of renalfailure, particularly acute renal failure, in patients who remainoliguric despite attempts to enhance urine flow by approaches toestablish urine output such as by the use of loop diuretics and osmoticdiuretics, intervention by inotropic agents that increase cardiaccontractility is generally attempted. Thus as discussed GIP compoundsprovide further benefit in patients with or at risk of compromisedmyocardium, and certain other conditions such as renal failure,independent of its insulinotropic action. Further the method includesadministering to patients in need thereof a therapeutically effectiveamount of a GIP compound that provides a sparing of cardiac muscle,which otherwise tends to atrophy in catabolic states.

Accordingly, in one embodiment the critical care patient has a diseaseor condition of catabolic change associated with a critical illness,sepsis, post-traumatic, post-surgical, post-shock, comatose patients,stress-induced hyperglycemia (for example after a vascular event),stroke, myocardial infarction, acute mesenteric ischemia, respiratorydistress, ventilator dependency, renal failure, congestive heartfailure, edema, hibernating myocardium, cardiomyopathies (ischemic,diabetic), lowering of BNP, ejection dysfunction, hypertension,polyneuropathy, ischemia/reperfusion injury (for examplepost-thrombolytic therapy, post cardiac surgery), histoprotection oforgan beds, myocardial infarction (mortality, function, symptomatology),acute coronary syndrome (stable/unstable angina, non-Q wave infarct, ECGpositive), disturbances of conduction or rhythm, papillary dysfunction,and/or pulmonary edema. For example, in a one embodiment the methodcomprises attenuating, ameliorating or reducing such disease orconditions including pre- or post-surgical catabolic changes,comprising, administering to a patient in need thereof a GIP compound.The GIP compound is designed to provide a therapeutic benefit, forexample a benefit measured for example as a reduction in APACHE score, areduction in mortality, a reduction in days in hospital, a reduction inneed for readmission, a reduction in hospitalization costs.

In one embodiment is a method for the treatment of a critically illpatient in need thereof, to prevent or decrease the incidence of bloodstream infection, sepsis or septic shock, to reduce morbidity associatedwith the critical care, to reduce mortality (e.g. in-hospital mortality)associated with the critical care, to prevent or decrease the incidenceof prolonged inflammation, to prevent or decrease the incidence of acuterenal failure and/or renal replacement therapy, to prevent or decreasethe incidence of critical care polyneuropathy, to reduce the use ofantibiotics, to prevent or decrease the incidence of immune-mediateddestruction of the beta cells, to reduce the likelihood of disturbancein markers of inflammation and/or inflammatory responses, to prevent ordecrease the incidence of systemic inflammatory response syndrome(SIRS), to reduce the amount of red cell transfusion, to reducestress-induced hyperglycemia, to protect from cholestasis, to reduce theneed for invasive treatment, to prevent or decrease the incidence ofendoneural edema, to decrease dialysis or hemofiltration, to reduce oreliminate a need of vital organ system support, to allow at least aboutone third of the caloric need through the normal enteral route, toreduce the risk or likelihood of multiple organ failure, to reduce therisk or likelihood of multiple organ failure associated with sepsis orseptic shock, to reduce the use of mechanical ventilatory support, toreduce the likelihood of disturbed kidney function parameters, to reducethe likelihood of hyperbilirubinemia, or to treat, prevent or alleviateor reduce the incidence of one or more of the other critical careconditions mentioned herein, which comprises administering atherapeutically effective amount of a GIP compound. In a furtherembodiment administration achieves a normo- or euglycemia, a lowering ofblood glucose, insulin secretion, a cardiovascular benefit as discussedherein, a reduction of catabolic effect, or any combination thereof.

Critical care patients can include those suffering from respiratorydistress in which the patient has difficulty breathing as a result ofpulmonary dysfunction. The patient may exhibit varying degrees ofhypoxemia that that may or may not be controlled with supplementaloxygen. Respiratory distress may occur in patients with impairedpulmonary function due to direct lung injury, such as from pneumonia,aspiration of gastric contents, pulmonary contusion, fat emboli,near-drowning, inhalation injury, high altitude and reperfusionpulmonary edema, or from indirect lung injury as from sepsis, severetrauma with shock and multiple transfusions, cardiopulmonary bypass,drug overdose, and acute pancreatitis. A critically ill patient may havea pulmonary disorders associated with chronic hypoxemia, which canresult in raised pressure within the pulmonary circulation calledpulmonary hypertension. A critically ill patient may have cor pulmonale,which is a failure of the right side of the heart caused by prolongedhigh blood pressure in the pulmonary artery and right ventricle of theheart. A critically ill patient may have acute respiratory distresssyndrome (ARDS) or chronic obstructive pulmonary diseases (COPDs) whichinclude emphysema and chronic bronchitis, which also cause respiratorydistress.

In another embodiment the critical care patient is one who with adisturbed glucose metabolism such as insulin resistance but no overtdiabetes, as well as a patient who for any reason cannot receivenutrition through the alimentary canal. Such patients include surgerypatients, comatose patients, patients in shock, patients withgastrointestinal disease, patients with digestive hormone disease, andthe like. In particular, obese patients, atherosclerotic patients,vascular disease patients, patients with gestational diabetes, patientswith liver disease such as liver cirrhosis, patients with acromegaly,patients with glucorticoid excess such as cortisol treatment or Cushingsdisease, patients with activated counter-regulatory hormones such aswould occur after trauma, accidents and surgery and the like, patientswith hypertriglyceridemia and patients with chronic pancreatitis can bereadily and suitably nourished according to the invention withoutsubjecting the patient to hypo- or hyperglycemia, while reducingundesirable catabolic changes and/or providing cardiovascular benefit.

In one embodiment the administration of a GIP compound, alone or withother agents, reduces morbidity or mortality in critically ill patients(who require intensive care) or the time they stay in the ICU. Areduction in morbidity means reducing the likelihood that the criticallyill patient will develop additional illnesses, conditions, or symptomsor reducing the severity of additional illnesses, conditions orsymptoms. For example reducing morbidity can be achieved by decreasingthe incidence of bacteremia or sepsis or complications associated withmultiple organ failure.

These indications need not be confined to those with dysglycemia, norrequire that euglycemia be achieved. Neither are they restricted to aninsulinotropic mechanism, or those individuals capable of respondingwith increased insulin secretion. Although GIP resistance has beenreported in type 2 diabetes, resistance to the insulinotropic effects ofGIP is not expected to be a feature of critically ill patients,including those with acute stress induced dysglycemia. Normalglucose-dependent stimulation of insulin secretion will occur in themajority of critically ill patients, and in those patients resistant toGIP efficacy can be attained with higher GIP doses or with the use ofthe GIP analogs and hybrids disclosed herein.

Thus in one embodiment is provided a method for inducing aninsulinotropic response, for providing an anti- or non-catabolic effect(e.g. reducing a catabolic effect) or providing any one of thecardiovascular benefits discussed herein, or a any combination of theabove, comprising administration of a therapeutically effective amountof a GIP compound to provide such desired beneficial action. Thesemethods are useful for treating critical care conditions or disordersthat can be alleviated by such effects, preferably in conjunction with areduction of catabolic effect, in critically ill patients in need ofsuch benefits.

The GIP compound includes GIP and GIP analogs and hybrids, particularlynovel GIP analogs as described herein, extended half-life GIP hybrids(e.g. DPP-IV cleavage resistant (such as a D-Ala2, N-Acetyl orN-pyroglutamyl analogs) optionally further comprising a peptidicenhancer such as a heterologous C-terminal tail, and GIP hybridscomprising at least one hormone module known to provide beneficialbenefit to a patient undergoing critical or intensive care. For example,GIP compounds of the invention particularly useful are the GIP hybridscomprising a DPP-IV resistant GIP analog with a peptidic enhancer suchas an exendin tail (e.g. Compound G), or GIP hybrids comprising a GIPanalog and a amylin family or salmon calcitonin hormone module, whichare additionally beneficial by their lack of or reduced anorectic effectwhile maintaining a desirable glucose lowering, insulinotropic and/orcardiovascular benefit.

In one embodiment administering a GIP compound reduces the problemsassociated with parenteral nourishment. Very often it is not possible toinfuse a desired amount of glucose even to people with healthymetabolism without provoking hyperglycemia. This can be exacerbated incritical care patients. Insulin secretion during parenteral nourishmentin the presence of a GIP compound can be controlled such that the plasmaglucose increase will be less than without the GIP compound. Thereforemore glucose can be delivered over a 24-hour period than otherwise. Thecalorie deficit seen with parenterally nourished patients can thus bebetter satisfied. Accordingly, provided is a method for non-alimentarynutrition comprising administering by a parenteral route to a patient inneed of parenteral nutrition, a nutritively effective amount of one ormore nutrients selected from the group consisting of carbohydrates, ammoacids, lipids, free fatty acids, mono- or diglycerides, glycerol and anycombination thereof and a GIP compound, wherein the administration ofthe nutrient(s) produces a blood glucose level in the patient of fromabout 80 to 180 mg glucose per deciliter of blood, and the rate ofadministration is calculated to deliver up to about 1000 g of glucose orits equivalent per patient per day. In a further embodiment the patientreceives at least about one third of the caloric need through the normalenteral route, at least about half of the caloric need through thenormal enteral route, or at least about two third of the caloric needthrough the normal enteric route. When the nutrient source iscarbohydrate, the source of carbohydrate can be present at aconcentration of about a 2% to about a 50% by weight of glucose or itsequivalent per liter. In a further embodiment enhance nutrientmetabolism is achieved via the parenteral route in patients with adisturbed glucose metabolism, a surgery patient, a comatose patient, apatient in shock, a patient with gastrointestinal disease, a patientwith digestive hormone disease, an obese patient, an atheroscleroticpatient, a patient with vascular disease, a patient with gestationaldiabetes, a patient with liver disease, a patient with liver cirrhosis,a patient with glucocorticoid excess, a patient with Cushings disease, apatient with activated counter-regulatory hormones that occur aftertrauma or a disease, a patient with hypertriglyceridemia, or a patientwith chronic pancreatitis, a nutritively effective amount of one or morenutrients or any combination thereof and one or more insulinotropicpeptides. In yet a further embodiment the patient in need of enhancedparenteral nutrition via a non-alimentary route is a critical carepatient.

In one embodiment for critical care use and parenteral nutritionenhancement use, a GIP compound is administered by continuousintravenous infusion to achieve blood glucose levels less than 200mg/dl, or in the range of 80 to 150 mg/dl, or in the range of 80 to 110mg/dl. For example, the GIP compound can be administered to maintainplasma glucose below the “renal threshold” of about 160 to 180milligrams per deciliter. Patients not suffering from hyperglycemia canalso be treated in view of the additional anti-catabolic andcardiovascular benefits provided by the GIP compounds.

As discussed herein, both acute and chronic administration by a range ofroutes is contemplated for critical care use and for enhancement ofparenteral nutrition. In one embodiment for critical care use, a GIPcompound is infused continuously at a rate of between about 0.1 and 100pmol/kg/min, between about 0.1 and 50 pmol/kg/min, between about 0.5 and30 pmol/kg/min, between about 0.1 and 10 pmol/kg/min, between about 0.5and 5 pmol/kg/min, or between about 1.0 and 3.0 pmol/kg/min. Asdiscussed elsewhere herein, the GIP compound can also be provided via asustained release formulation, e.g. comprising microspheres or a gelmatrix, and/or administered via discrete or superimpositioning dosages,via subcutaneous, nasal, intravenous or other routes. The GIP compoundcan be administered prior to, during and/or after commencement ofcritical care, such as surgery.

The therapeutically effective dose of the GIP, GIP analog, novel GIPanalog or GIP hybrid, or derivative thereof, will depend on a number offactors, including without limitation, the patient's sex, weight andage, the severity of inability to regulate blood glucose, the underlyingcause(s) of inability to regulate blood glucose, whether glucose oranother carbohydrate source is simultaneously administered, the route ofadministration and bioavailability, the persistence in the body, theformulation and the potency. It is within the skill of the ordinaryphysician to titrate the dose and rate of administration of a GIPcompound to achieve the desired clinical result.

Polypeptide Production and Purification.

The polypeptides described herein may be prepared using standardrecombinant techniques or chemical peptide synthesis techniques known inthe art, e.g., using an automated or semi-automated peptide synthesizer,or both.

The polypeptides of the invention can be synthesized in solution or on asolid support in accordance with conventional techniques. Such methodsare described, for example, herein and in U.S. Pat. No. 6,610,824 andU.S. Pat. No. 5,686,411 and in patent application Ser. No. 454,533(filed Dec. 6, 1999), the entirety of which are incorporated herein byreference. Various automatic synthesizers are commercially available andcan be used in accordance with known protocols. See, e.g., Stewart andYoung, Solid Phase Peptide Synthesis, 2d. ed., Pierce Chemical Co.(1984); Tam et al., J. Am. Chem. Soc. 105: 6442 (1983); Merrifield,Science 232: 341-7 (1986); and Barany and Merrifield, The Peptides,Gross and Meienhofer, eds., Academic Press, New York, 1-284 (1979).Solid phase peptide synthesis may be carried out with an automaticpeptide synthesizer (e.g., Model 430A, Applied Biosystems Inc., FosterCity, Calif.) using the NMP/HOBt (Option 1) system and tBoc or Fmocchemistry (see, Applied Biosystems User's Manual for the ABI 430APeptide Synthesizer, Version 1.3B Jul. 1, 1988, section 6, pp. 49-70,Applied Biosystems, Inc., Foster City, Calif.) with capping. Peptidesmay also be assembled using an Advanced Chem Tech Synthesizer (Model MPS350, Louisville, Ky.). Peptides may be purified by RP-HPLC (preparativeand analytical) using, e.g., a Waters Delta Prep 3000 system and a C4,C8, or C18 preparative column (10μ, 2.2×25 cm; Vydac, Hesperia, Calif.).Polypeptides can be synthesized by convergent methods such as “nativechemical ligation”, and variations thereof, in which two or more peptidefragments with appropriate orthogonally reactive ends are ligated withnative amide bond formation. The newly formed peptide can be furtherligated to create even longer polypeptides. The individual startingpeptides can be derivatized as desired or can be derivatized after aligation step.

Peptides analogs were synthesized on a Pioneer continuous flow peptidesynthesizer (Applied Biosystems) using PAL-PEG-PS resin (AppliedBiosystems) with a loading of 0.2 mmol/g (0.25 mmole scale). Fmoc aminoacid (4.0 eq, 1.0 mmol) residues were activated using 4.0 eq HBTU, 4.0eq of HOBT, 8.0 eq DIEA and coupled to the resin for 1 hour. The Fmocgroup was removed by treatment with 20% (v/v) piperidine indimethylformamide. Final deprotection and cleavage of the peptide fromthe solid support was performed by treatment of the resin with reagent B(93% TFA, 3% phenol, 3% water and 1% triisopropylsilane) for 2-3 hours.The cleaved peptide was precipitated using tert-butyl methyl ether,pelleted by centrifugation and lyophilized. The pellet was re-dissolvedin water (10-15 mL), filtered and purified via reverse phase HPLC usinga C-18 column and an acetonitrile/water gradient containing 0.1% TFA.The purified product was lyophilized and analyzed by ESI-LC/MS andanalytical HPLC and were demonstrated to be pure (>98%). Mass resultsall agreed with calculated values.

Alternatively, peptides were assembled on a Symphony® peptidesynthesizer (Protein Technologies, Inc., Woburn, Mass.) using Rink amideresin (Novabiochem, San Diego, Calif.) with a loading of 0.43-0.49mmol/g at 0.050-0.100 mmol Fmoc amino acid (Applied Biosystems, Inc. 5.0eq, 0.250-0.500 mmol) residues were dissolved at a concentration of 0.10M in 1-methyl-2-pyrrolidinone. All other reagents (HBTU, HOBT andN,N-diisopropylethylamine) were prepared as 0.55 M dimethylformamidesolutions. The Fmoc protected amino acids were then coupled to theresin-bound amino acid using, HBTU (2.0 eq, 0.100-0.200 mmol), HOBT (1.8eq, 0.090-0.18 mmol), N,N-diisopropylethylamine (2.4 eq, 0.120-0.240mmol) for 2 hours. Following the last amino acid coupling, the peptidewas deprotected using 20% (v/v) piperidine in dimethylformamide for 1hour. Once peptide sequence is completed, the Symphony® peptidesynthesizer is programmed to cleave the resin. Trifluoroacetic acid(TFA) cleavage of the peptide from resin was carried out using a reagentmixture composed of 93% TFA, 3% phenol, 3% water and 1%triisopropylsilane. The cleaved peptide was precipitated usingtert-butyl methyl ether, pelleted by centrifugation and lyophilized. Thepellet was dissolved in acetic acid, lyophilized and then dissolved inwater, filtered and purified via reverse phase HPLC using a C18 columnand an acetonitrile/water gradient containing 0.1% TFA. Analytical HPLCwas used to assess purity of peptide and identity was confirmed by LC/MSand MALDI-MS.

The active protein can be readily synthesized and then screened inscreening assays designed to identify reactive peptides.

The analog and hybrid polypeptides of the present invention mayalternatively be produced by recombinant techniques well known in theart. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual,2d ed., Cold Spring Harbor (1989). These GIP analog or hybridpolypeptides produced by recombinant technologies may be expressed froma polynucleotide. One skilled in the art will appreciate that thepolynucleotides, including DNA and RNA, that encode such GIP analog orhybrid polypeptides may be obtained from the wild-type cDNA, e.g. GIP,GLP1, amylin, taking into consideration the degeneracy of codon usage,or may be engineered as desired. These polynucleotide sequences mayincorporate codons facilitating transcription and translation of mRNA inmicrobial hosts. Such manufacturing sequences may readily be constructedaccording to the methods well known in the art. See, e.g., WO 83/04053.The polynucleotides above may also optionally encode an N-terminalmethionyl residue. Non-peptide compounds useful in the present inventionmay be prepared by art-known methods. For example, phosphate-containingamino acids and peptides containing such amino acids may be preparedusing methods known in the art. See, e.g., Bartlett and Landen, Bioorg.Chem. 14: 356-77 (1986).

A variety of expression vector/host systems may be utilized to containand express a GIP polypeptide coding sequence. These include but are notlimited to microorganisms such as bacteria transformed with recombinantbacteriophage, plasmid or cosmid DNA expression vectors; yeasttransformed with yeast expression vectors; insect cell systems infectedwith virus expression vectors (e.g., baculovirus); plant cell systemstransfected with virus expression vectors (e.g., cauliflower mosaicvirus, CaMV; tobacco mosaic virus, TMV) or transformed with bacterialexpression vectors (e.g., Ti or pBR322 plasmid); or animal cell systems.Mammalian cells that are useful in recombinant protein productionsinclude but are not limited to VERO cells, HeLa cells, Chinese hamsterovary (CHO) cell lines, COS cells (such as COS-7), WI 38, BHK, HepG2,3T3, RIN, MDCK, A549, PC12, K562 and 293 cells. Exemplary protocols forthe recombinant expression of the protein are described herein.

As such, polynucleotide sequences provided by the invention are usefulin generating new and useful viral and plasmid DNA vectors, new anduseful transformed and transfected procaryotic and eucaryotic host cells(including bacterial, yeast, and mammalian cells grown in culture), andnew and useful methods for cultured growth of such host cells capable ofexpression of the present GIP polypeptides. The polynucleotide sequencesencoding GIP analogs or hybrids herein may be useful for gene therapy ininstances where underproduction of GIP or other component peptidehormone(s) of the hybrid would be alleviated, or the need for increasedlevels of such would be met.

The present invention also provides for processes for recombinant DNAproduction of the present GIP polypeptides. Provided is a process forproducing the GIP polypeptides from a host cell containing nucleic acidsencoding such GIP polypeptides comprising: (a) culturing said host cellcontaining polynucleotides encoding such GIP polypeptides underconditions facilitating the expression of such DNA molecule; and (b)obtaining such GIP polypeptides.

Host cells may be prokaryotic or eukaryotic and include bacteria,mammalian cells (such as Chinese Hamster Ovary (CHO) cells, monkeycells, baby hamster kidney cells, cancer cells or other cells), yeastcells, and insect cells.

Mammalian host systems for the expression of the recombinant proteinalso are well known to those of skill in the art. Host cell strains maybe chosen for a particular ability to process the expressed protein orproduce certain post-translation modifications that will be useful inproviding protein activity. Such modifications of the polypeptideinclude, but are not limited to, acetylation, carboxylation,glycosylation, phosphorylation, lipidation and acylation.Post-translational processing, which cleaves a “prepro” form of theprotein, may also be important for correct insertion, folding and/orfunction. Different host cells, such as CHO, HeLa, MDCK, 293, WI38, andthe like, have specific cellular machinery and characteristic mechanismsfor such post-translational activities, and may be chosen to ensure thecorrect modification and processing of the introduced foreign protein.

Alternatively, a yeast system may be employed to generate the GIPpolypeptides of the present invention. The coding region of the GIPpolypeptide cDNA is amplified by PCR. A DNA encoding the yeastpre-pro-alpha leader sequence is amplified from yeast genomic DNA in aPCR reaction using one primer containing nucleotides 1-20 of the alphamating factor gene and another primer complementary to nucleotides255-235 of this gene (Kurjan and Herskowitz, Cell, 30: 933-43 (1982)).The pre-pro-alpha leader coding sequence and GIP polypeptide codingsequence fragments are ligated into a plasmid containing the yeastalcohol dehydrogenase (ADH2) promoter, such that the promoter directsexpression of a fusion protein consisting of the pre-pro-alpha factorfused to the mature GIP polypeptide. As taught by Rose and Broach, Meth.Enz. 185: 234-79, Goeddel ed., Academic Press, Inc., San Diego, Calif.(1990), the vector further includes an ADH2 transcription terminatordownstream of the cloning site, the yeast “2-micron” replication origin,the yeast leu-2d gene, the yeast REP1 and REP2 genes, the E. colibeta-lactamase gene, and an E. coli origin of replication. Thebeta-lactamase and leu-2d genes provide for selection in bacteria andyeast, respectively. The leu-2d gene also facilitates increased copynumber of the plasmid in yeast to induce higher levels of expression.The REP1 and REP2 genes encode proteins involved in regulation of theplasmid copy number.

The DNA construct described in the preceding paragraph is transformedinto yeast cells using a known method, e.g., lithium acetate treatment(Steams et al., Meth. Enz. 185: 280-97 (1990)). The ADH2 promoter isinduced upon exhaustion of glucose in the growth media (Price et al.,Gene 55: 287 (1987)). The pre-pro-alpha sequence effects secretion ofthe fusion protein from the cells. Concomitantly, the yeast KEX2 proteincleaves the pre-pro sequence from the mature GIP-polypeptides (Bitter etal., Proc. Natl. Acad. Sci. USA 81: 5330-4 (1984)).

GIP polypeptides of the invention may also be recombinantly expressed inyeast using a commercially available expression system, e.g., the PichiaExpression System (Invitrogen, San Diego, Calif.), following themanufacturer's instructions. This system also relies on thepre-pro-alpha sequence to direct secretion, but transcription of theinsert is driven by the alcohol oxidase (AOX1) promoter upon inductionby methanol. The secreted GIP polypeptide is purified from the yeastgrowth medium by, e.g., the methods used to purify GIP polypeptide frombacterial and mammalian cell supernatants.

Alternatively, the cDNA encoding GIP polypeptides may be cloned into thebaculovirus expression vector pVL1393 (PharMingen, San Diego, Calif.).This GIP-compound-encoding vector is then used according to themanufacturer's directions (PharMingen) to infect Spodoptera frugiperdacells in sF9 protein-free media and to produce recombinant protein. Theprotein is purified and concentrated from the media using aheparin-Sepharose column (Pharmacia, Piscataway, N.J.) and sequentialmolecular sizing columns (Amicon, Beverly, Mass.), and resuspended inPBS. SDS-PAGE analysis shows a single band and confirms the size of theprotein, and Edman sequencing on a Proton 2090 Peptide Sequencerconfirms its N-terminal sequence.

For example, the DNA sequence encoding the predicted mature GIP analogor hybrid polypeptide may be cloned into a plasmid containing a desiredpromoter and, optionally, a leader sequence (see, e.g., Better et al.,Science 240: 1041-3 (1988)). The sequence of this construct may beconfirmed by automated sequencing. The plasmid is then transformed intoE. coli, strain MC1061, using standard procedures employing CaCl₂incubation and heat shock treatment of the bacteria (Sambrook et al.,supra). The transformed bacteria are grown in LB medium supplementedwith carbenicillin, and production of the expressed protein is inducedby growth in a suitable medium. If present, the leader sequence willaffect secretion of the mature GIP analog or hybrid polypeptide and becleaved during secretion. The secreted recombinant protein is purifiedfrom the bacterial culture media by the method described herein.

Alternatively, the GIP polypeptides of the invention may be expressed inan insect system. Insect systems for protein expression are well knownto those of skill in the art. In one such system, Autographa californicanuclear polyhedrosis virus (AcNPV) is used as a vector to expressforeign genes in Spodoptera frugiperda cells or in Trichoplusia larvae.The GIP polypeptide coding sequence is cloned into a nonessential regionof the virus, such as the polyhedrin gene, and placed under control ofthe polyhedrin promoter. Successful insertion of GIP analog or hybridpolypeptide will render the polyhedrin gene inactive and producerecombinant virus lacking coat protein coat. The recombinant viruses arethen used to infect S. frugiperda cells or Trichoplusia larvae in whichGIP analog or hybrid polypeptide is expressed (Smith et al., J. Virol.46: 584 (1983); Engelhard et al., Proc. Natl. Acad. Sci. USA 91: 3224-7(1994)).

In another example, the DNA sequence encoding the GIP polypeptide may beamplified by PCR and cloned into an appropriate vector, for example,pGEX-3× (Pharmacia, Piscataway, N.J.). The pGEX vector is designed toproduce a fusion protein comprising glutathione-S-transferase (GST),encoded by the vector, and a protein encoded by a DNA fragment insertedinto the vector's cloning site. The primers for the PCR may be generatedto include, for example, an appropriate cleavage site. The recombinantfusion protein may then be cleaved from the GST portion of the fusionprotein. The pGEX-3×/GIP analog polypeptide construct is transformedinto E. coli XL-1 Blue cells (Stratagene, La Jolla, Calif.), andindividual transformants are isolated and grown at 37° C. in LB medium(supplemented with carbenicillin) to an optical density at wavelength600 nm of 0.4, followed by further incubation for 4 hours in thepresence of 0.5 mM Isopropyl beta-D-Thiogalactopyranoside (SigmaChemical Co., St. Louis, Mo.). Plasmid DNA from individual transformantsis purified and partially sequenced using an automated sequencer toconfirm the presence of the desired GIP polypeptide-encoding gene insertin the proper orientation.

The fusion protein, expected to be produced as an insoluble inclusionbody in the bacteria, may be purified as follows. Cells are harvested bycentrifugation; washed in 0.15 M NaCl, 10 mM Tris, pH 8, 1 mM EDTA; andtreated with 0.1 mg/mL lysozyme (Sigma Chemical Co.) for 15 min. at roomtemperature. The lysate is cleared by sonication, and cell debris ispelleted by centrifugation for 10 min. at 12,000×g. The fusionprotein-containing pellet is resuspended in 50 mM Tris, pH 8, and 10 mMEDTA, layered over 50% glycerol, and centrifuged for 30 min. at 6000×g.The pellet is resuspended in standard phosphate buffered saline solution(PBS) free of Mg⁺⁺ and Ca⁺⁺. The fusion protein is further purified byfractionating the resuspended pellet in a denaturing SDS polyacrylamidegel (Sambrook et al., supra). The gel is soaked in 0.4 M KCl tovisualize the protein, which is excised and electroeluted in gel-runningbuffer lacking SDS. If the GST/GIP polypeptide fusion protein isproduced in bacteria as a soluble protein, it may be purified using theGST Purification Module (Pharmacia Biotech).

The fusion protein may be subjected to digestion to cleave the GST fromthe mature GIP analog or hybrid polypeptide. The digestion reaction(20-40 μg fusion protein, 20-30 units human thrombin (4000 U/mg (Sigma)in 0.5 mL PBS) is incubated 16-48 hrs. at room temperature and loaded ona denaturing SDS-PAGE gel to fractionate the reaction products. The gelis soaked in 0.4 M KCl to visualize the protein bands. The identity ofthe protein band corresponding to the expected molecular weight of theGIP analog or hybrid polypeptide may be confirmed by partial amino acidsequence analysis using an automated sequencer (Applied Biosystems Model473A, Foster City, Calif.).

In a particularly exemplary method of recombinant expression of the GIPpolypeptides of the present invention, 293 cells may be co-transfectedwith plasmids containing the GIP analog or hybrid polypeptide cDNA inthe pCMV vector (5′ CMV promoter, 3′ HGH poly A sequence) and pSV2neo(containing the neo resistance gene) by the calcium phosphate method. Inone embodiment, the vectors should be linearized with ScaI prior totransfection. Similarly, an alternative construct using a similar pCMVvector with the neo gene incorporated can be used. Stable cell lines areselected from single cell clones by limiting dilution in growth mediacontaining 0.5 mg/mL G418 (neomycin-like antibiotic) for 10-14 days.Cell lines are screened for GIP analog or hybrid polypeptide expressionby ELISA or Western blot, and high-expressing cell lines are expandedfor large scale growth.

It is preferable that the transformed cells are used for long-term,high-yield protein production and as such stable expression isdesirable. Once such cells are transformed with vectors that containselectable markers along with the desired expression cassette, the cellsmay be allowed to grow for 1-2 days in an enriched media before they areswitched to selective media. The selectable marker is designed to conferresistance to selection, and its presence allows growth and recovery ofcells that successfully express the introduced sequences. Resistantclumps of stably transformed cells can be proliferated using tissueculture techniques appropriate to the cell.

A number of selection systems may be used to recover the cells that havebeen transformed for recombinant protein production. Such selectionsystems include, but are not limited to, HSV thymidine kinase,hypoxanthine-guanine phosphoribosyltransferase and adeninephosphoribosyltransferase genes, in tk-, hgprt- or aprt-cells,respectively. Also, anti-metabolite resistance can be used as the basisof selection for dhfr, that confers resistance to methotrexate; gpt,that confers resistance to mycophenolic acid; neo, that confersresistance to the aminoglycoside, G418; also, that confers resistance tochlorsulfuron; and hygro, that confers resistance to hygromycin.Additional selectable genes that may be useful include trpB, whichallows cells to utilize indole in place of tryptophan, or hisD, whichallows cells to utilize histinol in place of histidine. Markers thatgive a visual indication for identification of transformants includeanthocyanins, beta-glucuronidase and its substrate, GUS, and luciferaseand its substrate, luciferin.

Many of the GIP polypeptides of the present invention may be producedusing a combination of both automated peptide synthesis and recombinanttechniques. For example, a GIP polypeptide of the present invention maycontain a combination of modifications including deletion, substitution,and insertion by PEGylation. Such a GIP polypeptide may be produced instages. In the first stage, an intermediate GIP polypeptide containingthe modifications of deletion, substitution, insertion, and anycombination thereof, may be produced by recombinant techniques asdescribed. Then after an optional purification step as described herein,the intermediate GIP polypeptide is PEGylated through chemicalmodification with an appropriate PEGylating reagent (e.g., from NeKtarTransforming Therapeutics, San Carlos, Calif.) to yield the desired GIPpolypeptide. One skilled in the art will appreciate that theabove-described procedure may be generalized to apply to a GIPpolypeptide containing a combination of modifications selected fromdeletion, substitution, insertion, derivation, and other means ofmodification well known in the art and contemplated by the presentinvention.

It may be desirable to purify the GIP polypeptides generated by thepresent invention. Peptide purification techniques are well known tothose of skill in the art. These techniques involve, at one level, thecrude fractionation of the cellular milieu to polypeptide andnon-polypeptide fractions. Having separated the polypeptide from otherproteins, the polypeptide of interest may be further purified usingchromatographic and electrophoretic techniques to achieve partial orcomplete purification (or purification to homogeneity). Analyticalmethods particularly suited to the preparation of a pure peptide areion-exchange chromatography, exclusion chromatography, polyacrylamidegel electrophoresis, and isoelectric focusing. A particularly efficientmethod of purifying peptides is reverse phase HPLC, followed bycharacterization of purified product by liquid chromatography/massspectrometry (LC/MS) and Matrix-Assisted Laser Desorption Ionization(MALDI) mass spectrometry. Additional confirmation of purity is obtainedby determining amino acid analysis.

Certain aspects of the present invention concern the purification, andin particular embodiments, the substantial purification, of an encodedprotein or peptide. The term “purified peptide” as used herein, isintended to refer to a composition, isolatable from other components,wherein the peptide is purified to any degree relative to its naturallyobtainable state. A purified peptide therefore also refers to a peptide,free from the environment in which it may naturally occur.

Generally, “purified” will refer to a peptide composition that has beensubjected to fractionation to remove various other components, and whichcomposition substantially retains its expressed biological activity.Where the term “substantially purified” is used, this designation willrefer to a composition in which the peptide forms the major component ofthe composition, such as constituting about 50%, about 60%, about 70%,about 80%, about 90%, about 95% or more of the peptides in thecomposition.

Various techniques suitable for use in peptide purification will be wellknown to those of skill in the art. These include, for example,precipitation with ammonium sulphate, PEG, antibodies, and the like;heat denaturation, followed by centrifugation; chromatography steps suchas ion exchange, gel filtration, reverse phase, hydroxylapatite andaffinity chromatography; isoelectric focusing; gel electrophoresis; andcombinations of such and other techniques. As is generally known in theart, it is believed that the order of conducting the variouspurification steps may be changed, or that certain steps may be omitted,and still result in a suitable method for the preparation of asubstantially purified protein or peptide.

There is no general requirement that the peptides always be provided intheir most purified state. Indeed, it is contemplated that lesssubstantially purified products will have utility in certainembodiments. Partial purification may be accomplished by using fewerpurification steps in combination, or by utilizing different forms ofthe same general purification scheme. For example, it is appreciatedthat a cation-exchange column chromatography performed, utilizing anHPLC apparatus, will generally result in a greater “-fold” purificationthan the same technique utilizing a low pressure chromatography system.Methods exhibiting a lower degree of relative purification may haveadvantages in total recovery of protein product, or in maintaining theactivity of an expressed protein.

One may optionally purify and isolate such GIP polypeptides from othercomponents obtained in the process. Methods for purifying a polypeptidecan be found in U.S. Pat. No. 5,849,883. These documents describespecific exemplary methods for the isolation and purification of G-CSFcompositions that may be useful in isolating and purifying the GIPpolypeptides of the present invention. Given the disclosure of thesepatents, it is evident that one of skill in the art would be well awareof numerous purification techniques that may be used to purify GIPpolypeptides from a given source.

Also it is contemplated that a combination of anion exchange andimmunoaffinity chromatography may be employed to produce purified GIPpolypeptide compositions of the present invention.

Pharmaceutical Compositions.

The present invention also relates to pharmaceutical compositionscomprising a therapeutically or prophylactically effective amount of atleast one GIP polypeptide of the invention, or a pharmaceuticallyacceptable salt thereof, together with pharmaceutically acceptablediluents, preservatives, solubilizers, emulsifiers, adjuvants and/orcarriers useful in the delivery of the GIP polypeptides. Suchcompositions may include diluents of various buffer content (e.g.,acetate, citrate, tartrate, phosphate, TRIS-HCl), pH and ionic strength;additives such as surfactants and solubilizing agents (e.g., sorbitanmonooleate, lecithin, Pluronics, Tween 20 & 80, Polysorbate 20 & 80,propylene glycol, ethanol, PEG-40, sodium dodecyl sulfate),anti-oxidants (e.g., monothioglyercol, ascorbic acid, acetylcysteine,sulfurous acid salts (bisulfite and metabisulfite), preservatives (e.g.,phenol, meta-cresol, benzyl alcohol, parabens (methyl, propyl, butyl),benzalkonium chloride, chlorobutanol, thimersol, phenylmercuric salts,(acetate, borate, nitrate), and tonicity/bulking agents (glycerine,sodium chloride, mannitol, sucrose, trehalose, dextrose); incorporationof the material into particulate preparations of polymeric compounds,such as polylactic acid, polyglycolic acid, etc., or in association withliposomes. Such compositions will influence the physical state,stability, rate of in vivo release, and rate of in vivo clearance of thepresent GIP analog polypeptides. See, e.g., Remington's PharmaceuticalSciences 1435-712, 18th ed., Mack Publishing Co., Easton, Pa. (1990).

Optionally a GIP or a novel GIP analog can be formulated with (oralternatively administered in adjunct therapy with or alternativelycovalently linked or fused to) a second active agent. Such agents cancomprise activity that will complement or enhance a GIP effect. In oneembodiment such agents have glucose lowering or anti-diabetic activity.In another embodiment the agent inhibits or reduces gastric emptying. Inother embodiments the agent can comprise any other desirable activity,such as increasing bone density, reducing food intake, or the like.

In general, the present GIP analog and hybrid polypeptides will beuseful in the same way that GIP and/or the individual componentpolypeptides (in the case of a hybrid) are useful in view of theirpharmacological properties. Generally, the GIP polypeptides areperipherally administered for the treatment or prevention of metabolicconditions and disorders. In particular, the compounds of the inventionpossess activity as glucose lowering agents, insulinotropic agents,reducing or inhibiting gastric secretion, effecting weight loss,reducing nutrient availability, reducing food intake, suppressingappetite, ameliorating mortality and morbidity in critical (intensive)care applications, providing improved memory and other neurologicalbenefits, increasing or maintaining bone density, effectingcardiovascular benefits, providing cardioprotection, and effecting othertherapeutic benefits as discussed herein. In another embodiment, aexemplary use is to administer such hybrid polypeptides for thetreatment of diabetes or diabetes related conditions and disorders,obesity, and cardiovascular diseases and conditions. The present GIPpolypeptides may be formulated for peripheral administration, includingformulation for injection, oral administration, nasal administration,pulmonary administration, topical administration, or other types ofadministration as one skilled in the art will recognize. Moreparticularly, administration of the pharmaceutical compositionsaccording to the present invention may be via any common route so longas the target tissue is available via that route. In a exemplaryembodiment, the pharmaceutical compositions may be introduced into thesubject by any conventional peripheral method, e.g., by intravenous,intradermal, intramusclar, subcutaneous, intramammary, intraperitoneal,intrathecal, retrobulbar, intrapulmonary (e.g., term release); by oral,sublingual, nasal, buccal, intratracheal, anal, vaginal, transmucosal,pulmonary or transdermal delivery, by suppository or by surgicalimplantation at a particular site. In one embodiment the administrationis parenteral (including intravenous, intradermal, intraperitoneal,intramuscular and subcutaneous).

The treatment may consist of a single dose or a plurality of doses overa period of time. Controlled continual release of the compositions ofthe present invention is also contemplated.

Supplementary active ingredients also can be incorporated into thecompositions. For use by the physician, the compounds will be providedin dosage unit form containing an amount of a GIP or novel GIP analog,with or without another therapeutic agent, for example, aglucose-lowering agent, a gastric emptying modulating agent, a lipidlowering agent, or a food intake inhibitor agent. Therapeuticallyeffective amounts of a GIP or a novel GIP analog for example for use inthe control of blood glucose or in the control of gastric emptying andin conditions in which gastric emptying is beneficially slowed orregulated are those that decrease post-prandial blood glucose levels,preferably to no more than about 8 or 9 mM or such that blood glucoselevels are reduced as desired. In diabetic or glucose intolerantindividuals, plasma glucose levels are higher than in normalindividuals. In such individuals, beneficial reduction or “smoothing” ofpost-prandial blood glucose levels may be obtained. As will berecognized by those in the field, an effective amount of therapeuticagent will vary with many factors including the patient's physicalcondition, the blood sugar level or level of inhibition of gastricemptying to be obtained, or the desired level of food intake reduction,and other factors. In some cases, it will be convenient to provide a GIPpolypeptide and at least one other active agent, for example anotherfood-intake-reducing, plasma glucose-lowering or plasma lipid-alteringagent, such as an exendin or GLP1 or agonist thereof, amylin, an amylinagonist analog, a CCK or CCK agonist, or a leptin or leptin agonist or asmall molecule cannabinoid CB1 receptor antagonists, beta-hydroxysteroiddehydrogenase-1 inhibitors, sibutramine and other drugs marketed fortreatment of diabetes or obesity, in a single composition or solutionfor administration together. As has been discussed throughout, the GIPpolypeptide may be a GIP hybrid comprising the at least one other suchactive agent. In other cases, it may be more advantageous to administerthe additional agent separately from said GIP polypeptide.

In one embodiment a GIP polypeptide may be administered separately ortogether with one or more other compounds and compositions that exhibita long term or short-term action to lower blood glucose, reduce orinhibit gastric emptying or reduce or inhibit gastric secretions orreduce nutrient availability, including, but not limited to othercompounds and compositions that comprise an amylin or amylin analogagonist, salmon calcitonin, a cholecystokinin (CCK) or CCK agonist, aleptin (OB protein) or leptin agonist, an exendin or exendin analogagonist, or a GLP-1 or GLP-1 analog agonist. Suitable amylin agonistsinclude, for example, [^(25,28,29)Pro-] human amylin (also known as“pramlintide,” and described in U.S. Pat. Nos. 5,686,511 and 5,998,367).The CCK used is preferably CCK octapeptide (CCK-8), more preferably itssulfated form. Leptin is discussed in, for example, (Pelleymounter etal., Science 269: 540-3 (1995); Halaas et al., Science 269: 543-6(1995); Campfield et al., Science 269: 546-9 (1995)). Suitable exendinsinclude exendin-3 and exendin-4, and exendin agonist compounds include,for example, those described in PCT Publications WO 99/07404, WO99/25727, and WO 99/25728. Suitable agents also include variousanti-diabetic agents, e.g. metformin, sulfonyureas, TZDs. In anotherembodiment is provided a combination therapy of a GIP analog or hybrid,e.g. 0601GIP3794, with an incretin mimetic, e.g., exenatide orliraglutide. In a further embodiment sub-therapeutic doses of theincretin mimetic are used, which provide a therapeutic benefit whencombined with the GIP compound.

Accordingly, in one embodiment, particularly in patients subject toconditions associated with elevated glucose levels such as diabetic orglucose intolerant individuals, more particularly type 2 diabeticpatients, where plasma glucose levels are higher than in normalindividuals, GIP therapy in such individuals will benefit from abeneficial reduction or “smoothing” of post-prandial blood glucoselevels prior to or concomitant with administration of a GIP or novel GIPanalog.

In contrast to GLP-1, GLP-1 analogs and mimetics such as exenatide whichhave been shown to be efficacious in controlling glucose levels in type2 diabetic patients, the insulinotropic effect of GIP is significantlyreduced in diabetic subjects compared to normal individuals. While notto be bound by theory, it is believed that while GIP's incretin effectis attenuated during persistent hyperglycemia, GIP or its analogs willact with a similar potency in diabetic patients as their action innormal subjects once glucose control is improved in these individuals.Thus according to the present invention GIP insensitivity can be reducedby achieving in a patient in need thereof, a glucose-lowering or areduction or “smoothing” of post-prandial blood glucose levels byappropriate agents or means, prior to or concomitant with administrationof a GIP or novel GIP analog that will enable or prolong even furtherglucose-lowering. In one embodiment the agent or means is provided atleast one day prior to GIP administration. In another embodiment theagent or means is provided and a sufficient glucose-lowering is observedprior to GIP administration.

As mentioned herein suitable agents include exenatide, metformin,sulfonylureas, or combinations thereof. Primary glucose control endpointcan be measured by means known in the art to clinicians. One method issimply to determine blood glucose levels post-prandially. Another is tomeasure HbA1c levels, as is known in the art.

A particularly suitable target population is those patients who fail toattain normal glucose concentrations during treatment with aglucose-lowering agent (such as exenatide). A type of hemoglobin calledhemoglobin A1c (HbA1c) forms when glucose attaches to hemoglobin. Thishappens only when blood glucose levels are high. The hemoglobin A1clevel can be used to measure a subject's past average blood sugar, e.g.over two to three months. Normal HbA1c values for non-diabetics areapproximately 4.0-6.2 percent. The American Diabetes Associationrecommends that it should be below 7 percent for diabetics, to minimizethe complications from diabetes. Despite glucose-lowering therapies,such as exenatide, significant numbers of patients may still remain withelevated Hb1Ac. Consequently, in one embodiment such subjects whoseHbA1c level (despite treatment with a glucose-lowering agent) remainsabove normal, at least 7 percent, at least 8 percent, at least 9 percentor at least 10 percent, are suitable subjects for the GIP therapy andnovel adjunct therapy treatments of the invention. In yet anotherembodiment the Hb1Ac level is greater than normal but no greater than6.5%, no greater than 7%, no greater than 7.5%, no greater than 8.0%, nogreater than 8.5%, no greater than 9.0%, no greater than 9.5%, or nogreater than 10%. In yet another embodiment, while reduction of Hb1Aclevels is not reduced to normal levels with monotherapy, it ispreferably reduced at least 10 percent, at least 20 percent, at least30, 40, 50, 60, 70, 80 or at least 90 percent from pre-treatment levels,prior to GIP administration or application of a novel adjunct therapy ofthe invention. In such patients, adjunct therapy with GIP is indicatedaccording to the invention since reduction of hyperglycemia (e.g., as byexenatide) in treated patients, e.g. diabetic patients, poises thepatient for reduced GIP insensitivity. Whereas the chronic hyperglycemiccondition in type 2 diabetes patients attenuates GIP's insulinotropicresponse, improved glycemic control resulting from exenatide treatment,for example, would restore responsiveness of the pancreatic beta-cell toGIP stimulation. Therefore GIP therapy or novel adjunct therapy (e.g.co-administration, GIP phybrid, GIP fusion protein) of pharmacologicaldoses of GIP or novel GIP analogs with exenatide (or other glucoselowering agents or agents or methods that lower glucose or that reduceor inhibit gastric emptying) will attain GIP sensitivity and lead todesired normoglycemia in diabetic patients or patients suffering fromconditions associated with elevated glucose. Since GIP lacks the gastricemptying effect of GLP1, nausea may be avoided, thus permitting the useof higher GIP dosing regimens than for GLP1. In yet another embodiment,GIP therapy or novel adjunct therapy will reduce Hb1Ac levels to atleast normal levels, or at least 10 percent, at least 20 percent, atleast 30, 40, 50, 60, 70, 80 or at least 90 percent from pre-treatment(pre GIP therapy or pre-novel-adjunct therapy) levels.

In yet a further embodiment, the GIP therapy or novel adjunct therapycan act at least additively, and preferably synergistically, to reducethe dose, dosing, amount, frequency or extent of treatment associatedwith another agent as mentioned herein. For example, such GIP or noveladjunct therapy can result in at least a 10, 20, 30, 40, 50, 60, 70, 80or 90% reduction in the amount, dose, frequency of dosing, or length oftreatment associated with a the other agent. The agent can be aglucose-lowering agent such a exendin-4, or any other agent, fordiabetes or other conditions that benefit form the methods andcompositions of the present invention.

The GIP polypeptide of the invention may be prepared for administrationas solutions of free base, or pharmacologically acceptable salts inwater suitably mixed with surface active agents (e.g., sorbitanmonooleate, polyoxyethylene sorbitain monolaurate (Tween 20),polyoxyethylene sorbitan monooleate (Tween 80), lecithin,polyoxyethylene-polyoxypropylene copolymers (Pluronics),hydroxypropylcellulose,) or complexation agents (e.g.,hydroxypropyl-b-cyclodextrin, sulfobutyether-b-cyclodextrin (Captisol),polyvinylpyrrolidone). Pharmaceutically-acceptable salts include theacid addition salts (formed with the free amino groups of the protein)and which are formed with inorganic acids such as, for example,hydrochloric or phosphoric acids, or such organic acids as acetic,oxalic, tartaric, mandelic, and the like. Salts formed with the freecarboxyl groups also can be derived from inorganic bases such as, forexample, sodium, potassium, ammonium, calcium, or ferric hydroxides, andsuch organic bases as isopropylamine, trimethylamine, histidine,procaine and the like. Such products are readily prepared by procedureswell known to those skilled in the art. Dispersions also can be preparedin glycerol, liquid polyethylene glycols, and mixtures thereof and inoils. Under ordinary conditions of storage and use, these preparationscontain a preservative to prevent the growth of microorganisms.

In one embodiment, the pharmaceutical compositions of the presentinvention are formulated so as to be suitable for parenteraladministration, e.g., via injection or infusion. In one embodiment, theGIP polypeptide is suspended in an aqueous carrier, for example, in anbuffer solution at a pH of about 3.0 to about 8.0, preferably at a pH ofabout 3.5 to about 7.4, about 3.5 to about 6.0, about 3.5 to about 5.0or about 3.7 to about 4.7. Useful buffers include sodium acetate/aceticacid, sodium lactate/lactic acid, ascorbic acid, sodium citrate-citricacid, sodium bicarbonate/carbonic acid, sodium succinate/succinic acid,Histidine, Sodium benzoate/benzoic acid, and sodium phosphates, andTris(hydroxymethyl)aminomehane. A form of repository or “depot” slowrelease preparation may be used so that therapeutically effectiveamounts of the preparation are delivered into the bloodstream over manyhours or days following transdermal injection or delivery.

The pharmaceutical compositions suitable for injectable use includesterile aqueous solutions or dispersions and sterile powders for theextemporaneous preparation of sterile injectable solutions ordispersions. In all cases, the form should be sterile and should befluid to the extent that is easily syringable. It is also desirable forthe GIP polypeptide of the invention to be stable under the conditionsof manufacture and storage and must be preserved against thecontaminating action of microorganisms, such as bacteria and fungi. Thecarrier can be a solvent or dispersion medium containing, for example,water, ethanol, polyol (e.g., sorbitol, glycerol, propylene glycol, andliquid polyethylene glycol, and the like), dimethylacetamide, cremorphorEL, suitable mixtures thereof, and oils (e.g., soybean, sesame, castor,cottonseed, ethyl oleate, isopropyl myristate, glycofurol, corn). Theproper fluidity can be maintained, for example, by the use of a coating,such as lecithin, by the maintenance of the required particle size inthe case of dispersion and by the use of surfactants. The prevention ofthe action of microorganisms can be brought about by variousantibacterial an antifungal agents, for example, meta-cresol, benzylalcohol, parabens (methyl, propyl, butyl), chlorobutanol, phenol,phenylmercuric salts (acetate, borate, nitrate), sorbic acid,thimerosal, and the like. In many cases, it will be preferable toinclude tonicity agents (for example, sugars, sodium chloride).Prolonged absorption of the injectable compositions can be brought aboutby the use in the compositions of agents delaying absorption (forexample, aluminum monostearate and gelatin).

Sterile injectable solutions may be prepared by incorporating the activecompounds in the required amount in the appropriate solvent with variousother ingredients enumerated above, as required, followed by filteredsterilization. Generally, dispersions are prepared by incorporating thevarious sterilized active ingredients into a sterile vehicle thatcontains the basic dispersion medium and the required other ingredientsfrom those enumerated above. In the case of sterile powders for thepreparation of sterile injectable solutions, the exemplary methods ofpreparation are vacuum-drying and freeze-drying techniques that yield apowder of the active ingredient plus any additional desired ingredientfrom a previously sterile-filtered solution thereof.

Generally, a therapeutically or prophylactically effective amount of thepresent GIP polypeptides will be determined by the age, weight, andcondition or severity of the diseases or metabolic conditions ordisorders of the recipient. See, e.g., Remington's PharmaceuticalSciences 697-773. See also Wang and Hanson, Parenteral Formulations ofProteins and Peptides: Stability and Stabilizers, Journal of ParenteralScience and Technology, Technical Report No. 10, Supp. 42:2 S (1988).Typically, a dosage of between about 0.001 μg/kg body weight/day toabout 1000 μg/kg body weight/day, may be used, but more or less, as askilled practitioner will recognize, may be used. Dosing may be one,two, three, four or more times daily, or less frequently, such as once aweek, once a month, or once a quarter, depending on the formulation, andmay be in conjunction with other compositions as described herein. Itshould be noted that the present invention is not limited to the dosagesrecited herein.

Appropriate dosages may be ascertained through the use of establishedassays for determining level of metabolic conditions or disorders inconjunction with relevant dose-response data. The final dosage regimenwill be determined by the attending physician, considering factors thatmodify the action of drugs, e.g., the drug's specific activity, severityof the damage and the responsiveness of the patient, the age, condition,body weight, sex and diet of the patient, the severity of any infection,time of administration and other clinical factors. As studies areconducted, further information will emerge regarding appropriate dosagelevels and duration of treatment for specific diseases and conditions.

An effective dose will typically be in the range of about 0.5 to 30 μgto about 5 mg/day, preferably about 10 to 30 μg to about 2 mg/day andmore preferably about 5 to 100 μg to about 1 mg/day, most preferablyabout 5 μg to about 500 μg/day, for a 50 kg patient, administered in asingle or divided doses and/or controlled continual release, of two,three, four or more administrations. Ine one embodiment the GIP compoundis administered peripherally at a dose of about 0.5 μg to about 5 mg perday in single or divided doses or controlled continual release, or atabout 0.01 μg/kg to about 500 μg/kg per dose, more preferably about 0.05μg/kg to about 250 μg/kg, most preferably below about 50 μg/kg.

Accordingly, exemplary doses can be derived from the total amount ofdrug to be given a day and the number doses administered a day. Forexample, exemplary doses can range from about 0.125 μg/dose (0.5 μggiven four times a day) to about 2 mg/dose (2 mg given once a day).Other dosages can be between about 0.01 to about 100 μg/kg/dose. Theexact dose to be administered may be determined by one of skill in theart and is dependent upon the potency of the particular compound, aswell as upon the age, weight and condition of the individual.Administration should begin whenever the therapeutic benefit, e.g.suppression of nutrient availability, food intake, weight loss orcontrol, blood glucose or plasma lipid lowering or modulation, isdesired, for example, at the first sign of symptoms or shortly afterdiagnosis of obesity, diabetes mellitus, or insulin-resistance syndrome.In one embodiment the GIP compound is administered prophylactically.Administration may be by any route, e.g., injection, preferablysubcutaneous or intramuscular, oral, nasal, transdermal, etc. Dosagesfor certain routes, for example oral administration, may be increased toaccount for decreased bioavailability, for example, by about 5-100 fold.

In general, the GIP compounds may be formulated into a stable, safepharmaceutical composition for administration to a patient.Pharmaceutical formulations contemplated for use in the methods of theinvention may comprise approximately 0.01 to 20% (w/v), preferably 0.05to 10%, of the GIP compound. The GIP compounds may be in an acetate,phosphate, citrate or glutamate buffer allowing a pH of the finalcomposition of about 3.0 to about 7.0; containing carbohydrate orpolyhydric alcohol as tonicity modifier and, optionally, approximately0.005 to 5.0% (w/v) of a preservative selected from the group consistingof m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabensand phenol. Such a preservative is generally included if the formulatedpeptide is to be included in a multiple use product.

In a particular embodiment of the present invention, a pharmaceuticalformulation of the present invention may contain a range ofconcentrations of GIP compounds, e.g., between about 0.01% to about 98%w/w, or between about 1 to about 98% w/w, or preferably between 80% and90% w/w, or preferably between about 0.01% to about 50% w/w, or morepreferably between about 10% to about 25% w/w in this embodiment. Asufficient amount of water for injection may be used to obtain thedesired concentration of solution. The pharmaceutical formulationsdescribed herein may be lyophilized. An exemplary formulation can be 1mg/mL GIP compound in 10 mM sodium acetate buffer solution, pH 4.2,containing 9.3% sucrose as an osmolality modifier.

In one embodiment, where the pharmaceutical formulation is to beadministered parenterally, the composition is formulation so as todeliver a dose of GIP polypeptide ranging from 0.1 μg/kg to 100 mg/kgbody weight/day, preferably at doses ranging from 1 μg/kg to about 50mg/kg body weight/day. Exemplary daily amounts may be in the range of alower limit of 2, 5, 10, 20, 40, 60 or 80 to an upper limit of 80 100,150, 200, or 250. Parenteral administration may be carried out with aninitial bolus followed by continuous infusion to maintain therapeuticcirculating levels of drug product. Those of ordinary skill in the artwill readily optimize effective dosages and administration regimens asdetermined by good medical practice and the clinical condition of theindividual patient.

In one embodiment the dose of GIP compound, either GIP analog,derivative or hybrid, for treatment of a human can be about 5 to about50 fold lower than the dose used in a mouse to elicit a similar effect,such as the doses depicted herein. In a further embodiment, the dose fora human can be a 10 to 30-fold lower dose than that used in a mouse, orfor example about 3 to 10 nmol/kg/d. In another embodiment, the dose inhumans can be from about 0.1 to 20 ug/kg/day, and can be 0.5 to 10ug/kg/d, and can be 1-2 ug/kg/d. These amounts may be achieved fromeither single or multiple dosing per day or from a sustained releasedelivery. For example, a sustained release composition if taken onceweekly, can be provided at about 0.1 to 1.0 milligrams of GIP compound,depending factors as discussed herein and as would be known to a skilledpractitioner. Once monthly or bi-monthly dosing would be adjustedaccordingly. Should nausea occur that would compromise patientcompliance, an escalating dose scheme can be used, starting from a lowerdose that does not elicit substantial nausea to increasing doses untilthe therapeutic effective dose is achieved.

The frequency of dosing will depend on the pharmacokinetic parameters ofthe agents and the routes of administration. The optimal pharmaceuticalformulation will be determined by one of skill in the art depending onthe route of administration and the desired dosage. See, e.g.,Remington's Pharmaceutical Sciences, supra, pages 1435-1712. Suchformulations may influence the physical state, stability, rate of invivo release and rate of in vivo clearance of the administered agents.Depending on the route of administration, a suitable dose may becalculated according to body weight, body surface areas or organ size.Further refinement of the calculations necessary to determine theappropriate treatment dose is routinely made by those of ordinary skillin the art without undue experimentation, especially in light of thedosage information and assays disclosed herein, as well as thepharmacokinetic data observed in animals or human clinical trials.

In one embodiment a formulation of the invention is a liquid, solid, orsemi-solid depot, slow, or continuous release formulation capable ofdelivering an active ingredient of the invention (or multiple activeingredients as for use in the adjunct therapies mentioned herein) over atime period of at least one hour. The release can occur over a period of24 hours to four months. Such slow or extended release formulations can,in some embodiments, comprise the active ingredient in a slow dissolvingform or formulation, such as a slow-dissolving peptide crystal (such asdisclosed in, for example, U.S. Pat. No. 6,380,357), in a matrix, or ina coating such as, e.g., an enteric coating or slow-dissolving coating(e.g., coated granules of active ingredient). Slow release matrices arecommonly a biodegradable polymer, non-biodegradable polymer, wax, fattymaterial, etc., and are known in the art (e.g., see U.S. Pat. Nos.6,368,630 and related patents, 6,379,704 and related patents). Inaddition, parenteral controlled release delivery can be achieved byforming polymeric microcapsules, matrices, solutions, implants anddevices and administering them parenterally or by surgical means. Thesedosage forms would typically have a lower bioavailability due toentrapment of some of the peptide in the polymer matrix or device. (Seee.g., U.S. Pat. Nos. 6,379,704, 6,379,703, and 6,296,842).

In one embodiment are microencapsulated GIP compounds, either a GIPanalog, derivative or hybrid, for sustained delivery. Suitable polymermatrix and excipient formulations, and methods for making them, areprovided for example, in US2005271702 published Dec. 8, 2005, forexample. The matrix may be formulated as microspheres for injection orotherwise configured as an implantable device. Such a composition forthe sustained release of biologically active GIP compound whilecomprise, preferably consist essentially of, a biocompatible polymer,the GIP compound and a sugar. The sugar can stabilize the peptide duringmanufacture, storage and use. The sustained release composition cancomprise GIP compound from about 0.1% w/w to about 10% w/w of the totalweight of the sustained release composition. The GIP polypeptide can bepresent from about 0.5% w/w to about 5% w/w of the total weight of thesustained release composition. In one embodiment the GIP compound willbe present from about 2% to 5%. In one embodiment, to minimize initialburst and to increase the sustained release period, the sustainedrelease composition can have a low porosity. In such embodiments, thesustained release composition has a total pore volume of about 0.1 mL/gor less. In addition the total pore volume can be from 0.0 to 0.1 mL/gand from 0.01 to less than 0.1 mL/g For example, in one embodiment thetotal pore volume is about 0.1 mL/g or less as determined using mercuryintrusion porosimetry. The sugar can be present from about 0.01% w/w toabout 10% w/w of the total weight of the sustained release composition.In one embodiment the sugar is present from about 0.1% w/w to about 5%w/w of the total weight of the sustained release composition. In anotherembodiment the total combined percent weight of drug and excipient(s) isfrom about 2% to about 8%. The sugar can be selected from amonosaccharide, a disaccharide, a sugar alcohol or a combinationthereof. In one embodiment the sugar is selected from sucrose, mannitol,trehalose, and combinations thereof. While any biocompatible,biodegradable polymer may be used, the polymer can be selected from thegroup consisting of poly(lactides), poly(glycolides),poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s,poly(lactic acid co-glycolic acid)s, polycaprolactone, polycarbonates,polyesteramides, polyanhydrides, poly(amino acids), polyorthoesters,polycyanoacrylates, poly(p dioxanone), poly(alkylene oxalate)s,biodegradable polyurethanes, blends thereof and copolymers thereof. Inone embodiment of particular interest the polymer comprisespoly(lactide-co-glycolide), and further can be a 50:50poly(lactide-co-glycolide), and further can have an inherent viscosityof between about 0.3 and 0.5 dL/g. In another embodiment when thesustained release compositions have a low porosity as described herein,which serves to both reduce initial release and to provide longersustained release with a desirable Cmaxto Cave ratio, additionalexcipients can be present. Such agents preferably will have little or nosubstantial effect on release rate. Such excipients can include thosethat provide or enhance agent stability, either during manufacturing,storage or release. Suitable stabilizers include, for example,carbohydrates, amino acids, fatty acids and surfactants and are known tothose skilled in the art. Further, stabilizers include “antioxidants”such as methionine, vitamin C, vitamin E and maleic acid. Theantioxidant can be present as part of a stabilized aqueous formulationor added into the polymer phase. Further a pH buffer can be added.Buffers are solutions containing either a weak acid and a related saltof the acid, or a weak base and a salt of the base. Buffers can maintaina desired pH to stabilize the formulation during any step ofmanufacturing, storage or release. For example, the buffer can be amonobasic phosphate salt or dibasic phosphate salt or combinationsthereof or a volatile buffer such as ammonium bicarbonate. Other buffersinclude but are not limited to acetate, citrate, succinate and aminoacids such as glycine, arginine and histidine. The buffer can be presentin the formulation from about 0% to about 10% of the total weight, orless than about 10, 15, 20, 25 or 30 mM.

As discussed herein one of ordinary skill in the art can readilydetermine frequency, timing and dose of a GIP or novel GIP analog of theinvention for treatment, particularly for conditions associated withelevated glucose, and further when used in adjunct therapy. For examplea dose-response relationship over time for the glucose-lowering effectof agent of interest can be first determined, followed by determining adose-response relationship with the added GIP or novel GIP analog inrelation to the doses selected for the other agent. In one examplepatients with type 2 diabetes are treated and assessed followingrandomized, subcutaneous injection of placebo, and various amounts ofagent on separate days following an overnight fast. Injections are givenimmediately before ingestion of a standardized Sustacal® meal (7kcal/kg) followed by collection of plasma glucose samples at frequentintervals during the subsequent 300 minutes. Glycemic response can bequantified as the time-weighted mean (±SE) change in plasma glucoseconcentration during the 5-hr period. An ED₅₀ for the glucose loweringeffect is determined, and appropriate dose of agent that lowerspostprandial plasma glucose concentrations is selected. Subsequently, ina similar study, this dosage is administered to patients whileadministering varying doses of GIP or a novel GIP analog in order todetermine an appropriate dose of GIP that will act in concert with thefirst agent to further lower or prolong glucose lowering.

Further, if desired, the timing of administration of the GIP doserelative to when or how long the first agent was administered isexamined in order to identify an optimal dosing regimen. For example, adose of exenatide can be given on day 1, followed by administration ofGIP on day 2, preferably once a glucose lowering response is observedresulting from the exenatide alone. In another embodiment, alternatingagent dosing with GIP dosing is provided. The agent may be administeredevery other period alternating with GIP administration. The period canbe 1, 2, 3, 4, 5, 6, or 7 days, 1, 2, 3, or 4 weeks, or 1, 2, 3, 4, 5 or6 months. The period can be varied, such as GIP administration 2 daysafter agent and agent administration 7 days after GIP treatment.Sustained release formulations or methods will extend the period in eachcase. Further, GIP or novel GIP analogs can be provided in adjuncttherapy with (or after cessation of) beta cell neogenesis therapy orislet or beta cell transplantation, where beta cells are increased innumber, thus providing a glucose-lowering post treatment. Consequently,in one embodiment such treatment, while not entirely creating anormoglycemia, nonetheless provides a patient with a sufficientlylowered glucose level, that resistance to GIP is attenuated such thatfurther or more normal glucose levels are achieved post-prandially.

In one embodiment the agent will have been administered or the methodwill have been applied at least twenty-four hours prior to commencingGIP administration. More specifically the intervening period can be 24,36, 48, 60 or 72 hours to 4, 5, 6, 7 or more days, to 2, 3, 4, 5, 6 ormore weeks, or any particular intervening time in hours or minuteswithin the above range. Alternatively, blood glucose levels can bemonitored regularly or post-prandially as would be known in the art tomeasure the effect of the glucose-lowering agent, using methods wellknown in the art, during and/or following administration of the agent.The administration of GIP can then be performed either at a time whenthe subject shows a level of response e.g., blood glucose level,indicative of reduced resistance to GIP, at which time or thereafter GIPor a novel GIP analog can be administered.

As discussed herein, in another embodiment of adjunct therapy with a GIPor novel GIP analog, the therapy comprises an agent or method that slowsnutrient to the duodenum (or other more distal nutrient-sensingGIP-secreting sites) that results in lowering glucose levels compared tothe absence of the agent or method. In yet another embodiment adjuncttherapy comprises an agent or method that slows gastric emptying. Inaddition to the viscous decelerants, such as described herein (e.g.,guar and fiber), the agent includes pharmacologic decelerants of gastricemptying, and includes gut hormones for which gastric slowing is aphysiologic event. Such agents include agonists of amylin (e.g.pramlintide), agonists of GLP1 and exendin (e.g. exenatide, NN2211,ZP-10. liraglutide), agonists of CCK, agonists of PYY, agonists ofsecretin, agonists of GRP, agonists of neuromedins, and agonists ofurocortin. In further embodiments are agents that directly or indirectlypromote agonist signaling of the physiologic gastric decelerants. Suchagents include secretagogues of endogenous gastric decelerants, andinhibitors of their degrading enzymes, including dipeptidyl dipeptidaseinhibitors, or other inhibitors of their clearance, especially at thekidney. In other embodiments are therapeutic strategies that slow theappearance of nutrient stimulus at GIP-secreting cells. Examples includemodulation of digestive functions through inhibition of digestivesecretions (e.g. gastric acid, pancreatic enzymes, bile) or throughinhibition of the digestive effect of such secretions (e.g. acidneutralization, enzyme inhibition, bile sequestration). Inhibitingdigestive secretion can occur via agents that directly achieve this(e.g. somatostatin, amylin, calcitonins, PYY) or by agents thatinterfere with endogenous pro-secretory pathways (e.g. luminalCCK-releasing factor). In one embodiment the adjunct therapy comprises amethod that achieves slower gastric emptying and lower nutrient uptake,e.g. diminishes nutrient drive at GIP secreting cells. In one suchembodiment is gastric bypass surgery, for example Roux-En-Y GastricBypass Surgery, lap band, or physical devices that physically divertnutrient flow from the duodenum.

In yet other embodiments adjunct therapy comprises methods thatstimulate secretion of, or slow degradation of, gastric decelerants. Asmentioned guar gum ingestion is one example, for example 10 grams guargum flour per meal. In Another agent is xanthum gum. Other decelerantsof nutrient absorption include fiber, as for example provided in a highfiber diet, and as rough fiber in breads and bran. Another agent is aglucosidase inhibitor, such as acarbose, which slows the rate at whichglucose (and fructose) is generated from sucrose at gut brush borderdisaccharidases. Yet another agent is Miglitol, another a glucosidaseinhibitor.

In yet another embodiment gastric emptying is achieved or mediated byadministering a peptide or peptide agonist. Based on the rat, doses ofthe following peptides have been determined to slow gastric emptying,and are entirely suitable as agents for adjunct therapies of theinvention: amylin (e.g., pramlintide doses of 60-600 μg/day); GLP1 orexendin agonist (e.g., exenatide dose range of 10-50 μg/day); CCK andagonists (see Young et al. “Dose-responses for the slowing of gastricemptying in a rodent model by glucagon-like peptide (7-36)NH2, amylin,cholecystokinin, and other possible regulators of nutrient uptake.”Metabolism 451-3 (1996); incorporated herein by reference). Other agentsinclude Secretin and agonists, CGRP and agonists, Neuromedin agonists,Urocortin agonists, GRP and bombesin agonists, and PYY and agonists.

In the embodiments herein, a method of defining doses can be based on adesired degree of slowing, which can be readily determined. For example,therapeutic doses of pramlintide (30, 60 90 μg; see Kong et al. “Theeffect of single doses of pramlintide on gastric emptying of two mealsin men with IDDM.” Diabetologia. 41577-583 (1998)) approximately doubledthe half-emptying time of the stomach. Accordingly, in one embodimentadjunct therapy comprises an agent or method that increases thehalf-emptying time of the stomach by about 200%, however in otherembodiments the t ½ of stomach emptying can increased by more than about25%, 50%, 75%, 100%, 200%, 300% and even 400% or more.

By example, an ED50 for exenatide slowing of gastric emptying has beenreported at about 0.05 μg/kg (e.g., approximately currently usedclinical dose) (see Kolterman et al. “Dose-response for inhibition ofglucagon secretion and gastric emptying by synthetic exendin-4 (AC2993)in subjects with type 2 diabetes.” Diabetes 49 (suppl 1)A114 Abstract460-P (2000)). In adjunct therapy with a GIP or a novel GIP analog suchslowing will provide a increased benefit to the subject. Consequently,in one embodiment agents or methods that provide an equivalent slowingof gastric emptying at pharmaceutically acceptable doses are suitableagents or methods. As discussed throughout, other embodiments of adjuncttherapy comprise mammalian amylins, the (25,28,29)proline-human amylinanalog (pramlintide), and salmon calcitonin, those being amongst themost potent. Additional suitable peptides and their EC50 (EC(50)nmol/kg_sem (EC(50) in μg): Pramlintide, 0.09_(—)0.08 log (0.07 μg);Human amylin, 0.19_(—)0.11 log (0.15 μg); Rat amylin, 0.23_(—)0.08 log(0.18 μg); Salmon calcitonin, 0.28_(—)0.07 log (0.19 μg); Ratcalcitonin, 0.94_(—)0.18 log (0.64 μg); Rat CGRP, 2.13_(—)0.29 log (1.62μg); GLP-1 (7-36)NH2, 2.76_(—)0.12 log (1.82 μg); Secretin, 3.09_(—)0.20log (1.87 μg); CCK-8, 12.8_(—)0.20 log (2.93 μg); Gastrin releasingpeptide, 49.9_(—)0.05 log (28.5 μg) (see Gedulin et al. “Comparison of21 peptides on inhibition of gastric emptying in conscious rats.” Dig.Dis. Week. A742 (abstract 2967) (1996); This study reported the potencyand effect of 21 peptides to modulate gastric emptying in dose-responsestudies in conscious rats (n=˜18 rats/peptide, rat weight ˜200 g).Peptide was injected subcutaneously 5 min before gavage with an acaloricdye-labeled methyl cellulose gel Animals were sacrificed 20 min laterand the dye content of the stomach measured spectroscopically to assessemptying. Only 10 peptides were found to fully inhibit gastric emptyingat doses up to 100 ug/rat. Peptides found to be either weakly active orinactive at doses of 100 μg were vasoactive intestinal peptide (VIP),gastric inhibitory peptide (GIP), pancreatic polypeptide, neuropeptideY, glucagon, insulin (if plasma glucose was maintained constant),gastrin, somatostatin, pituitary adenylate cyclase activating peptide(PACAP38), adrenomedullin and deamidated pramlintide.). In otherembodiments of the invention the agent comprise a agonist of any of thepeptides mentioned herein, such as an antibody or antibody fragmentagonist or small molecule agonist.

As described throughout, such agents (or their combination) can beadministered either separately or together with GIP or can comprise achimeric molecule with a GIP, e.g., either chemically linked orrecombinant fusion. As described throughout (e.g., see times and periodsmentioned herein), when administered separately GIP can be administeredeither at a designated time point after administration of the agent(s)or method, or it can be administered at or shortly after a desiredeffect has been obtained by prior administration of the agent or method,such effect associated with reducing the subject's GIP resistance.

It will be appreciated that the pharmaceutical compositions andtreatment methods of the invention may be useful in fields of humanmedicine and veterinary medicine. Thus the subject to be treated may bea mammal, preferably human or other animal. For veterinary purposes,subjects include for example, farm animals including cows, sheep, pigs,horses and goats, companion animals such as dogs and cats, exotic and/orzoo animals, laboratory animals including mice, rats, rabbits, guineapigs and hamsters; and poultry such as chickens, turkeys, ducks andgeese.

In addition, the present invention contemplates a kit comprising a GIPanalog or hybrid polypeptide of the invention, components suitable forpreparing said GIP compound polypeptide of the invention forpharmaceutical application, and instructions for using GIP compoundpolypeptide and components for pharmaceutical application.

The following formulation method can be used with the GIP compounds, aswell as with other suitable drug compounds. Generally, while screeningfor and formulating peptide or protein candidates for pharmaceuticalapplications, formulation scientists seek compounds where the solubilityand physical stability and/or chemical stability are somewhat within thesame pH range, making it easier to formulate and have sufficiently longshelf-life for clinical use. However, compounds that have solubility andstability maxima at different pH ranges present a formulation challenge.Because the solubility and stability of these drug candidates occur atdifferent pH ranges, a common practice is to screen excipients toenhance the solubility where the peptide is most stable. Often times,however, the solubility increased only slightly by the solubilityenhancer, but compromised the chemical stability of the peptide/protein.Exemplary bioactive GIP compounds where solubility and physical/chemicalstability are at different ranges of pH include AC163794, AC164326.AC164850, AC164190, AC164847, AC164957, AC164947 and AC164948. Forexample, a drug compound that is a candidate for this method may haveoptimal physical/chemical stability at about pH 6, instability near theisoelectric point (e.g. pI ˜5), and chemically stability, but lackdesired solubility near the desired pH for formulation, e.g. pH 4. Incontrast, exemplary compounds where the properties share the same pHrange include AC164233, AC164815, AC164816, AC164853, AC164854, andAC164855.

Because the solubility and stability of peptides can occur at differentpH ranges, a common practice is to screen excipients to enhance thesolubility where the peptide is most stable. However, in many cases thesolubility enhancer increases only slightly the solubility, butcompromises the chemical stability of the peptide/protein. However, thepresent invention is based on a different approach to the problem. Themethod entails solubilizing the drug at a pH range at which the drug ismaximally soluble, optimally soluble or at a sufficient and desirableconcentration. Long-term physical or chemical stability (such asdetermine by an accelerated stability study, typically 40 degrees C. for1 to 7 or more days) is not of concern at this step, since the drug needonly be sufficiently stable until and during the subsequent processingstep. By long-term stability is meant a period of time and under suchconditions during which the drug is stored during transport and prior totherapeutic use. The concentrated drug solution (first solution) may beused as a bulk solution to fill commercial vials, etc. The drug solutionis then dried to remove the aqueous phase. This is typically done invial form or in the container for therapeutic use. Just prior to use orupon use, the dried material is reconstituted, and used foradministration. In one embodiment, the drug solution pH is firstoptimized to attain the desired drug concentration (solubility, mg/mL)(i.e. the first solution). Secondly, the first solution is treated toremove the aqueous phase, as by lyophilization. The dried materialprovides a stable storage form. Thirdly, prior to or upon therapeuticuse the lyophilized material is reconstituted with a buffered solutionsuch that the dissolved drug is at a suitable dosing concentration thatis stable during the use period.

A wide variety of buffers can be used at various pHs to provide thefirst solution where the protein has maximal, optimal or desiredsolubility, as would be known to the formulation chemist with regard tothe drug compound of interest. In one embodiment the buffer is volatile,such as an acetate. In another embodiment, the buffer is not volatilebut does not significantly affect the stability of the compound in thefinal formulation upon reconstitution prior to use. In yet anotherembodiment, the buffer comprises and contributes to the finalformulation upon reconstitution.

In a further embodiment a tonicity modifier and/or lyo/cryoprotectantcan be used as would be known by a formulation chemist with regard tothe drug of interest. For peptide and polypeptide compounds, theseexcipients can include mannitol, sucrose, trehalose, or glycerol. Thesecompounds can be included in the first solution, if solubility is notadversely affected, or can be included in the reconstitution vehicle ordiluent.

The method can be used to formulate drug products containingbiomolecules (e.g., peptides or proteins), that have low inherentsolubility in the pH range where these compounds are optimally stable.Other examples of suitable biologically active agents that can have lowinherent solubility in the pH range where these compounds are optimallystable include GLP-1 peptides and analogs, immunoglobulins, antibodies,cytokines (e.g. lymphokines, monokines, chemokines), blood clottingfactors, hemopoietic factors, interleukins (IL-2, IL-3, IL-4, IL-6),interferons (β-IFN, α-IFN and γ-IFN), erythropoietin, nucleases, tumornecrosis factor, colony stimulating factors (e.g., GCSF, GM-CSF, MCSF),insulin, enzymes (e.g., superoxide dismutase, tissue plasminogenactivator), tumor suppressors, blood proteins, hormones and hormoneanalogs (e.g., growth hormone, adrenocorticotropic hormone andluteinizing hormone releasing hormone (LHRH)), vaccines (e.g., tumoral,bacterial and viral antigens); somatostatin; antigens; blood coagulationfactors; growth factors (e.g., nerve growth factor, insulin-like growthfactor); protein inhibitors, protein antagonists, and protein agonists;nucleic acids, such as antisense molecules; oligonucleotides; andribozymes. Small molecular weight agents suitable for use in the methodso long as they have low inherent solubility in the pH range where thesecompounds are optimally stable.

The following are examples present exemplary solutions and formulations,which can also be used with GIP analogs presented herein. In oneembodiment, Formulation 1, the first solution is about 2 mg/mL drug(e.g. AC163794, AC164850, or AC164288 having a solubility range of about0.5-5 mg/mL) in 10 mM Tris buffer (range: 10-50 mM) with about 5.07%mannitol at about pH 8.5 (range: ±0.5). The aqueous phase is removed,for example by lyophilization. Prior to use, the material isreconstituted with an (acidic) diluent to bring the pH to 7 (range:±0.5). In another embodiment, Formulation 2, the first solution is about2 mg/mL drug (e.g. AC163794, AC164850, or AC164288 (range: 0.5-5 mg/mL)in 10 mM glycylglycine buffer (range: 10-50 mM) with about 5.07%mannitol at about pH 8.5 (range: ±0.5). The aqueous phase is removed,for example by lyophilization. Prior to use, the material isreconstituted with an (acidic) diluent to bring the pH to 7 (range:±0.5). In another embodiment, Formulation 3, the first solution is about2 mg/mL drug (e.g. AC163794, AC164850, or AC164288 (range: 0.5-5 mg/mL)in 10 mM glycine (range: 10-50 mM) with 5.07% mannitol at pH 8.5 (range:±0.5). The aqueous phase is removed, for example by lyophilization.Prior to use, the material is reconstituted with an (acidic) diluent tobring the pH to 7 (range: ±0.5). In another embodiment, Formulation 4,the first solution is about 2 mg/mL drug (e.g. AC163794, AC164850, orAC164288 (range: 0.5-5 mg/mL) in 10 mM Ethanolamine buffer (range: 10-50mM) with about 5.07% mannitol at about pH 8.5 (range: ±0.5). The aqueousphase is removed, for example by lyophilization. Prior to use, thematerial is reconstituted with an (acidic) diluent to bring the pH to 7(range: ±0.5). In another embodiment, Formulation 5, the first solutionis about 2 mg/mL drug (e.g. AC163794, AC164850, or AC164288 (range:0.5-5 mg/mL) in 10 mM phosphate buffer (range: 10-50 mM) with about5.07% mannitol at about pH 8.0 (range: −1.0). The aqueous phase isremoved, for example by lyophilization. Prior to use, the material isreconstituted with an (acidic) diluent to bring the pH to 7 (range:±0.5).

The present application hereby incorporates by reference in theirentirety commonly-owned: PCT/US05/04178 filed Feb. 11, 2005 andpublished as WO2005/077072; PCT/US2005/004351 filed Feb. 11, 2005;PCT/US2005/004631 filed Feb. 11, 2005; PCT/US2005/045471 filed Dec. 15,2005; U.S. patent application Ser. No. 11/055,093; U.S. patentapplication Ser. No. 11/201,664 filed Aug. 10, 2005; and U.S. Ser. No.206,903 filed Aug. 17, 2005. The applications teach compounds and usesrelated to and useful for the present invention. Also incorporatedherein by reference is applicant's co-pending applicationPCT/US2006/005020 to Levy et al. An alternative embodiment to each ofthe embodiments disclosed herein is the proviso that the specific GIPpeptides, analogs, and derivatives disclosed in PCT/US2006/005020 arespecifically excluded. An alternative embodiment to each of theembodiments disclosed herein is the proviso that the specific GIPhybrids disclosed in PCT/US2006/005020 are specifically excluded. In yetanother alternative embodiment to each of the embodiments disclosedherein is the proviso that the specific GIP peptides, analogs, andderivatives disclosed in PCT/US2006/005020 are specifically excluded,except when combined to generate a novel GIP hybrid not specificallymentioned in PCT/US2006/005020 or for uses and treatment methods forwhich they were not specifically mentioned in PCT/US2006/005020.

Additional References

1. Fehmann H C, Goke B, Goke R, Trautmann M E, Arnold R. Synergisticstimulatory effect of glucagon-like peptide-1 (7-36) amide andglucose-dependent insulin-releasing polypeptide on the endocrine ratpancreas. FEBS Lett. 1989 252:109-12

2. Nauck M A, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additiveinsulinotropic effects of exogenous synthetic human gastric inhibitorypolypeptide and glucagon-like peptide-1-(7-36) amide infused atnear-physiological insulinotropic hormone and glucose concentrations. JClin Endocrinol Metab. 1993 76:912-7

3. Vilsboll T, Krarup T, Madsbad S, Holst J J. Both GLP-1 and GIP areinsulinotropic at basal and postprandial glucose levels and contributenearly equally to the incretin effect of a meal in healthy subjects.Regul Pept. 2003; 114:115-21

4. Jones I R, Owens D R, Moody A J, Luzio S D, Morris T, Hayes T M. Theeffects of glucose-dependent insulinotropic polypeptide infused atphysiological concentrations in normal subjects and type 2(non-insulin-dependent) diabetic patients on glucose tolerance andbeta-cell secretion. Diabetologia. 1987 30:707-12.

5. Nauck M A, Heimesaat M M, Orskov C, Holst J J, Ebert R, CreutzfeldtW. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide]but not of synthetic human gastric inhibitory polypeptide in patientswith type-2 diabetes mellitus. J Clin Invest. 1993 91:301-7.

6. Elahi D, McAloon-Dyke M, Fukagawa N K, Meneilly G S, Sclater A L,Minaker K L, Habener J F, Andersen D K. The insulinotropic actions ofglucose-dependent insulinotropic polypeptide (GIP) and glucagon-likepeptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 1994 Apr.14; 51(1):63-74.

7. Holst J J, Gromada J, Nauck M A. The pathogenesis of NIDDM involves adefective expression of the GIP receptor. Diabetologia. 1997 40:984-6.

8. Lynn F C, Pamir N, Ng E H, McIntosh C H, Kieffer T J, Pederson R A.Defective glucose-dependent insulinotropic polypeptide receptorexpression in diabetic fatty Zucker rats. Diabetes. 2001 50:1004-11

9. Meier J J, Hucking K, Holst J J, Deacon C F, Schmiegel W H, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide infirst-degree relatives of patients with type 2 diabetes. Diabetes. 200150:2497-504.

10. Meier J J, Gallwitz B, Kask B, Deacon C F, Holst J J, Schmidt W E,Nauck M A. Stimulation of insulin secretion by intravenous bolusinjection and continuous infusion of gastric inhibitory polypeptide inpatients with type 2 diabetes and healthy control subjects. Diabetes.2004 53 Suppl 3:S220-4.

11. Vilsboll T, Knop F K, Krarup T, Johansen A, Madsbad S, Larsen S,Hansen T, Pedersen O, Holst J J. The pathophysiology of diabetesinvolves a defective amplification of the late-phase insulin response toglucose by glucose-dependent insulinotropic polypeptide-regardless ofetiology and phenotype. J Clin Endocrinol Metab. 2003 88:4897-903.

12. Vilsboll T, Krarup T, Madsbad S, Hoist J J. Defective amplificationof the late phase insulin response to glucose by GIP in obese Type IIdiabetic patients. Diabetologia. 2002 45:1111-9.

13. Young A A, Gedulin B R, Rink T J. Dose-responses for the slowing ofgastric emptying in a rodent model by glucagon-like peptide (7-36) NH2,amylin, cholecystokinin, and other possible regulators of nutrientuptake. Metabolism. 1996 45:1-3.

14. Meier J J, Goetze O, Anstipp J, Hagemann D, Hoist J J, Schmidt W E,Gallwitz B, Nauck M A. Gastric inhibitory polypeptide does not inhibitgastric emptying in humans. Am J Physiol Endocrinol Metab. 2004286:E621-5.

15. Kieffer T J. Gastro-intestinal hormones GIP and GLP-1. AnnEndocrinol 2004 65:13-21.

16. Jones I R, Owens D R, Moody A J, Luzio S D, Morris T, Hayes T M. Theeffects of glucose-dependent insulinotropic polypeptide infused atphysiological concentrations in normal subjects and type 2(non-insulin-dependent) diabetic patients on glucose tolerance andB-cell secretion. Diabetologia. 1987 30:707-12.

17. Nauck M A, Heimesaat M M, Orskov C, Hoist J J, Ebert R, CreutzfeldtW. Preserved incretion activity of glucagon-like peptide 1 [7-36 amide]but not of synthetic human gastric inhibitory polypeptide in patientswith type-2 diabetes mellitus. J Clin Invest. 1993 91:301-7.

18. Elahi D, McAloon-Dyke M, Fukagawa N K, Meneilly G S, Sclater A L,Minaker K L, Habener J F, Andersen D K. The insulinotropic actions ofglucose-dependent insulinotropic polypeptide (GIP) and glucagon-likepeptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 1994 Apr.14; 51(1):63-74.

19. Hoist J J, Gromada J, Nauck M A. The pathogenesis of NIDDM involvesa defective expression of the GIP receptor. Diabetologia. 1997 40:984-6.

20. Young A A, Gedulin B R, Rink T J. Dose-responses for the slowing ofgastric emptying in a rodent model by glucagon-like peptide (7-36) NH2,amylin, cholecystokinin, and other possible regulators of nutrientuptake. Metabolism. 1996 45:1-3.

21. Kieffer T J. Gastro-intestinal hormones GIP and GLP-1. AnnEndocrinol 2004 65:13-21.

22. Deacon C F, Nauck M A, Toft-Nielsen M, Pridal L, Willms B, Hoist JJ. Both subcutaneously and intravenously administered glucagon-likepeptide 1 are rapidly degraded from the NH2-terminus in type II diabeticpatients and in healthy subjects. Diabetes 1995 44:1126-1131.

23. Deacon C F, Johnsen A H, Hoist J J. Degradation ofglucagon-like-peptide-1 by human plasma in vitro yields an N-terminallytruncated peptide that is a major endogenous metabolite in vivo. J.Clin. Endocrinol. Metab. 1995 80:952-957.

24. Kieffer T J, McIntosh C H, Pederson R A. Degradation ofglucose-dependent insulinotropic polypeptide and truncated glucagon-likepeptide 1 in vitro and in vivo by dipeptidyl peptidase IV.Endocrinology. 1995 August; 136(8):3585-96.

25. Plamboeck A, Holst J J, Carr R D, Deacon C F. Neutral endopeptidase24.11 and dipeptidyl peptidase IV are both involved in regulating themetabolic stability of glucagon-like peptide-1 in vivo. Adv Exp Med.Biol. 2003; 524:303-12.

26. Hupe-Sodmann K, McGregor G P, Bridenbaugh R, Goke R, Goke B, TholeH, Zimmermann B, Voigt K. Characterisation of the processing by humanneutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of thesubstrate specificity of the enzyme for other glucagon-like peptides.Regul Pept. 1995 Aug. 22; 58(3):149-56.

27. Gault V A, Flatt P R, Harriott P, Mooney M H, Bailey C J, O'Harte FP. Improved biological activity of Gly2- and Ser2-substituted analoguesof glucose-dependent insulinotrophic polypeptide. J Endocrinol. 2003January; 176(1):133-41.

28. Hinke S A, Gelling R W, Pederson R A, Manhart S, Nian C, Demuth H U,McIntosh C H. Dipeptidyl peptidase IV-resistant[D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improvesglucose tolerance in normal and obese diabetic rats. Diabetes. 2002March; 51(3):652-61.

29. Hudson F M, Andersen N H. Exenatide: NMR/CD evaluation of the mediumdependence of conformation and aggregation state. Biopolymers. 200476:298-308.

30. Andersen N H, Brodsky Y, Neidigh J W, Prickett K S.Medium-dependence of the secondary structure of exendin-4 andglucagon-like-peptide-1. Bioorg Med. Chem. 2002 10:79-85.

31. Neidigh J W, Fesinmeyer R M, Prickett K S, Andersen N H. Exendin-4and glucagon-like-peptide-1: NMR structural comparisons in the solutionand micelle-associated states. Biochemistry. 2001 40:13188-200.

32. Thum A, Hupe-Sodmann K, Goke R, Voigt K, Goke B, McGregor G P.Endoproteolysis by isolated membrane peptidases reveal metabolicstability of glucagon-like peptide-1 analogs, exendins-3 and -4. ExpClin Endocrinol Diabetes. 2002 110:113-8.

33. Fehmann H C, Goke B. Characterization of GIP(1-30) and GIP(1-42) asstimulators of proinsulin gene transcription. Peptides. 1995 16:1149-52.

Throughout this application various publications are referenced. Thedisclosures of these publications in their entirety are herebyincorporated by reference into this application in order to more fullydescribe the state of the art to which this invention pertains.

To assist in understanding the present invention, the following Examplesare included. The experiments relating to this invention should not, ofcourse, be construed as specifically limiting the invention and suchvariations of the invention, now known or later developed, which wouldbe within the purview of one skilled in the art are considered to fallwithin the scope of the invention as described herein and hereinafterclaimed.

EXAMPLES

The examples illustrate the preparation of the present GIP polypeptides,and the testing of these GIP polypeptides of the invention in vitroand/or in vivo.

Example 1 Preparation of GIP Polypeptides

Peptides of the invention may be assembled on a Symphony peptidesynthesizer (Protein Technologies, Inc.) using Rink amide resin(Novabiochem) with a loading of 0.43-0.49 mmol/g at 0.050-0.100 mmol ora pre-loaded Wang Resin (Fmoc-Tyr(tBu)-Wang resin) 0.63 mmol/g(Novabiochem). Fmoc amino acid (5.0 eq, 0.250-0.500 mmol) residues aredissolved at a concentration of 0.10 M in 1-methyl-2-pyrrolidinone. Allother reagents (HBTU, 1-hydroxybenzotriazole hydrate andN,N-Diisopropylethylamine) are prepared as 0.55 M dimethylformamidesolutions. The Fmoc protected amino acids are then coupled to theresin-bound amino acid using, HBTU (2.0 eq, 0.100-0.200 mmol),1-hydroxybenzotriazole hydrate (1.8 eq, 0.090-0.18 mmol),N,N-diisopropylethylamine (2.4 eq, 0.120-0.240 mmol) for 2 hours.Following the last amino acid coupling, the peptide is deprotected using20% (v/v) piperidine in dimethylformamide for 1 hour. Once peptidesequence is complete, the Symphony peptide synthesizer is programmed tocleave the resin. Trifluoroacetic acid (TFA) cleavage of the peptidefrom resin is carried out using 93% TFA, 3% phenol, 3% water and 1%triisopropylsilane for 1 hour. The cleaved peptide is precipitated usingtert-butyl methyl ether, pelleted by centrifugation and lyophilized. Thepellet is re-dissolved in water (10-15 mL), filtered and purified viareverse phase HPLC using a C18 column and an acetonitrile/water gradientcontaining 0.1% TFA. The resulting peptides are purified to homogeneityby reverse phase HPLC and the purity is confirmed by LCMS.

A general procedure for N-capping the peptides of the invention withfatty acids (e.g., octanoic and stearic acids) is as follows: Peptide onrink amide resin (0.1 mmol) is suspended in NMP (5 mL). In a separatevial, HBTU (0.3 mmol), HOBt (0 3 mmol) is dissolved in DMF (5 mL)followed by the addition of DIEA (0.6 mmol). This solution is added tothe resin and this suspension is shaken for 2 hrs. The solvent isfiltered and washed thoroughly with NMP (5 mL×4) and CH₂Cl₂ (20 mL),dried and is subjected to the TFA cleavage for 1 hr. The yield of thedesired peptide is ca. 40 mg after cleavage and purification.

PEG modification may be carried out in solution on a free epsilon-aminogroup of lysine or a terminal amino group of a purified peptide usingcommercially available activated PEG esters. The resulting PEGylatedderivatives are purified to homogeneity by reverse phase HPLC and thepurity is confirmed by LC/MS and MALDI-MS.

Example 2 Binding Assays

The GIP polypeptides of the invention may be tested in a variety ofreceptor, e.g. GIPR, GLP-1R, amylin receptor, binding assays usingbinding assay methodologies generally known to those skilled in the art.Such assays include those described herein.

GIP Receptor Binding Assay: To identify GIP analog peptides havingaffinity for the human GIP receptor the following assay was performed ina high throughput format. Cell membranes were prepared from confluentcultures of an HEK293 cell line stably expressing the human GIP receptor(HEK-GIPR), snap frozen, and stored at −80 degrees C. until use. At thetime of assay, membranes were thawed on ice and diluted to 0.02 mg/mL inice cold binding buffer (20 mM HEPES pH 7.4, 0.5% BSA, 5 mM MgCl2, 1 mMCaCl2, 170 μM Phosphoramidon, 1.5 mM Bestatin-HCL, and 70 mMBacitracin). Heterologous binding assays were initiated by combiningmembranes with 30 pM 125I-GIP and 10 nM individual unlabeled GIP analogsdiluted in assay buffer. Reactions were allowed to proceed toequilibrium for 90′ at room temperature with constant shaking. Bindingwas then terminated by rapid filtration through 96-well glass fiberfilter plates separating bound and unbound fractions of radioligand.Displacement of radioligand for each analog was calculated relativemaximal displacement by human GIP (100%), and non-specific binding (0%)in the absence of any competing ligand. Analog peptides displacing morethan 50% of total ligand were segregated to a ‘positive” test group andre-tested for accurate IC50 determination using the aforementionedformat with increasing concentrations of unlabeled analog (10 pM-1 uMfinal concentration). Analogs displacing more than 50% of total ligandwere scored to have IC50 values less than 10 nM.

Amylin binding assay: Evaluation of the binding of some exemplarycompounds of the invention to amylin receptors may be carried out asfollows in nucleus accumbens membranes prepared from rat brain. MaleSprague-Dawley® rats (200-250) grams are sacrificed by decapitation.Brains are removed and place in cold phosphate-buffered saline (PBS).From the ventral surface, cuts are made rostral to the hypothalamus,bounded laterally by the olfactory tracts and extending at a 45° anglemedially from these tracts. This basal forebrain tissue, containing thenucleus accumbens and surrounding regions, is weighed and homogenized inice-cold 20 mM HEPES buffer (20 mM HEPES acid, pH adjusted to 7.4 withNaOH at 23° C.). Membranes are washed three times in fresh buffer bycentrifugation for 15 minutes at 48,000×g. The final membrane pellet isresuspended in 20 mM HEPES buffer containing 0.2 mM phenylmethylsulfonylfluoride (PMSF).

To measure ¹²⁵I-amylin binding (see, Beaumont K et al. Can J PhysiolPharmacol. 1995 July; 73(7):1025-9), membranes from 4 mg original wetweight of tissue are incubated with ¹²⁵I-amylin at 12-16 pM in 20 mMHEPES buffer containing 0.5 mg/ml bacitracin, 0.5 mg/ml bovine serumalbumin, and 0.2 mM PMSF. Solutions are incubated for 60 minutes at 2°C. Incubations are terminated by filtration through GF/B glass fiberfilters (Whatman Inc., Clifton, N.J.) that are presoaked for 4 hours in0.3% poylethyleneimine in order to reduce nonspecific binding ofradiolabeled peptides. Filters are washed immediately before filtrationwith 5 ml cold PBS, and immediately after filtration with 15 ml coldPBS. Filters are removed and radioactivity assessed in a gamma-counterat a counting efficiency of 77%. Competition curves are generated bymeasuring binding in the presence of 10⁻¹² to 10⁻⁶ M unlabeled testcompound and are analyzed by nonlinear regression using a 4-parameterlogistic equation (Inplot program; GraphPAD Software, San Diego).

CGRP receptor binding assay: Evaluation of the binding of compounds ofthe invention to CGRP receptors are essentially as described for amylinexcept using membranes prepared from SK-N-MC cells, known to expressCGRP receptors (Muff, R. et. al., Ann NY Acad. Sci. 1992: 657, 106-16).Binding assays are performed as described for amylin except using 13,500cpm 125I-hCGRP/well or 21.7 pM/well (Amersham).

Adrenomedullin binding assay: Binding to the adrenomedullin receptor maybe investigated using HUVECs that contain the adrenomedullin receptor(Kato J et. al., Eur J Pharmacol. 1995, 289:383-5) using the PerkinElmer AlphaScreen™ assay for cyclic AMP using an optimum of 25-30,000cells per well. Elevation of cAMP levels is not large for HUVEC comparedto CHO cells. As such, CHO cells may be chosen as a negative controlsince they do not express the adrenomedullin receptor if desired.

Calcitonin receptor binding assay: Binding to the calcitonin receptormay be investigated using CHO cells or T47D cells, which also expressthe calcitonin receptor (Muff R. et. al, Ann NY Acad. Sci. 1992,657:106-16 and Kuestner R. E. et. al. Mol. Pharmacol. 1994, 46:246-55),as known in the art.

Leptin binding assay: Two in vitro bioassays are routinely used toassess leptin binding and receptor activation (see e.g., White, et al.,1997. Proc. Natl. Acad. Sci. U.S.A. 94: 10657-10662). An alkalinephosphatase(“AP”)-leptin (“OB”) fusion protein (“AP-OB”) may be used tomeasure inhibition of leptin binding in the absence or presence ofrecombinant mouse leptin (positive control) or peptide, by COS-7 cellstransfected with the long (signaling) form of the mouse OB receptor(“OB-RL”). Signal transduction assays may be done in GT1-7 cellscotransfected with AP reporter and OB-RL constructs. Secreted alkalinephosphatase(“SEAP”) activity in response to stimulation with mouseleptin or peptide may be measured by chemiluminescence.

Y1 receptor binding assay: Membranes are prepared from confluentcultures of SK-N-MC cells that endogenously expresses the neuropeptideY1 receptors. Membranes are incubated with 60 pM [125I]-human Peptide YY(2200 Ci/mmol, PerkinElmer Life Sciences), and with unlabeled testcompound for 60 minutes at ambient temperature in a 96 well polystyreneplate. Then well contents are harvested onto a 96 well glass fiber plateusing a Perkin Elmer plate harvestor. Dried glass fiber plates arecombined with scintillant and counted on a Perkin Elmer scintillationcounter.

Y2 receptor binding assay: Membranes are prepared from confluentcultures of SK-N-BE cells that endogenously expresses the neuropeptideY2 receptors. Membranes are incubated with 30 pM [125I]-human Peptide YY(2200 Ci/mmol, PerkinElmer Life Sciences), and with unlabeled testcompound for 60 minutes at ambient temperature in a 96 well polystyreneplate. Then well contents are harvested onto a 96 well glass fiber plateusing a Perkin Elmer plate harvestor. Dried glass fiber plates arecombined with scintillant and counted on a Perkin Elmer scintillationcounter.

Y4 receptor binding assay: CHO-K1 cells are transiently transfected withcDNA encoding neuropeptide Y4 gene, and then forty-eight hours latermembranes are prepared from confluent cell cultures. Membranes areincubated with 18 pM [125I]-human Pancreatic Polypeptide (2200 Ci/mmol,PerkinElmer Life Sciences), and with unlabeled test compound for 60minutes at ambient temperature in a 96 well polystyrene plate. Then wellcontents are harvested onto a 96 well glass fiber plate using a PerkinElmer plate harvestor. Dried glass fiber plates are combined withscintillant and counted on a Perkin Elmer scintillation counter.

Y5 receptor binding assay: CHO-K1 cells are transiently transfected withcDNA encoding neuropeptide Y5 gene, and then forty-eight hours latermembranes are prepared from confluent cell cultures. Membranes areincubated with 44 pM [125I]-human Peptide YY (2200 Ci/mmol, PerkinElmerLife Sciences), and with unlabeled test compound for 60 minutes atambient temperature in a 96 well polystyrene plate. Then well contentsare harvested onto a 96 well glass fiber plate using a Perkin Elmerplate harvestor. Dried glass fiber plates are combined with scintillantand counted on a Perkin Elmer scintillation counter.

GLP-1 receptor binding assay: GLP-1 receptor binding activity andaffinity may be measured using a binding displacement assay in which thereceptor source is RINm5F cell membranes, and the ligand is [125I]GLP-1.Homogenized RINm5F cell membranes are incubated in 20 mM HEPES bufferwith 40,000 cpm [125I]GLP-1 tracer, and varying concentrations of testcompound for 2 hours at 23° C. with constant mixing. Reaction mixturesare filtered through glass filter pads presoaked with 0.3% PEI solutionand rinsed with ice-cold phosphate buffered saline. Bound counts aredetermined using a scintillation counter. Binding affinities arecalculated using GraphPad Prism software (GraphPad Software, Inc., SanDiego, Calif.).

Example 3 Mouse Food Intake Assay

The GIP hybrid polypeptides of the invention may be tested for appetitesuppression in the mouse food intake assay and for their effect on bodyweight gain in diet-induced obesity (DIO) mice. The experimentalprotocols for the screens are described herein.

Female NIH/Swiss mice (8-24 weeks old) are group housed with a 12:12hour light:dark cycle with lights on at 0600. Water and a standardpelleted mouse chow diet are available ad libitum, except as noted.Animals are fasted starting at approximately 1500 hrs, 1 day prior toexperiment. The morning of the experiment, animals are divided intoexperimental groups. In a typical study, n=4 cages with 3 mice/cage.

At time=0 min, all animals are given an intraperitoneal injection ofvehicle or compound, typically in an amount ranging from about 10nmol/kg to 75 nmol/kg, and immediately given a pre-weighed amount (10-15g) of the standard chow. Food is removed and weighed, typically at 30,60, and 120 minutes, to determine the amount of food consumed (Morley,Flood et al., Am. J. Physiol. 267: R178-R184, 1994). Food intake iscalculated by subtracting the weight of the food remaining at the e.g.,30, 60, 120, 180 and/or 240 minute time point, from the weight of thefood provided initially at time=0, Significant treatment effects areidentified by ANOVA (p<0.05). Where a significant difference exists,test means are compared to the control mean using Dunnett's test (Prismv. 2.01, GraphPad Software Inc., San Diego, Calif.).

Activity in the food intake assay and sequence of parent molecules usedwith GIP for the synthesis of hybrids herein include:

Mouse Food Intake, % 60 min basal ED50 30  60 120 180 Description(nmol/kg) Sequence min min min min Dose PYY(3-36) 1 3 IKPEAPGEDASPEELNR−31 −38 −40 −26 10 (SEQ ID NO: 47) YYASLRHYLNLVTRQR nmol/ Y-NH2 KgExendin-4 5 HGEGTFTSDLSKQMEEE −41 −60 −61 −60 4.8 (SEQ ID NO: 5)AVRLFIEWLKNGGPSSG nmol/ APPPS-NH2 Kg Exendin-4 (1-28) 11 0.3HGEGTFTSDLSKQMEEE −50 −62 −49 −49 16.3 (SEQ ID NO: 287) AVRLFIEWLKN-NH2nmol/ Kg Exendin-4 (1-28) 12 13 HGEGAFTSDLSKQLEEE −53 −61 −50 −53 16.7[Ala5, Leu14, AVRLFIEFLKN-NH2 nmol/ Phe25] Kg (SEQ ID NO: 288)Rat Amylin (SEQ 9 KCNTATCATQRLANFL −58 −40 −36.5 −35.5 25 ID NO: 33)VRSSNNLGPVLPPTNVG nmol/ SNTY-NH2 Kg hAmylin(1 -7)- 10 26KCNTATCVLGRLSQEL −60 −47 −42.5 −32 25 ^(11,18)Arg-sCT(8-27)-HRLQTYPRTNTGSNTY- nmol/ Amylin(33-37) NH2 Kg (SEQ ID NO: 95) CCK-8 26DY(SO3)MGWMDF-NH2 −92 −56 −27 10 (SEQ ID NO: 289) nmol/ Kg

Example 4 Body Weight Gain in Fattened C57B1/6 (Diet-Induced-Obesity, orDIO) Mice

Male C57BL/6 mice (4 weeks old at start of study) are fed high fat (HF,58% of dietary kcal as fat) or low fat (LF, 11% of dietary kcal as fat)chow. After 4 weeks on chow, each mouse is implanted with an osmoticpump (Alzet #2002) that subcutaneously delivers a predetermined dose ofhybrid polypeptide continuously for two weeks. Body weight and foodintake are measured weekly (Surwit et al., Metabolism—Clinical andExperimental, 44: 645-51, 1995). Effects of the test compound areexpressed as the mean+/−sd of % body weight change (i.e., % change fromstarting weight) of at least 14 mice per treatment group (p<0.05 ANOVA,Dunnett's test, Prism v. 2.01, GraphPad Software Inc., San Diego,Calif.).

Example 5 Further Testing of GIP Compounds and Hybrids

Circular dichroism (CD) and NMR studies of Exendin-4 in aqueous mediaand in media containing organic cosolvents reveal that the C-terminalsegment containing the sequence, LFIEWLKNGGPSSGAPPPS (SEQ ID NO: 183)(residue 21-39) forms a unique hydrophobic Trp-cage cluster resultingfrom interactions of Pro37 with Phe22 and Pro38 with Trp25 (14-16).Interestingly, there is no evidence of Trp-cage formation in watercontaining dodecylphosphocholine (DPC), a micellar state that mimics abiological membrane environment. NMR spectral data indicate rapidsegmental motion of the eight C-terminal residues, presumably becausethe Trp-cage is destabilized due to energetically favorable associationof the Trp residue with the phosphocholine head groups. This Trp-cagecluster motif is the first example of a protein-like tertiary structuredisplayed by a peptide, and could be responsible for imparting greatermetabolic stability by masking protease-sensitive sites in the moleculein vivo (17).

Thus, in one embodiment GIP analog or hybrids were designed with thepremise that these peptides could assume the Trp cage structure reportedfor Exendin-4 by appending the Exendin tail sequence to the C-termini ofthe truncated GIP peptides GIP-(1-30) and GIP-(1-26). In addition,substitutions of the Tyr and Ala residues at the N-terminus of GIP werealso made to confer resistance to DPP-IV peptidase degradation. Thesemetabolically stable GIP analog or hybrids can be used as monotherapy oras an adjunct therapy with Exendin-4 (or other GLP-1 agonists) orant-diabetic drugs such as metformin, sulphonylureas,thiazolidinediones, pramlintide and insulin for treatment of type 2diabetes.

Analogs can and were screened in GIP receptor binding and acute glucoselowering assays in NIH Swiss or diabetic db/db mice. See FIGS. 2-4. Invitro GLP-1 and glucagon receptor binding counterscreens were carriedout to assess receptor specificity. The enzymatic stability of these GIPanalog or hybrids are also being tested by incubation of the peptideswith kidney brush-border membrane extract, membrane extract from RINm5Fcells and purified neutral endopeptidase 24.11, followed by analysis ofthe cleavage products by LC-MS/MS (data not shown).

Analogs can be and were characterized further to assess theiranti-diabetic effects, and in particular, the insulin secretionenhancement (insulinotropic effect) and glucose lowering action. Forexample, in normal mice Compound G was found to be significantly moreefficacious than full length GIP (FIGS. 3A and 3B). As seen in FIG. 4,Compound G shows a pronounced and long-acting effect in lowering glucosein a diabetic mouse model, whereas the action of GIP at a 10 fold higherdose is modest and wanes over time. The glucose lowering profile ofCompound G also differs from that of Exendin-4 (Compound K), which has amore rapid onset of action.

Example 6 Enhanced Glucose Lowering Effects of GIP Analogs and Hybrids

Glucose lowering effect in vivo of novel GIP analog or hybrids wasdetermined FIGS. 8A and 8 b provide a result of one such study. Pointsrepresent mean±sem. Peptide was injected IP at t=0 immediately followingbaseline sample into 2-hour fasted NIH/Swiss mice. Samples were taken att=60, 120, 180 and 240 minutes. Blood glucose was measured with aOneTouch® Ultra® (LifeScan, Inc., a Johnson & Johnson Company, Milpitas,Calif.). *p<0.05 vs. vehicle control; ANOVA, Dunnett's test.

Tested were: Compound Number A, human GIP acid form:

-   YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ-OH (SEQ ID NO: 2);-   Compound No. I, D-Ala2 GIP acid form:-   Y(D-Ala)EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ-OH (SEQ ID NO:479);    and Compound No. G, D-Ala2GIP(1-30)-PSSGAPPPS (SEQ ID NO: 1) amide    form:-   Y(D-Ala)EGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO:186).

The data demonstrates that a D-alanine substitution at position 2 in thenovel GIP analog or hybrids herein improves glucose lowering ability invivo. Addition of D-Ala even to full length improves glucose loweringcompared to unmodified GIP: improved activity is seen in the first hour,but wanes over time. In contrast, a clearly superior and surprisingprofile is observed when both a protease resistant N-terminus and aTrp-cage C-terminal shield are present. For example, the profile ananalog (see Compound G) comprising both aspects shows graduallyincreasing activity that peaks at t=120 min, and is more sustained thannative GIP or its D-Ala2 version.

FIG. 9 depicts glucose lowering effect of novel GIP analog or hybrids,particularly the effect of a Trp-cage. Points represent mean±sem.Peptide was injected IP at t=0 immediately following baseline sampleinto 2-hour fasted NIH/Swiss mice. Samples were taken at t=60, 120, 180and 240 min. Blood glucose was measured with a OneTouch® Ultra®(LifeScan, Inc., a Johnson & Johnson Company, Milpitas, Calif.). *p<0.05vs. vehicle control; ANOVA, Dunnett's test.

Tested were: Compound No. H, (D-Ala2)GIP(1-30) amide form:

-   Y(D-Ala)EGTFISDYSIAMDKIHQQDFVNWLLAQK-NH2; and Compound No. G,    (D-Ala2)GIP(1-30)-PSSGAPPPS (SEQ ID NO: 1) amide form:    Y(D-Ala)EGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO:186).

The data demonstrates that the presence of a C-terminal Trp-cagesequence provides a significant and surprising benefit to GIP activity,particularly in truncated GIP analog or hybrids.

Glucose lowering effect in vivo of various analogs and hybrids wasdetermined and shown in FIGS. 10A and 10B. In this example, Acmodification and a Pro3 substitution did not significantly enhanceglucose lowering ability. Points represent mean±sem. Peptide wasinjected IP at t=0 immediately following baseline sample into 2-hourfasted NIH/Swiss mice. Samples were taken at t=60, 120, 180 and 240 min.Blood glucose was measured with a OneTouch® Ultra® (LifeScan, Inc., aJohnson & Johnson Company, Milpitas, Calif.). *p<0.05 vs. vehiclecontrol; ANOVA, Dunnett's test.

Tested were:

-   Cmpd. A, Human GIP acid form:    YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ (SEQ ID NO: 2);-   Cmpd. B: (AcY)(D-Ala)GIP(1-30)-PSSGAPPPS (SEQ ID NO: 1) amide form:-   Ac-Y(DAla)EGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO:455);-   Cmpd. C: (Ac-Y)GIP acid form:-   AcY-AEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQPSSGAPPPS (SEQ ID NO:    290);-   Cmpd. D, Pro3GIP(1-30)-PSSGAPPPS (SEQ ID NO: 1) amide:-   YAPGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO: 245);-   Cmpd E, Pro3GIP(1-42) acid form:-   YAPGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ(SEQ ID NO: 291);-   Cmpd F, Pro3GIP(1-30) amide:-   YAPGTFISDYSIAMDKIHQQDFVNWLLAQK-NH2 (SEQ ID NO: 292); and-   Cmpd G, (D-Ala2)GIP(1-30)-PSSGAPPPS (SEQ ID NO: 1) amide (also    referred to as 0601GIP3794):-   Y(D-Ala)EGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS-NH2 (SEQ ID NO:186).

To compare the insulinotropic effect of various GIP analog hybrids inresponse to an intravenous glucose challenge, GIP analog hybrids weretested in an intra venous glucose tolerance test (IVGTT assay) at 100pmol/kg/min infusion dose in rats. GIP compounds were selected thatdisplayed significant glucose lowering in vivo. For example, whilenative GIP displayed no or little activity in basal glucose lowering(basal glucose lowering (% maximal decrease) at 0% and OGTT response of−10%), the analog 0601GIP4042 and the analog hybrids 0601GIP 3794 and0601GIP 4178 displayed, respectively, a very transient −11%, −20% anddelayed onset −20% for basal glucose lowering, and “ND” (notdetermined), −21% and −20% decrease in the OGTT assay. The delayed onsetwith 0601GIP 4178 is consistent with the view that it binds to plasmaproteins from which it is slowly released.

Duration of action of GIP compounds and hybrids was determined in anIVGTT assay. In the typical IVGTT assays the test sample wasadministered by IV infusion. The IV infusion of sample was initiated att=−30 min and continued through t=90. IV glucose was given at t=0. Todetermine a duration of action using the IVGTT assay, the sample wasinjected SC as a single injection at one time point indicated (e.g.,t=−240, −120, −60 or −30) prior to administration of glucose. IV glucosewas given at t=0. Insulin levels were determined at 0-30 minutes as AUC.Exemplary activities in a rat IVGTT duration of action assay system areshown below.

Standard IVGTT assay Duration of action in assay IV infusion SC inj SCinj SC inj SC inj Compd # (100 pmol/min/kg) T = −30 min T = −60 min T =−120 min T = −240 min Vehicle 57 — — — — (saline) Human GIP 226  57 — —— 0601GIP3794 249 198 159 204 79 0601GIP4233 234 115 —  69 — 0601GIP4252218 — — 125 63

GIP, 0601GIP3794 and 0601GIP4042 (dAla2-GIP(1-42) acid form) producedsignificant enhancement of the insulinotropic response to an intravenousglucose challenge (IVGTT assay), similar in magnitude to the effects ofexenatide and GLP-1 (data not shown). 0601GIP4178(octylglycine-GIP(1-30)-Exendin-4-(31-39)), showed a diminishedinsulinotropic response, possibly due to its association with plasmaproteins via the octylglycine group, which would however provide acompensating benefit of an even further extended duration of action.GIP, 0601GIP3794 and 0601GIP4178 produced a significant rise in insulinlevels prior to the glucose challenge. All three analogs produced asignificant lowering of the glucose excursion in response to the glucosechallenge (data not shown). As described, fed, isoflurane anesthetizedHSD male rats were intubated and cannulated via femoral artery and veinand allowed to stabilize for 1 hour. Following stabilization, an i.v.infusion of saline, GIP, or GIP analog hybrid was started (t=−30). Att=0, an i.v. bolus of 5.7 mmol/kg D-glucose was administered over 2minutes. Samples for glucose measurement and insulin concentrations weretaken at various time points before and after (0 to 90 minutes) glucoseinfusion.

Additional GIP hybrids that will be active in the IVGTT assay include:

-   0601GIP4252 [dAla2]GIP-(1-30)-[Octylglycine 34] Exendin-4 (31-39);-   0601GIP4285 [dAla2, Leu14, Ala18, glu21] GIP-(1-30)-Exendin-4    (31-39);-   0601GIP4233 [dAla2] GIP-(1-30)-fGLP-1v2-(31-37); and-   0601GIP4179 [dAla2, Leu14, beta-Ala31, beta-Ala32]    GIP-(1-32)-Exendin-4 (31-39).

Also performed were insulin secretion enhancement assays using mouseislet cells. Islet cells were isolated as follows. Mouse islets wereisolated with technique described previously (Gotoh M, Maki T, KiyoizumiT, Satomi S, Monaco AP (1985) An improved method for isolation of mousepancreatic islets. Transplantation 40(4):437-438). Briefly, 0.35 mg/mlLiberase R1 (Roche Applied Science) solution was injected intopancreatic duct and pancreas was digested for 18 min at 37° C. Isletswere separated from exocrine tissue using Histopaque-1077(Sigma-Aldrich, Inc.) discontinuous density gradient centrifugation for20 min at 900 g. Before insulin secretion experiments, islets werecultured for 2 days in RPMI-1640 (Invitrogen) supplemented with 10%fetal calf serum, 10 mM Hepes, 100 U/ml penicillin, and 100 mg/mlstreptomycin at 37° C. with 5% CO2. The insulin secretion in vitro assaywas performed as follows. Glucose- and peptide-induced insulin secretionwas performed according to previously described method with slightmodifications (Tatarkiewicz k, Garcia M, Omer A, Van Schilfgaarde R,Weir G C, De Vos P (2001) C-peptide responses after meal challenge inmice transplanted with microencapsulated rat islets. Diabetologia44(5):646-53). Before stimulation, islets were washed 3 times andpreincubated with RPMI-1640 supplemented with 0.5% BSA and containing1.67 mM glucose. After 1 hr preincubation, islets were washed again 3times to remove residual insulin and islets were aliquoted into 24-wellplates with culture inserts (Millicell-PCF, Millipore) containingstimulation medium. The static incubation was performed with approx. 10islets per well in triplicates for 1 hr at 37 degrees C. Stimulatorymedium contained 16.7 mM glucose with GIP analogs in doses of 1, 10, 100nM. At the end of insulin secretion experiment, inserts with islets wereremoved, media were collected and frozen at −20 degrees C. for insulinELISA assay (Crystal Chem, Inc.). Acid ethanol was applied for overnightextraction of insulin from remaining islets. Total islet insulin contentper well was used to normalize insulin release results.

Example 7 Peptide Stability and Protease Resistance

Resistance to proteases was determined according to the protocol ofHupe-Sodmann et al. (Peptides 18(5):625-632 (1997)) using the cell lineRINmF5. This well-differentiated cell line is generally accepted as apancreatic beta-cell model. The indicated GIP compounds (30 μM) wereincubated with RINm5F cell membrane extracts at 37° C., and degradationof peptides, in proportion to percentage of the parent peptide wasmonitored at different intervals for 6 hr using LC-MS. The data (seeFIG. 11) indicate that the [DAla2]-GIP(1-30)-PSSGAPPPS GIP hybrid(Compound G (also designated 0601GIP3794); with C-terminally Trp-cageshield (e.g., exendin-4 tail)) is more stable than its parent moleculeGIP(1-30) without the shield or the full length GIP(1-42). Accordinglythe addition of a Trp-cage shield provides a surprisingly superiorprotease resistance compared to the absence of the cage or the presenceof an alternate non-cage-forming sequence, such as the native GIPC-terminal sequence. Further the data indicates that a GIP(1-30)truncation can accommodate foreign sequences at its C-terminus and, inparticular, can accommodate a Trp-cage shield sequence.

Analogs were also tested for stability in human plasma. Briefly, testcompounds were dissolved water (or in very dilute DMSO as needed), addedto human plasma or human kidney brush border membrane (hKBBM)preparations, incubated for 37° C. for time-points (0, 1, 2, 3, 4, and 5hrs), extracted with methanol (1:4 ratio), and the supernatant analyzeby LC/MS/MS. Typically, the GIP samples were prepared from a stocksolution of peptides in water at 1 mg/mL concentration. The plasmastability samples were prepared by spiking a human plasma pool with thestock solution to a final concentration of 20 ug/mL. The hKBBM sampleswere prepared by adding 5 uL of kidney membrane proteins (at 10 mg/mL)to 650 uL of PBS, and then spiking stock solution of the peptides to afinal concentration of 20 ug/mL. After incubation at different timepoints (0, 1, 2, 3, 4, 5 hrs) at 37 degrees C., 25 uL of each of thesamples were diluted 1:4 with an aqueous solution of 1% formic acidusing a BioTek™ Precision™ liquid handler. 50 μL of this diluted samplewas injected into the Symbiosis Pharma™ system, and online solid phaseextraction was performed. A 2 micron filter was used as a pre-column toprevent clogging of the Analytical (PLRPS, 1×20 mm) column. The HPLCpumps, Reliance™ autosampler and on-line solid phase extraction (SPE)were parts of an integrated system (Symbiosis Pharma™,Spark Holland,Inc.) controlled by a driver on the Mass Spectrometer (Analyst™)software. An Applied Biosystems API 4000™ Qtrap mass spectrometerprovided MRM detection. The HPLC gradient form 95:5 to 5:95, combinedsolvent A that consisted of water and solvent B that consisted ofacetonitrile, both with 0.05% trifluoroacetic acid (TFA) and 0.005%heptafluorobutyric acid (HFBA). Total analysis time was about 3.6minutes per sample. A SPE cartridge (Hysphere GP resin, 2.0×4 mm, 10-15μm) was used for sample extraction. After washing, samples were elutedwith methanol for the analytical analysis. The integrated peak areas forthe peptides were used to generate the following parameters: 1)normalized area counts for all time points to time zero for allpeptides; 2) calculated Area Under the Curves (AUC) for all peptides,and 3) normalized all AUCs to AUC for exendin-4, which is given a valueof 100% (the positive control).

In the human plasma stability assays, “stable” was scored as greaterthan about 90% remaining at 5 hours of treatment to human plasma,“intermediately stable” was scored as greater than about 75% remainingat 2 hours and less than about 90% remaining at 5 hours, and “unstable”was scored as less than about 75% remaining at 2 hours. Unstable analogsand hybrids would generally be unsuited in the methods presented herein.Exemplary compounds were tested. Compounds scored as stable were0601GIP3794, 0601GIP 4150 and 0601GIP4233. Compounds scored asintermediately stable were 0601GIP4149, 0601GIP4152, 0601GIP4153,0601GIP4176, 0601GIP4177, 0601GIP4215, 0601GIP4284, and 0601GIP4289.Compounds scored as unstable were 0601GIP1540, 0601GIP4147, 0601GIP4292,0601GIP4293, and 0601GIP4294. GIP Compound 0601GIP4178 which contains anoctylglycine, was scored as unstable, however it is DPP-IV resistant,and binds to plasma proteins complicating its extraction and detection;it is nonetheless believed to be a stable compound for the purposes ofthe methods herein. The GIP analog hybrid 0601GIP3794 and GIP compoundshaving a C-terminal frog GLP-1 “tail” were surprisingly at least asstable or more stable than exendin-4.

Example 8 Further Exemplary GIP/Amylin-sCT Hybrids

Further exemplary GIP phybrids, amide forms, were prepared. (As usedherein, lower case single amino acid code indicates a “D” amino acid.For example, YaE indicates a D-Alanine in position 2.)

SEQ ID NO: Cmpd # Description Sequence 186 1 GIP(1-30)dAla²-YAEGTFISDYSIAMDKIHQQDFVNWLLAQKPSSGAPPPS exendin4(31-39) 480 2GIP-(1-30)dAla²- YaEGTFISDYSIAMDKIHQQDFVNWLLAQK-miniPEG(8)- miniPEG(8)-K(CNTATC)VLGRLSQELHRLQTYPRTNTGSNTY-NH2 hAmylin(1-7)-^(11,18)Arg-sCT(8-27)- Amylin(33-37) 481 3 GIP(1-30)dAla²-YaEGTFISDYSIAMDKIHQQDFVNWLLAQK-bAla-bAla- bAla-bAla-K(CNTATC)VLGRLSQELHRLQTYPRTNTGSNTY-NH2 hAmylin(1-7)-^(11,18)Arg-sCT(8-27)- Amylin(33-37) 51 4 GLP(7-36)HAEGTFTSDVSSYLEGQAALEFIAWLVKGR 95 10 hAmylin(1-7)-KCNTATCVLGRLSQELHRLQTYPRTNTGSNTY-NH2 ^(11,18)Arg-sCT(8-27)-Amylin(33-37) 482 GIP(1-30)dAla2-YaEGTFISDYSIAMDKIHQQDFVNWLLAQK-Gly-Gly-Gly- GlyGlyGly-K(CNTATC)VLGRLSQELHRLQTYPRTNTGSNTY-NH2 hAmylin(1-7)-^(11,18)Arg-sCT(8-27)- Amylin(33-37)

The compounds were tested for receptor binding as described herein:

GIP GLP CT RBA AMY CGRP Cmpd# RBA RBA (C1A) RBA RBA Cyclase 3 0.10 4480.15 0.20 108 199 4 0.13 664 0.12 0.30 110 215 10 Nd nd 0.03 0.03 2.301.40 1 3.8 1000 nd nd nd 519

The hybrids effectively and selectively bound and activated the relevantreceptors.

The compounds were also assayed in for food intake inhibition, loweringof blood glucose assay and Oral Glucose Tolerance Test (OGTT) asdescribed herein. In the food intake assays (FIGS. 13A, 14, 15 and16A-16B) points represent mean+/−sd of n=4 cages (3 mice/cage). Peptidewas injected IP at t=0. Food was introduced immediately after injectionand amount consumed measured at t=30, 60, 120, and 180 minutes. *p<0.05versus vehicle control; ANOVA, Dunnett's test.

In FIG. 13B bars represent mean+/−sd. Peptide was injected IP at t=−5minutes into 4-hour fasted NIH/Swiss female mice. Gavage (1.5 g/kg) wasgiven at t=0, Sample was taken at t=30 minutes. *p<0.05 versus vehiclecontrol; ANOVA, Dunnett's test. In FIG. 17 points represent mean+/−sem.Peptide was injected IP at t=) immediately following baseline sampleinto 2-hour fasted NIH/Swiss mice. Samples were taken at t=60, t=120 andt=180. Blood glucose was measured with a ONETOUCH ULTRA (LifeScan, Inc.,Milpitas Calif.). *p<0.05 versus vehicle control; ANOVA, Dunnett's test.As shown in FIGS. 23A and 23B the GIP-amylin/sCT/amylin hybrid slowsgastric emptying and reduces intracellular calcium, which are hallmarksof an amylin family hormone module. Thus these GIP hybrid compoundscombine the insulinotropic action (and other actions) of a GIP analogwith a gastric emptying effect or beneficial calcium modulation effect(e.g. as for bone density maintenance) of an amylin mimetic. In oneembodiment for each of these GIP hybrids a Gly linker is used, e.g.GlyGlyGly. While the amylin-sCT-amylin chimera did not lower bloodglucose compared to vehicle, the GIP hybrids containing theamylin-sCT-amylin chimera effectively lowered blood glucose. Exemplarycompounds of GIP and an amylin family module with this activity include0601GIP4090 and 0601GIP4091. Compared to the parent compounds thesecompounds displayed the following properties:

Amylin-sCT-amylin GIP chimera Hybrid Food Intake not active activeactive OGTT decreases increases decreases Glucose mice weak increasesdecreases Glucose rats not active increases not active Gastric notactive active active Emptying iCa not active active active BWt (mDIO)not active not active active Body Comp No effect on lean mass not activeimproves (mDIO) Heart Rate (rat) increases increases increases MAP (rat)not active not active not active

GIP hybrids bind and activate desired receptors as well as display invivo properties consistent with the selected properties of the GIPhybrid. This is further shown below. Column RBA1 indicates “GIP RBA(RIN)or(% Inh10 nM, GIP-LF)”; column A1 indicates “AUC Change in Insulin PreIVGTT”; column A2 the “AUC Change in Insulin Post IVGTT”; column B1“Basal Glucose Lowering 80 nmol/Kg”; column IV1 the “IVGTT activitycompared to 0601GIP3794”; column C1 the “GLP/GIP/CT CYCLASE(RIN) V.2activity”

OGTT/GL(%) GLP CT CGRP CT Cmpd# RBA1 350 nmol/Kg B1 A1 A2 IV1 C1 RBAcyclase RBA RBA 0601GIP4091 0.1 −35  −9%, AUC180 31.8 +− 5.8 153.2 +−9.9 < 199 448 40 108 0.15 0601GIP4090 0.13 −15 −13%, AUC180 215 664 57110 0.12 0601GIP4501 332 21.3

Example 9 Direct Action of GIP Compounds on Cardiomyocytes

Cyclic AMP (adenosine 3′,5′-cyclic monophosphate) is a key secondmessenger in the G-Protein Coupled Receptor (GPCR) signaling pathway.The binding of a ligand to the receptor leads to G protein activationwhich in turns regulates Adenylyl Cyclase, the enzyme responsible formodulating intracellular levels of cAMP. Measurement of cAMP levels iswidely used as an indicator of receptor function. Activation ofcardiomyocyte Gs- and Gi-coupled receptors was determined as a measureof cAMP production.

Cell Isolation. Neonatal cardiomyocytes were isolated using acommercially available system. The Cellutron Isolation kit (nc-6031)(Cellutron, N.J.) and protocol was used for cell isolation. SpragueDawley neonatal rats (1-2 days old) were decapitated and the beatingheart dissected out into digestion buffer (Cellutron D1 buffer) todissociate cells. For 15 rat hearts, 8 digestions with 6 mls of buffer(Cellutron D2 buffer) were sufficient. The resuspended cells incubatedin buffer (Cellutron D3 buffer) for sufficient time to allow optimaldispersion and minimize the need for pipetting to break up clumps. Cellsreleased from the first 2 digestions were discarded since a significantportion of these is red blood cells. Resuspended cells were filtered andallowed to pre-plate for 1 hour on plastic in an incubator in NS media(Cellutron, N.J.) in order to remove fibroblasts. After 1 hour ofpre-plating, floating cells are removed and the flask rinsed with NSmedia. The floating cells and the cells in the rinse media were combinedand counted. Residual red blood cells, which are smaller that thecardiac myocytes, were not counted.

Cell Plating. At Day 0 of an experiment, the cells were isolated andplated in NS media at 8,000/384 well, 50,000/96 well or 500,000/12 wellfor 24 hours. At Day 1, the NS media was replaced with fresh NS media.It was observed that the recommended NW (Cellutron, N.J.) media did nottypically support adequate cell growth or morphology.

cAMP Assay. GIP compounds were tested for cAMP induction on theisolated, cultured cardiomyocytes. Test-compound induced cAMP levelswere determined using a commercially available CisBio (Bedford Mass.)HRTF® (homogeneous time-resolved fluorescence) cAMP dynamic assay in aGs/Gi 384-well adherent format, essentially as described by themanufacture (see also Gabriel et al., High throughput screeningtechnologies for direct cyclic AMP measurement, Assay & Drug Dev.Technol. 2:291-303 (2003) and Cenni et al., HTRF® cyclic AMP assay: newoptimized cell-based assay for better investigation of Gi coupledreceptors, in Smart assays for screening, IIR Congress, Zurich (CH)(2003)). Dose response was determined.

For Gs assays the positive control was 10 uM forskolin and negativecontrol was buffer. For Gi assays the positive control was buffer andthe negative control was 10 uM forskolin. Test compound was incubatedwith cells for 30 minutes at 37 degrees C. in stimulation buffer ((200mls contains 198.3 ml 1×HBSS, 1 ml 1M Hepes, 670 ul 30% BSA titrated topH 7.4 with 1M NaOH). To measure cAMP produced, cells were lysed andcAMP assayed according to the manufacturers protocol. Exemplary resultsare shown in FIGS. 18A (GIP: human GIP(1-42) acid form) and 18B (GIPhybrid Compound G). The Y-axis is a ratio of time resolved fluorescencemeasurements taken at 665 nM divided by measurements taken at 620 nM. Inthis experiment the EC50 was 11.7 nM for the GIP hybrid and 9.1 nM forGIP. GLP-1 and exendin-4 displayed very low to no significant activity(data not shown). Further, from three independent experiments ofcardiomyocyte Gs-coupled receptor activation, the EC50 (nM) was 15.6 forGIP, 0.7 for urocortin and 29.8 for the GIP hybrid Compound G. Urocortinis a known cardiac myocyte Gs-coupled receptor activator used as apositive control. GIP and the GIP hybrid typically gave receptoractivation responses greater than 50%. Usdin et al. (Endocrinology133:2861-2870 (1993)) reported cloning of a rat GIP receptor and its insitu hybridization to RNA in various rat tissues, including the heart,particularly the cardiac endothelium, which was consistent with labelingof the endothelium of major blood vessels. The results indicate that GIPcompounds can provide a direct action on the heart.

Example 10 Measurement of Circulatory System Effects in Conscious Ratsby Telemetry after Administration of GIP Compounds

Male Harlan Sprague Dawley rats housed at 22.8±0.8° C. in a 12:12 hourlight:dark cycle were used to study the effects of test compounds on thecirculatory system through the use of telemetry. The experiments wereperformed during the light cycle. Telemetry allows for real-timehemodynamic readings including arterial blood pressure, heart rate andarterial dP/dt, via an implanted radio transmitter in conscious,non-anesthetized, unrestrained rats. In the present Example, rats wereinjected with either vehicle, 80 nmol/kg GIP (human GIP(1-42) acidform), or 80 nmol/kg of 0601GIP3794 by remote intravenous dosing. Remoteintravenous dosing was achieved through in-dwelling vascular accessports (Access Technologies (Skokie, Ill.). The port is secured to theunderlying muscle just below the skin between the scapulae. The catheterresides in the jugular vein. Data were collected for up to 60 minutesfollowing injection.

As shown in FIGS. 19A-E the effect of the GIP hybrid to increase heartrate was transient relative to GIP (human GIP(1-42) acid form) (FIG.19B), that that the GIP hybrid decreased mean arterial pressure whileGIP had no effect (FIG. 19A), and that both compounds increased dP/dtsimilarly (FIG. 19C). FIGS. 19D and 19E demonstrate that the GIP hybridprovides a sustained lowering of systolic and diastolic pressurescompared to either vehicle or GIP. Hybrid 0601GIP4091 had a beneficialeffect on these cardiovascular parameters, similar to that of GIP andthe amylin-sCT-amylin chimera Compound 10 (also referred to AC2307).

From the data it can be seen that GIP displays a positive inotropiceffect in intact rats without elevating arterial pressure. GIP alsodisplayed a chronotropic (heart rate elevating) effect. The GIP hybriddisplayed a prolonged inotropic effect (shown here as peak rate ofincrease in arterial pressure; dP/dt), compared to GIP, without causingcardiac acceleration, and invoked a decrease in arterial pressure.Accordingly, GIP hybrids can display vasodilation and perfusion benefitsthat are not associated with an increase in cardiac work. In additionthe sustained lowering of either systolic pressure or diastolicpressure, including both, is a recognized beneficial cardiovasculareffect linked to reducing hypertension and cardiovascular-associatedmorbidity and mortality events.

Example 11 Lack of Effect of GIP on Weight Loss

The effect of GIP(1-42) and a GIP DPP-IV resistant analog/exendin tailhybrid (0601GIP3794) were tested for effect on food intake and on weightloss in DIO mice as described herein. As shown in FIG. 20A, it wasobserved that GIP did not acutely inhibit food intake in mice. Incomparison, rat amylin at one tenth the dose caused a significantdecrease in food intake within 30 min, relative to control. A trend forGIP to decrease food intake at later time points (60, 120 min) may havebeen an indirect effect due to its stimulation of amylin secretion.Points represent mean±sd of n=4 cages (3 mice/cage). Peptide wasinjected IP at t=0. Food was introduced immediately after injection andamount consumed measured at t=30, 60, and 120 min. * p<0.05 vs. vehiclecontrol; ANOVA, Dunnett's test. Similarly the DPP-IV resistant GIPanalog hybrid comprising an exendin tail, Compound 0601GIP3794, did notacutely inhibit food intake as reflected by no difference from vehiclecontrol intake at 30 min (FIG. 20B). As with GIP, a trend for thiscompound to decrease food intake at later time points (60, 120 min) mayhave been due to its stimulation of amylin secretion. Points representmean±sd of n=4 cages (3 mice/cage). Peptide was injected IP at t=0. Foodwas introduced immediately after injection and amount consumed measuredat t=30, 60, and 120 min. * p<0.05 vs. vehicle control; ANOVA, Dunnett'stest. In contrast to GIP and GIP agonists, exenatide and GLP 1 agonistsdirectly and acutely inhibit food intake, independent of their effect tostimulate amylin secretion. A reduction in food intake is apparent atthe first time point (FIG. 20C). Similarly, effects of GLP-1 andexenatide on gastric emptying and post-prandial glucose profiles havebeen reported in type 1 diabetic subjects, indicating the effect is notdependent upon the presence of b cells or amylin.

As shown in FIG. 21, GIP did not cause weight loss in diet-induced-obesemice. In mice in which body weight had been increased by feed a high-fatdiet (HF Saline group), GIP infused via min-osmotic pump for 2 weeks hadno effect on body weight change. In contrast, exenatide infused at a30-fold lower rate reduced body weight change to that observed in micefed a low fat diet (LF group). * P<0.05; ANOVA vs HF Saline. Thisdemonstrates an anti- or non-catabolic effect of GIP. In contrast, itwas observed herein that a GIP hybrid having an appropriate choice of asecond hormone module, such as an amylin/sCT/amylin chimera, did cause areduction in food intake and weight loss. Further a GIP hybridcontaining an exendin family module also resulted in weight loss. Theexendin-GIP hybrid 0601GIP4526[HGEGTFTSDLSKQMEEEAVRLFIEWLKN(beta-A)(beta-A)K(#C)-NH2] (SEQ ID NO: 484)[YaEGTFISDYSIAMDKIHQQDFVNWLLAQK(beta-A)(beta-A)K#] (SEQ ID NO:483) inwhich the two molecules were linked C-terminal to C-terminal displayedreduction of body weight sustained to day 7. This hybrid also reducedfood intake in a mouse model. This hybrid bound to and activated boththe GIP and the GLP-1 receptor.

Example 12 Solubility and Physical Stability

GIP analogs comprising the modifications described here havesurprisingly good solubility (at least about 1 mg/ml or at least about2.5 mg/ml or even at least about 5 mg/ml) at at least several pHsrelevant for pharmaceutical formulation, storage and administration,while retaining superior bioactivity, duration of action and/or physicalstability, as compared to human GIP or to a parent GIP compound such as0601GIP3794. The following method can be used to compare solubility andphysical and chemical stability at various pHs. The following exemplarypH and buffers can be used: pH 3.0 in 30 mM citrate, pH 4.0 in 30 mMacetate, pH 5.0 in 30 mM acetate, pH 6.0 in 30 mM histidine, pH 7.0 in30 mM histidine, pH 8.0 in 30 mM phosphate and pH 9.0 in 30 mM borate.Two hundred ml of buffer is added to a vial containing the test peptideto achieve a 10 mg/ml or a 5 mg/ml solution. After vortexing forapproximate 30 seconds, the appearance of the solution is observed undera Fiber-Lite. Buffer is continued added in 200 ml aliquots until thetotal volume of the solution reaches 1000 ml. The appearance of thesolution is recorded after each 200 ml of buffer is added. Theappearance versus the peptide concentration is recorded as clear,slightly hazy, hazy or cloudy. In one embodiment the GIP analog achievesa clear solution at at least 2.5 mg/ml concentration at pH 4-8 or pH5-7, and further at at least 5.0 mg/ml at pH 4-8 or at pH 5-7.

To assess stability at a pH, the solution above is filtered into a 2-mLSchott vial, and equally divided into 3 vials. Each vial is stopperedand tightly sealed. A first vial is incubated at 5° C. for 7 days, thesecond at 40° C. for 3 days, and the third at 40° C. for 7 days. Afterincubation, the appearance of all samples is recorded under theFiber-Lite. If the peptide solution becomes cloudy or precipitated, thesolution is filtered prior to HPLC analysis (reverse-phase HPLC methodusing Vydac C18 column) to determine amount of intact peptide remainingin solution. Alternatively, bioactivity can be measured. Stability isrecorded as percent potency loss using the calculation [(% peptide attest day −% peptide at T0 at 5 C)/% peptide at T0 at 5 C] times 100.FIG. 27 presents an exemplary pH versus solubility profile and a pHversus stability profile of 0601GIP5082.

While the present invention has been described in terms of exemplaryexamples and embodiments, it is understood that variations andmodifications will occur to those skilled in the art. Therefore, it isintended that the appended claims cover all such equivalent variationswhich come within the scope of the invention as claimed.

What is claimed is:
 1. A compound comprising the amino acid sequence ofSEQ ID NO:186.
 2. The compound of claim 1, wherein the C-terminal end ofthe compound is amidated or acylated.
 3. The compound of claim 1,wherein the C-terminal end of the compound is amidated.
 4. A compoundcomprising the amino acid sequence of SEQ ID NO:186, SEQ ID NO:902, SEQID NO:907, SEQ ID NO:908, SEQ ID NO:876, SEQ ID NO:877, SEQ ID NO:878,SEQ ID NO:872, SEQ ID NO:873, SEQ ID NO:874, SEQ ID NO:875, or SEQ IDNO:859.
 5. The compound of claim 4, wherein the C-terminal end of thecompound is amidated or acylated.
 6. The compound of claim 4, whereinthe C-terminal end of the compound is amidated.